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Summary 
 
Prior focus has largely been on the role of CD4+ T cells in Multiple sclerosis (MS) 
disease pathogenesis, but there is mounting evidence for the role of CD8+ T cells. This 
thesis aimed to explore the role of CD8+ T cells by; (i) analysing clinical outcomes in MS 
patients treated with alemtuzumab, (ii) performing an in-depth phenotypic analysis of 
cerebrospinal fluid (CSF)-resident T cells in MS patients, (iii) examining the CSF-
resident T cell receptor (TCR) repertoire in MS patients, and; (iv) identifying the 
pathogenic triggers/antigenic targets of dominant CSF-resident TCRs. Alemtuzumab 
was shown to be an effective treatment for relapsing MS. Immunophenotyping 
demonstrated an increased number of CSF-resident CD4+ and CD8+ T cells in MS 
patients compared with controls although the majority of CSF-resident T cells were of 
an effector memory phenotype across all groups. This suggests that effector memory T 
cells enter the CSF as part of normal central nervous system (CNS) 
immunosurveillance, and is consistent with the fact that I was able to detect Epstein-
Barr virus-specific TCRs in all groups at similar frequencies. Clonal expansions were 
observed in the CD4+ and CD8+ T cell repertoire of all patient groups and so are not a 
unique feature of MS. However, I did observe a significant increase in TCR diversity in 
the CD4+ and CD8+ TCR repertoire in MS patients compared to controls. Overall, the 
results from the Alemtuzumab study strongly support a central role for T cells in MS 
pathogenesis. Immunophenotyping and clonotyping analysis suggest that CD4+ and 
CD8+ T cells with an effector memory phenotype preferentially accumulate in the CSF 
as part of normal immune surveillance. In MS, increased TCR diversity warrants further 
investigation as it suggests that a more diverse response to CNS antigens may play a 
role in disease pathogenesis.  
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Chapter 1 
 
Introduction 
 
1.1 Multiple sclerosis 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) 
that causes demyelination and destroys oligodendrocytes, neurons and axons.1 MS is 
the most common chronic neurological disease affecting young adults in the Western 
word, with a lifetime risk of 1 in 400. Clinical disease is heterogeneous but most 
commonly is characterised by a relapsing/remitting course with episodes of CNS 
inflammation and demyelination manifesting as subacute episodes of clinical 
neurological dysfunction, which may include sensory, motor, visual, and cognitive 
deficits.2 Clinical presentation is determined by the spatiotemporal dissemination of 
characteristic MS lesions within the CNS.3 These CNS lesions are pathognomonic of MS 
and are caused by parenchymal immune cell infiltrates that promote inflammation, 
demyelination, gliosis and neuroaxonal degeneration, leading to disruption of 
neuronal signalling.3 Autoreactive T cells are considered to initiate the disease process, 
mounting aberrant immune responses against CNS autoantigens, the exact nature of 
which remains unknown.3 Later in the course of the disease, neuroinflammation is less 
prominent with neurodegeneration becoming the main feature in the secondary 
progressive phase. A smaller proportion (10-20%) of patients present without discreet 
episodes of neuroinflammation with a progressive disease course from onset; primary 
progressive MS (Figure 1.1).2  
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Figure 1.1. Association between inflammation, clinical relapses and progression in Multiple sclerosis. 
Relapsing-remitting disease is the most common form of disease presentation, characterised by 
inflammation and demyelination occurring in eloquent areas of the CNS and reaching a threshold that 
produces clinical symptoms. Recovery occurs as inflammation improves, but with residual disability. 
Following this relapsing phase, patients become secondary progressive - the disease is no longer 
characterised by inflammation and relapses but a gradual accrual of disability related to axonal and 
brain volume loss. Figure adapted from Dendrou et al.3  
 
Disease pathogenesis is likely to be multifactorial with a contribution from 
environmental factors in addition to a genetic predisposition.2 Genome Wide 
Association Studies (GWAS) indicate that there is an association with the Human 
Leukocyte Antigen (HLA) regions with genetic variation thought to account for 
approximately 30% of the overall disease risk. In total, more than 100 genetic regions 
have been associated with MS.3 This, along with evidence from the composition of MS 
plaques and animal models supports the central role of T cells in MS disease 
pathogenesis.2 As such, treatment options are currently focused on the relapsing stage 
of the disease and are aimed at interfering with cell trafficking,4, 5 lymphocyte 
function6-8 and lymphodepletion.8, 9 
 
 3 
Although there is a large body of research focusing on the role of CD4+ T cells in MS 
pathogenesis,10 interest in the role of CD8+ T cells is increasing with a growing body of 
evidence suggesting they have a central role to play in disease development. 
Throughout this introduction the evidence for the role of CD8+ T cells in MS will be 
explored as a background for setting out the objectives of this thesis. Understanding 
the possible pathogenic and regulatory role of CD8+ T cells has clear implications for 
unravelling disease pathogenesis and for the development of novel therapeutics. 
 
1.2 The immune system 
The innate immune system is the first line of defence against invading pathogens, 
incorporating macrophages, dendritic cells (DCs), mast cells, neutrophils, eosinophils, 
and NK cells.11 The adaptive immune system is divided into humoral and cell-mediated 
immunity involving B- and T-cells, respectively. B cells secrete antibodies, which bind 
to epitopes on invading pathogens, identifying them for removal by other components 
of the immune system, such as macrophages. The cell-mediated immune system, 
which will be the focus of this thesis, involves the activation of T cells. The majority of 
T cells express only one T cell receptor (TCR), which after recognition of a specific 
antigen proliferate by clonal expansion.12, 13 
 
1.3 T cells 
T lymphocytes or T cells, ubiquitously characterised by the presence of the co-receptor 
molecules CD4 or CD8, orchestrate human cellular immunity. Central to the interaction 
between T cells and antigen (presented in combination with major histocompatibility 
complex (MHC), or HLA in humans) is the T cell receptor (TCR). The majority of TCRs 
are heterodimers comprised of two subunit chains (α- and β-), which both contain 
constant and variable domains (Figure 1.2). Because of the need for a large number of 
unique TCRs given the number of potential TCR/antigen interactions, the immune 
system has a unique way of introducing diversity. TCR diversity is generated during the 
early stages of T cell development in the thymus. During cell division, extensive gene 
recombination occurs between the V(variable)- and J(junctional)- segments, and the V-
, D(diversity)- and J- segments, in the TCR α and TCR β genes respectively - a process 
referred to as V(D)J recombination. The region of TCR β that spans the V-D and D-J 
junctions is known as the complementarity determining region 3 (CDR3) and is unique 
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to each TCR β variant. Following this process, T cells that lack sufficient affinity for 
MHC molecules and those that recognise self-antigens are eliminated (positive and 
negative selection respectively).14 
 
 
Figure 1.2 Interaction of T cells with antigen presenting cells. CD8+ T cells interact via T cell receptors 
and peptide/MHC class I on antigen presenting cells. CD4+ T cells interact via peptide/MHC class II 
binding. Figure adapted from The Immune System, Parham P, Garland Science, 2009.15 
 
1.4 T cell immune surveillance of the central nervous system 
The central nervous system has long been considered an immune-privileged site for 
several reasons;16 (i) the expression of MHC molecules is limited within the CNS 
parenchyma,17 (ii) the entry of immune cells into the CNS via the blood-cerebrospinal 
fluid (CSF) barrier, the CSF-brain barrier and the blood brain barrier (BBB) is 
restricted,18 (iii) the antigenic representation in peripheral lymph nodes may not be an 
accurate representation of the CNS due to the special features of CNS lymphatic 
drainage (Figure 1.3).16, 19 
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Figure 1.3. Lymphatic drainage of the central nervous system. CSF and interstitial fluid (ISF) drain to 
lymph nodes by different pathways. (i) CSF drains into venous sinuses through arachnoid villi and 
granulations (AG). Lymphatic drainage of CSF occurs via nasal and dural lymphatics and along cranial and 
spinal nerve roots. Channels that pass from the subarachnoid space through the cribriform plate allow 
passage of CSF T cells and antigen-presenting cells (APC) into nasal lymphatics and cervical lymph nodes 
(CLN). CSF from the lumbar subarachnoid space drains to lumbar lymph nodes. (ii) ISF from the brain 
parenchyma drains along basement membranes in the walls of cerebral capillaries and arteries to 
cervical lymph nodes. There is interchange between CSF and ISF (glymphatic system), as CSF enters the 
surface of the brain alongside penetrating arteries.20 Figure adapted from Engelhardt et al.20 
 
Despite this, T cells are central for CNS immune surveillance and maintaining 
homeostasis, with a fine balance to be struck between control of infectious agents and 
immune-mediated damage. As the CNS is a common target of viral infections and 
autoimmune disorders, then T cells must be able to access the CNS despite its 
supposed immune privileged status. As such, the brain and spinal cord are under 
continual immune surveillance to detect and eliminate potential mediators of infection 
and damage. Two possible scenarios have been proposed as to how this may occur 
(Figure 1.4).16  
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Figure 1.4 Two proposed scenarios of T cell CNS immune surveillance despite supposed immune 
privileged status. (a) CNS inflammation initiated in the CNS-draining lymph nodes (upper panel). After 
primary virus infection of the CNS, T cell priming due to aberrant leakage of CNS antigens occurs in the 
CNS-draining lymph nodes. T cells then home back to the CNS in order to eliminate foreign antigens or 
to cause autoimmune inflammation. (b) T cells that recognise target antigens in the CNS are primed by 
non-CNS, peripheral antigens due to cross-reactivity or molecular mimicry (lower panel).16 Figure 
adapted from Korn et al.16 
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In the first scenario, CNS inflammation is initiated in the CNS-draining lymph nodes. Up 
until recently, the lack of lymphatic drainage of the CSF was thought to be a major 
contributor to its immune-privileged status. However, the recent discovery of a CNS 
lymphatic drainage system21 and the newly named ‘glymphatic system’, related to 
drainage from the parenchymal interstitial fluid to the CSF,22 has helped to explain 
how T cell immunity may occur. Antigen – either virus infected cells or self-antigens - 
might be exported from the CNS and presented in CNS-draining lymph nodes. After 
priming of antigen-specific T cells in the CNS-draining lymph nodes, these T cells may 
then home back to the CNS in order to eliminate foreign antigens or to cause 
autoimmune inflammation.16 In an alternative scenario, non-CNS peripheral antigens 
prime T cells recognising target antigens in the CNS. These antigens may be molecular 
mimics of CNS antigens or antigens that are produced by viruses that cause a systemic 
infection before infecting the CNS.16 
 
Once homed back to the CNS, T cells may be activated and regain entry via several 
different proposed routes (Figures 1.5).23 T cell reactivation may occur in the choroid 
plexus,24 the meninges,25 and the perivascular space within the CNS parenchyma 
(Figure 1.6).26 Interestingly, in a mouse model, it has recently been  
shown that T cells gain the capacity to enter the CNS after residing transiently in lung 
tissue.27  
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Figure 1.5. Suggested sites of T cell entry into the CNS. (1) Through the fenestrated blood vessels of the 
choroid plexus, across the ependymal layer and into the CSF, (2) through the perivascular or Virchow-
Robin space, (3) directly into the CNS parenchyma through postcapillary venules.23 Figure adapted from 
Ousman et al.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Suggested sites of T cell-CNS interactions in MS. (a) peripheral activation of T cells against 
CNS antigens with subsequent CNS infiltration. (b) CNS-intrinsic T cell activation as a result of normal 
immune surveillance. (c) Intra-parenchymal inflammation.3 Figure adapted from Dendrou et al.3 
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In addition to the above scenarios, and with particular regard to CD8+ T cells, 
protection of the CNS from reinfection was recently found to depend on tissue 
resident memory (TRM) cells.26 TRM cells are non-circulating T cells that are located in 
non-lymphoid tissues to provide immediate protection from re-infection.28 
Interestingly, the systemic reactivation of T cells, which then home to the CNS to clear 
the pathogen, is usually associated with pathology that ultimately may be more 
harmful than the potential pathogen-induced damage.29 Conversely, TRM cells have 
been shown to clear the CNS of pathogen during reinfection efficiently and with less 
collateral pathology.16 
 
A disruption of the constant immune surveillance that occurs in immunosuppressive 
disease (e.g. human immunodeficiency virus, HIV) or with immune-modulating drugs 
highlights its importance. A striking example of this is the occurrence of progressive 
multifocal leucoencephalopathy (PML) that occurs secondary to John Cunningham (JC) 
virus.30 The majority of humans harbour this virus, which is normally controlled by the 
immune system. However, upon depletion of usual CNS immune surveillance, due to 
immunosuppressive disease or therapeutics (in particular, natalizumab, a monoclonal 
antibody against the adhesion molecule very late antigen-4 (VLA-4), preventing 
lymphocyte egress into the CNS), the virus enters the brain resulting in an untreatable, 
and often fatal infection.30  
 
In summary, potential pathogens are likely to be commonly frequenting the CNS and 
as such humans require a constant, active, immune surveillance to keep these 
potential infections under control. Immunosuppressive disease and drugs that alter 
this fine balance highlight the importance of this. In addition, aberrant immune 
stimulation and activation has the potential to lead to autoimmune disease such as 
MS. 
 
1.5 Overview of T cell involvement in the pathogenesis of Multiple 
sclerosis 
The exact cause of MS remains unclear and in particular whether there is a common 
provoking factor or pathway across all affected individuals. There is a clear genetic 
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predisposition with contribution from environmental factors but as yet the pathogenic 
trigger and antigenic target remain elusive. 
 
The question of whether MS originates in the periphery or in the CNS is still to be 
comprehensively determined although it is clear that there is an ever-evolving immune 
response. Early in the disease, immune cells infiltrate the CNS parenchyma.3 These 
cells, in association with activated microglia and astrocytes, promote demyelination 
and oligodendrocyte and axonal injury.  Later in the disease process, immune cell 
infiltration is less prominent, with more CNS-intrinsic inflammation and 
neurodegeneration.3 Consistent with general CNS immune surveillance, both 
peripheral and central models of disease pathogenesis have been suggested. 
 
As discussed in section 1.4, the peripheral model of MS pathogenesis suggests 
autoreactive T cells are activated at peripheral sites through molecular mimicry,31 
bystander activation or the co-expression of TCRs with different specificities.32 T cells 
are then thought to traffic to the CNS along with activated B cells and monocytes 
(Figure 1.7).3  
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Figure 1.7. Immune system dysregulation outside the CNS. CNS-directed autoreactive T cells that 
escape both central and peripheral tolerance (1.) may be activated in the periphery and subsequently be 
pathogenic to CNS antigens (2.). This process may occur through molecular mimicry, novel autoantigen 
presentation, recognition of sequestered CNS antigen released into the periphery or bystander 
activation. Genetic and environmental factors, including infectious agents and smoke constituents, 
contribute to these events. Figure adapted from Dendrou et al.3 
 
With the emerging understanding of CNS immune surveillance, an alternative 
hypothesis suggests central disease development, with a CNS-intrinsic inflammatory 
response to an as yet unknown CNS viral infection. This may then result in secondary 
infiltration of autoreactive T cells (Figure 1.4).16 
 
In addition to genetic risk discussed later in this chapter, environmental factors also 
influence disease pathogenesis.3 Firstly, viruses or microbes may be directly involved in 
the triggering of autoreactive T cells.31 Secondly, CNS infectious agents may promote 
the release of sequestered CNS antigens into the periphery.33 Thirdly, environmental 
influences may also alter the activation threshold of T cells.16 Lastly, cytokines secreted 
at sites of peripheral inflammation secondary to infection, may also have an influence 
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on CNS immune responses, leading to local inflammation and disease. Interestingly, 
this last point raises the possibility that MS could be triggered by infection at a distant 
site rather than a CNS-directed autoreactive immune response.3  
 
In addition to a pathogenic role for T cells, defective regulatory T cells may also have a 
contributory role in MS pathogenesis.3 These cells are discussed in more detail later in 
this chapter. Further to this general introduction to CNS immune surveillance and MS 
pathogenesis, the remainder of this chapter will focus on the evidence for the role of 
CD8+ T cells in MS. 
 
1.6 CD8+ T cells 
CD8+ T cells are primary effector cells of the adaptive immune system34 and are the 
main determinants of immunity to intracellular pathogens and cancer cells.35 They 
recognise protein antigens presented in association with MHC class I (MHCI; HLA-A, -B 
and -C in humans) molecules on the surface of target cells (CD4+ T cells interact with 
MHC class II molecules (MHCII; HLA-DR, -DQ, -DP in humans)).35 MHCI is expressed on 
almost all nucleated cells, enabling the immune system to scan the cell surface to 
detect internal anomalies.34 Following activation, CD8+ T cells expand and deliver a 
range of effector functions. After clearance of the initial infection, only a small 
proportion of these expanded cells survive and exist as the memory population.34 
Production of the cytokines interferon(IFN)-γ and tumour necrosis factor(TNF)-α 
occurs after CD8+ T cells differentiate into effector cells, with perforin and granzyme B 
also offering some direct cytotoxic action.36 After infection, memory T cell clones 
persist to fight against recurrent infection.36 An issue that may be of particular 
relevance in MS is that if the stimulating antigen cannot be cleared, then CD8+ T cells 
can become chronically stimulated and cause autoimmune disease.34, 37  
 
In addition to their cytotoxic role, CD8+ T cells can also perform regulatory functions, 
with evidence to suggest relevance to clinical disease.38 Regulatory CD8+ T cells (CD8+ 
Tregs) have been shown to exert their regulatory effects by a variety of mechanisms. 
This can either be via direct cell death, the induction of negative cell signalling 
molecules through cell-cell interactions and by the secretion of immunosuppressive 
cytokines such as interleukin(IL)-10.38 Interestingly, it has been demonstrated that IL-
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10 is secreted at the peak of the inflammatory response by CD8+ T cells in a proposed 
autocrine regulation to prevent unwanted tissue damage.39  
 
1.7 Genome wide association studies (GWAS) implicate CD8+ T cells in 
MS disease pathogenesis 
MS has historically been considered to be a CD4+ T cell mediated disease due to strong 
associations with HLA class II regions in genome wide association studies.40 In addition 
to the evidence for the role of CD4+ T cells, there is also some indication from these 
studies that CD8+ T cells play a role. The first genome wide association studies found 
disease association with several immunological, neurological and non-neurological 
genes. Of the immunological genes, risk was shown to be conferred by alleles of the 
HLA genes. In particular, the class II allele, DRB1*1501 was shown to confer risk along 
with the class I molecule HLA*0301, although HLA*0201 was shown to be protective.41 
These results suggested a key role for CD4+ (HLA-DR) and CD8+ (HLA-A) T cells in the 
pathogenesis of MS. However, the associated risk for developing MS with HLA-A*0301 
was not found in a subsequent large GWAS, although the protective role for HLA-
A*0201 was replicated.42  
 
A further meta-analysis has confirmed the association of HLA-DRB1*1501 as well as 
other class II alleles DRB*0301, *1303, *0404, *0401 and *1401, with HLA-A*0201 
again found to be protective, with its association attributed to an amino acid 
polymorphism in the peptide-binding groove of the HLA-A molecule.43 Investigation of 
the mechanism of the potential pathogenic and protective role of the earlier identified 
HLA-A3 and HLA-A2 alleles was performed in a novel transgenic mouse model. Friese 
et al developed a humanised transgenic mouse expressing the potential risk variant 
HLA-A3 either alone or with a myelin proteolipid protein (PLP) TCR. Double transgenic 
(2D1-TCR and HLA-A3) mice developed spontaneous experimental autoimmune 
encephalomyelitis (EAE) at a low frequency, which increased following immunisation 
with the PLP peptide. Interestingly, 2D1-TCR+CD8+ T cells were found in typical MS 
anatomical sites such as the cerebellum and spinal cord, and in contact with HLA-A3 
expressing oligodendrocytes with demyelination and axonal damage observed. These 
findings confirmed that an HLA-A3 restricted myelin specific TCR in a humanised HLA-
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A3 mouse model can induce an MS-like disease. Further experiments confirmed that 
2D1-TCR+CD8+ T cells mediated earlier disease but later manifestations were due to 
epitope spreading, with CD4+ T cells more implicated. Intriguingly, the addition of an 
HLA-A2 transgene to the double transgenic mouse prevented an MS-like disease 
occurring.  This was shown to be secondary to a reduction in numbers of the splenic 
2D1-TCR+CD8+ T cells due to altered thymic selection and reduced responsiveness of 
these cells.44  
 
In addition to the associations seen with HLA alleles, 110 genetic variants have now 
been identified that are associated with susceptibility to MS.45 Of those identified, 
genes coding for cytokine pathways, co-stimulatory molecules and signal transduction 
have been identified42 in addition to differences in central tolerance mechanisms, 
peripheral T cell function and activation, cytokine production and homeostatic 
proliferation in disease pathogenesis.3 These findings strongly implicate the cellular 
immune system in disease pathogenesis. 
 
1.8 CD8+ T cells in Multiple sclerosis plaques 
In addition to GWAS studies, there is convincing neuropathological evidence for the 
role of CD8+ T cells in the pathogenesis of MS. CD8+ T cells are not usually present in 
significant numbers in normal central nervous system tissue.46 Although the MS plaque 
comprises several different cell types including T cells, activated macrophages and 
microglia,47 CD8+ T cells are the most predominant immune cell present (Figure 1.8). 
This was first demonstrated in the 1980s by Booss et al with CD8+ T cells outnumbering 
CD4+ T cells in the CNS from MS patients, with numbers not affected by disease 
duration, speed of evolution or immunosuppressive therapy.48 Furthermore, a few 
years later, perivascular cuffs around MS lesions were shown to contain up to fifty 
times more CD8+ than CD4+ T cells, as well as CD8+ T cells predominating in normal 
appearing white matter.49 This cellular discrepancy has further been demonstrated in 
active MS lesions where the CD4+:CD8+ ratio is approximately 1:3.47 This reverses the 
usual CD4+:CD8+ ratio of 2:1 in normal blood, and 3:1 to 6:1 ratio in CSF.50 More recent 
studies have confirmed these findings using modern techniques including single cell 
analysis.51-54 In addition to white matter, CD8+ T cells are also found in early cortical 
lesions.55  
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Figure 1.8. Lymphocytic perivascular infiltrate in the human forebrain meninges. Staining of CD20 (top 
right), CD4 (bottom left) and CD8 (bottom right). Image courtesy of Dr Owain Howell and Prof Richard 
Reynolds (unpublished). 
 
1.9 Interaction of CD8+ T cells with MHC class I  
Although there is evidence that CD8+ T cells are present in MS lesions, in order for 
CD8+ T cells to interact with host antigen, MHC class I molecules need to be present to 
allow antigen presentation. Normally neurons and oligodendrocytes only express low 
levels of MHC class I constitutively, while astrocytes, microglia, blood vessel 
endothelial cells, and bone marrow derived-APC (BM-APC) do express MHC class I 
constitutively but do not synthesise myelin antigens.46, 47, 56-58 However, BM-APC and 
blood vessel endothelial cells can cross-present exogenously synthesised proteins on 
MHC class I molecules,59-61 making them the most likely candidates to be presenting 
myelin peptides.1 In addition, although not constitutively expressing MHC class I, 
oligodendrocytes can express MHC in response to IFN-gamma56, 58, 62, 63 and therefore 
CD8+ T cells may be able to target oligodendrocytes once inflammation begins.1  
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In support of this, upregulated MHC class I antigens on neurons, axons, astrocytes and 
oligodendrocytes in acute, chronic, active MS and inactive MS lesions have been 
shown to correlate with disease severity and lesion activity making these cells 
potential targets for pathogenic CD8+ T cells.56 In addition, CD8+ T cells interact with 
antigen-presenting cells (APCs) at the margin of chronic and active lesions64 and acute 
axonal injury has been correlated with the number of CD8+ T cells and macrophages 
present.65, 66 CD8+ T cells have also been shown to directly damage CNS target cells,67-72 
including axonal transection,69 which has been observed in MS lesions.73 Damage may 
also occur through collateral bystander damage.74 CD8+ T cells are able to exert their 
cytotoxic effects against neuronal cells, with levels of granzyme A and B increased in 
the CSF during acute relapse75 and granzyme B expressing CD8+ T cells found in close 
proximity or attached to oligodendrocytes or demyelinated axons.1 In contrast to 
MHCI expression, only microglia when stimulated in vitro express MHC class II 
molecules perhaps making them unlikely to be the sole driver of disease.76  
 
1.10 T-cell trafficking into the central nervous system 
In order for CD8+ T cells to exert their effect in the CNS, they need to be able to traffic 
from the blood into the CNS. As previously discussed, this may occur through three 
possible routes. These include trafficking from blood to the CSF across the choroid 
plexus, from blood to the subarachnoid space through meningeal vessels, and from 
blood to parenchymal perivascular spaces.25, 77  
 
It has recently been shown that T cell trafficking may be influenced by the levels of 
TWIK-related potassium channel-1 (TREK1), with downregulation of TREK1 causing 
increased migration of immune cells and upregulation blocking it.78 The α-4 integrin of 
VLA-4 has also been shown to be involved in the recruitment and passage of CD8+ T 
cells across the BBB,79 with its relevance demonstrated by the effectiveness of 
natalizumab, a monoclonal antibody used in the treatment of MS. Natalizumab targets 
the α-4 integrin and thus prevents cell migration.80 A recent study has also highlighted 
a role for P-glycoprotein, a transporter that influences CD8+ T cell migration across the 
BBB by regulating endothelial C-C chemokine ligand 2 (CCL2), a chemokine involved in 
cell migration.81 Mice lacking P-glycoprotein or CCL2 showed significantly reduced 
CD8+ migration into the brain.81, 82 Melanoma cell adhesion molecule (MCAM) has 
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been shown to be expressed by effector CD8+ T cells and is upregulated during MS 
relapses. Crucially, blockade of MCAM restricts the transmigration of CD8+ T cells 
across the BBB in vitro and reduces neurological deficits in vivo in different 
experimental autoimmune encephalomyelitis (EAE) models.83 Junctional adhesion 
molecule-like (JAML) has also recently been demonstrated to be upregulated in MS 
patients at the BBB with monocytes and CD8+ T cells with migratory capacity 
compromised when JAML was blocked.84 In addition, under inflammatory conditions, 
CD8+ T cells have been shown to express vascular endothelial growth factor (VEGF), 
which promotes BBB permeability.85 Recently, α4β1-integrin has been shown to be 
involved in CD8+ T cell interaction with BBB endothelium86, and MHCI expression on 
BBB endothelial cells has also been shown to be important for CD8+ T cell trafficking in 
the CNS.59 Once migrated across the BBB into the CNS87 CD8+ T cells follow a reticular 
system of fibres, which is induced by inflammation to guide trafficking.88 CD8+ T cells 
have also been shown to be able to induce disruption of the BBB.89 
 
1.11 CSF-resident T cells  
Whole CSF from healthy individuals contains between 175,000 and 500,000 leukocytes 
- approximately 1,000 to 3,000 per ml.50, 90 Although lymphocytes predominate, 
erythrocytes, monocytes and granulocytes are also present to a lesser extent.90 
Similarly, T cells are the most predominant cell type found in the CSF of patients with 
MS, other inflammatory and non-inflammatory neurological diseases (NIND) and in 
healthy controls.91 In particular, CD4+ T cells outnumber CD8+ T cells91, 92 with an 
increased CSF CD4/CD8 ratio seen in MS and inflammatory neurological diseases 
compared with non-inflammatory disease93, 94 and a significant increase of CD4+ T cells 
in CSF compared with controls.95 The immunophenotype of these CSF-resident cells in 
MS has been further characterised in several studies although results are inconsistent 
and the difficulty in obtaining CSF from healthy volunteers in some cases makes 
interpretation difficult.  
 
Expression of CCR7, a chemokine receptor that helps recruit T cells to the lymphoid 
system, alongside the naïve cell marker CD45RA helps to identify naïve 
(CD45RA+CCR7+), central memory (CD45RA-CCR7+), effector memory (CD45RA-CCR7-) 
and effector memory-RA (CD45RA+CCR7-) T cells.93 CD45RO can also be used instead of 
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CD45RA.96 In previous studies, effector memory CD4+ and CD8+ T cells have been 
demonstrated to be the predominant CSF-resident population in MS in some studies79, 
93, 97 although memory, and specifically central memory T cells were the dominant 
population in others.50, 91, 98-102 Central memory T cell populations have also been 
shown to be the predominant T cell population in control populations.50, 98, 99, 103  
 
Interestingly, although effector memory or central memory T cells have been shown to 
be enriched in MS CSF, this seems not to be exclusive to this group of patients. For 
example, Mullen et al demonstrated that both patients with MS and patients with 
other inflammatory CNS disorders had a higher percentage of effector memory T cells 
in the CSF compared with non-inflammatory controls.93  
 
Giunti et al demonstrated a similar observation albeit with central memory cells being 
increased in the CSF of patients with MS and other inflammatory neurological 
diseases.98 Perhaps more strikingly, Kivisakk et al showed an enrichment of central 
memory CD4+ and CD8+ T cells in the CSF of patients with non-inflammatory 
neurological disorders with no difference in MS CD4+ T cells when compared with 
NIND.50, 99 Similarly in a relatively large study by de Graaf et al on patients attending 
for routine surgery, a predominance of central memory T cells was observed in CSF-
resident CD4+ and CD8+ T cells.103 Svenningsson et al91 did not show any differences 
between MS patients, other neurological disorders (OND) or healthy volunteers, where 
the majority of CSF-resident T cells were shown to be of memory phenotype 
(CD45RO+). Other studies have shown differences between MS CSF and controls97, 101, 
102 or been hampered by the lack of control CSF.79, 100 In another recent study 
investigating the phenotype, function and reactivity between peripheral blood, CSF, 
normal appearing white matter (NAWM) and white matter lesions (WML) in 27 
patients with MS,104 central memory T cells predominated in the CSF and effector 
memory T cells were enriched in the NAWM and WML. Where no differences have 
observed between MS patients and controls, it has been suggested that this is 
consistent with general CNS immune surveillance.91  
 
Other T cell subtypes have also been studied in MS, with CD4+ and CD8+ Tregs 
increased105, 106 and decreased107 respectively when compared with peripheral blood, 
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with CD8+ Tregs decreased during relapse.108 In addition, regulatory CD4+CD25+ CSF-
resident T cells have been shown to be increased in MS patients compared with 
controls109 and can increase during relapse.110 
 
Interestingly, a recent study looking at 14 different immune cell subtypes in blood and 
CSF in a variety of different inflammatory and non-inflammatory neurological disorders 
concluded that there is a poor correlation between blood and CSF immune cells and 
therefore inferences about disease pathogenesis cannot simply be made by studying 
the peripheral compartment.111 
 
Markers of T cell migration have also been studied in MS. Expression of CCR2 on CD4+ 
and CD8+ T cells has been shown to be significantly increased in CSF from MS patients 
compared with inflammatory neurological disease controls.112 In addition, CCR2 and 
CCR5 have been shown to enriched in the CSF compared with blood in patients with 
MS.113 CSF CD4+ and CD8+ T cells have been shown to express higher levels of CCR5 
and CXCR3 as compared with blood in patients with MS114, 115 although the percentage 
of CSF CD8+ CXCR3 cells has been demonstrated to be decreased during relapse.116 
Magnetic resonance imaging (MRI) disease activity has also been shown to be 
associated with an increase in CXCR3 positive CSF-resident T cells.117 Intercellular 
adhesion molecule (ICAM)-1 and 3 have also been shown to be increased and 
decreased respectively in CSF-resident T cells in MS patients during remission 
compared with relapses.118, 119 Lymphocyte function-associated antigen 1 (LFA-1) has 
also been shown to be enriched in CSF-resident T cells compared with blood in 
patients with MS.91 The lack of control CSF in many of these studies however, limits 
the significance of these findings.  
 
1.12 Clonal expansion of CD8+ T cells 
There is a growing body of evidence that CD8+ T cells demonstrate clonal expansion in 
different tissue compartments in patients with MS. In an early study, Oksenberg et al 
demonstrated restricted expression of T cell TCRVα gene expression in brain lesions 
from 3 patients with MS, not observed in control brains.120 Further to this, oligoclonal 
T cell clones were observed in the CSF and blood of patients with MS, which in some 
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cases were identical.121 Other early studies demonstrated a bias for particular TCRVb 
gene rearrangements in MS patients.122, 123  
 
Babbe et al subsequently demonstrated oligoclonal repertoires of CD8+ T cells (not 
observed in the CD4+ compartment) from single cell analysis of brain lesions in 2 
patients with MS. Interestingly, the same clonal expansions were seen in the blood at 
two separate time points in one patient.51 In a follow-up study, the same clonal 
expansions seen in the brain were also observed in the CSF and blood, with one 
sample taken 7 years after the original brain biopsy.54 Gestri et al also found 
oligoclonal T cell expansions in MS and other neurological disorders.124 Muraro et al 
analysed TCRVb usage in blood and found that expansions of TCRVb genes in MS 
patients were significantly more frequent than in controls, were predominantly 
oligoclonal and were significantly correlated with inflammatory disease activity 
detected by MRI.125 Matsumoto et al demonstrated TCRVb expansions in blood 
compared with controls and also in CSF, although no control CSF was available.126  
 
Complementarity determining region 3 length distribution (CDR3-LD) alteration has 
also been shown to be significantly higher in MS patients compared with controls and 
correlates with lesion activity on MRI.127, 128 A change in the expression of TCRVb has 
also been shown to be different when taken during relapse or remission.129 Jacobsen 
et al, studying TCRVb usage in blood and CSF from 36 MS patients also demonstrated a 
skewing of the CD8+ CSF repertoire in MS patients although no difference was seen in 
the peripheral blood repertoire between patients and controls. Of note, no control CSF 
was available in this study for comparison.130 A further study of 4 MS brains has 
demonstrated identical T cell clones detected in separate brain regions including 
normal appearing white matter and were unique for each patient.52 CDR3 regions also 
contained silent mutations suggesting that these clones had responded in response to 
a particular antigen. In a more recent study of TCRVb clonality in blood, CSF and brain 
from 3 patients with MS, CD8+ T cells clones were shown to exhibit strong sharing 
between the 3 compartments, especially between the CSF and brain lesions.53 Again, 
control samples of blood only were available for comparison. 
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Although these studies make a convincing case for CD8+ T cell clonal expansion being 
pathogenic, other studies perhaps suggest caution in over interpreting these data. 
Early studies demonstrated no oligoclonal expansions in CSF-resident T cells in 2 MS 
patients,131 and a polyclonal repertoire seen in active MS plaques.132 In addition, 
although TCRVb usage was shown to be skewed in blood, this was not observed in CSF 
or brain in another study.133 Gran et al also demonstrated TCRVb skewing that was 
present in MS patients and controls, with MS TCRVb expansion returning to normal 
when analysed at a second time point.134 In a separate study, the TCR Vb5-JB and TCR 
Vb17-JB repertoire showed a less diverse pattern in the CSF samples compared with 
blood not just in MS but also in patients with other neurological diseases.135 In an 
interesting twin study of blood, a Gaussian distribution was observed in CD4+ T cells 
with widely skewed TCR spectratypes in the CD8+ T cell population. However, no 
correlation was found between oligoclonality and disease, with sequencing revealing 
shared TCRs between intra- and inter-pair twin members. The authors suggest that this 
may be a ‘MS predisposing trait’.136 Clonal dominance has also been shown within PLP-
specific CD8+ T cells in MS, although clonal dominance in MBP-specific CD8+ T cells was 
only demonstrated in healthy controls, not seen in MS.137 Another recent study using 
deep sequencing technology demonstrated a significantly higher frequency of clonal 
expansions in MS blood and CSF compared with controls, although cells were not 
sorted into CD4+ and CD8+ populations.138 
 
Although these studies suggest that CD8+ T cell clonal expansion is pathogenic, further 
evidence is required before this is definitive. In particular, the main limitations of all 
the studies performed on CD8+ T cell oligoclonality is either the lack of controls entirely 
or if present, the lack of access to CSF and brain samples to compare the CD8+ T cell 
repertoire.51, 53, 54, 127, 130 It is also of note that CD8+ T cell clonal expansions are thought 
to be a common feature of the normal human T cell repertoire,139 and may be 
important for CNS immune surveillance.52 CD8+ T cell clonal expansion also occurs with 
increasing age140, in particular in response to chronic cytomegalovirus infection.141 
Clearly this area needs further exploration to understand the relevance of clonal T cell 
expansions in MS and if pathogenic then it will be important to identify the antigenic 
target of these cells in order to develop targeted therapeutics. 
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1.13 Antigenic targets of CD8+ T cells in vitro  
Despite candidate proteins being identified in vitro, the antigenic trigger and 
pathogenic target of CNS infiltrating CD8+ T cells remains unknown. Several candidate 
target proteins have been identified with autoreactive CD8+ T cells being shown to be 
induced by myelin derived peptides; myelin-basic protein (MBP),142 proteolipid protein 
(PLP), myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein 
(MOG),63, 143 glial fibrillary acidic protein (GFAP)144 and transaldolase (TAL) a peptide 
expressed in oligodendrocytes.145 Furthermore, autoreactive CD8+ T cells induced by 
PLP have also been shown to cross-react with an environmental organism146 and a viral 
infection has been shown to activate CD8+ T cells, whose TCRs are also capable of 
recognising MBP.32 Ji et al demonstrated that the expression of dual TCRs allowed 
activation by a viral antigen and subsequent recognition of MBP.32 Autoreactive CD8+ T 
cells specific for apoptotic epitopes (apoptotic T cells) have also been shown to be 
present at significantly higher frequencies in the blood and CSF of patients with MS, 
with a strong potential to produce IFN-γ or IL-17.147 Perhaps mitigating against a 
myelin antigen being the cellular target is that the frequency of myelin-reactive T cells 
has been shown to be the same in MS patients and controls,143 although other studies 
have shown an increased number of these cells which are of an activated/memory 
phenotype.148 A recent study, albeit with small patient numbers, did not demonstrate 
any substantial CD8+ T cell activity to candidate MS antigens.149 
 
In addition to the antigenic target of CD8+ T cells in MS, there is debate about whether 
a pathogenic trigger exists and if so, what it is. Epstein-Barr virus150, 151 and human 
herpes virus-6 (HHV-6)152 have been suggested as possible candidates, but no 
definitive link has as yet been proven. 
 
With regard to EBV, in a recent review of systematic reviews, a biomarker of EBV 
infection (anti-EBV nuclear antigen-1 (EBNA) IgG seropositivity) and a history of 
infectious mononucleosis (in addition to smoking) showed the strongest consistent 
evidence of association of developing MS.153 Interestingly, although EBV infection is 
common in healthy controls (85-95%), EBV seronegativity in MS is rare.154 MS risk has 
also been shown to increase with elevated serum anti-EBNA titres.155 With regard to 
CSF, studies have mostly shown higher levels of CSF antibodies that react to EBV 
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antigens compared with controls,156-159 although these findings are not universal.160 
The presence of EBV DNA itself in CSF has only been demonstrated in one MS 
patient.161, 162 
 
An increased frequency of EBV-reactive CD8+ T cells has been observed in MS 
patients163, 164, and in clinically isolated syndrome (CIS)165-167. In contrast, other studies 
have demonstrated no increase in the frequency of EBV-reactive CD8+ T cells in either 
CIS or MS.168, 169 The CD8+ T cell response to EBV has been shown to be dysregulated, 
with a lower response seen in patients with MS.164, 170, 171 The presence of EBV in MS 
brains is controversial with its presence172, and absence both being reported.162, 173, 174 
A recent study has also demonstrated brisk white matter lesion-derived T cell 
reactivity (mainly CD8+) towards autologous EBV infected B cells.104 
 
1.14 CD8+ T cell driven animal models of MS 
Multiple animal models for MS exist but no single model demonstrates the 
inflammatory mechanisms and neurodegeneration seen in MS in their entirety.175 
Experimental autoimmune encephalomyelitis mediated by class II-restricted, MBP-
specific CD4+ T cells is the most widely used, although the phenotype is less diverse 
than that seen in humans.176 It has only been in the last 15 years that CD8+ T cell driven 
mouse models for MS have been developed. 
 
Rivera-Quinones et al were the first to demonstrate the importance of CD8+ T cells in 
causing demyelination, with MHC class I deficient mice retaining neurological function 
in a Theiler's murine encephalomyelitis virus (TMEV) model of MS.177 An anti-CD8 
monoclonal antibody in this mouse model also resulted in less meningeal inflammation 
and fewer demyelinating lesions in the spinal cord.178 In 2001, Sun et al induced EAE 
with MOG-specific CD8+ T cells, which was more severe and permanent than with 
MOG injection alone. Interestingly, these CD8+ T cells were not pathogenic in the 
absence of beta-2 microglobulin, a component of MHC class I molecules.179 These 
findings were later confirmed with CD8+ T cells shown to produce IFN- γ.180 In the same 
year as Sun et al, a different group similarly induced EAE but with MBP-specific CD8+ T 
cells with clinical features more similar to MS than that seen with CD4+ T cell induced 
EAE. In this study, co-administration with anti-IFN γ abrogated disease severity.181 
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Since these initial investigations, subsequent studies have focused on CD8+ T cell 
responses to epitopes expressed by oligodendrocytes. Saxena et al produced a 
transgenic mouse model with haemagglutinin (HA) expressed exclusively by 
oligodendrocytes. Transfer of pre-activated HA-specific CD8+ T cells led to 
inflammatory lesions in the optic nerve, spinal cord and brain with focal loss of 
oligodendrocytes, demyelination and microglia activation similar to that observed in 
MS pathology. Again in this study activated CD8+ T cells produced IFN- γ in addition to 
granzyme B.182 In a similar model with ovalbumin (OVA) expressed by 
oligodendrocytes, OVA-specific CD8+ T cells developed spontaneous EAE with 
demyelination and infiltrated lesions, a response exacerbated by the addition of IFN- 
γ.183 Blockade of the OVA-peptide/MHCI complex prevented disease development.184 
Humanised mouse models, including that by Friese et al discussed in section 1.7 have 
also been developed, further implicating a role for CD8+ T cells in disease 
pathogenesis.44, 185 Experiments in TMEV have also demonstrated that virus specific 
CD8+ T cells secreting perforin can induce CNS vascular permeability.186 CD8+ T cells 
can also cause demyelination and axonal damage in a living brain tissue system.74 CD4+ 
T cell mediated CNS autoimmunity has also been shown to lead to determinant 
spreading to myelin-specific CD8+ T cells.187 
 
1.15 IL-17 producing CD8+ T cells in MS 
Several studies have suggested a role for IL-17 producing CD8+ T cells in MS 
pathogenesis. In a study by Tzartos et al on brain tissue, both CD4+ and CD8+ T cells 
were shown to express IL-17 in active and chronic active lesions, with expression being 
lower in chronic inactive lesions and in NAWM.188 IL-17 producing CD8+ T cells have 
also been shown to be present at higher percentages in the blood of MS patients 
during relapse than controls189 and are required for Th17 induction of EAE in mice.190  
 
A distinct subset of CD8+ T cells in humans that produce IL-17 has been discovered to 
express CD161.191 In MS patients compared with controls, an enrichment of 
CD161+CD8+ T cells has been shown and these cells are also detectable in brain 
immune infiltrates, capable of producing IFN-γ.192 CD161+CD8+ T cells are dominated in 
peripheral blood by mucosal-associated invariant T (MAIT) cells,193 which are 
responsible for elimination of microbes through the MHC-class I related protein I 
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(MR1)193 and have been shown to be associated with some human autoimmune 
diseases.194 The role of MAIT cells in MS is still unclear195, 196 but they have been 
observed in MS brain lesions.197, 198 Other IL-17 producing CD8+ T cell subsets have also 
been identified such as those expressing MCAM.199 Although the significance to clinical 
disease of these CD8+ T cell subsets is still to be determined, targeting IL-17 producing 
CD8+ T cells may be a candidate for future therapeutics.200 
 
1.16 Regulatory CD8+ T cells (CD8+ Tregs) 
The main role of regulatory T cells (CD8+ Tregs) is to maintain immunological tolerance 
against self-antigens.201 CD8+ Tregs have stimulated considerable interest in a wide 
range of autoimmune disorders, and evidence in MS suggests that these cell 
populations may be important in regulating disease pathogenesis.202, 203  
 
The first animal models seemed to show a regulatory function for CD8+ T cells,204-206 
with the mouse protein Qa-1 (HLA-E in humans)207, 208 and CD8+CD28- T cells playing a 
role in disease suppression.209 Interaction of Qa-1 with CD94/NKG2A on CD8+ T cells 
downregulates their suppressive effects with specific disruption of this interaction 
enhancing suppression and preventing EAE induction.210 In support of this, a HLA-E 
restricted CD8+ T cell population expressing an increased level of CD94/NKG2A has 
been isolated from MS patients during exacerbations211 and HLA-E expression is 
upregulated in T and B cells from MS patients. In addition, significantly increased HLA-
E expression has also been observed in white matter MS lesions.212 Interestingly, in Qa-
1 deficient mice, CD4+ T cells were resistant to the effects of CD8+ T cell suppressor 
activity and increased susceptibility to EAE.207 Further evidence for CD8+ Tregs has 
been demonstrated by MOG-specific CD8+ T cells transferred from C57BL/6 mice, 
regulating disease via suppression/killing of CD4+ T cells.213 Several new regulatory 
subsets of CD8+ T cells have also been discovered in recent years, including CD8+/LAP+ 
cells214 and CD8+/CD122+ cells215 from MS animal studies and CD8+/CD161-/CD56+ T 
cells in vitro.216 The importance of CD8+ Tregs has also been demonstrated in clinical 
studies. 
 
CD8+ Tregs have been found in patients with MS, in whom HLA-E-restricted CD8+ T 
cells display a less regulatory phenotype than those in healthy individuals.217 A 
 26 
deficiency of CD8+ Tregs has also been observed during clinical relapse with an 
increase in numbers during recovery.218, 219 Similarly, neuroantigen-specific CD8+ T cells 
may have less suppressive capacity during relapses.218 CD8+ Tregs expressing HLA-G 
have also been recognised, with reduced levels associated with post-partum 
relapses.220, 221 MRI supports the evidence for a role for CD8+ Tregs with increased 
radiological lesion load negatively correlated with the number of CD8+ T cells in 
peripheral blood in MS patients.222 CD8+ Treg regulatory function is mediated by direct 
killing of activated CD4+ T cells or by secretion of immunosuppressive cytokines such as 
IL-10 and transforming growth factor-β.34 Interestingly, it has been suggested that 
Tregs may not be important for CNS protection during homeostasis but once tolerance 
is broken are required to re-establish homeostasis in the CNS.16 
 
1.17 The role of CD4+ T cells in MS pathogenesis 
CD4+ helper T cells interact with MHC class II molecules on antigen presenting cells and 
exert their effect by the release of cytokines, which act on target cells.12 Although this 
thesis will focus primarily on CD8+ T cells, it is worth noting the evidence for the role of 
CD4+ T cells in MS disease pathogenesis. As discussed in section 1.7, the genetic 
association with DRB1*1501 and other immune system genes supports the role of 
CD4+ T cells in MS pathogenesis.42 
 
The differentiation of naïve CD4+ T cells is determined by the exposure to different 
cytokines secreted by dendritic cells, which are APCs as well as cells of the innate 
immune system.223 In the presence of IL-12, naïve CD4+ T cells differentiate into IFN-γ 
secreting Th1 helper cells. If IL-23 predominates then IL-17 secreting Th17 cells 
predominate. When these cell types are activated in autoimmune disease, the 
production of pro-inflammatory effector cytokines is thought to be deleterious.223 
 
The current understanding of the role of Th1 and Th17 cells relates to the pathological 
mechanisms discussed in section 1.5. Activation may occur in the periphery223 with 
subsequent migration across the BBB into the CNS. In response to CNS antigens they 
are reactivated, which in turn induces an inflammatory response.223 Pro-inflammatory 
cytokines induce macrophage and microglial activation, which leads to the production 
of other pro-inflammatory mediators. Then the production of oxygen and nitric oxide 
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radicals lead to the pathological hallmarks of MS – demyelination and axonal loss.224, 
225 
 
Both Th1 and Th17 cells have been shown to be present in the brain and plaques in MS 
patients226, 227 and knocking out these genes in mice228, 229 or administering anti IL-17 
or IL-23 antibodies suppresses disease activity.230, 231 In clinical studies, the number of 
Th17 cells have been found to be increased in the blood of MS patients232 and during 
relapse compared to remission.233 Similarly, the number of Th17 cells in the CSF has 
also been shown to be increased during relapse.234 Clearly therefore, there is evidence 
that CD4+ T cells have a central role in MS pathogenesis but further discussion of this is 
outside the remit of this thesis. 
 
1.18 Evidence from therapeutics for a central role for CD8+ T cells in MS 
The majority of patients with MS present at onset with relapsing disease, with 
recurrent episodes of subacute clinical disability due to areas of inflammation and 
demyelination in clinically eloquent areas.235 The main drug treatments or disease 
modifying therapies (DMTs) are therefore aimed at reducing inflammation and in turn 
the relapse rate in these patients. There are currently no neuroprotective therapies 
available. Understanding the mechanisms of action of disease modifying therapy 
demonstrates the importance of CD8+ T cells to disease pathogenesis. 
 
Interestingly, therapies aimed purely at CD4+ T cells have not shown benefit in MS 
patients,236-238 despite showing promise in animal models.239 In contrast, those 
targeting both CD4+ and CD8+ T cells are effective.36 For example, alemtuzumab, an 
anti-CD52 monoclonal antibody, which depletes both CD4+ and CD8+ T cells has been 
shown in clinical trials to be an effective treatment for MS9, 240, 241 as has fingolimod, 
which prevents T cell migration242 and natalizumab, a monoclonal antibody against 
VLA-4.80 Although the mechanism of action of fingolimod, natalizumab and 
alemtuzumab are more direct to CD8+ T cell function, the first-line therapies of 
interferon-β and glatiramer acetate affect CD8+ T cells in more subtle ways and offer 
further insights into disease pathogenesis. The effect of different licensed therapeutics 
on CD8+ T cells will be discussed in more detail below. 
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1.18.1 Interferon-β 
Interferon-β (IFN-b) is an anti-viral treatment,243 which has a modest effect on relapse 
prevention but a relatively small side-effect profile.244 It is thought to modulate 
cytokine levels, affect the expression of MHCII molecules, and stabilize the BBB, 
thereby inhibiting transmigration of autoreactive T cells into the CNS. IFN-b is also 
thought to inhibit T cell activation and proliferation directly.7 Zafranskaya et al 
demonstrated that treatment with IFN-b can restore normal levels of CD45RO+ 
memory T-cells (both CD4+ and CD8+) in the peripheral blood of MS patients and 
reduce CD45RO+ T cell reactivity towards MOG. IFN-b can also suppress the 
proliferation of CD4+ and CD8+ T-cells; and attenuate the production of IFN-γ.7 This 
finding was confirmed in another study with IFN-b also being shown to expand 
numbers of CD4+ and CD8+ Tregs during the first year of IFN-b treatment.245 In 
addition, the frequency of CD8+CD161+ T cells in patients treated with IFN-b have 
recently been shown to be reduced.246 Therefore, this treatment has the ability to 
target both CD4+ and CD8+ T-cell reactivity, possibly by exerting a regulatory effect. 
 
1.18.2 Glatiramer acetate 
Glatiramer acetate (GLA) is a random copolymer of alanine, lysine, glutamic acid 
and tyrosine,247 which along with IFN-β is used as a first line treatment in relapsing-
remitting MS.248 Similar to interferon-β, studies looking at the mechanism of action of 
this drug offer unique insights into MS pathogenesis and in particular a role for CD8+ T 
cells. At a cellular level, the beneficial effect of GA on the course of MS is currently 
hypothesised to be in part due to a Th2 shift induced in GA-reactive CD4+ T cells.249 As 
well as this shift of CD4+ T cell phenotype, CD8+ T cell responses were found to be 
lower in untreated MS patients compared to those treated with GA but upregulation 
of CD8+ T cell responses was seen post-treatment. CD4+ T cell responses however, 
were downregulated suggesting that CD8+ T cells may play a role in regulating the role 
of CD4+ in disease pathogenesis, perhaps by direct cytotoxic killing.250-252  
 
There is differing evidence as to whether GA effects the TCR population in MS patients 
with one study not demonstrating influence on the TCR repertoire in CD8+ 
populations,253 but with another demonstrating that an oligoclonal expansion does 
occur with upregulation of IL-4, IL-5, IL-10 and Transforming growth factor(TGF)-β in 
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the CD8+ subset indicating regulatory potential. However, restoration of the pro-
inflammatory cytokine, TNF-α was also observed.254 Conversely, in a separate study, 
GA treatment suppressed the expression of TNF-α, IL-10 and IL-4.247 As well as 
affecting T cell populations, GA has also been shown to attenuate the profile of cell-
bound adhesion molecules in patients with MS. 255 
 
1.18.3 Other therapies 
Alemtuzumab, an anti-CD52 humanised monoclonal antibody, has recently been 
licensed for the treatment of relapsing Multiple sclerosis in Europe.256 The anti-CD52 
effect of alemtuzumab results in rapid and profound depletion of circulating 
lymphocytes after initial infusion as a result of antibody-dependent cell-mediated 
cytotoxicity.257 Although the exact mechanism of action remains unclear, it is thought 
to be related to remodelling of the immune system,258 rather than immunodeficiency, 
a hypothesis supported first by the lack of disease activity in most patients despite 
normalizing levels of lymphocytes and by the relative lack of opportunistic infections 
seen in treated patients.9, 240, 241 Although exhibiting a degree of individual variability, 
the rate of immune reconstitution is not thought to predict disease activity.259 Clinical 
trials have demonstrated superior efficacy against an active comparator, with 
reduction in annualised relapse rates and sustained accumulation of disability at 3 
years and sustained efficacy at 5 years.9, 240, 241, 260  
 
Natalizumab is reserved for patients with highly active disease, experiencing frequent 
relapses and active inflammation on MRI. It is a monoclonal antibody targeted against 
VLA-4, preventing egress across the BBB.80 Studies of CSF from patients treated with 
natalizumab show a reduction in both CD4+ and CD8+ T cells261 with an increase in 
activated CD4+ and CD8+ T cells in peripheral blood.262  
 
Methylprednisolone, either in oral or intravenous form is used to treat clinical relapses 
in patients with MS.248 Aristimuño et al demonstrated that it causes a reduction in 
activated and effector memory T cells and an increase in naïve and regulatory T 
cells.263  
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Fingolimod, the first licensed oral disease modifying treatment in the United Kingdom 
for MS, available as a second line treatment,264 causes internalisation of sphingosine-1 
phosphate receptors, trapping T cells in lymph nodes and thus affecting T cell 
migration.242 In addition to this mechanism, another separate effect of fingolimod on 
CD8+ T cell function has been demonstrated, with inhibition of IFN-γ and granzyme B 
production in CD8+ T cells.265, 266 In patients taking fingolimod, both CD4+ and CD8+ T 
cell counts are reduced in the peripheral blood, with naïve and central memory T cells 
particularly affected.267 The proportion of CD8+CCR7- cells expressing the CCL2 
receptor, CCR2 are also significantly reduced with more CD27-CD28- (late effector) 
memory cells, which have less expression of CCR2 compared with early (CD27-CD28+) 
effector memory cells. Therefore, fingolimod treatment results in a subset of CD8+ T 
cells with distinct functional migratory properties.268 In addition to its anti-migratory 
effect fingolimod has also been shown to reduce the number of effector T cells 
producing IFN-γ either alone or in combination with IL-17 and to increase the number 
of TReg cells.269 In a separate study by Kowarik et al, fingolimod increased the 
percentage of CD8+ T cells compared to treatment naive patients in the CSF of MS 
patients, although more detailed phenotypes were not examined.270  
 
Teriflunomide, a new oral treatment for relapsing MS has recently been licensed in the 
UK.271 It acts as an inhibitor of dihydroorotate-dehydrogenase (DHODH), a 
mitochondrial enzyme involved in the de novo synthesis of pyrimidines, and which is 
particularly active in proliferating cells.272 It appears therefore to selectively reduce the 
activity of proliferating T and B cells and has been shown to reduce relapse rates by 
approximately one third.273-275 The development of teriflunomide again demonstrates 
that inhibition of both CD4+ and CD8+ T cells produces a clinical benefit in patients with 
MS and provides evidence for their role in disease pathogenesis. 
 
Dimethylfumarate (DMF) is another newly licensed oral medication,276 which acts by 
activating the nuclear factor (erythroid-derived 2)–like 2 (Nrf2) and subsequent 
upregulation of anti-oxidant target genes. This effect then leads to cytoprotection for 
neurons and astrocytes against oxidative stress. It may also be beneficial through 
increasing mitochondrial function.277 Other effects of the drug include an observed 
reduction in circulating CD4+ and CD8+ T cells, although being more marked in the CD8+ 
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compartment.278 In addition, DMF reduces the central and effector memory T cell 
populations279, 280 in peripheral blood with a relative expansion of naïve cells.280 
Interestingly, similar to the effect of natalizumab, DMF has also been demonstrated to 
inhibit expression of α4 integrin on circulating lymphocytes.281 
 
In addition to the established treatments in MS, vitamin D deficiency has been 
postulated to be involved in disease pathogenesis. Interestingly, addition of vitamin D 
to CD8+ T cells of MS patients showed that these cells secreted less IFN-γ and TNF-α 
and more IL-5 and TGF-β suggesting a direct effect of vitamin D on CD8+ T cells.282 
Autologous haematopoietic stem cell transplantation results in the persistent 
depletion of CD8+ MAIT T cells, suggesting an important role in MS disease 
pathogenesis.195  
 
1.19 Discussion and summary 
There is mounting evidence that CD8+ T cells play a role in the complex pathogenesis 
of MS. Initial results from genome wide association studies mainly suggest a protective 
role for CD8+ T cells but subsequent evidence from neuropathological, in vitro and in 
vivo studies have demonstrated a pathological role as well as a regulatory role for CD8+ 
T cells in MS. Firstly, clonal expansion of CD8+ T cells has been shown in blood, CSF and 
brain of MS patients which has not been observed in the CD4+ T cell compartment. 
Secondly, CD8+ T cells outnumber CD4+ T cells in white and grey matter lesions in MS. 
Thirdly, MHCI is expressed by various cells types in the CNS, which have been shown to 
interact with CD8+ T cells resulting in axonal damage. In addition, studies investigating 
the effect of different MS therapies on CD8+ T cell function add further weight to the 
argument for a role for CD8+ T cells in the pathogenesis of MS.  
 
It is clear that in the inflamed CNS of patients with MS, a complex milieu of cytotoxic 
and regulatory CD8+ T cells, CD4+ T cells, B cells and macrophages exists in addition to 
other inflammatory cells and cytokines. Further understanding of the roles and 
interactions of all these cells will be key to understanding the pathogenesis of MS. 
Future therapy may be aimed at CD8+ T cells, either by upregulating regulatory T 
cells,283 targeting pathogenic CD8+ T cells,284 targeting MHC class I/peptide 
complexes,184 or with individualised therapy to epitope-specific T cells. In addition to 
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treating MS, removing select populations of T cells would also mitigate against the risk 
of infections associated with immunosuppressive therapy, such as progressive 
multifocal leucoencephalopathy (PML) associated with natalizumab.285 The key aim is 
clearly to modulate the immune system to an extent that disease activity is controlled 
but so that adverse immunosuppressive events are also minimised.  
 
Despite mounting evidence for the role of CD8+ T cells, the antigenic trigger and target 
antigen in humans is unknown. It is hypothesised that CD8+ T cells may be activated by 
a pathogen and then due to the promiscuous nature of the TCR cause autoimmunity 
by attacking a self-antigen.286 This search is made difficult because of molecular 
mimicry, epitope spreading, bystander activation, and/or dual TCRs.287 Interestingly, 
the frequency of autoreactive T cells to myelin antigens is still debated with some 
studies showing no difference to healthy controls and other studies suggesting a 
contrary view. It is postulated that differences in activation state may therefore 
account for MS disease risk.288 
 
Further studies are clearly required to fully elucidate the role of CD8+ T cells in MS. It is 
still unclear what activates CD8+ T cells in the periphery, what their cellular 
interactions are and how they mediate damage in situ. It is clear however that they 
have a central role in disease pathogenesis and understanding their role may lead to 
future therapeutic drug developments.  
 
1.20 Specific aims of this thesis 
 
Aim 1: Clinical outcomes of MS patients treated with the anti-CD52, lymphocyte 
depleting monoclonal antibody, alemtuzumab. 
The first aim of this thesis was to undertake a detailed analysis of clinical outcomes in 
MS patients treated with alemtuzumab. Although clinical trials performed over a 2-3 
year period demonstrate positive clinical outcomes, ‘real-world’ observational studies 
are required to confirm the duration of this effect and highlight any potential adverse 
events. Because alemtuzumab is an anti-CD52, lymphocyte-depleting agent, beneficial 
long-term outcomes will help confirm the central role of CD8+ and CD4+ T cells in MS 
disease pathogenesis.  
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Aim 2: Perform an in-depth phenotypic analysis of T cell populations in the CSF of MS 
patients.  
Recent advances have extended the boundaries of flow cytometric analysis through 
new developments in instrumentation and fluorochrome technology, enabling the 
simultaneous and independent measurement of up to 18 colour markers.289, 290 
Although previous studies have attempted to analyse the immunophenotype of CD4+ 
and CD8+ T cells of CSF-resident T cells, the results have been inconsistent. The second 
aim of this thesis therefore was to perform an in-depth phenotypic analysis of CSF-
resident T cells in patients with MS. In addition, we aimed to perform a similar analysis 
in patients with idiopathic intracranial hypertension (IIH) and other neurological 
disease (OND) as controls. 
 
Aim 3: Examine the CSF-resident T cell receptor (TCR) repertoire in MS patients and 
identify dominant TCRs. 
Although clonal expansions of CD8+ T cells has been observed in MS, the numbers of 
patients in these studies are small and control populations are either limited or absent 
altogether. I therefore aimed to analyse the TCR usage in CSF-resident T cells in MS 
using a strand-switch anchored RT-PCR approach that enables the quantitative 
characterization of TCR gene usage without bias.291 In addition, cells sorted from IIH 
patients and OND were to be used as control populations. 
 
Aim 4: To identify the pathogenic triggers and antigenic targets of dominant CSF-
resident TCRs. 
To identify the pathogenic triggers and antigenic targets of dominant CSF-resident 
TCRs I aimed to use two different strategies. The first strategy was to perform a TNFα 
capture assay to activate and sort EBV-specific T-cell populations for clonotypic 
analysis.292 Any overlap between TCR usage in the CSF and the peripheral EBV-specific 
repertoire would then be determined. Secondly, I aimed to use combinatorial peptide 
library (CPL) screening286, 293 technology to identify the peptide sequences recognized 
by dominant MHCI-restricted TCRs. Here, the TCR sequences would be built into a 
lentiviral construct and expressed on the surface of primary CD8+ T-cells. 
 
The main focus of this thesis was CD8+ T cells because of the more limited literature  
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regarding the role of these cells in MS pathogenesis. However, results from CD4+ T 
cells were also analysed in parallel. 
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Chapter 2 
 
Materials and methods 
 
2.1 Materials 
 
2.1.1 Buffers and media 
PSG medium: Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, 
Thermofisher, Waltham, MA, USA) with 2mM L-glutamine (Invitrogen, Carlsbad, 
California, USA), 100 units/ml penicillin (Invitrogen, Carlsbad, California, USA) and 1% 
100 μg/ml streptomycin solution (Invitrogen, Carlsbad, California, USA). 
 
R10 medium: PSG medium containing 10% Foetal Bovine Serum (Invitrogen, Carlsbad, 
California, USA). 
 
R2 medium: PSG medium containing 2% Foetal Bovine Serum (Invitrogen, Carlsbad, 
California, USA). 
 
DMEM medium: Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Thermofisher, 
Waltham, MA, USA). 
 
D10 medium: Dulbecco’s Modified Eagle Medium with 2mM L-glutamine (Invitrogen, 
Carlsbad, California, USA), 100 units/ml penicillin (Invitrogen, Carlsbad, California, 
USA), 1% 100 μg/ml streptomycin solution (Invitrogen, Carlsbad, California, USA) and 
10% Foetal Bovine Serum (Invitrogen, Carlsbad, California, USA). 
 
Freezing medium: 90% foetal bovine serum with 10% dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich, Gillingham, UK). 
 
Cytotoxic T lymphocyte (CTL) medium: PSG (22.5 ml), Click’s medium (22.5 ml, Sigma-
Aldrich, Gillingham, UK) with 10% foetal bovine serum. 
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LB medium: 25 capsules of LB-medium (10g Tryptone, 5g Yeast Extract, 10g NaCl, MP 
Biomedicals, Santa Ana, California, USA) was put in 1 litre water and autoclaved at 
121oC.  
 
MACS buffer: Dulbecco’s Phosphate buffered saline (dPBS, Sigma-Aldrich, Gillingham, 
UK) with 0.5% Bovine Serum Albumin (Sigma-Aldrich, Gillingham, UK) and 2 mM EDTA 
(Sigma-Aldrich, Gillingham, UK). 
 
T cell medium: PSG with 10% heat inactivated AB serum (Welsh Blood Service, 
Pontyclun, UK), IL-15 (25 ng/ml, PeproTech, Rocky Hill, NJ, USA), IL-2 (200 iu/ml, 
Pharmacy department, University Hospital of Wales, Cardiff, UK). 
 
Agarose gel: 1% agarose gel was made by combining 1X Tris Acetate-EDTA (TAE) buffer 
(Sigma-Aldrich, Gillingham, UK) with 1g of UltraPure agarose (Thermofisher, Waltham, 
MA, USA) per 100ml buffer (50ml/gel). The gel was then microwaved at 800W for 
approximately 1 minute until the agarose had dissolved and then cooled on ice for 
approximately 2 minutes. The agarose gel was then poured into a gel tank and allowed 
to cool. Solidified gel was covered in 1X TAE buffer. 
 
2.2 Reagents  
 
2.2.1 Cell lines 
C1R-A2 lines were courtesy of Professor Linda Wooldridge (University of Bristol) and 
T2-B7/T2-A2 from Professor Scott Burrows (University of Queensland). 293T cells were 
used courtesy of Sian Llewelyn-Lacey (Cardiff University).  
 
2.2.2 Human antibodies used for flow cytometry 
Antibodies used are outlined in table 2.1. 
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Table 2.1 Antibodies used for flow cytometry of CSF.  
 
2.2.3 Primers 
Primers used are outlined in table 2.2 below; 
 
Table 2.2 Primers used for clonotyping of sorted CSF-resident T cells. 
 
 
 
 
 
Specificity Flourochrome Volume1used1(in1501μL1PBS) Supplier
CD14 V500 1.5)μL BD,)Oxford,)UK
CD19 V500 1.5)μL BD
CD3 APC:H7 4)μL BD
CD8 BV711 1)μL Biolegend,)San)Diego,)USA
CD4 PECy5.5 0.5μL Thermofisher,)Waltham,)USA
CD27) Qdot605 0.5μL Thermofisher
CD45RA ECD 4)μL Beckman)Coulter,)Brea,)USA
CD57 FITC 1μL BD
CD95) PE:Cy5 3μL Biolegend
CCR7 PE:Cy7 3μL BD
CD127 BV421 3μL Biolegend
CD49d APC 3μL Biolegend
PD:1/CD279 PE 5μL BD
Pan)γδ PE 0.5μL BD
TNFα PECy7 15μL BD
CD28 N/A 3μL BD
CD49d N/A 3μL BD
Rat)CD2 PE 2μL Biolegend
Primer&name Sequence
SMARTer(oligo 5’/(AAGCAGTGGTATCAACGCAGAGTACXXXXX
5’(CDS 5’/(T)25VN/3’
Universal&Primer&Mix
Long(Universal(Primer 5'–CTAATACgACTCACTATAgggCAAgCAgTg/(gTATCAACgCAgAgT–3'(
Short(Universal(Primer 5'–CTAATACgACTCACTATAgggC–3'(
MBC2( 5’/tgcttctgatggctcaaacacagcgacct/3’
MAC2 5’/GGAACTTTCTGGGCTGGGGAAGAAGGTGTCTTCTGG/3’
M13F TTT(TCC(CAG(TCA(CGA(C(
M13R CAG(GAA(ACA(GCT(ATG(AC
 38 
2.3 Methods  
 
2.3.1 Patient selection and ethics 
Patients were recruited from the neurology day unit at the University Hospital of 
Wales (UHW), Cardiff. Patients attending for diagnostic lumbar puncture for 
investigation of Multiple sclerosis were consented, in addition to patients being 
investigated or treated for idiopathic intracranial hypertension and other neurological 
diseases. Consent was obtained under pre-existing ethics agreements  - An 
epidemiological study of Multiple sclerosis in South East Wales (05/WSE03/111) and 
Welsh Neuroscience Research Tissue Bank (15/WA/0073). In most cases patients were 
attending for diagnostic investigations and subsequent clinical case note review was 
performed to confirm eventual diagnoses. 
 
2.3.2 Sample collection 
Lumbar puncture was performed in the left lateral position under aseptic technique. 
10 ml cerebrospinal fluid (CSF) was obtained from the L3/4 or L4/5 intervertebral 
space and collected into either a 30 ml universal container or 15 ml falcon tube. 20 ml 
peripheral blood was collected immediately following the procedure.  
 
2.3.3 Isolation of peripheral blood mononuclear cells (PBMC) and 
storage 
Ten millilitres of peripheral blood was carefully layered on top of two 50 ml falcon 
tubes containing 20 ml of histopaque (Sigma-Aldrich, Gillingham, UK) and spun at 2000 
rpm for 20 minutes with the break off. The buffy coat was removed using a pastette 
pipette, washed with 50 ml PSG and spun at 1500 rpm for 10 minutes. The cell pellet 
was then resuspended in 50 ml PSG and centrifuged at 1500 rpm for 6 minutes. The 
resulting cell pellet was resuspended and cells counted manually with a 
haemocytometer.  
 
2.3.4 Freezing of PBMCs and cell lines 
If not used immediately (for Epstein Barr Virus (EBV) B95.8 lymphoblastoid cell line 
generation, see section 2.3.8.1) PBMCs were spun again (1500 rpm for 5 minutes), 
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resuspended in freezing media and aliqouted at 10 x 106 cells/ml. 1ml cryovials were 
frozen slowly in Mr. Frosty (Thermofisher, Waltham, MA, USA) in a -80oC freezer, then 
subsequently transferred to liquid nitrogen for long-term storage. 
 
2.3.5 Thawing of PBMCs and cell lines 
Frozen PBMCs were removed from liquid nitrogen and placed in a water bath at 37oC 
until thawed. Cells were then added to 9ml PSG and centrifuged at 1500 rpm for 5 
minutes. Supernatant was discarded and cells resuspended in 1ml PSG and counted. 
 
2.3.6 Immunophenotyping of CSF-resident T cells 
 
2.3.6.1 CSF preparation 
Within 1 hour of collection, CSF was transferred to the laboratory and centrifuged at 
2000 rpm for 10 minutes. CSF supernatant was collected and 300 μL aliquots stored at 
-80oC. Although the cell pellet was never visible, 50μL PBS was added and cell 
resuspension performed by pipetting. This was subsequently transferred to a FACS 
tube with a pastette pipette. 
 
2.3.6.2 Antibody staining of CSF 
With the light in the CATII safety cabinet turned off, Aqua (Thermofisher, Waltham, 
MA, USA) was reconstituted with 50μL DMSO to a new vial, and then diluted 1 in 40 
with PBS. 8μL of the diluted aqua solution was then added to the cell suspension and 
incubated for 10 minutes at room temperature. Following this time, the following 
antibody panel was added and the cell suspension incubated at 4oC for 20 minutes; 
CD14 V500, CD19 V500, CD3 APC-H7, CD8 BV711, CD4 PECy5.5, CD27 Qdot605, 
CD45RA ECD, CD57 FITC, CD95 PE-Cy5, CCR7 PE-Cy7, CD127 BV421, CD49d APC and 
PD-1/CD279 PE. For some samples, PD-1 PE was substituted for pan γδ PE. Of note, the 
CSF stain for patients LC20552 and LJ20639 used different antibodies for CD127, CD95 
and CD27. For LC20552 – PE, APC and PECy5 respectively; for LJ20639 - Pacific blue, PE 
and PECy5 respectively. In addition, CD49d was not used for these samples. (For a full 
list of antibodies used for each patient, see Appendix, Section 8.1). 
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During cell incubation, compensations were made. Firstly, 8 drops of anti-mouse Ig 
κ/negative control compensation particles (BD, Oxford, UK) were added to 800μL PBS 
in a FACS tube. 50μL of this solution was then added to each individual compensation 
FACS tube. The same amount of corresponding antibody used in the cell stain was then 
added to the relevant tube. Antibodies were left to stain for 10 minutes at room 
temperature when 150μL PBS was then added. For the CCR7 PE-Cy7 compensation 
tube, 50μL of anti-rat Ig κ/negative control compensation particles (BD, Oxford, UK) 
was used instead. 
 
Following 20 minutes incubation at 4oC, 1ml PBS was added to each cell suspension 
tube and then centrifuged for 2 minutes at 2000 rpm. Supernatant was subsequently 
discarded with the tube then blotted onto paper. Cells or beads were then 
resuspended in 100μL PBS and transferred for cell sorting. 
 
2.3.6.3 Flow cytometry and cell sorting 
CD4+ and CD8+ T cells were sorted on a BD FACSAria II (BD, Oxford, UK) into RNAlater 
(Ambion, Thermofisher, Waltham, MA, USA). After sorting, cells were centrifuged at 
13,000 rpm for 2 minutes then stored at -80oC until required. 
 
2.3.7 Clonotyping of sorted CSF-resident T cells 
 
2.3.7.1 mRNA extraction of sorted CD4+ and CD8+ T cells from CSF 
mRNA isolation was performed using Miltenyi Biotec’s μMACS mRNA Isolation kit 
(Miltenyi Biotec, Bisley, UK) in a dedicated RNA laboratory. The worktop was cleaned 
with bleach before use and the worktop, pipettes, pipette tip boxes, magnet, sample 
rack and collection boxes cleaned with RNAase away (Sigma-Aldrich, Gillingham, UK) 
before use. When ready for use, sorted cell samples were removed from -80oC storage 
and left to thaw on the bench. When almost fully defrosted, vials were transferred to a 
centrifuge pre-chilled to 4oC and spun at 15000 g for 7 min. During centrifugation, 
MACS columns were placed in the magnet and lysateclear columns put in plastic 
centrifuge tubes. Following centrifugation, RNAlater was removed, 900 μL lysis/binding 
buffer added and the vial vortexed vigorously for 1 minute. Samples were then spun 
for 2 minutes at 13000 rpm to remove the foam caused by lysing. Lysate was then 
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added on top of the lysate clear column and centrifuged for 3 minutes at 13000 rpm. 
50 μl Oligo(dT) beads were then added to the cleared lysate and mixed by pipetting. 
MACS columns were then rinsed with 100 μl lysis/binding buffer and allowed to run 
through. Lysate (950 μL total) was then applied onto the column and left to run 
through. The column was then washed with 2x 200 μl lysis/binding buffer followed by 
4x 100 μl wash buffer. Elution buffer was heated to 72oC and 27 μl of hot buffer added 
directly to the column to remove wash buffer from the column. RNA was subsequently 
eluted with 30 μl hot elution buffer into a 1.5 ml screw-topped microtube.  
 
2.3.7.2 cDNA synthesis 
cDNA was synthesised using SMARTerTM RACE cDNA Amplification kit (Takara Clontech, 
Saint-Germain-en-Laye, France). Reagents were stored at -20oC and defrosted before 
use. 1 µl 5’CDS (oligo dT primer) was added to a 1.5 ml screw-topped microtube and 6 
µl mRNA added. The remaining mRNA was then stored at -20oC and SMARTer oligo 
thawed out, after storage at -20oC. Samples were then heated to 72oC for 3 minutes, 
then 42oC for 2 minutes. The following reagents were then added to each sample; 
SMARTer oligo (1µl), 5xRT Buffer (2µl), DTT (1µl), dNTPs (1µl), RNase inhibitor (1µl), 
SuperScript II (1µl, Thermofisher, Waltham, MA, USA). RNAase inhibitor and 
SuperScript II were kept at -20 oC until needed for use. Samples were then placed at 
42oC for 2 hours. After 2 hours, 10µL tricine buffer was added with the sample then 
placed at 72oC for 8 minutes. Approximately 24µl of cDNA was made and either used 
immediately for cDNA PCR or stored at –80oC. 
 
2.3.7.3 Amplification of MBC2 (TCR β-chain) or MAC2 (TCR α-chain) gene product 
In a 0.2 ml PCR tube, the following reagents were added for cDNA PCR; sigma water 
(19μl, Sigma-Aldrich, Gillingham, UK), 10x Buffer (5µl), 10x UPM (10µl), MBC2 or MAC2 
primer (1µl, Thermofisher, Waltham, MA, USA), dNTPs (1µl), cDNA (13µl), AdvanTaq2 
(1µl, Takara Clontech, Saint-Germain-en-Laye, France). 13 µl sigma water was used 
instead of cDNA as a negative control. Samples were then placed in a Gene Amp PCR 
thermocycler (Thermofisher, Waltham, MA, USA) and run on the following settings; 
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2.3.7.4 Isolating PCR product by agarose gel electrophoresis 
6µl of 1kb ladder was added to the first lane of each gel and 10µl of 6x TrackIt 
Cyan/Orange Loading Buffer (Sigma-Aldrich, Gillingham, UK) was added to each 
sample. Samples were then loaded onto the gel and run at 65V/180mA (per gel) for 50 
minutes. After 50 minutes, gels were transferred to a blue tip box top and covered 
with the TAE buffer from the gel box. 15µl SYBR Gold (Carlsbad, California, USA) was 
then added to the gel box and placed on a rocker for at least 25 minutes. Gels were 
then visualised under low intensity UV light to identify a band between 500 and 700 bp 
(Figure 2.1). If present, the DNA band was cut out on a UV light box with sterile 
scalpels and placed into 1.5 ml screw-topped microtubes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Isolation of PCR product by agarose gel electrophoresis. Amplified DNA was observed 
between 500 and 700 bp (arrows). 
 
Temperature)(oC) Duration)(seconds) Number)of)cycles
95 30 1
95 5
72 120
95 5
70 10 5
72 120
95 5
68 10 35
72 120
5
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2.3.7.5 Gel extraction of PCR product 
PCR product was extracted and cloned using the TOPO® TA Cloning® Kit for Sequencing 
with One Shot® MAX Efficiency® DH5α-T1R E. coli as per the manufacturers 
instructions (Thermofisher, Waltham, MA, USA). Screw-topped tubes containing gel 
DNA-amplicons were weighed and 2μL NT buffer added for each 1mg of gel. Tubes 
were then placed in a heating block at 50oC for 10 minutes and vortexed every 2-3 
minutes to dissolve the gel. If not dissolved after 10 minutes, the sample was heated 
for longer until no gel was visible. 700µL of the NT solution was then pipetted onto the 
binding column and centrifuged at 11,000 xg for 30 secs. Flow-through was then 
removed from the collection tube by pipetting. This step was repeated if more than 
700µL solution was present. 
 
700μL of NT3 buffer was then pipetted onto the column (after addition of ethanol to 
the NT3 buffer). The column was then centrifuged at 11,000 xg for 30 secs and flow-
through removed by pipetting. The column was then centrifuged again at 11,000 xg for 
1 minute to remove excess ethanol. To finally elute DNA, the column was removed 
from the collection tube and placed in a 1.5 mL screw-topped tube and 30µL of NE 
buffer added directly onto the column and left for 1 minute. The tube was then 
centrifuged at 11,000 xg for 1 minute with the flow-through containing the amplified 
DNA. Extracted DNA was then either stored at -80oC or used immediately for the 
ligation step. 
      
2.3.7.6 Product ligation into plasmid vector 
If frozen, DNA product was thawed to room temperature. 4μL of DNA product was 
then added to a fresh 1.5 mL screw-topped tube. 1μL salt solution was added to the 
DNA product, followed by 1μL linear TOPO vector (stored at -20oC, transferred to ice 
when ready to use and used immediately). Tubes were then mixed gently and 
incubated at room temperature for a maximum of 30 minutes. Following 30 minutes 
incubation, samples were put on ice to stop the reaction then proceeded to bacterial 
transformation. 
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2.3.7.7 Bacterial transformation 
Max Efficiency DH5a Competent E. coli cells were allowed to thaw on ice (1 
tube/ligation sample). Once thawed, 50µL of bacterial cells were added to each 
ligation tube without mixing. Samples were subsequently left on ice for a maximum of 
30 minutes. Samples were then heat shocked at 42°C for exactly 30 seconds and then 
returned to ice for 2 minutes. Next, using sterile technique, 950µL SOC media 
(Thermofisher, Waltham, MA, USA) was added and samples incubated on a 
thermomixer at 37°C, 750rpm for 1.5 hours. 
 
2.3.7.8 Preparation of LB-AIX plates for bacterial growth 
32 capsules of LB agar medium (Sigma-Aldrich, Gillingham, UK) were added to 800ml 
water and placed in an autoclave at 121oC and allowed to cool to ~60oC. 800µl 
ampicillin (100 mg/ml, Sigma-Aldrich, Gillingham, UK) was then added to a final 
concentration of 100 µg/ml. 50mg X-GAL (Invitrogen, Thermofisher, Waltham, MA, 
USA) was then dissolved in 2.5ml of dimethyl formamide (DMF, Sigma-Aldrich, 
Gillingham, UK), with 2ml X-Gal then added. Bacterial medium was then plated out in 
petri dishes at 20ml/dish and allowed to set. Plates were kept at 4oC for long-term 
storage. 
 
2.3.7.9 Plating bacteria 
100-200µL transformed bacteria were transferred to an LB-AIX plate and spread evenly 
with a glass L-shaped spreader after flaming in ethanol. 2 plates were spread for each 
sample. Once spread, plates were put in an incubator overnight at 37oC with 
subsequent white-coloured colonies containing inserts. 
 
2.3.7.10 Colony PCR of inserted CDR3 amplicon 
Polymerase chain reaction (PCR) mix was made with the following reagent volumes 
per plate to be analysed; 10x PCR buffer, 250 µL (Takara Clontech, Saint-Germain-en-
Laye, France); dNTP, 50 µL (Thermofisher, Waltham, MA, USA); M13F, 100 µL 
(Thermofisher, Waltham, MA, USA); M13R, 100 µL (Thermofisher, Waltham, MA, USA); 
Advantage 2 Taq, 5 µL (Takara Clontech, Saint-Germain-en-Laye, France); Sigma water, 
1995 µL (Sigma-Aldrich, Gillingham, UK). Mastermix was poured into a plastic reservoir 
and 25μL/well pipetted into a 96 well plate. Using sterile toothpicks, white colonies 
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were selected and transferred to the 96 well plate (one colony/well). Plates were then 
centrifuged briefly to 600 rpm and PCR performed with the following program; 95°C 
for 30 secs, 57°C for 30 secs and 68° C for 3 mins for 35 cycles. 
 
2.3.7.11 Checking for amplification 
In order to check for amplification following colony PCR, 12 of the 96 PCR products 
were run on a 1% agarose gel (Figure 2.2). 5μl SYBR Safe (Invitrogen, Thermofisher, 
Waltham, MA, USA) was added to a 1% agarose gel (one gel/96 well plate) and 
covered with 1X TAE buffer. Gels were protected from the light whilst being allowed to 
set. 1µL of TrackIt Cyan/Orange Buffer (Sigma-Aldrich, Gillingham, UK) was 
subsequently mixed with 5µL of PCR product from the following wells: A1, B2, C3, D4, 
E5, F6 G7, H8, G9, F10, E11, D12 and added to the gel. The gel was subsequently run at 
65V and 180mA for 30 minutes. After this time, the gel was visualised under UV light 
for bands at approximately 750bp. Following confirmation of amplification, plates 
were prepared for sequencing by diluting the PCR product with 25µL Sigma water 
(Sigma-Aldrich, Gillingham, UK) and 25µL transferred to a new, skirted 96-well plate. 
Plates were covered with an aluminium plate cover, wrapped in clingfilm and stored at 
-80oC until sent for sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Confirming amplification of colony PCR. DNA bands were observed at approximately 750bp 
(arrows). 
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2.3.7.12 Sequencing of plates 
96 well plates were sent to genewiz (South Plainfield, USA) for sequencing. 
 
2.3.7.13 Analysis of sequencing data 
Analysis of sequencing data was performed using sequencher software (Gene codes 
corporation, Ann Arbor, USA) and the IMGT (international ImMunoGeneTics 
information system, Montpellier, France) website. 
 
2.3.7.14. Data processing and analysis 
Following sequencing, data was imported into sequencher and sequence ends 
trimmed. If quality scores for each individual sequence were <50%, data was excluded 
from the analysis. Included data was then converted to TCR sequences using the IMGT 
website and exported into Microsoft Excel. TCRs were then filtered and only ‘in-frame’ 
sequences chosen for further analysis. Once determined, TCR frequencies were sorted 
according to the following hierarchy; (i) frequency count (ii) CDR3 amino acid length 
(iii) Highest TRBV (iv) highest TRBJ. Data analysis was performed in Microsoft Excel and 
Graphpad prism (La Jolla, USA).  TCRs were checked against the IMGT CDR3 expected 
sequences, (Table 2.3)294 and excluded if amino acid sequences were not consistent. 
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Table 2.3. Expected CDR3 region starting sequences for given TRBV genes. 
 
 
 
IMGT%TRBV%gene FR3.IMGT%(positions%66.104) CDR3.IMGT%(positions%105.115)
TRBV2& IRSTKLEDSAMYFC ASSE.......
TRBV341 INSLELGDSAVYFC ASSQ.......
TRBV441 LHALQPEDSALYLC ASSQ.......
TRBV442 TENNSVP.SRFSPECP.NSSHLFLHLHTLQPEDSALYLC ASSQ.......
TRBV443 VENNSVP.SRFSPECP.NSSHLFLHLHTLQPEDSALYLC ASSQ.......
TRBV541& VSTLELGDSALYLC ASSL.......
TRBV543 VSALELGDSALYLC ARSL.......
TRBV544& VNALELDDSALYLC ASSL.......
TRBV545& RQF.PNYSSELNVNALLLGDSALYLC ASSL.......
TRBV546& RFSGHQF.PNYSSELNVNALLLGDSALYLC ASSL.......
TRBV547& QFSGHQF.PNYSSELNVNALLLGDSALYLC ASSL.......
TRBV548& VNALELEDSALYLC ASSL.......
TRBV641 SLRLESAAPSQTSVYFC ASSE.......
TRBV642* GLESAAPSQTSVYFC ASSY.......
TRBV643* GLESAAPSQTSVYFC ASSY.......
TRBV644 LASAVPSQTSVYFC ASSD.......
TRBV645& LLSAAPSQTSVYFC ASSY.......
TRBV646& LELAAPSQTSVYFC ASSY.......
TRBV647& KLESAAPSQTSVYFC ASSY.......
TRBV648& LVSAAPSQTSVYLC ASSY.......
TRBV649 PLRLESAAPSQTSVYFC ASSY.......
TRBV741 FQRTQQGDLAVYLC ASSS.......
TRBV742 TIQRTQQEDSAVYLC ASSL.......
TRBV743 IQRTERGDSAVYLC ASSL.......
TRBV744& IQRTEQGDSAVYLC ASSL.......
TRBV746& QDKSGLPNDRFSAERP.EGSISTLTIQRTEQRDSAMYRC ASSL.......
TRBV747& PDKSGLPSDRFSAERP.EGSISTLTIQRTEQRDSAMYRC ASSL.......
TRBV748 KIQRTQQEDSAVYLC ASSL.......
TRBV749& IQRTEQGDSAMYLC ASSL.......
TRBV9& LSSLELGDSALYFC ASSV.......
TRBV1041 LESAASSQTSVYFC ASSE.......
TRBV1042 LESATRSQTSVYFC ASSE.......
TRBV1043 LESATSSQTSVYFC AISE.......
TRBV1141 IQPAELGDSAMYLC ASSL.......
TRBV1142& IQPAKLEDSAVYLC ASSL.......
TRBV1143 IQPAELGDSAVYLC ASSL.......
TRBV1243* STLKIQPSEPRDSAVYFC ASSL.......
TRBV1244* STLKIQPSEPRDSAVYFC ASSL.......
TRBV1245 ATLKIQPSEPRDSAVYFC ASGL.......
TRBV13 MSSLELGDSALYFC ASSL.......
TRBV14 VQPAELEDSGVYFC ASSQ.......
TRBV15 IRSPGLGDTAMYLC ATSR.......
TRBV16 IQATKLEDSAVYFC ASSQ.......
TRBV17 IHPAEPRDSAVYLY SSG........
TRBV18& IQQVVRGDSAAYFC ASSP.......
TRBV19 VTSAQKNPTAFYLC ASSI.......
TRBV2041 VTSAHPEDSSFYIC SAR........
TRBV2341& ILSSEPGDTALYLC ASSQ.......
TRBV2441 LESAIPNQTALYFC ATSDL......
TRBV2541& LESARPSHTSQYLC ASSE.......
TRBV27& LESPSPNQTSLYFC ASSL.......
TRBV28 LESASTNQTSMYLC ASSL.......
TRBV2941& VSNMSPEDSSIYLC SVE........
TRBV30& SKKLLLSDSGFYLC AWS........
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2.3.7.15 Additional bio-computational analysis  
Further to my original analysis, additional analysis was performed by Dr Vanessa 
Venturi (Infection Analysis Program, The Kirby Insitute, UNSW Austrialia, Sydney, NSW 
2052, Australia) and Dr Adel Rahmani (School of Mathematical Sciences Physical 
Sciences, University of Technology Sydney, 15 Broadway, Ultimo, NSW 2007, 
Australia). Dr Venturi and Dr Rahmani have expertise in using computational biology 
approaches in order to understand immunological data. 
 
2.3.8 Tumour necrosis factor alpha (TNFα) capture assay to determine 
antigen specificity of CSF-resident T cells 
 
2.3.8.1 Generation of Epstein Barr Virus (EBV) B95.8 lymphoblastoid cell lines (EBV-
LCLs) 
When setting up from frozen samples, donor PBMCs were thawed in a water bath, 
added to 9ml R10 and centrifuged at 1500 rpm for 5 mins. Supernatant was discarded 
and cells resuspended in 2ml R10.  1ml was then pipetted into 2 wells of a 24 well 
plate (5x106 cells/well). Epstein Barr Virus B95.8 (European Collection of Authenticated 
Cell Cultures, ECACC, Public Health, Porton Down, UK) was passed through a 0.45 μm 
filter and 1 ml added to each well containing PBMCs. 20 μl (10 μl/ml) ciclosporin (50 
μg/ml, Pharmacy department, University Hospital of Wales, Cardiff, UK) was then 
added to each well and the plate incubated at 37oC for 1 week. After 1 week, 1 ml of 
media was removed and fresh R10 added in addition to a further 20 μl ciclosporin. 
Following this, cells were grown, split and fed as necessary and kept in a T75 flask with 
R10 media. If lines were synthesised from freshly processed PBMCs, 5x106 cells were 
put in one well of a 24 well plate and the same protocol followed. 
 
2.3.8.2 Generation of EBV stimulated T cell lines 
PBMCs were thawed, counted and 2x106 resuspended in 2ml of CTL media in one well 
of a 24 well plate. γ-irradiated (40 Gy), autologous EBV-LCLS were then added at a ratio 
of 40:1 ratio (PBMC:LCLs). After 9-12 days, cells were removed, added to R10 and 
centrifuged at 1500 rpm for 5 mins. Cells were then resuspended in fresh CTL medium 
at 0.5x106 cells/ml and restimulated with irradiated autologous EBV-LCLs at a ratio of 
4:1 (i.e. 1x106:2.5x105 – CTL:EBV-LCLs). At days 13-16, cells were fed with fresh 
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medium containing IL-2 at 50 U/ml. Cells were then stimulated weekly using a 4:1 ratio 
of CTL:EBV-LCLs with twice weekly addition of IL-2. 
 
2.3.8.3 TNFα capture assay 
On the day before the experiment, EBV stimulated T cell lines were restimulated with 
EBV-LCLs at the following ratios in FACS tubes; CTL:LCL 1:1, 1:0 and 1:1 ratio without 
anti-TNFα. To each tube, 10μl (10μM) of TAPI-O (Millipore, Watford, UK) (TAPI-O (1mg) 
reconstituted in 2.19ml of DMSO and 100μl aliquots made) was added. 15μl of anti-
TNFα PECy7 (BD, Oxford, UK) was then added to each FACS tube along with 3μl each of 
CD28 (BD, Oxford, UK) and CD49d (BD, Oxford, UK). Samples were then incubated 
overnight at 37oC. The following day, 1 ml PBS was added to each tube and centrifuged 
at 2000 rpm for 2 minutes. Supernatant was discarded and the wash step was 
repeated. 8μL aqua (diluted in PBS at a 40:1 ratio) was subsequently added to each 
tube and left to incubate for 10 minutes at room temperature. Compensations were 
made as described above in section 2.3.6.2. Samples were stained with the following 
antibodies and incubated for 20 mins at 4oC; CD14, CD19, CD3, CD8 and CD4. After 20 
minutes, 1ml PBS was added and samples centrifuged for 2 minutes at 2000 rpm. 
Supernatant was then discarded and 100μL PBS added. Flow cytometry and cell sorting 
was performed of TNF+CD4+ and CD8+ populations. Following cell sorting, clonotyping 
of these cell populations was performed as previously described. 
 
2.3.9 Cloning of donor TCR and lentivirus synthesis 
 
2.3.9.1 TCR design 
Patient TCR constructs were codon optimised and synthesised by Genewiz Inc (USA). 
Figure 2.3 demonstrates the vector map with TCR and rat CD2 inserts. 
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Figure 2.3. Vector map demonstrating TCR and rat CD2 inserts. Figure courtesy of Dr John Bridgeman. 
 
2.3.9.2 Digest and ligation of donor TCR into pELN 
Donor TCR was used at 0.1 μg/μl. Donor TCR and pELN.003 (James L Riley, UPenn, USA) 
were digested with XbaI (Thermofisher, Waltham, MA, USA) and BamHI enzymes 
(Thermofisher, Waltham, MA, USA) on ice as follows; XbaI 1μl, BamHI 1μl, FD buffer 
2μl, donor TCR 10 μl and 6 μl molecular biology water to make up to 20 μl. For pELN, 
1μl of the plasmid was used with 15 μl water. Digests were performed in PCR tubes at 
37oC for 1 hour. Digest products were subsequently run on a 1% agarose gel with 
donor TCR and pELN.003 plasmid cut out under UV light and gel extracted as per 
section 2.3.7.5 (Figure 2.4). After DNA elution, nanodrop was performed to quantify 
the amount of DNA present. Following this, samples were set up for ligation reactions 
at 3 different vector:insert ratios; 1:0.5, 1:1 and 1:2. Ligase buffer (2 μl, Thermofisher, 
Waltham, MA, USA) and ligase (1 μl, Thermofisher, Waltham, MA, USA) were added 
along with water to make up to 20 μl. Samples were incubated at 4oC overnight. 
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Figure 2.4. Digest of donor TCRs. Lane 3 and 4; donor TCRs (arrows). Lane 5; pELN.003 (arrow). 
 
2.3.9.3 Bacterial transformation of ligation reactions 
4 μl of ligation reaction was added to 45 μl XL10 gold bacteria (Agilent Technologies, 
Santa Clara, USA). Tubes were mixed gently and incubated on ice for 30 mins. Samples 
were then heat-shocked for 30 secs at 42oC followed by 2 minutes. 900 μl SOC media 
was then added and incubated for 1 hour at 37oC with shaking at 225-250 rpm. 
Samples (150 μl) were then spread on plates made as described (2.3.7.8) but without 
XGAL and incubated overnight at 37oC. The following day, 5 separate colonies were 
picked with a pipette tip and added to a 5ml universal container containing 5ml of LB 
media. Prior to inserting in the universal containers, colonies were streaked on a 
separate plate. Universal containers were then placed on a rocker overnight (220 rpm) 
at 37oC and miniprep performed the following day. 
 
2.3.9.4 Miniprep of amplified donor TCRs 
Following overnight incubation, pipettes were removed and universal containers 
centrifuged at 0oC for 5 minutes at 4000 rpm. Supernatant was discarded in bleach 
with the pellet resuspended in 600 μl PBS and added to a 1.5 ml centrifuge tube. A 
miniprep (Zymo Research, Irvine, USA) was performed as per the kit instructions. 100 
μl 7x lysis buffer was added to the centrifuge tube and inverted 4-6 times. Within 2 
minutes, 350 μl neutralisation buffer was added and inverted until the sample turned 
yellow. The tube was then spun at 13,000 xg for 2 mins and 900 μl of the supernatant 
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added to a centrifuge column. The column was then centrifuged at 11,000 xg for 15 
secs with the flow through discarded. 200 μl endo-wash buffer was then added and 
the sample spun at 11,000 xg for 15 secs. 400 μl zyppy wash buffer was added and 
centrifuged at 11,000 xg for 30 secs. Flow through was transferred to a clean tube and 
30 μl zyppy elution buffer added and allowed to stand for 1 min at room temperature. 
Samples were then centrifuged at 11,000 xg for 15 secs to elute DNA. DNA was 
quantified on a nanodrop and sent for sequencing to confirm the presence of 
amplified TCR. 
 
2.3.9.5 Maxiprep of amplified donor TCRs 
After confirmation of the amplified donor TCR, maxiprep (Thermofisher, Waltham, MA, 
USA) was performed as per manufacturers instructions. 5 μl ampicillin was added to 5 
ml LB media in a universal container. From the stored streak plate, the colony 
containing the amplified donor TCR was then picked and added to the container and 
incubated at 37oC during the day on a rocker. At the end of the day, the culture was 
added to 500 ml LB media in a 2L conical flask (with 500 μl ampicillin) and incubated 
overnight on a rocker. Two small and two large plastic pots, lids and rubber seals were 
autoclaved in preparation for maxiprep. Optical density was measured before 
proceeding with maxiprep. 30ml equilibrium buffer was added directly into the 
filtration cartridge inserted in the maxi column. LB media was added to the two large 
autoclaved pots and weighed to within 0.1 g of each other. Samples were centrifuged 
at 4000 xg for 10 minutes with pellets then resuspended in 10ml resuspension buffer. 
10ml of lysis buffer was then added and incubated at room temperature for 5 minutes. 
10ml precipitation buffer was then added and the precipitated lysate transferred to 
the column. The lysate was allowed to filter through the column by gravity flow. Next, 
the inner filtration cartridge was discarded and the column washed with 50ml wash 
buffer. A sterile 50ml centrifuge tube was placed under the filter column and 15ml 
elution buffer added. The solution was allowed to drain by gravity flow and the column 
discarded with the elution tube containing the purified DNA. 
 
To precipitate DNA, 10.5 ml propan-2-ol was added to the eluate and mixed well. The 
tube was then centrifuged at >12,000 xg for 30 minutes at 4oC and the supernatant 
removed. 5ml 70% ethanol was added to the pellet and the tube centrifuged at 
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>12,000 xg for 5 minutes at 4oC and the supernatant removed. The pellet was air-dried 
for 10 minutes and resuspended in 200 μl TE buffer and nanodrop performed. 
 
2.3.9.6 Culture of 293T cells 
When culturing 293T cells, D10 media was used. For feeding, D10 media was removed 
and cells washed with 10ml PBS. 10ml 0.05% Trypsin-EDTA (1X) (Gibco, Thermofisher, 
Waltham, MA, USA) was then added and left for 2-3 mins for cells to disassociate from 
the plastic.  Trypsin was then removed (2ml left behind) and 25ml D10 added. 
 
2.3.9.7 CaCl2 transfection for lentiviral production 
On the day prior to transfection, 15-20 x 106 293T cells were put in a T175 flask. In 2x 
50ml falcon tubes, 1.25ml 1M Hepes buffer (Sigma Aldrich, Gillingham, UK) was added 
and topped up to 50ml with serum free DMEM. Sodium hydroxide (Sigma-Aldrich, 
Gillingham, UK) was added by pastette pipette so that one volume of media was at pH 
7.1 and the other pH 7.9. Both volumes of media were filtered through 0.2 μm filters. 
1M CaCl2 solution was made by adding 50ml water to 7.35g hydrated CaCl2 (Sigma-
Aldrich, Gillingham, UK) and filtered. Aliquots were stored in the freezer (-20oC). 
 
In a 15ml falcon, the following reagents were added; 15 μg pELN lentivirus vector 
(James L Riley, UPenn, USA) containing donor TCR, 18 μg pRSV.Rev, 7 μg pVSVg, 18 μg 
pMDLg/pRRE, pH7.1 media (to make up to 2850 μl – added first) per flask, 150 μl of 
CaCl2 (added last). This solution was vortexed and incubated at 10-30 mins at room 
temperature.295 
 
Old media was removed from 293T cells and 12ml pH 7.9 media gently added. The 
DNA mix was then vortexed briefly and added dropwise to the surface of the media 
then incubated at 37oC. The following day, media was replaced with 20ml D10 and 
returned to the incubator. 48 hours post transfection the media was collected and put 
through a 0.45 μm filter. Supernatant was replaced with 20 ml fresh D10. 72 hours 
post transfection, a second collection of media was performed. Supernatants were 
then centrifuged at 24,000 xg for 2 hours at 4oC. Following centrifugation, the 
supernatant was removed and the pellet resuspended in 1ml T cell medium. Aliquots 
of lentivirus were snap frozen on dry ice and stored at -80oC until further use. 
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2.3.9.8 CD8+ T cell isolation 
PBMCs were prepared as described (Section 2.3.3). CD8+ T cells were then isolated 
from PBMCs by MACS separation as per manufacturers instructions (Miltenyi Biotec, 
Bisley, UK). MACS buffer (80 μl/107 cells) was added to the PBMC cell pellet followed 
by 20 μl CD8 beads/107 cells. Cells were incubated in the fridge for 15 mins. During 
incubation, MACS column was prepared and 500 μl MACS buffer added. Following 
incubation, 4 ml MACS buffer was added and centrifuged for 10 mins at 1500 rpm. 
Supernatant was removed with a pastette pipette and resuspended with 500 μl MACS 
buffer, then added to the MACS column. Following flow through, 3 x 500 μl MACS 
buffer was added. The column was then placed over a universal container and 2 ml 
MACS buffer added. A plunger was then used to push through isolated CD8+ T cells. 
Cells were then centrifuged at 1500 rpm for 5 mins and resuspended in 1 ml T cell 
media and counted. 75 μl of CD3+CD28+ (Thermofisher, Waltham, MA, USA) beads 
were then added and the cell suspension put in 1 well of a 24 well plate and incubated 
overnight at 37oC. 
 
2.3.9.9 Lentivirus transfection of isolated CD8+ T cells 
Following overnight incubation of CD8+ T cells CD3+CD28+ beads, one lentivirus aliquot 
(1ml) was added along with 1 μl/ml (2 μl) of polybreen (Insight biotechnology, 
Wembley, UK).  One week later, lentivirus positive cells were sorted as follows. Cells 
were centrifuged (1500 rpm, 5 mins) and resuspended in 1 ml PBS and added to a 
FACS tube. Cells were further centrifuged (2000 rpm, 2 mins) and the supernatant 
discarded. Cells were stained with the following antibodies; Aqua, CD14, CD19, CD8 
and ratCD2 and incubated at 4oC for 20 mins. Following this, 1ml PBS was added and 
cells centrifuged at 2000 rpm for 2 mins. Cells were then resuspended in 150 μl PBS 
and transferred for cell sorting. Rat CD2 positive cells were sorted into TCM. The 
following day, PBMCs from 3 separate donors were prepared to feed cells. PBMCs 
were separated as described and irradiated for 13 mins at 3000 Rads. Cells were 
mixed, centrifuged (1500 rpm for 5 mins) and resuspended in 5ml TCM. After counting, 
15x106 cells were added to a T25 flask and 20ml TCM added. 20 μl PHA (Thermofisher, 
Waltham, MA, USA) was added to the flask along with the sorted lentivirus positive 
CD8+ T cells. The flask was then incubated at 37oC (flask tilted). After 7 days, CD8+ T 
cells were centrifuged (1500 rpm for 5 mins) and resuspended in 2-3 ml. Cells were 
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counted and resuspended in a 24 well plate at 2x106 cells/well. 14 days after lentivirus 
transfection, cells were prepared for flow cytometry as described to check for purity. 
Cells were either frozen or 10x106 cells resuspended in 5x wells of a 24 well plate in 
TCM. Cells were fed when necessary with fresh TCM. 
 
2.3.10 Sizing scan and combinatorial peptide library (CPL) screen of CD8+ 
T cells expressing dominant CSF-resident TCRs 
 
2.3.10.1 Sizing scan and combinatorial peptide library (CPL) screen 
On day 1, CD8+ T cells were washed in PSG and put in R2 overnight. On day 2, cell 
cultures were set up for sizing scans or CPL screens. 5 μl of each either sizing scan or 
CPL peptide mix (at a concentration of 10mM or 1mM, respectively) per well was 
plated in 96 well round bottom plates (in duplicate).  
 
For the sizing scan, the following mixtures were used to define the MHCI-peptide 
length preference of the donor TCR: X8, X9, X10, X11, X12, and X13 (where X is any of the 
19 proteogenic L-amino acids excluding cysteine; Pepscan, Lelystad, The Netherlands). 
Sizing scan parameters are detailed in the table 2.4. The 8mer CPL was synthesized in 
positional scanning format (Figure 2.5, Pepscan, Lelystad, The Netherlands).35 CPL 
parameters are detailed in Table 2.5.  
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Table 2.4 Sizing scan parameters.293 n indicates the number of degenerate positions. *When mixtures are used at a concentration of 100μM. Figure adapted from 
Ekeruche-Makinde et al.293 
 
 
 
 
 
Table 2.5. CPL scan parameters.293 n indicates the number of degenerate positions; O, fixed sequence position (1 of the 20 proteogenic L-amino acids; O is moved 
systematically through the peptide backbone in a full CPL); X, degenerate position (1 of 19 proteogenic L-amino acids, excluding cysteine); and a, full peptide length. 
*When mixtures are used at a concentration of 100μM. Figure adapted from Ekeruche-Makinde et al.293 
CPL$ID
Sequence$of$position$
one$sublibraries
Total$no.$of$peptides$in$
library$(a$+$19)$×$19n
No.$of$
sublibraries
No.$of$peptides$in$
each$sublibrary$(19n)
Concentration$of$each$
peptide$in$sublibrary*
8mer OXXXXXXX 2.4*×*1010 160 8.9*×*108 1.1*×*10−13*M
Sizing&scan&ID
Sequence&of&sizing&scan&
mixture
Total&no.&of&peptides&in&scan&
mixture&(19n)
Concentration&of&each&peptide&
in&scan&mixture*
8mer XXXXXXXX 1.7)×)1010 5.9)×)10−15)M
9mer XXXXXXXXX 3.2)×)1011 3.1)×)10−16)M
10mer XXXXXXXXXX 6.1)×)1012 1.6)×)10−17)M
11mer XXXXXXXXXXX 1.2)×)1014 8.6)×)10−19)M
12mer XXXXXXXXXXXX 2.2)×)1015 4.5)×)10−20)M
13mer XXXXXXXXXXXXX 4.2)×)1016 2.4)×)10−21)M
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Figure 2.5. Schematic representation of a 8mer combinatorial peptide library (CPL). The 8mer 
combinatorial peptide library contains a total number of 2.4×1010 ((8+19) ×198) different 8mer peptides 
and is divided into 160 different peptide mixtures (or sub-libraries) as indicated. In every peptide 
mixture, one of the 20 natural proteogenic L-amino acids is fixed at one position (circles) but all other 
positions are degenerate (squares), with the possibility of any one of 19 natural L-amino acids being 
incorporated in each individual position (cysteine is excluded). Thus, each library mixture consists of 
8.9×108 (198) different 8mer peptides in approximately equimolar concentrations. Figure adapted from 
Wooldridge et al.35 
 
Target cells were centrifuged at 1500 rpm for 5 mins, counted and resuspended in R2 
to a concentration of 1.3x106 cells/ml. 45 μl (approx. 60,000) target cells were added 
to each well of the peptide plates. Plates were then incubated at 37oC for 1-2 hours for 
peptide pulsing. CD8+ T cells were similarly prepared to a concentration of 6x105 
cells/ml. Following peptide pulsing, 50 μl (approx. 30,000 cells) of CD8+ T cells were 
added to each well. Control wells of T cells only, target cells only and both together 
were also performed, as well as PHA (Thermofisher, Waltham, MA, USA) as a positive 
control. Plates were incubated overnight. For MIP1-β ELISA (Duoset kit, R&D Systems 
Inc. Minneapolis, MN, USA), plates were coated with capture antibody at a 
concentration of 0.9 μg/ml. 50 μl per well was added and the plate incubated 
overnight at room temperature.  
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The following day, 50 μl supernatant was harvested from each well into a new plate 
and diluted in 70 μl R2. The coated plates were next washed 3 times with 200 μl/well 
wash buffer (PBS tween – PBS made by adding one tablet (Oxoid, Thermofisher, 
Waltham, MA, USA) per 100ml water with 0.05% tween 20 (Sigma-Aldrich, Gillingham, 
UK)). Following this, the plate was blotted dry and 150 μl reagent diluent (PBS with 1% 
BSA, (Sigma-Aldrich, Gillingham, UK)) added per well and incubated for a minimum of 1 
hour at room temperature. The plate was washed again and either 50 μl of cell 
supernatant or standards (1000, 500, 250, 125, 62.5, 31.2, 15.6 and 0 pg/ml) added 
and incubated for 1 hr 15 mins at room temperature.  After further washing, 50 μl 
detection antibody (diluted 1 in 200 in reagent diluent) was added to each well and 
incubated for a further 1 hr 15 mins. After this time, plates were washed again and 50 
μl streptavidin-HRP (diluted 1 in 200) added and incubated for 20 mins at room 
temperature being kept away from direct light. After further washing, 50 μl per well of 
colour reagents A & B were added and incubated until blue colour seen (approximately 
20 mins). 25 μl/well of stop solution was added to stop the reaction and plates read at 
450nm on a Biorad iMark microplate absorbance reader (Biorad, Hercules, USA). The 
readouts from the standards were utilised to calculate the concentration of MIP1-β 
present for each well, with the background readout subtracted. N.B. The above 
protocol was used whether performing a sizing scan or peptide library screen. 
 
2.3.10.2 Analysis of combinatorial peptide library screening 
Results from the CPL screen were inputted into the Warwick Systems Biology Centre 
webtool (http://wsbc.warwick.ac.uk/wsbcToolsWebpage/resetpass.php, University of 
Warwick, UK) for peptide identification from CPL screens.296 
 
2.3.10.3 Assessing TCR response against chosen peptides identified by combinatorial 
peptide library screen 
Peptides were chosen based on scores from the CPL screens and for disease relevance 
(Pepscan, Lelystad, The Netherlands). Peptides were first diluted to an 8mM stock and 
then further diluted in PSG to a concentration of 1mM (10-3M). Peptides were then 
diluted to concentrations of 10-4, 10-5, 10-6, 10-7, 10-8, 10-9 and 10-10. 5μl of each 
peptide concentration was then moved to an ELISA plate and made up to final 
concentrations of 10-5, 10-6, 10-7, 10-8, 10-9, 10-10 and 10-11 following the addition of 
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45μl of target cells. MIP-1β ELISA was then set up in duplicate as described in section 
2.3.10.1. 
 
2.3.10.4 HLA typing 
Donor PBMCs were HLA typed at A, B and C loci by Proimmune (Oxford, UK). 
 
2.3.11 TCR V beta staining of peripheral blood 
PBMCs were thawed and centrifuged at 1500 rpm for 5 mins. Cells were resuspended 
in 8ml PBS and divided between 8 FACS tubes. Tubes were then centrifuged at 2000 
rpm for 2 mins and supernatant discarded. 8 μl aqua was then added to each sample 
and incubated for 10 mins at room temperature. After 10 mins, V beta antibodies (A-H) 
(IOTest® Beta Mark, Beckman Coulter, Brea, USA) were added to each of the 8 tubes 
along with the following antibodies (CD14, CD19, CD3, CD8, CD4, CD27, CD45, CD95, 
CCR7, CD127, CD49d) and incubated for 30 mins at 4oC. Following this, 1 ml PBS was 
added to each tube and centrifuged at 2000 rpm for 2 minutes. Supernatant was then 
discarded, 100 μl PBS added and samples analysed on the FACSAria II. The IOTest® 
Beta Mark Kit is a multi-parametric analysis tool designed for quantitative 
determination of the TCRVβ repertoire of human T lymphocytes by flow cytometry. 
Eight vials (labeled A-H) each containing 3 different TCRVβ mAb are used. The first 
mAb within each labelled vial is FITC-conjugated, a second one is PE-conjugated and a 
third one is a mixture of a PE- and a FITC-conjugated form. The 8 vials containing 
mixtures of conjugated TCRVβ antibodies correspond to 24 different specificities 
(about 70% coverage of normal human TCRVβ repertoire). The TCRVβ included in this 
assay are as follows; 4-1 4-2 4-3, 5-5, 28, 3-1, 19, 14, 5-1, 18, 30, 6-5 6-6 6-9, 6-6, 12-3 
12-4, 5-6, 10-3, 20-1, 9, 11-2, 13, 2, 25-1. 
 
2.4 Methods for chapter 3: Treatment of Multiple sclerosis with 
alemtuzumab; an anti-CD52, lymphocyte depleting monoclonal antibody 
 
2.4.1 Patients and data collection 
Patients referred to and assessed in the neurology department at the University 
Hospital of Wales, Cardiff were identified as candidates for treatment with 
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alemtuzumab if they had a relapsing disease course and evidence of aggressive disease 
characterised by a high relapse rate, active disease on cranial MR imaging, rapidly 
accumulating disability, early motor, cerebellar or cognitive dysfunction or 
combinations of these factors, and were considered to have poor prognosis. A smaller 
number of patients were treated locally at regional specialist neuroscience centres in 
Swansea and Bristol following regional network case-based discussions. Patients 
receiving alemtuzumab as part of externally sponsored clinical trials were excluded 
from analysis. 
 
Prior to treatment, all patients had a normal blood count, thyroid function tests, 
routine blood indices and white cell immunophenotyping. At the time of treatment no 
patient had evidence of active infection and treatment during relapse was avoided 
whenever possible. Consent for treatment was obtained and explanation of potential 
risks and benefits provided.  
 
2.4.2 Treatment regimen and adverse event monitoring 
Prior to 2006, patients received an initiation dose of 24–30 mg alemtuzumab 
intravenously per day for 5 days, with 1 g intravenous methylprednisolone given as 
pre-treatment on the first 3 days only in order to ameliorate the expected infusion 
reaction side-effects related to cytokine release.297 After 2006, the daily dose of 
alemtuzumab was reduced to 12 mg. Routine top-up treatment was administered after 
12 months, consisting of 3 daily doses of alemtuzumab with concurrent steroid pre-
treatment. Additional courses were given as indicated after intervals of not less than 
12 months, as a result of one or more of the following factors; (1) disabling clinical 
relapse, (2) evolving disability with or without objective change in EDSS, (3) the 
development of new or enhancing lesions on MRI performed 12 months or more after 
a prior treatment cycle.  
 
A monitoring program for adverse autoimmune events included monthly full blood 
count and urea and electrolytes in addition to thyroid function tests with anti-
thyroperoxidase antibodies at least 6 monthly intervals. Urinalysis was performed 
when indicated or during concomitant illness. Additional tests for relevant 
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autoimmune immune disease(AID)-related antibodies were performed when 
appropriate. 
 
2.4.3 Data analysis 
Patients were identified from a regional clinical database298 and a systematic review of 
notes was performed to validate the dataset. Data was collected on demographics, 
EDSS scores, relapses, adverse events and prior medication use in order for further 
analysis to be performed. Final data capture was performed on 23rd April 2015. 
Retreatment rates, annualised relapse rates (ARR) pre- and post- treatment, disability 
outcomes, adverse events including rates of AID and outcomes of pregnancies were 
investigated. 6-month sustained accumulation (SAD) and reduction of disability (SRD) 
was calculated according to established definitions299 
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Chapter 3 
 
Treatment of Multiple sclerosis with alemtuzumab; an anti-
CD52, lymphocyte depleting monoclonal antibody 
 
Willis MD et al. Mult Scler. 2016;22(9):1215-23 
 
3.1 Introduction 
 
3.1.1 The use of alemtuzumab in Multiple sclerosis 
The range of effective treatments for relapsing MS is rapidly expanding, leading to an 
ever-greater choice for both patients and clinicians. Although the new disease-
modifying therapies have undergone rigorous clinical trials before reaching the clinic, 
post-marketing surveillance and reporting are essential in order to fully understand 
safety and efficacy, and in some cases have been key in modifying use in clinical 
practice. In particular, given the proposed role of CD8+ T cells in MS, studies on the 
effectiveness of therapeutics that affect the function of these cells can offer further 
insights into their role in disease pathogenesis. 
 
Alemtuzumab was first proposed as a treatment for MS in the 1990s.300, 301 Following 
clinical trials demonstrating a dramatic effect on relapse rates, in addition to a positive 
effect on longer-term disability outcomes,9, 240, 241 it has now been approved for use in 
49 countries worldwide.302 Its primary indication is for active relapsing disease, either 
as first or second line treatment, although in a small number of countries has been 
restricted to patients who have had an inadequate response to two or more 
established disease-modifying therapies. As well as having an impressive clinical effect 
across a number of end points including relapse rate, brain atrophy and measures of 
disability, treatment with alemtuzumab has also offered some fascinating insights297, 
303 into clinical aspects of MS and allowed a greater understanding of disease 
pathogenesis. In addition, one of the recognised adverse events of alemtuzumab is the 
side effect of disease specific autoimmunity. This has provided an unintended, but 
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intriguing window into the origins of human autoimmune disease the discussion of 
which is outside the remit of this thesis. By studying the clinical outcomes of 
alemtuzumab, the effects of lymphocyte depletion in vivo can be observed and 
indicate a pathogenic role for T cells. 
 
3.1.2 Mechanism of action of alemtuzumab 
Alemtuzumab is a humanised monoclonal antibody, which targets CD52304, a 12 amino 
acid glycosylated glycosylphosphatidylinositol-linked protein expressed on the cell 
surface of lymphocytes, monocytes, macrophages, eosinophils and NK cells.305-307 The 
function of this molecule is largely unknown, although is thought to contribute to T cell 
activation,308 migration309 and the induction of regulatory T cells.309 The anti-CD52 
effect of alemtuzumab results in rapid and profound depletion of circulating 
lymphocytes following intravenous infusion, as a result of antibody-dependent cell-
mediated cytotoxicity,257 complement-dependent cytolysis and induction of 
apoptosis.310 However, CD52 is not expressed on haematopoietic precursors, so 
allowing beneficial immune reconstitution and return of immune competency.258, 311  
 
Reconstitution occurs via two mechanisms; proliferation of mature lymphocytes that 
escape deletion (‘homeostatic proliferation’) and via bone marrow/thymic 
repopulation.312 Following treatment, rates of lymphocyte recovery vary by cell type, 
with B cells first to recover, followed by CD8+ and CD4+ T cells.259, 313, 314 Although 
controversial, the rate and pattern of lymphocyte reconstitution is not currently 
thought to correlate with subsequent re-emergence of disease activity.259, 315, 316 As 
immune reconstitution becomes more established, regulatory CD4+ T cells (Tregs) 
dominate the T cell population, and is considered to be one of the factors contributing 
to long-term efficacy rather than this being solely a result of lymphodepletion.317-319 In 
particular, a recent study reporting results from the phase III trials has demonstrated a 
significant increase in Treg cell percentage at 24 months after treatment.320 An 
increased representation of memory T cells is also observed,321 although the impact of 
this phenomenon is less clear. Furthermore, mRNA levels of pro-inflammatory 
cytokines and anti-inflammatory cytokines are down- and up-regulated respectively 
following treatment, which may also contribute to the drug’s unique durability in 
MS.320  
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3.1.3 Early experience 
Prior to its use as a therapy for MS, alemtuzumab was licensed for fludarabine 
resistant chronic lymphocytic leukaemia in addition to its application in organ 
transplantation and other autoimmune disorders.322 Early in the clinical development 
program for MS, alemtuzumab was used in patients with advanced progressive 
disease. Although radiological outcomes were encouraging, disability accumulation 
continued with increased cerebral atrophy 7 years after treatment.300, 301, 303, 322 In 
contrast, patients with relapsing disease experienced a reduction in annualised relapse 
rates (ARR) and an improvement in disability. This dichotomy of clinical outcomes 
between patients treated at an earlier stage of disease and those with progressive 
disease offered important insights into disease pathogenesis and timing of 
interventions. Early disease was concluded to be the result of a more active 
inflammatory demyelinating phase and followed by a later phase of axonal 
degeneration and accumulation of disability. Subsequent investigation therefore 
focused on the inflammatory disease subtype characterized clinically by a relapse 
dominant disease course, with two open label trials in treatment naïve and treatment 
refractory patients showing encouraging clinical outcomes.323, 324  
 
3.1.4 Clinical trials (CAMMS223, CARE-MSI & CARE-MSII) 
Early open label studies demonstrated a marked reduction in relapse rates and slowing 
of disability accumulation when given early in the course of disease.300, 301, 303, 322-324 
The phase II (CAMMS223)9 and two phase III (Comparison of Alemtuzumab and Rebif® 
Efficacy in Multiple Sclerosis (CARE-MS) I & II)240, 241 clinical trials were undertaken 
following positive early experiences. CAMMS223 compared low- and high-dose 
alemtuzumab against a high dose active comparator (subcutaneous interferon beta 1-
a, Rebif®, 44μg three times weekly) in patients with early, active, relapsing-remitting 
MS.9 CARE-MSI240 and CARE-MSII241 investigated the use of alemtuzumab in treatment 
naïve patients and in patients previously on disease modifying therapy who had 
experienced an inadequate response (≥1 relapse) respectively. As with the phase II 
study, interferon beta 1-a was used as an active comparator. Inclusion criteria and 
clinical outcomes for these trials are summarised in Table 3.1. 
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Table 3.1. Clinical outcomes and adverse events of alemtuzumab treated patients in phase II (CAMMS223) and phase III (CARE-MSI and II) clinical trials. Table 
adapted from Coles AJ.325 Abbreviations: SAD; sustained accumulation of disability. RTA; road traffic accident. EDSS; expanded disability status score. 
 
 
 
CAMMS223 CARE)MSI+(treatment(naïve)+ CARE)MSII+(previous(treatment)
All(patients 125mg(group(only
Number+of+alemtuzumab+treated+patients 222 376 426
Follow)up+(years) 3 2 2
Relapse+rate+reduction+(alemtuzumab(vs(interferon(beta51a) 74%((p(<(0.001) 55%((p(<(0.0001) 49%((p(<(0.0001)
Annualised+relapse+rate+(alemtuzumab(vs.(interferon(beta51a) 0.10(vs.(0.36 0.18(vs.(0.39 0.26(vs.(0.52
%+patients+with+6)month+SAD 9%(vs.(26%((p(<(0.01) 8%(vs.(11%((not(significant) 13%(vs.(21%((p(<(0.01)
Change+in+mean+EDSS+from+baseline
Improvement(of(0.39(compared(
with(deterioration(of(0.38(on(
Interferon(beta51a((p(<(0.01)
No(significant(change Improvement(of(0.17(compared(with(
deterioration(of(0.24(on(interferon(beta5
1a((p(<(0.0001)
Deaths 1((ITP),(1((myocardial(infarction) 1((RTA) 1((RTA),(1((aspiration(pneumonia)
Autoimmunity
Thyroid 26% 18% 17%
ITP 0.90% 0.80% 1%
Goodpasture’s(syndrome 0 1 0
Neoplasia+(alemtuzumab(vs.(interferon(beta51a) 2.8%(vs.(0.9% 0.5%(vs.(0 0.6%(vs.(1.5%
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3.1.5 CAMMS223 
334 treatment naïve patients with a diagnosis of relapsing-remitting MS were 
randomised to alemtuzumab 12mg/day, alemtuzumab 24mg/day or high dose 
subcutaneous interferon beta 1-a three times weekly. Results from this study were 
impressive both for clinical and radiological outcomes. The pooled (12mg and 24mg) 
alemtuzumab groups demonstrated a reduction in annualised relapse rate (ARR) of 
74%, reduction in sustained accumulation of disability (SAD; a ≥1-point increase in 
Expanded Disability Status Score (EDSS)326 from baseline if baseline EDSS >0, or ≥1.5 
point increase if baseline EDSS=0, persistent over a 6-month period) of 71% and 
improvement in mean EDSS score of 0.39 points at 36 months. In contrast, patients 
treated with interferon beta 1-a experienced a worsening of EDSS score of 0.38 points 
over the same time period. Radiologically, reduction in brain volume was significantly 
less in the pooled alemtuzumab treatment group. Similarly, although reduction in 
lesion volume on T2-weighted MRI was seen in both alemtuzumab and beta interferon 
patients, this was more notable in the alemtuzumab groups, with significance seen at 
12 and 24 months; however, at 36 months this effect was not significant.9  
 
The cohort of patients involved in CAMMS223 continued to demonstrate 
improvements in EDSS at 5 years of follow-up although the majority of this effect was 
in the first 36 months.260 A post-hoc analysis using a new disability outcome, sustained 
reduction of disability (SRD, a reduction from baseline of at least 1 EDSS point 
confirmed over 6 months for patients with a baseline EDSS ≥2.0) demonstrated more 
alemtuzumab treated patients achieved this outcome compared with interferon 
treated patients.327 
 
3.1.6 CARE-MSI & CARE-MSII 
In the phase III follow-up to CAMMS223, CARE-MSI and CARE-MSII investigated 
alemtuzumab therapy in treatment naïve and treatment experienced patients 
respectively. These studies were conducted over a 2-year period with the primary 
endpoints of ARR and time to 6-month SAD.240, 241 In CARE-MSI, patients received 
alemtuzumab at a dose of 12mg/day.240 In CARE-MSII alemtuzumab patients were 
randomised to a dose of either 12mg/day or 24 mg/day although after one year of the 
study, all patients received 12mg.241 Discontinuation of randomization to the 
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24mg/day group was undertaken because of safety concerns following the reported 
case of ITP but also to aid recruitment to the remaining study groups. 
 
Once again alemtuzumab demonstrated superiority to interferon beta 1-a. Patients 
experienced a reduction of ARR in CARE-MSI and CARE-MSII by 55% and 49% 
respectively.240, 241 EDSS score was also improved in the alemtuzumab groups in both 
studies. Although this was significant in CARE-MSII (improvement of 0.17 points on 
alemtuzumab vs. a worsening of 0.24 in the interferon beta 1-a group) both groups 
experienced an improvement in EDSS in CARE-MSI (improvement of 0.14 points in 
both groups), which did not achieve significance.240, 241 Similarly, in CARE-MSII 
significantly fewer patients had SAD (13% vs. 20%) and more patients had SRD (22% vs. 
9%) in the alemtuzumab group.  Again, in contrast to CARE-MSII significance was not 
achieved in SAD in CARE-MSI, although SRD was not measured.240, 241 
 
Radiological outcomes were also significantly better in the alemtuzumab treated 
patients compared with interferon beta 1-a. In particular, change in brain volume (BV), 
gadolinium enhancing lesions and patients with new or enlarging T2 hyperintense 
lesions on MRI were significantly better in the alemtuzumab groups in both studies.240, 
241  
 
Interestingly, it has been suggested that the improvement in disability observed 
following treatment might be as a result of increased lymphocytic delivery of 
neurotrophins to the CNS aiding neuroprotection.328  
 
3.1.7 Side-effect profile of alemtuzumab 
Despite the clear beneficial effects of alemtuzumab on MS disease activity, there have 
been concerns regarding its side-effect profile, initially cited by the US Food and Drug 
Administration as a reason not to approve its use in the United States, although later 
revoked. In particular, secondary autoimmune disease (AID) is said to affect 
approximately 30% of patients, with the thyroid gland the most common target.325 
Other serious, but less common forms of AID include idiopathic thrombocytopaenic 
purpura (ITP), haemolytic anaemia, autoimmune neutropaenia and glomerulonephritis 
(Goodpasture’s syndrome).9, 240, 241, 325 In addition, predictable adverse infusion related 
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reactions including headaches, rigors, pyrexia and rash affect the majority of 
patients.297 Because of these issues, long-term follow-up data from both controlled 
trials and open label studies will continue to be of value in informing patient selection, 
retreatment strategies and long-term surveillance protocols. 
 
3.1.8 Aims and objectives 
Alemtuzumab has been used in selected centres in the UK since 2000 as a practical, 
alternative treatment for patients with early, aggressive disease with poor prognostic 
indicators at a time when access to more effective treatments was limited, and 
therefore offers a unique opportunity to access long term follow-up data collected in 
routine clinical practice. Here, I aimed to conduct a study of patients presenting with 
high relapse rates329 together with poor prognostic features330-332 who were 
considered candidates for treatment with alemtuzumab. In this chapter, data is 
presented of a ‘real-world’ experience of the use of alemtuzumab in MS across three 
UK MS centres, focusing on relapse rates, disability data, re-treatment rates and 
adverse events.  
 
3.2 Methods 
 
3.2.1 Patients and data collection 
Patients referred to and assessed in the neurology department at the University 
Hospital of Wales, Cardiff were identified as candidates for treatment with 
alemtuzumab if they had a relapsing disease course and evidence of aggressive disease 
characterised by a high relapse rate, active disease on cranial MR imaging, rapidly 
accumulating disability, early motor, cerebellar or cognitive dysfunction or 
combinations of these factors, and were considered to have poor prognosis. A smaller 
number of patients were treated locally at regional specialist neuroscience centres in 
Swansea and Bristol following regional network case-based discussions. Patients 
receiving alemtuzumab as part of externally sponsored clinical trials were excluded 
from analysis. 
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Prior to treatment all patients had a normal blood count, thyroid function tests, 
routine blood indices and white cell immunophenotyping. At the time of treatment no 
patient had evidence of active infection and treatment during relapse was avoided 
whenever possible. Consent for treatment was obtained and explanation of potential 
risks and benefits provided.  
 
3.2.2 Treatment regimen and adverse event monitoring 
Prior to 2006, patients received an initiation dose of 24–30 mg alemtuzumab 
intravenously per day for 5 days, with 1 g intravenous methylprednisolone given as 
pre-treatment on the first 3 days only in order to ameliorate the expected infusion 
reaction side-effects related to cytokine release.297 After 2006, the daily dose of 
alemtuzumab was reduced to 12 mg. Routine top-up treatment was administered 
after 12 months, consisting of 3 daily doses of alemtuzumab with concurrent steroid 
pre-treatment. Additional courses were given as indicated after intervals of not less 
than 12 months, as a result of one or more of the following factors; (1) disabling 
clinical relapse, (2) evolving disability with or without objective change in EDSS, (3) the 
development of new or enhancing lesions on MRI performed 12 months or more after 
a prior treatment cycle.  
A monitoring program for adverse autoimmune events included monthly full blood 
count and urea and electrolytes in addition to thyroid function tests with anti-
thyroperoxidase antibodies at least 6 monthly intervals. Urinalysis was performed 
when indicated or during concomitant illness. Additional tests for relevant AID-related 
antibodies were performed when appropriate. 
 
3.2.3 Data analysis 
Patients were identified from a regional clinical database298 and a systematic review of 
notes was performed to validate the dataset. Data was collected on demographics, 
EDSS scores, relapses, adverse events and prior medication use in order for further 
analysis to be performed. Final data capture was performed on 23rd April 2015. 
Retreatment rates, annualised relapse rates (ARR) pre- and post- treatment, disability 
outcomes, adverse events including rates of AID and outcomes of pregnancies were 
investigated. 6-month sustained accumulation (SAD) and reduction of disability (SRD) 
was calculated according to established definitions.299 
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3.3 Results 
  
3.3.1 Demographics  
One hundred patients treated with alemtuzumab since 2000 were identified (female 
67, male 33) with a total follow-up of 607 patient-years.  Ninety-seven patients had 
relapsing onset disease at time of first treatment. Three patients were subsequently 
re-classified as secondary progressive disease with frequent relapses with the benefit 
of hindsight. Demographic characteristics of the cohort are summarised in Table 3.2.  
 
 
Table 3.2. Demographics and baseline characteristics of 100 patients treated with alemtuzumab. SD = 
Standard deviation. DMT = Disease Modifying Therapy. Non-responders were classified as patients with 
≥10 post treatment relapses and a combined post treatment ARR of >1. 
 
The majority of patients (79%) have been followed-up for between 2 and 10 years with 
a small proportion being followed-up for less than 2 (9%) and more than 10 (12%) 
years respectively. 27% patients had been on at least one prior disease-modifying 
therapy (DMT). These included Avonex (4), Azathioprine (2), Betaferon (5), Copaxone 
(5), Extavia (1), Methotrexate (1), Mycophenolate mofetil (2), Natalizumab (3) and 
Rebif (18). Of the 3 patients treated with Natalizumab, 2 patients developed thyroid 
autoimmunity; another patient was subsequently diagnosed with haemolytic anaemia 
and ITP. Three patients commenced alternative DMTs a mean of 3.4 years following 
first alemtuzumab infusion. Two patients from this cohort have died; one following an 
ischaemic stroke 6.9 years after initial treatment and another patient 8 years after the 
first treatment infusion from aspiration pneumonia. 
 
Demographics- All-patients- Responders- Non5responders-
Number'of'patients' 100 96 4
Female' 67 63 4
Relapsing'disease' 97 93 4
Mean'age'at'disease'onset'(SD)' 28.4'years'(8.9)' 28.5'(8.9)' 26.5'(10.5)'
Mean'baseline'EDSS'(SD)' 4.0'(1.9)' 3.8'(1.9)' 4.5'(1.1)'
Mean'time'from'disease'onset'to'first'treatment'(SD) 4.4'years'(3.7)' 4.4'years'(3.7)' 4.4'years'(2.1)'
Mean'time'from'diagnosis'to'first'treatment'(SD)' 2.0'years'(2.0)' 2.0'(2.1)' 1.3'(1.7)'
Mean'followHup'post'first'treatment' 6.1'years' 6 8.2
Median'followHup'post'first'treatment'(range)' 6.2'years'(0.2–12.9)' 6.0'(0.2–12.9)' 8.5'(6.2–9.7)'
Prior'DMT'use' 27 26 1
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3.3.2 Retreatment rates 
The majority of patients (53%) underwent or were planned to complete the standard 2 
cycles of treatment. 28% patients received 3 treatments, 11% 4 treatments and 1 
patient 5 treatments. Seven patients received 1 treatment cycle only, with the 
commonest reasons being: concerns related to monitoring adherence (n=2), 
development of precancerous comorbidity (n=1) or severe infusion reactions (n=3). 
One of the first patients to be treated also only received one cycle when experience of 
using alemtuzumab was more limited. Indications for 53 re-treatment cycles in 40 
patients are outlined in Table 3.3.  
 
Table 3.3. Reasons for retreatment.  
 
Figure 3.1 demonstrates the temporal relationship between retreatment events and 
duration of follow-up. Between 2 and 5 years, 27% of patients had been retreated 
increasing to 51% and 58% at 5 to 10 years and greater than 10 years follow-up 
respectively. 
 
 
 
 
 
 
 
 
 
Reason'for'retreatment Number'of'treatment'cycles %
Clinical'relapse'only 13 25
New'radiological'lesions'(with'or'without'enhancement)'only 14 26
Clinical'relapse'and'new'lesions'(with'or'without'enhancement) 19 36
Worsening'disability'and'new'lesions 2 4
Worsening'disability'only' 5 9
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Figure 3.1. Temporal variation in retreatment rates. Horizontal lines represent duration of follow-up for 
each individual patient from first dose of alemtuzumab. Successive treatments are indicated by the 
different symbols along each line as indicated in the figure legend. 
 
3.3.3 Relapses 
One hundred patients experienced a total of 766 relapses of which 170 (22%) followed 
the initial treatment cycle. The mean pre-treatment annualised relapse rate (ARR) was 
2.1 (median 1.8). Following first treatment cycle the ARR reduced to 0.2 (median 0.1) 
(p<0.0001) (Figure 3.2).  
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Figure 3.2. Pre- and post-treatment relapses for patients treated with alemtuzumab. Each individual 
patient is represented across a horizontal line from the y axis. The vertical line represents the start of 
the first treatment. Pre-treatment relapses (black dots) are shown to the left of the vertical line. Post-
treatment relapses are shown to the right of the line. 
A small number of patients were unresponsive to treatment and continued to 
experience frequent clinical relapses: 4 patients had ≥10 post treatment relapses and 
had a post treatment ARR of >1. The reduction in ARR was sustained over follow-up of 
up to 8 years (Figure 3.3). 
 
 
 
 
 
 
 
 
 
Figure 3.3. Annualized relapse rate by year of follow-up. Mean annualized relapse rate was calculated 
for each year post first dose of alemtuzumab. The numbers of patients (N) for each year - 0-1, 1-2, 2-3, 
3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10 and 10-11 are shown. 
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3.3.4 Disability 
Disability in MS is rated by the Expanded Disability Status Score (EDSS).326 This score 
ranges from 0 (no disability) to 10 (death) and is utilised in clinical trials to assess 
disability outcomes. In this study, mean baseline EDSS was 4.0. Mean change in EDSS 
from treatment baseline was +0.14. For 2 patients who died of non-MS related causes, 
the last EDSS recorded in life was selected as their final EDSS assessment. A negative 
change in EDSS was seen for each of the first 3 years of follow-up and then again 
towards the later years of follow-up although the numbers were small in these latter 
groups (Figure 3.4). 27% had a SAD although none had developed this status within 2 
years of follow-up. 25% patients achieved sustained reduction in disability (SRD). 
Twelve patients (12%) were considered to have developed secondary progressive 
disease a mean of 3.8 years after initial treatment.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Mean change in EDSS by year of follow-up. Patients were grouped by duration of follow-up. 
Mean change in EDSS in these groups was calculated by comparing the latest EDSS to baseline. Black 
dots represent the mean. Arrow heads represent the lower and upper 95% confidence intervals.  
 
3.3.5 Adverse events 
3.3.5.1 Infusion reactions 
87% patients experienced early infusion related adverse events, which occurred 
despite concomitant steroid use but tended to be mild and responded to conservative 
treatment. 
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3.3.5.2 Acquired autoimmune disease 
Fifty-one AID diagnoses were made in a total of 47 patients. As noted in previous 
studies, the thyroid gland was the most common site of autoimmunity with 35% 
patients affected. Three patients developed idiopathic thrombocytopaenic purpura 
(ITP) and 13 other separate autoimmune disorders were diagnosed; 1 case each of 
haemolytic anaemia, pancytopaenia, autoimmune hepatitis, type II diabetes mellitus, 
and anti-phospholipid syndrome and 2 cases each of alopecia, neutropaenia, 
autoimmune alveolitis and vitiligo. Mean time to development of AID was 995 days 
(median 898, range 30 – 3180 days, Figure 3.5) following first treatment and a mean of 
578 days (median 394, range 0 – 3180 days) after the most recent treatment.  
 
Figure 3.5. Risk of developing autoimmune disease by duration of follow-up. Onset of autoimmune 
disease is demonstrated in relation to years from first dose of alemtuzumab. Lined columns = thyroid 
autoimmune disease; grey columns = idiopathic thrombocytopaenic purpura; black columns = other 
autoimmune conditions.  
The risk of developing secondary autoimmunity was greatest in the first 5 years of 
follow-up and reduced after this time. No autoimmune kidney disease was observed in 
this cohort. In addition to the reported 3 cases of ITP, a transient infusion related 
thrombocytopaenia was observed in 2 patients but resolved without intervention. 
 
A total of 34 different novel auto-antibodies (excluding thyroid receptor and anti-TPO 
antibodies) were detected in 30 different patients during the period of follow-up; 13 
ANA, 9 ANCA, 3 anti-smooth muscle antibodies, 2 anti-centromere antibodies, 2 
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parietal cell antibodies, 1 rheumatoid factor, 1 anti-dsDNA, 1 anti-cardiolipin, 1 Beta 2 
Glycoprotein 1 antibody and 1 anti-GBM antibody. Importantly, the patient who 
developed anti-GBM antibodies had normal renal function throughout the course of 
treatment. The majority of these detected auto-antibodies were transient with only 4 
antibodies persisting after subsequent testing. These included 1 anti-centromere 
antibody, 2 ANCA and 1 anti-cardiolipin antibody.  
 
3.3.5.3 Infections 
Forty-two documented infections occurred in 23 patients. All infections were mild or 
moderate in severity and responded to standard treatment. Urinary tract infections 
were most common (12%). Eight (8%) patients developed herpes zoster and six (6%) 
respiratory tract infections. Other diagnoses were less common and included; 
influenza (3%), pityriasis (2%), sinusitis (2%), tonsillitis (2%), genital herpes simplex 
(1%), conjunctivitis (1%), mastitis (1%), mumps (1%), acute cholangitis (1%) and 
cellulitis (1%). One patient (1%) developed cryptosporidium infection during a hospital 
inpatient stay for a surgical operation. 
 
3.3.5.4 Pre-malignant/malignant conditions 
Ten patients developed pre-malignant or malignant conditions during the period of 
follow-up. Five patients (5%) developed cervical dysplasia, 3 patients (3%) were 
identified with a low level IgG paraprotein or monoclonal gammopathy of uncertain 
significance (one of which was also diagnosed with meningioma) and 2 patients were 
diagnosed with basal cell carcinoma.  
 
3.3.5.5 Pregnancy 
Thirteen pregnancies were recorded in twelve women (18%). Two pregnancies 
resulted in miscarriage and one was terminated. The child of one patient who 
developed thyroid AID following treatment experienced transient neonatal 
hyperthyroidism. 
 
3.6 Discussion 
Alemtuzumab has had encouraging results in both clinical trials and open-label studies 
but long-term follow up data is required to confirm its efficacy and safety. Tuohy et 
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al299 have recently published long-term results of a cohort of patients treated in open-
label studies in Cambridge, UK but additional data from other centres is also required 
to understand practical application and longer-term adverse events in routine clinical 
practice.  
 
3.6.1. Disability outcomes and durability of treatment 
In the phase II (CAMMS223) and phase III trials (CARE-MSI and CARE-MSII), 
alemtuzumab was shown to reduce the ARR by 74%, 55% and 49.4% respectively. The 
findings in this study confirm that up to a mean 6.1 year follow-up the percentage 
reduction in ARR is maintained and in this cohort was 90%. In particular, the treatment 
seems to be durable in relation to relapses up to 8 years following treatment. After 
this time the ARR reduces but the number of patients in this group is small. Four 
patients clearly did not respond to treatment with ≥10 post treatment relapses and a 
combined post treatment ARR of >1 and represent an interesting sub-group which may 
warrant more detailed analysis of disease biology. However, these data are 
commensurate with the long-term efficacy outcomes of the Cambridge cohort where 
52% received the standard 2 cycles of treatment, 36% received 3 cycles, 8% 4 cycles 
and 1 patient 5 cycles.299 In our dataset the trend for requiring re-treatment increased 
over time implying that the majority of patients are likely to require further treatment 
cycles. So far 40% of patients have required retreatment. An important practical 
consideration was that significant cognitive deficits were identified as a barrier to 
informed consent and adherence to long term monitoring protocols and we have now 
altered our local selection criteria to offer alternative treatments for these patients. 
Three (3%) patients were also intolerant of treatment as a result of severe infusion 
reactions or pancytopaenia following infusion.  
 
Previous studies have suggested an expectation of an improvement in EDSS from 
baseline following treatment with alemtuzumab when compared with an active 
comparator (interferon beta 1-a). In the CAMMS223, phase II study, the mean change 
in EDSS from baseline was -0.39 (p<0.001),(15) CARE-MSI -0.14 (p=0.97),(16) CARE-
MSII -0.17 (p<0.0001)(17) and CAMMS223 5 year follow-up -0.3 (p=0.0002).(27) 
Although the improvement in EDSS in the CAMMS223 cohort achieved statistical 
significance over 5 years of follow-up, this significance was not observed when months 
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36-60 only were analysed. This would imply that the proposed effect on disability was 
short-lived and not sustained. Conversely our cohort experienced an overall worsening 
in EDSS score of +0.14 from treatment baseline. The previous phase II and two phase 
III trials have shown rates of SAD in the alemtuzumab treatment groups of 9%, 8% and 
13% at 3, 3, and 2 years respectively. Similarly 11% of patients had SAD in the 
CAMMS223 5-year follow-up study. We identified a much higher proportion of 
patients who had SAD over 6 years follow-up so that 27% of patients were deemed to 
have progressed in our cohort. These results however were comparable to the levels 
of SAD found in the open-label Cambridge long-term follow-up study with 32% of 
patients found to have SAD over a median 7-year follow-up.299 Only 27% of patients 
had a SRD in our cohort compared to 43.5% in the Cambridge cohort.299 Differences in 
disability outcomes may in part be explained by the fact that in our cohort there were 
a larger number of EDSS assessors, as would be expected in a ‘real-world’ clinical 
setting, but may have introduced some increased variability. Although the mean 
change in EDSS score was +0.14, we would still consider this an encouraging outcome 
given the particularly aggressive disease profile of this cohort of patients.  
 
3.6.2 Adverse events 
 
3.6.2.1 Secondary autoimmune disease 
The most significant adverse event of alemtuzumab treatment is secondary AID. 
Secondary thyroid autoimmunity has previously been shown to be unaffected by the 
cumulative dose, dosage interval or dosage frequency suggesting that total risk is 
acquired at the time of first dose.333 47% of patients in this study developed AID, with 
35% developing thyroid autoimmunity.9, 240, 241, 300, 303, 333 Rates of ITP (3%) were also 
comparable to published data. Other AIDs were seen at lower frequencies but without 
a control group for comparison, the relationship of these to alemtuzumab treatment is 
difficult to confirm. This risk of developing secondary AID appears to be maximum in 
the first 5 years following initial treatment, with only three cases (all thyroid AID) seen 
after this time. This would seem to suggest that autoimmune surveillance should be 
continued for a minimum of 5 years after first treatment cycle. This is commensurate 
with the current monitoring guidelines of 4 years after the last dose of alemtuzumab. 
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Although 34 novel antibodies were detected during post treatment monitoring only 4 
of these persisted and have not so far been associated with relevant disease. 
3.6.2.2 Infections 
Despite alemtuzumab causing profound and prolonged lymphopaenia, serious 
infections are rare. This is thought to be due to the relative preservation of the innate 
immune system, haemopoetic stem cells and the nature of subsequent immune 
reconstitution.311 In addition, as a result of the interval between treatments, 
lymphocyte repopulation occurs. Most infections following alemtuzumab treatment 
are mild to moderate and respond to conventional therapies. We observed similar 
findings in this study with urinary, respiratory and herpes zoster infections being most 
common. One case of cryptosporidium infection was associated with an inpatient stay 
for a surgical procedure. We are unaware of any serious infections occurring in our 
cohort. 
 
3.6.2.3 Malignancy 
Within the clinical trials, the rate of pre-malignant or malignant conditions was 0.5-
2.8% although the studies were not powered in such a way as to detect small changes 
as compared with interferon beta-1a. Outside of trials, one case of malignant 
melanoma has been reported334 and a further patient developed Castleman’s disease 
(a prelymphomatous condition) and is now in remission following R-CHOP 
chemotherapy.325 We observed pre-malignant/malignant conditions in 10% of 
patients. In particular, we are aware of 5 female patients who developed cervical 
dysplasia (5%). The occurrence of cervical dysplasia may be affected by 
immunosuppression335 and these data perhaps suggest that stringent pre- and post-
treatment cervical screening should be performed and is now included as routine in 
our protocols. In addition to these findings, an IgG paraprotein or MGUS was also 
detected on screening in 3 patients. The significance of this is difficult to ascertain at 
present, but is a novel finding in MS patients receiving alemtuzumab, although 
persistent paraproteinaemias have previously been reported following alemtuzumab 
therapy in the context of stem cell transplantation.336 
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3.6.2.4 Pregnancy 
The pregnancy rate of 18% in this cohort despite advice on appropriate contraception, 
may reflect the positive effect on quality of life following alemtuzumab that many 
patients reported, leaving them more confident to start families. No unexpected 
adverse pregnancy outcomes have so far been observed in this cohort.  
 
3.6.3 5-year follow-up outcomes of phase III clinical trials 
Similar to the results obtained in this open label cohort, the recently published follow-
up data from the phase III extension study has demonstrated marked durability over 5 
years.337, 338 For patients enrolled in CARE-MSI and CARE-MSII the low ARR was 
maintained in year 3 (0.19 and 0.22 respectively) to year 5 (0.15 and 0.18). For years 0-
5, 80% patients in CARE-MSI and 75% patients in CARE-MSII were free from 6-month 
SAD. Impressively, 82% and 77% patients respectively had stable or improved EDSS 
scores after 5 years and 33% and 43% patients experienced SRD in years 0-5.337, 338  
 
In the extension study, radiological changes also appear to have durability after 5 years 
of follow-up. Median rate of BV loss decreased progressively over 4 years in CARE-MSI 
and remained low in year 5 (Year 1: -0.59%, Year 2: -0.25%, Year 3: -0.19%, Year 4: -
0.15%, Year 5: -0.20%). Similarly, median rate of BV loss progressively slowed over 3 
years in CARE-MS II and remained low in Years 4 and 5 (Year 1: -0.48%, Year 2: -0.22%, 
Year 3: -0.10%, Year 4: -0.19%, Year 5: -0.07%). Strikingly, the majority of patients (69% 
in CARE-MSI and 60% in CARE-MSII) had not received further courses of alemtuzumab 
treatment since month 12.337, 338 Durability of MRI outcomes have also been shown in 
the extension study with respect to gadolinium (Gd)-enhancing lesions, new/enlarging 
T2 or new T1 lesions. In years 3, 4 and 5 after initial treatment the proportion of 
patients free of the aforementioned measures were similar to those in year 2 (i.e. the 
end of the original phase III studies). In addition, most patients were free of MRI 
activity in each of years 3, 4 and 5.337, 338 No new safety concerns were highlighted 
from these follow-up studies. 
 
3.6.4 Conclusion 
In conclusion, this follow-up study in a highly selected group of MS patients with poor 
prognostic indicators treated with alemtuzumab in routine clinical practice confirms a 
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durable effect on relapse rates but no improvement in disability. AID has affected 
nearly half of the cohort to date but this figure is likely to rise with longer follow-up. 
Unexpected findings included 3 cases of a low level IgG paraprotein and 5 cases of 
cervical dysplasia. Although the lack of a comparative control group does not allow 
definitive conclusions to be drawn, it will be important to monitor these in larger post-
marketing surveillance studies. However, alemtuzumab appears to be an effective 
treatment for relapsing MS in routine clinical practice, and its side-effects for the most 
part are predictable and treatable. The clinical efficacy of alemtuzumab and its unique 
mechanism of action also help to confirm a central role for T cells in MS disease 
pathogenesis.  
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Chapter 4 
 
Immunophenotyping of cerebrospinal fluid-resident T cells in 
Multiple sclerosis 
 
4.1 Introduction 
Genome wide association studies (GWAS),42 histology,47 animal models181, in vitro 
experiments,63 and response to therapeutics325 provide evidence for the role of T cells 
in Multiple sclerosis (MS). Although T cells constitute the most common cell type 
present in cerebrospinal fluid (CSF), both in MS patients and controls,92 the definitive 
immunophenotype of these cells has not been consistently reported. It is therefore 
important to understand what T cell subpopulations are present in CSF and whether 
there is any difference between MS patients and controls. Firstly, this will help to 
further understand disease pathogenesis and the role for T cells and secondly to be 
able to identify certain cellular subpopulations as therapeutic targets. 
 
4.1.1 T-cell differentiation  
Following development, T cells are released from the thymus as naïve T cells (TN) 
specific for a given peptide/MHC (pMHC) antigen. After activating in response to their 
cognate pMHC antigen these cells expand and differentiate into effector cells in order 
to destroy their target.96 The expression of different cell surface markers allows 
identification of the stage of differentiation. The C-C chemokine receptor 7 (CCR7), 
which mediates homing to lymph nodes96 can be used in combination with CD45RA, a 
tyrosine phosphatase339 to define subsets of T cells based on their stage of 
differentiation (Figure 4.1).96 CCR7+ CD45RA- T cells are called central memory (TCM) T 
cells due to their potential to home to secondary lymphoid tissues. Conversely, CCR7- 
CD45RA- T cells are called effector memory (TEM) T cells because of their effector 
function and their potential to home to peripheral lymphoid tissues.96 Further subsets 
have been defined including T cells with stem cell-like properties, termed stem cell 
memory T cells (TSCM), which precede TCM cells in the differentiation pathway.96 
Transitional memory T cells (TTM) represent a further subgroup, which are more 
 83 
differentiated than TCM cells but not as fully differentiated as TEM cells. CCR7- cells that 
are CD45RA positive, represent cells with low proliferative and functional capacity, 
indicating terminal differentiation. These cells are termed terminal effector cells (TTE or 
TTEMRA).96 Figure 4.1 outlines the expression of CCR7, CD45RA and other cell surface 
proteins, which help to define these subsets. Phenotypic, functional and gene 
expression properties of these T cell subsets supports a linear progression of 
differentiation in humans (TN, TSCM, TCM, TTM, TEM, TTEMRA). In addition, the expression of 
other proteins can be used to help determine the differentiation stage or functional 
properties of these cells.96 TN cells are antigen inexperienced and more dependent on 
co-stimuluatory signals compared with memory T cells. TN and TCM T cells home to 
secondary lymphoid organs whereas TEM and TEMRA T cells home to peripheral sites 
where they exert their effector functions.340 
 
In this study, I have focused on determining the frequency of the four main T cell 
subsets based on the expression of CCR7 and CD45RA; TN (CD45RA+CCR7+), TCM 
(CD45RA-CCR7+) , TEM (CD45RA-CCR7-) and TTEMRA (CD45RA+CCR7-).93 Of note, as well as 
CD45RA, CD45RO can be used to determine differentiation state. Cells expressing 
CD45RO are considered to be of ‘memory’ phenotype i.e. either TCM, TTM or TEM.96  
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Figure 4.1. Stages of T cell differentiation. Different stages of T cell differentiation can be identified 
based on the expression of specific cell surface markers. The positive or negative expression of CD45RA, 
CD45R0, CCR7, CD28, and CD95 identifies six major subsets of T cells. While differentiating, memory T 
cells lose or acquire specific functions. Following encounter with antigen, these quiescent T cells 
develop into effectors. When the antigen is cleared, surviving effector T cells return to a quiescent 
memory state.96 Figure adapted from Mahnke et al.96  
 
4.1.2 The immunophenotype of CSF-resident T-cells: inconsistencies in 
the literature 
In CSF, CD4+ T cells outnumber CD8+ T cells91, 92, with a significant increase of CD4+ T 
cells in CSF from MS patients compared with controls.95 An increased CSF CD4+/CD8+ 
ratio has also been observed in MS and inflammatory neurological diseases compared 
with non-inflammatory disease.93, 94 The immunophenotype of CSF-resident T cells in 
MS has been further characterised in several studies although the difficulty in some 
cases of obtaining CSF from healthy volunteers or a control population makes 
interpretation of the results difficult. The results of these studies have often been 
inconsistent with different T cell subpopulations predominating, and either significant 
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or no significant differences reported compared with controls (summarised in Table 
4.1). 
 
Following activation and differentiation in response to antigenic stimuli, T cells acquire 
an effector memory (or effector memory-RA) phenotype. If CD8+ T cells are pathogenic 
in MS, it would be reasonable to expect differentiated CD8+ T cells in the CSF. 
Consistent with this, previous studies have demonstrated that effector memory T cells 
are the most predominant subtype in the CSF and enriched (compared with peripheral 
blood) in patients with MS.79, 93, 97  
 
When comparing effector memory populations between the CSF and blood, Jilek et al 
demonstrated that the majority of CSF-resident CD4+ T cells in MS had a central or 
effector memory phenotype. In this study, the majority of CSF-resident CD8+ T cells 
also had an effector memory phenotype. The proportion of effector memory T cells 
was higher in the CD8+ T cell compartment than the CD4+ T cell compartment, with a 
higher proportion in patients with active disease i.e. relapsing-remitting MS 
(RRMS)/possible MS.97 However, in this study, patients with other neurological 
diseases (OND) also demonstrated a CSF enrichment with highly differentiated cells.97 
In subsequent studies, effector memory T cells were shown to be the predominant 
population in the CSF79, 93 with a higher percentage of effector memory T cells present 
in the CSF compared to patients with non-inflammatory neurological disease.93 In the 
study by Ifergan et al, no control CSF was available for comparison.79 
 
Conversely, memory (CD45RO+) T cells have been shown to be the predominant CSF 
population in MS91, 100, 102 with either no differences observed between MS and control 
groups91, a higher proportion in the CD8+ T cell compartment,102 or no control CSF for 
comparison.100 A reduced frequency of memory CD8+ T cells in the CSF of MS patients 
compared with healthy volunteers has also been observed.101 
 
Other studies have shown an enrichment of central memory T cells in both MS and 
non-inflammatory neurological disease.50, 98, 99 In one study of 84 individuals without 
history of neurological disease or cancer undergoing routine surgery, central memory T 
cells were the predominant population in CSF-resident T cells.103 
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4.1.3 Aims and objectives 
To help clarify the immunophenotype of CSF-resident T cells in MS, we performed, to 
our knowledge, the most in-depth phenotypic analysis to date using polychromatic 
flow cytometry. Recent advances have extended the boundaries of flow cytometric 
analysis through new developments in instrumentation and fluorochrome technology, 
enabling the simultaneous and independent measurement of up to 18 cell surface 
markers.290, 291 MS CSF-resident T cell populations were compared to those from 
patients with idiopathic intracranial hypertension (IIH) and OND patients as controls. 
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Table 4.1. Immunophenotyping studies of CSF-resident T cells in Multiple sclerosis. MS=Multiple sclerosis; OIND=Other inflammatory neurological disease; 
OND=Other neurological disease; NIND, Non-inflammatory neurological disease; CSF=Cerebrospinal fluid; HV=Healthy volunteers; AM=Aseptic meningitis; 
RRMS=Relapsing remitting Multiple sclerosis; PPMS=Primary progressive Multiple sclerosis. *other adhesion/activation markers 
 
Author Year Cell,type Markers Tissue No.,of,MS,Pts. No.,of,controls Findings
Svenningsson)et)al91 1993 CD3+ CD45RO CSF)&)Blood 11 6)AM Majority)of)CSF)T)cells)have)a)memory)phenotype)(CD45RO+).
CD45RA 16)HV No)differences)among)all)patient)groups.)
other)markers* Lower)levels)of)VLAR6)expression)in)MS)and)AM)CSF)compared)with)HV.
Svenningsson)et)al101) 1995 CD4+ CD45RO CSF)&)Blood 21 15)HV Reduced)frequency)of)memory)(CD45RO+))CD8+)T)cells)in)blood)and)CSF)of)MS)compared)with)controls.
CD8+ CD29
Vrethem)et)al102 1998 CD4+ CD45RO CSF)&)Blood 28 13)meningitis Majority)of)CSFRresident)CD4+)and)CD8+)T)cells)have)a)memory)phenotype)(CD45RO+))in)all)groups.
CD8+ CD45RA 16)OND Higher)proportion)of)CD8+)memory)T)cells)in)MS)compared)to)controls.
16)HV
Giunti)et)al98) 2003 CD4+ CD45RO CSF)&)Blood 21 14)OIND Majority)of)CSFRresident)CD4+)and)CD8+T)cells)have)a)central)memory)phenotype)(CD45RO+CCR7+CD27+)
CD8+ CCR7 Increased)expression)of)CXCR3)and)CCR5)in)both)groups.
CD27 No)differences)between)MS)patients)and)controls.
Other)CXCR/CCR
Kivisakk)et)al50) 2003 CD4+ CD45RA CSF)&)Blood 0 69)NIND Majority)of)CSFRresident)CD4+)and)CD8+)T)cells)have)a)central)memory)(CD45RARCD27+))phenotype.
CD8+ CD27 CSFRresident)T)cells)expressed)high)levels)of)CCR7)and)LRselectin.
CCR7
CD69
LRselectin
Kivisakk)et)al99) 2004 CD4+ CD45RO CSF)&)Blood 25 29)NIND Majaroity)of)CSFRresident)CD4+)T)cells)have)a)central)memory)(CCR7+CD45RO+CD27+))phenotpye.
CD27 2)OIND No)difference)compared)with)NIND.
CCR7
Okuda)et)al100) 2005 CD4+ CD45RO CSF)&)Blood 39 21)HV)(blood)only) Majority)of)CSFRresident)CD4+)and)CD8+)T)cells)have)a)memory)phenotype)(CD45RO+).
CD8+ CD25 No)control)CSF)for)comparison.
Jilek)et)al97 2007 CD4+ CD45RA CSF)&)Blood 33)MS/poss.)MS 19)OND Majority)of)CSFRresident)CD4+)T)cells)have)a)central)(CCR7RCD45RAR))or)effector)memory)(CCR7RCD45RAR))phenotype.
CD8+ CCR7 Majority)of)CSFRresident)CD8+)T)cells)have)an)effector)memory)(CCR7RCD45RAR))phenotype.
Enrichment)of)highly)differentiated)(CCR7RCD45RA+))T)cells)in)CSF)compared)with)blood.)
Higher)in)CD8+)than)CD4+)T)cells.)Higher)in)RRMS/Possible)MS)patients)vs.)PPMS/OND)patients.
Ifergan)et)al79) 2011 CD4+ CCR7 CSF)&)Blood 17 10)HV)(blood)only) CD8+)only)commented)on.)
CD8+ CD62L)(LRselectin) Majority)of)CSFRresident)CD8+)T)cells)have)an)effector)memory)(CCR7RCD62LR))phenotype.
de)Graaf)et)al103 2011 CD4+ CD45RA CSF)&)Blood 0 84)nonRneurological)disease Majority)of)CSFRresident)CD4+)and)CD8+)T)cells)have)a)central)memory)(CD45RARCD27/28+))phenotype.
CD8+ CD)27/28
Mullen)et)al93 2012 CD4+ CD45RA CSF)&)Blood 37)MS 51)OIND Majority)of)CSFRresident)CD4+)and)CD8+)T)cells)have)an)effector)memory)(CCR7RCD45RAR))phenotype.
CD8+ CCR7 11)poss.)MS 43)OND Higher)percentage)of)CSFRresident)effector)memory)T)cells)(CD4+)and)CD8+))in)inflammatory)diseases
compared)with)nonRinflammatory)controls.
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4.2 Methods 
Patients attending for diagnostic lumbar puncture for investigation of Multiple 
sclerosis were consented under pre-existing ethical agreements. In addition, patients 
being investigated or treated for idiopathic intracranial hypertension and other 
neurological diseases were included in the study. As the majority of patients were 
attending for diagnostic investigations, subsequent clinical case note review was 
required to confirm eventual diagnoses. No patients had received prior disease 
modifying therapy. Up to 10ml cerebrospinal fluid (CSF) was obtained and processed 
within 1 hour of collection (Figure 4.2). Twenty millilitres of peripheral blood was 
obtained immediately after lumbar puncture, which was then processed and stored for 
further experiments (discussed in later chapters of this thesis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Flow chart for collection, handling and analysis of clinical samples.  
 
CSF was centrifuged at 2000 rpm for 10 minutes and the cell pellet resuspended in 
50μL phosphate buffered saline (dPBS, Sigma-Aldrich, Gillingham, UK). Cells were then 
stained with aqua (Thermofisher, Waltham, MA, USA) for 10 minutes at room 
temperature and subsequently incubated at 4oC for 20 minutes with the following 
antibody panel CD14 V500, CD19 V500, CD3 APC-H7, CD8 BV711, CD4 PECy5.5, CD27 
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Qdot605, CD45RA ECD, CD57 FITC, CD95 PE-Cy5, CCR7 PE-Cy7, CD127 BV421, CD49d 
APC and PD-1/CD279 PE or Pan γδ PE. Of note, the CSF stain for patients LC20552 and 
LJ20639 used different antibodies for CD127, CD95 and CD27. For LC20552 – PE, APC 
and PECy5 respectively;  for LJ20639 - Pacific blue, PE and PECy5 respectively. In 
addition, CD49d was not used for these samples (For a full list of antibodies used for 
each patient, see Appendix, Section 8.1).  
 
During incubation, corresponding compensation tubes were set up. Firstly, 8 drops of 
anti-mouse Ig κ/negative control compensation particles (BD, Oxford, UK) were added 
to 800μL PBS in a FACS tube. 50μL of this solution was then added to each individual 
compensation FACS tube. The same amount of corresponding antibody used in the cell 
stain was then added to the relevant tube. Antibodies were left to stain for 10 minutes 
at room temperature when 150μL PBS was then added. For the CCR7 PE-Cy7 
compensation tube 50μL of anti-rat Ig κ/negative control compensation particles (BD, 
Oxford, UK) was used instead. Following CSF incubation, 1ml PBS was added then cells 
centrifuged for 2 minutes at 2000 rpm. Supernatant was subsequently discarded and 
cells resuspended in 100μL PBS in preparation for data acquisition and cell sorting. 
CD4+ and CD8+ T cells were sorted using a BD FACSAria II (BD, Oxford, UK) into 
RNAlater (Ambion, Thermofisher, Waltham, MA, USA). After sorting, cells were 
centrifuged at 13,000 rpm for 2 minutes then stored at -80oC until required. Analysis of 
acquired flow cytometry data was performed using Flowjo software with cell 
populations compared using the Kruskall-Wallis test with Dunn’s multiple comparison 
test using Prism software when 3 groups were compared together. When only 2 
groups were compared, the Mann-Whitney test was utilised. Fluorescence minus ones 
(FMOs) were analysed on peripheral blood in order to set gates in Flowjo. It was not 
possible to perform FMOs on CSF due to the limited number of cells available. Figures 
4.3 - 4.5 demonstrate a typical flow cytometry gating strategy. 
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Figure 4.3. Flow cytometric analysis and sorting of CSF-resident CD4+ and CD8+ T-cell populations. The 
figure depicts a typical flow cytometry sort report from a patient with MS. CSF was spun at 2000 rpm for 
10 mins, the supernatant discarded and the remaining cells stained with the following polychromatic 
flow panel: CD14 V500, CD19 V500, CD3 APC-H7, CD8 BV711, CD4 PECy5.5, CD27 Qdot605, CD45RA 
ECD, CD57 FITC, CD95 PE-Cy5, CCR7 PE-Cy7, CD127 BV421, CD49d APC and PD-1/CD279 PE or Pan γδ PE. 
Data were acquired on a custom-built 20-parameter BD FACSAria II flow cytometer. 
 
 
 
Figure 4.4. Flow cytometric gating strategy to determine stage of cell differentiation (CD45RA vs. 
CCR7). Examples of gating strategy for CD8+ T cells from selected patients from each patient group. (a) 
MS, (b) IIH, (c) OND. Cells were prepared as discussed in the methods and legend of figure 4.3. 
 
 
 
 
 
 
 
 
 
 
 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Flow cytometric gating strategy to determine expression of individual cell surface proteins. 
Example of gating strategy used for CD8+ T cells from patient AL22847. Cells were prepared as discussed 
in the methods and legend of figure 4.3. 
 
4.3 Results 
 
4.3.1 Patient cohort 
46 CSF samples were collected; 21 MS/clinically isolated syndrome (CIS) – hereafter 
referred to as ‘MS’; 14 IIH; 11 OND. Of the initial 21 MS CSF samples collected, 1 
sample was not sorted due to minimal cells being present (DD22299) and the results of 
one sample were not saved in error (LS20460). Of the 14 IIH samples collected, 1 was 
not included in the analysis as it was macroscopically contaminated with peripheral 
blood (VE25562). Four OND samples were not included in the analysis; 1 due to 
deficient antibody staining (SE29703), 1 due to a mechanical fault with the FACS Aria II 
(DL37517), 1 because no live cells were present (JJ37566) and 1 because of visible 
macroscopic blood (JP24822). Figure 4.6 summarises the samples collected and 
available for analysis. Tables 4.2 - 4.4 outlines patient demographics for each group, 
the volume of CSF collected and the number of sorted cells. The MS group contained 8 
male and 13 female patients. In the IIH group, all patients were female with 3 male 
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and 8 females in the OND group. The median age at lumbar puncture was 47.6 years 
(range 20 – 68.7) in the MS group, compared with 28.6 (21.2 – 45.8) and 45.1 (21.9 – 
55.1) in the IIH and OND groups respectively. 
 
 
 
 
 
 
 
 
Figure 4.6. CSF samples collected and available for immunophenotyping. 
Idiopathic*intracranial*
hypertension*(IIH)*
14*
Other*neurological*
disorders*(OND)**
11*
Phenotyped*
13*
1*not*sorted*
Phenotyped*
7*
4*not*included*(see*
text)*
46*CSF*samples*
MulEple*sclerosis*(MS)*
21*
*1*not*sorted*
1*not*saved*
Phenotyped*
19*
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Table 4.2. Demographics of Multiple sclerosis/clinically isolated syndrome patients included in the study. N.B.*denotes patients where CSF was collected but not 
included in the phenotyping analysis as described in section 4.3.1. Abbreviations: RR, relapsing remitting; PP, primary progressive; SP, secondary progressive; SPR, 
secondary progressive with relapses. 
 
Patient'ID Sex Age'at'LP'(yrs) Diagnosis Course Vol.'CSF'(ml) No.'of'CD4+'cells' No.'of'CD4+'cells/ml' No.'of'CD8+'cells' No.'of'CD8+'cells/ml
LC20552 F 42.6 MS RR 7 5078 725.4 618 88.3
LJ20639 F 55.7 MS PP 10 4923 492.3 361 36.1
LS20460* F 58.6 MS RR 10 5 5 5 5
MJ19588 M 39.9 MS SPR 10 5807 580.7 707 70.7
EB21510 F 35.6 MS RR 10 6111 611.1 686 68.6
KG19967 F 34 MS SP 10 1601 160.1 237 23.7
LH18836 F 29.8 MS RR 9.5 12180 1282.1 719 75.7
NW21326 F 43.1 MS RR 10 538 53.8 116 11.6
MW21576 M 57.4 MS PP 10 1877 187.7 272 27.2
CS21983 F 56.1 MS RR 10 2114 211.4 587 58.7
AL28847 M 51.8 CIS 5 10 6485 648.5 2533 253.3
MK21405 M 63.3 MS RR 10 3662 366.2 554 55.4
SA23376 F 20 MS RR 4 4159 1039.8 911 227.8
RM22664 M 31 MS RR 10 32095 3209.5 4196 419.6
TL22789 F 47.6 MS RR 10 4985 498.5 743 74.3
CT25364 F 51.5 MS PP 6 1774 295.7 256 42.7
HD21265 F 32.6 MS RR 10 1472 147.2 47 4.7
MH21407 M 41.2 MS RR 10 6884 688.4 452 45.2
RW21309 M 68.7 MS SP 10 547 54.7 196 19.6
DD22299* M 57.6 MS PP 10 5 5 5 5
CG41964 F 51.2 MS PP 10 5428 542.8 456 45.6
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Table 4.3. Demographics of idiopathic intracranial hypertension patients included in the study. N.B. *denotes patients where CSF was collected but not included in 
the phenotyping analysis as described in section 4.3.1. 
 
 
 
Patient'ID Sex Age'at'LP'(yrs) Diagnosis Vol.'CSF'(ml) No.'of'CD4+'cells' No.'of'CD4+'cells/ml' No.'of'CD8+'cells' No.'of'CD8+'cells/ml
EC21870 F 27.9 IIH 10 500 50 57 5.7
HS25204 F 28.1 IIH 10 1075 107.5 85 8.5
LH25311 F 24.1 IIH 10 962 96.2 302 30.2
ML25308 F 21.2 IIH 10 970 97 130 13
SW25353 F 31 IIH 10 4147 414.7 261 26.1
RY21758 F 27.2 IIH 10 737 73.7 42 4.2
DC37877 F 28.1 IIH 10 94 9.4 18 1.8
ES37889 F 33 IIH 10 409 40.9 9 0.9
FC24414 F 43.7 IIH 10 11 1.1 3 0.3
VE25562* F 27.6 IIH 7.5 : : : :
CC40712 F 45.8 IIH 10 2258 225.8 171 17.1
RC41200 F 29.9 IIH 8 507 63.4 84 10.5
KA38079 F 29 IIH 10.5 3487 332.1 195 18.6
CC41471 F 32.7 IIH 10 655 65.5 61 6.1
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Table 4.4. Demographics of other neurological disease patients included in the study. N.B. *denotes patients where CSF was collected but not included in the 
phenotyping analysis as described in section 4.3.1. 
Patient'ID Sex Age'at'LP'(yrs) Diagnosis Vol.'CSF'(ml) No.'of'CD4+'cells' No.'of'CD4+'cells/ml' No.'of'CD8+'cells' No.'of'CD8+'cells/ml
SE29703* M 26.9 Autoimmune4encephalitis 10 2541 254.1 303 30.3
JG33488 F 51.6 Normal4pressure4hydrocephalus 10 742 74.2 69 6.9
ND37140 F 45.1 Fibromyalgia 10 523 52.3 121 12.1
DL37517* M 45.1 GuillainJBarré4syndrome 10 J J J J
CS19395 F 47.3 Cerebrovascular4disease 9 54 6 8 0.9
AG20355 F 51.8 Visual4field4defect4of4unknown4aetiology 5 427 85.4 77 15.4
JM25229 M 31 Pseudopappiloedema4J4drusen/OSA 10 2672 267.2 499 49.9
AB25236 F 21.9 Migraine 11 3996 363.3 398 36.2
CJ26014 F 28.9 Migraine 10 849 84.9 118 11.8
JJ37566* F 26 Migraine 10 79 7.9 22 2.2
JP24822* F 55.1 Small4vessel4disease 9 217 24.1 88 9.8
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4.3.2 Cellular constituents of cerebrospinal fluid 
CD4+ T cells significantly outnumbered CD8+ T cells across all patient groups (Tables 4.2 
– 4.4, & Figure 4.7). Within the MS group a mean of 620.8 CD4+ T cells/ml was 
observed. This contrasted with means of 121.3 and 109.1 for the IIH and OND groups 
respectively. The mean number of CD8+ T cells in the MS group was 86.8 CD8+ T 
cells/ml compared with 11 CD8+ T cells/ml in the IIH groups and 19 CD8+ T cells/ml for 
the OND patients. Figure 4.8 gives an overview of the numbers of CD4+ and CD8+ T 
cells per ml of CSF.  
 
 
 
 
 
 
 
 
 
Figure 4.7. Number of CD4+ and CD8+ T cells/ml of CSF collected by patient group. Cells were prepared 
as discussed in the methods and legend of figure 4.3. Data was analysed with Flowjo software and 
Graphpad prism.* = p<0.05 
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Figure 4.8. Number of CD4+ and CD8+ T cells/ml of CSF collected. Cells were prepared as discussed in 
the methods and legend of figure 4.3. Data was analysed with Flowjo software and Graphpad prism. 
 
The number of CD4+ T cells/ml in MS was significantly higher (p<0.05) than the number 
of CD4+ T cells within the IIH and OND patient groups (Figure 4.9). Similarly, the 
number of CD8+ T cells in the MS group was significantly higher than CD8+ T cells in the 
IIH and OND group (Figure 4.10).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Number of CD4+ T cells/ml CSF across all patient groups. Cells were prepared as discussed in 
the methods and legend of figure 4.3. Data was analysed with Flowjo software and Graphpad prism.* = 
p<0.05 
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Figure 4.10. Number of CD8+ T cells/ml CSF across all patient groups. Cells were prepared as discussed 
in the methods and legend of figure 4.3. Data was analysed with Flowjo software and Graphpad prism.* 
= p<0.05 
 
With respect to the percentage of CD4+ and CD8+ T cells within the CD3+ T cell 
population, CD4+ T cells were the dominant population making up a mean 81.4%, 
78.5% and 79.1% CD3+ cells across MS, IIH and OND groups respectively. CD8+ T cells 
contributed 12.3%, 10% and 12% across the MS, IIH and OND groups (summarised in 
Figure 4.11).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Percentage of CD3+ cells that are either CD4+ or CD8+ across all patient groups. Cells were 
prepared as discussed in the methods and legend of figure 4.3. Data was analysed with Flowjo software 
and Graphpad prism.* = p<0.05 
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No significant differences were observed between the percentage of CD3+ T cells, 
which were either CD4+ or CD8+ in all the different patient groups (Figure 4.12).  
 
Figure 4.12. Percentage of CD3+ cells that were either CD4+ or CD8+ across all patient groups. Cells 
were prepared as discussed in the methods and legend of figure 4.3. Data was analysed with Flowjo 
software and Graphpad prism.* = p<0.05 
 
The percentage of CD4+ T cells in the MS group was significantly higher than the 
percentage of CD8+ T cells observed in this group. Similarly, the percentage of CD4+ T 
cells in the IIH group outnumbered CD8+ T cells in the IIH group. In addition, OND CD4+ 
T cells outnumbered OND CD8+ T cells (Figure 4.13). 
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Figure 4.13. Percentage of CD3+ cells that were CD4+ vs. CD8+ across all patient groups. Cells were 
prepared as discussed in the methods and legend of figure 4.3. Data was analysed with Flowjo software 
and Graphpad prism.* = p<0.05 
 
4.3.3 Expression of cell surface markers on CSF-resident CD4+ T cells 
Following determination of the number and percentage of CD4+ and CD8+ T cells 
present, further analysis investigated the expression of a variety of cell surface 
markers. Figure 4.14 gives an overview of the expression of these markers on CD4+ T 
cells.  
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Figure 4.14. Expression of cell surface markers on CD4+ T cells. Cells were prepared as discussed in the 
methods and legend of figure 4.3. Data was analysed with Flowjo software and Graphpad prism.* = 
p<0.05 
 
When comparing individual cell surface markers (Figure 4.15) only CD4+CD49d+ and 
CD4+CD27+ T cells were significantly higher in the MS group compared with IIH CD4+ T 
cells (p<0.05). Otherwise, no differences were observed between the cell surface 
marker expression in all three groups. CD4+ T cells appear to be of CD27+CD49+CD57-
CD95+CD127+ phenotype. In a subset of MS patients (n=12), PD-1 expression was 
analysed with a mean expression of 4.6% of CD4+ T cells. 
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Figure 4.15. Expression of individual cell surface markers on CD4+ T cells. Cells were prepared as 
discussed in the methods and legend of figure 4.3. Data was analysed with Flowjo software and 
Graphpad prism.* = p<0.05 
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4.3.4 Expression of cell surface markers on CSF-resident CD8+ T cells. 
Figure 4.16 gives an overview of the expression of cell surface markers on CD8+ T cells.  
 
Figure 4.16. Expression of cell surface markers on CD8+ T cells. Cells were prepared as discussed in the 
methods and legend of figure 4.3. Data was analysed with Flowjo software and Graphpad prism.* = 
p<0.05 
 
In contrast to CD4+ T cells, more differences were observed in CD8+ CSF-resident T 
cells. In particular, expression of CD27, CD49d and CD57 by CSF-resident CD8+ T cells 
was significantly higher amongst MS patients than IIH controls (Figure 4.17). However, 
across all groups, the majority of CSF-resident CD8+ T cells in our study were 
CD27+CD49+CD57-CD95+ with CD127 expressed more variably when compared with the 
CD4+ population. A mean of 2.4% CD8+ T cells in the MS group expressed PD-1 (n=10). 
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Figure 4.17. Expression of individual cell surface markers on CD8+ T cells. Cells were prepared as 
discussed in the methods and legend of figure 4.3. Data was analysed with Flowjo software and 
Graphpad prism.* = p<0.05 
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4.3.5 Differentiation of CSF-resident CD4+ T cells 
The majority of cells present in the CD4+ T cell population were of the effector memory 
subtype as determined by the expression of CCR7 and CD45RA (CCR7-CD45RA-) (Figure 
4.18).  
 
 
 
 
 
 
 
 
 
 
Figure 4.18. Percentage of naïve, central memory, effector memory and effector memory-RA (TEMRA) 
CD4+ T cells. Cells were prepared as discussed in the methods and legend of figure 4.3. Data was 
analysed with Flowjo software and Graphpad prism. 
 
The mean percentage of naïve CD4+ T cells for the MS, IIH and OND groups was 0.1%, 
0.4% and 0.2% respectively. For central memory cells the mean percentages were 
1.4%, 9.5% and 5.7% for the MS, IIH and OND groups respectively. Effector memory 
percentages were: MS, 90.7%; IIH, 82.3%; OND 89.8% and for effector memory-RA 
CD4+ T cells: MS, 7.8%; IIH, 7.9% and OND, 4.3%. No significant differences were 
observed between patient groups for the percentage of naïve, central memory, 
effector memory or effector memory-RA cells present (Figure 4.19).  
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Figure 4.19. Percentage of naïve, central memory, effector memory and effector memory-RA (TEMRA) 
CD4+ T cells displayed by patient group. Cells were prepared as discussed in the methods and legend of 
figure 4.3. Data was analysed with Flowjo software and Graphpad prism. 
 
4.3.6 Differentiation of CSF-resident CD8+ T cells 
As with CD4+ CSF-resident T cells, the majority of cells present in the CD8+ T cell 
population were of the effector memory phenotype (Figure 4.20).  
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Percentage of naïve, central memory, effector memory and effector memory-RA (TEMRA) 
CD8+ T cells. Cells were prepared as discussed in the methods and legend of figure 4.3. Data was 
analysed with Flowjo software and Graphpad prism. 
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The mean percentage of naïve CD8+ T cells for the MS, IIH and OND groups was 0.1%, 
1.8% and 3.3% respectively. For central memory cells the mean percentages were 
0.3%, 1.5% and 6% for the MS, IIH and OND groups respectively. Effector memory 
percentages were: MS, 65.3%; IIH, 69.2; OND 66.1% and for effector memory-RA cells: 
MS, 34.3%; IIH, 27.5% and OND, 24.5%. No significant differences were observed 
between patient groups for the percentage of naïve, central memory, effector memory 
or effector memory-RA cells present (Figure 4.21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21. Percentage of naïve, central memory, effector memory and effector memory-RA (TEMRA) 
CD8+ T cells displayed by patient group. Cells were prepared as discussed in the methods and legend of 
figure 4.3. Data was analysed with Flowjo software and Graphpad prism. 
 
Interestingly, in the MS group the percentage of naïve, central memory and effector 
memory cells in the CD4+ T cell compartment was significantly higher than in the CD8+ 
T cell compartment. However, this was reversed for TEMRA cells whereby the 
percentage of CD8+ TEMRA cells was significantly higher (Figure 4.22).  
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Figure 4.22. Percentage of naïve, central memory, effector memory and effector memory-RA (TEMRA) 
cells for the CD4+ and CD8+ compartments in the MS group. Cells were prepared as discussed in the 
methods and legend of figure 4.3. Data was analysed with Flowjo software and Graphpad prism.* = 
p<0.05 
 
In the IIH group, the percentage of central memory and effector memory cells in the 
CD4+ T cell compartment outnumbered the percentage observed in the CD8+ T cell 
compartment, although again the percentage of TEMRA cells in the CD8+ T cell 
compartment outnumbered the percentage of TEMRA cells observed within the CD4+ T 
cell compartment (Figure 4.23).  
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Figure 4.23. Percentage of naïve, central memory, effector memory and effector memory-RA (TEMRA) 
cells for the CD4+ and CD8+ compartments in the IIH group. Cells were prepared as discussed in the 
methods and legend of figure 4.3. Data was analysed with Flowjo software and Graphpad prism.* = 
p<0.05 
 
In OND patients, the percentage of effector memory cells within the CD4+ T cell 
compartment was significantly higher than in the CD8+ T cell compartment, with the 
percentage of TEMRA cells in the CD8+ T cell compartment again being significantly 
higher than that observed within the CD4+ T cell compartment (Figure 4.24). 
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Figure 4.24. Percentage of naïve, central memory, effector memory and effector memory-RA (TEMRA) 
cells for the CD4+ and CD8+ compartments in the OND group. Cells were prepared as discussed in the 
methods and legend of figure 4.3. Data was analysed with Flowjo software and Graphpad prism.* = 
p<0.05 
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4.4 Discussion 
As Multiple sclerosis is considered to be of inflammatory aetiology, it is of central 
importance to understand the complex milieu of CSF-resident cells present in the 
disease. In particular, as CD4+ and CD8+ T cells have been demonstrated to play a key 
role in disease pathogenesis, developing a clear picture of their immunophenotype is 
crucial. Results of previous studies have yielded inconsistent findings with respect to 
the prevalence of different cell populations present in CSF and in some cases have 
been hampered by the lack of CSF from control populations or by the use of a limited 
number of phenotypic markers. When control populations have been studied this has 
also varied between studies, therefore making comparisons difficult. 
 
Expression of CCR7 and CD45RA helps to identify naïve (CD45RA+CCR7+), central 
memory (CD45RA-CCR7+), effector memory (CD45RA-CCR7-) and effector memory-RA 
(CD45RA+CCR7-) T cells.93 In previous studies, CD4+ and CD8+ effector memory T cells 
have been demonstrated to be the predominant CSF-resident population in MS79, 93, 97 
although memory, and specifically central memory T cells were the dominant 
population in other studies (Table 4.1).50, 91, 98-102 Central memory T cell populations 
have also been shown to be the predominant T cell population in controls including 
those without history of neurological disease attending for routine surgery.50, 98, 99, 103  
 
Although effector memory or central memory T cells have been shown to be enriched 
in MS CSF, this is not exclusive to this group of patients (Table 4.1). For example, 
Mullen et al demonstrated that patients with MS had a higher percentage of effector 
memory T cells in the CSF compared with non-inflammatory controls, but this was also 
observed in patients with other inflammatory central nervous system disorders 
(OIND).93 Giunti et al demonstrated a similar observation albeit with central memory 
cells being increased in the CSF of patients with MS and OIND.98 Kivisakk et al showed 
an enrichment of central memory CD4+ and CD8+ T cells in the CSF in patients with 
non-inflammatory neurological disorders (NIND) and in MS CD4+ T cells, with no 
difference when compared with NIND.50, 99 Similarly in a relatively large study by de 
Graaf et al which involved patients attending for routine surgery, a predominance of 
central memory T cells was observed in CSF-resident CD4+ and CD8+ T cells.103 
Svenningsson et al91 did not show any differences between MS patients, other 
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neurological disorders (OND) or healthy volunteers, where the majority of CSF-resident 
T cells were shown to be of memory phenotype (CD45RO+). Other studies have shown 
differences between MS CSF and controls97, 101, 102 or been hampered by the lack of 
control CSF.79, 100 
 
In another recent study investigating differences in phenotype, function and reactivity 
between peripheral blood, CSF, and normal appearing white matter (NAWM) versus 
white matter lesions (WML) in 27 patients with MS,104 the distribution of CD8+ naive, 
central memory, effector memory and TEMRA cells in these compartments resembled 
data on white matter and CSF under ‘normal’ CSF conditions.103, 341 Central memory T 
cells predominated in the CSF and effector memory T cells were enriched in the 
NAWM and WML. Contrary to normal CNS conditions, effector memory CD8+ T cells In 
MS lesions expressed a cytotoxic effector phenotype indicative of local antigenic 
stimulation.104 However, a limitation of this study was that all samples were taken post 
mortem and therefore may not reflect the situation during life. In addition, all patients 
had a long progressive disease course and therefore the findings may not be relevant 
to earlier, relapsing forms of the disease. There were also no control groups, with 
previous studies used as comparisons. Of note, earlier studies that demonstrated 
memory or central memory T cells as the dominant population CSF-resident T cell 
population present used different cell markers to determine differentiation status such 
as CD45RO rather than the more accepted CCR7, CD45RA used now.50, 91, 98-102 
 
Because of the lack of differences between MS and control groups, some authors have 
suggested that CSF-resident T cells could have a similar immunophenotype in both 
patients and controls, representative of generic CNS immune surveillance.50, 91 Indeed, 
with recent advances in our understanding of CNS lymphatic drainage,21, 22 increased 
attention is being paid to normal immune surveillance of the CNS. The immune-
privileged status of the CNS is being revaluated and it is now becoming accepted that 
constant immune monitoring is being performed.  As such, similarities or differences 
between MS and controls will be important in understanding normal homeostasis as 
well as MS disease pathogenesis. 
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In addition to variations in patient numbers and whether control groups were used or 
not, when defining CSF-resident T cell populations, previous studies have used a 
limited number of different phenotypic markers (Table 4.1). In this study, 8 different 
cell surface markers were used; CCR7, CD45RA, CD27, CD57, CD127, CD49, CD95 and 
Pan γδ. Programmed cell death protein 1 (PD-1) was also used in a subset of MS 
patients. In addition to CCR7 and CD45RA, the expression of these other cell surface 
markers in a polychromatic flow cytometry panel helps to confirm the population of 
cells present. CD27 is a costimulatory molecule, the expression of which is gradually 
lost as cells differentiate.96 The function of CD57 is unknown but expression increases 
as cells differentiate.96 The IL-7 receptor CD127 increases in expression when cells 
differentiate from a naïve to central memory phenotype and is then lost again as cells 
differentiate further.96 CD95 (Fas), a death receptor is expressed by all memory T cells, 
after they have differentiated from a naïve state.96 CD49d (α-4 integrin) is the main 
adhesion molecule involved in lymphocyte trafficking to the CNS.342 PD-1 is expressed 
on activated T cells, B cells, and myeloid cells, and its expression is enhanced by classic 
programmed cell death. PD-1 and its ligand, programmed cell death ligand 1 (PD-L1), 
interact to downregulate the activation of T cells in autoimmune disease, chronic 
infection, and cancer.343 
 
In this study, idiopathic intracranial hypertension (IIH) patients constitute the largest of 
two control groups. After retrospective clinical case note review some patients 
investigated for a potential diagnosis of CIS/MS were deemed not to have 
inflammatory neurological disease. Along with other recruited cases, these patients 
formed a second control group of other neurological disorders (OND). IIH is a disorder 
characterised by raised intracranial pressure that is most prevalent in obese females 
between the ages of 20-44344. Clinically it can present with headaches, visual loss, 
pulsatile tinnitus, and back and neck pain.345 After appropriate neuroimaging, lumbar 
puncture is used to confirm raised intracranial pressure and may subsequently be used 
to relieve further episodes of headache or visual disturbance. Because of the necessity 
for repeated lumbar punctures and due to the patients being largely sex- and age 
matched to patients with MS, IIH makes an attractive control group. Although adipose 
tissue is now considered to be metabolically active,346 with one small study of eight 
patients with IIH having higher levels of chemokine ligand 2 (CCL2) compared with 
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controls in CSF347 there is little other evidence to consider the aetiology of IIH to be 
inflammatory in origin. In particular, it is largely thought to be a disorder of CSF 
dynamics either due to increased CSF production, malabsorption of CSF, increased 
venous sinus pressure or by a combination of these three factors.345 
 
Our results demonstrate that the number of CD4+ T cells/ml outnumber CD8+ T cells/ml 
across all patient groups. The number of CD4+ and CD8+ T cells/ml were also higher in 
the MS compared with the IIH and OND groups. With regard to CCR7 and CD45RA 
expression, the majority of both CD4+ and CD8+ CSF-resident T cells were CCR7-
CD45RA- therefore being of an effector memory phenotype. The other phenotypic 
markers in the panel demonstrated CD4+ T cells to be CD27+CD49+CD57-CD95+CD127+. 
CD8+ T cells demonstrated similar expression albeit with more variable expression of 
CD127. Interestingly, TEMRA cells were significantly higher in CD8+ T cells as compared 
with CD4+ T cells in all patient groups. This may indicate CD8+ T cells to be further 
differentiated than CD4+ T cells. The lack of expression of CD57 was surprising as this 
would be expected to be more highly expressed in differentiated cells. CD27 and 
CD49d expression was higher in the MS CD4+ population compared with IIH CD4+ T 
cells. Within CD8+ T cells, the expression of CD27, CD49d and CD57 were all 
significantly higher in the MS group as compared with IIH. Pan γδ expression was low 
across all patients groups as was PD-1 expression in a subset of MS patients. The 
significantly higher expression of CD49d suggests greater homing activity of CSF-
resident T cells in MS. The higher levels of CD27 may be relevant to regulatory activity, 
with expression of this molecule shown to correlate with regulatory activity.348 
 
Interestingly, apart from these small differences, no other significant differences in 
differentiation status were observed across all three different patient groups. This is 
intriguing as CSF-resident memory T cells in MS are generally thought to represent a 
pathogenic subset. With the control groups in our study consisting of patients with IIH 
and other non-inflammatory diseases it appears that these differentiated effector 
memory cells are a constant and may represent normal immune surveillance in the 
CNS. Although PD-1 was expressed at a low level across our patients, a recent study of 
peripheral blood CD8+ T cells has demonstrated high PD-1 expression in CD57+ CD8+ T 
cells in patients with stable MS as opposed to those with active disease.349 Therefore, 
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despite not being in clinical relapse, this suggests that our patients may have had 
vigorous, subclinical disease activity.  
 
T cells and other cells of the adaptive and innate immune systems are required to 
eliminate both pathogenic self and foreign antigens from the CNS. These cells may 
either be activated in the periphery or more centrally in CNS draining lymph nodes. 
These cells are then able to remove potentially pathogenic agents.16 The importance of 
CNS immune surveillance is demonstrated by the risk of a potential fatal brain 
infection, progressive multifocal leucoencephalopathy (PML) (caused by John 
Cunningham (JC) virus) following administration of natalizumab.261 Natalizumab, a 
monoclonal antibody against VLA-4 is licensed for use in relapsing remitting MS and 
prevents lymphocyte egress into the CNS and therefore reducing T cell mediated viral 
immune surveillance. 
 
If the immunophenotype of CSF-resident T cells is not unique to MS, then the question 
of how these cells are pathogenic arises. Despite very few differences in 
immunophenotype, there were significantly more CD4+ and CD8+ T cells/ml in patients 
with MS compared with IIH, which may be contributory. This would be consistent with 
the increased trafficking across the blood-brain barrier and blood-CSF barrier observed 
in MS.20 With these findings, it seems difficult to apportion blame for MS pathogenesis 
purely to the differentiation status of CSF-resident T cells. It is likely that differentiated, 
effector T cells are a natural component of the CNS acquired immune system but 
clearly a pathogenic subset must still be present to cause disease. As well as being 
activated (either peripherally or centrally) by their cognate antigen, differences in T 
cell function, cytokine responsiveness, cytokine production and homeostatic 
proliferation may also contribute to an individuals risk for MS.3, 350 In addition, perhaps 
the increased numbers of activated T cells tip the balance from homeostasis to 
disease. 
 
There may be an alternative explanation for the difference in T cell immunophenotype 
between our study and others demonstrating central memory T cells as the 
predominant cell type. Instead of being reflective of the normal CNS immune 
surveillance apparatus, it could be argued that the control samples in our study also 
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have an inflammatory basis. Autoimmune encephalitis and Guillain-Barre syndrome 
are well recognised to be autoimmune in nature, with the immune system also having 
a role to play in IIH,347 migraine351 and cerebrovascular disease.352 
 
In summary, CSF-resident CD4+ and CD8+ T cells have a similar phenotype across 
patients with MS, IIH and other neurological diseases. The majority of these cells have 
an effector memory phenotype suggesting they are antigen experienced and primed to 
elicit a rapid and robust response to target cells expressing specific pMHC molecules, 
resulting in their destruction. However, the observed T cell phenotype is likely to be a 
universal observation consistent with normal CNS immune surveillance and that 
additional factors are likely to contribute to disease pathogenesis. A limitation of this 
study was the lack of comparison with both peripheral blood and central nervous 
system tissue. Although peripheral blood was collected for additional experiments, 
brain or spinal cord tissue was not available in this study. If CNS tissue was available, it 
would be of obvious interest to investigate the detailed immunophenotype of T cells 
resident in the brain both of patients with MS and in controls and could be an avenue 
for future enquiry. Although previous studies have also analysed blood and CSF 
simultaneously, a recent study has indicated that blood samples are not representative 
of the CSF. A poor correlation between blood and CSF of 14 different immune cell 
subtypes in different inflammatory and non-inflammatory disorders was observed.111 
Therefore, it seems of importance to ensure future studies are aimed at CSF and CNS 
tissue, rather than focusing on the more easily accessible peripheral blood. Of note, 
we did not specifically examine for regulatory T cell populations in our samples, which 
may have contributed to the cellular populations present. It should also be noted that 
the median age at lumbar puncture was higher in the MS group compared with the IIH 
group. As intra-CNS inflammation is thought to decrease with older age, this should 
also be considered when interpreting the overall results. 
 
If the phenotype of CSF-resident T cells is the same across different patient groups, a 
key question raised would be how best to identify pathogenic T cell subsets from CSF 
or CNS tissue and whether the increased numbers of T cells is non-specific infiltration. 
Further characterisation of these CSF-resident T cells is important to understand if the 
significantly increased cell numbers observed is pathologically or clinically relevant. 
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This is of great importance with regard to future therapeutic drug design. Rather than 
using general immunosuppressants or immunomodulators that is current practice, 
knowledge of pathogenic T cell populations present in individual patients could lead to 
personalised T cell targeted medication. As such we performed TCR repertoire analysis 
of these T cell populations to investigate this further and is discussed in the following 
chapter. 
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Chapter 5 
 
Analysis of the CSF-resident T cell receptor repertoire in 
Multiple sclerosis 
 
5.1 Introduction 
 
5.1.1 T cell receptor structure and development 
T cells are characterised by the presence of the co-receptor molecules CD4 or CD8. 
Central to the interaction between T cells and antigen presented in combination with 
major histocompatibility complexes (MHC) is the T cell receptor (TCR). The majority of 
TCRs are heterodimers comprised of two subunit chains (α- and β-), which both 
contain constant and variable domains (Figure 5.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Two different classes of T cell receptors are determined by the presence of α and β, or γ 
and δ chains. Figure adapted from The Immune System, Parham P, Garland Science, 2009.15 
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Because of the need for a large diversity of TCRs, given the number of potential 
pathogens, the immune system utilises a system for diversification. TCR diversity is 
generated during the early stages of T cell development. During cell division, T cell 
progenitors undergo extensive gene recombination between the variable (V-) and 
junctional (J-) segments, and the V-, diversity (D-) and J- segments, in the TCR- α and 
TCR- β genes respectively. The region of TCR-β that spans the V-D and D-J junctions is 
known as the complementarity determining region 3 (CDR3) and is unique to each 
TCR-β variant (Figure 5.2). Following somatic diversification, T cells that lack sufficient 
affinity for MHC molecules and those that recognise self-antigens are eliminated 
(positive and negative selection respectively).14 
 
 
 
 
 
 
 
 
Figure 5.2. Complementarity determining region 3 (CDR3) region of the TCR-β chain. 
 
5.1.2 T cell clonal expansion 
Following activation, CD8+ T cells clonally expand and deliver a range of effector 
functions.  After clearance of the initial infection, a small proportion of these expanded 
cells survive and persist as a memory population.34 The previous chapter in this thesis 
has demonstrated that cerebrospinal fluid (CSF)-resident T cells in Multiple sclerosis 
(MS), idiopathic intracranial hypertension (IIH) and other neurological diseases (OND) 
are mainly of an effector memory phenotype. In keeping with a differentiated, effector 
phenotype, clonal expansion of this cellular subset would demonstrate prior activation 
and response to an antigenic stimulus.  
 
Although T cells and other constituents of the immune system have been implicated in 
MS pathogenesis2 and causative agents have been suggested151, the pathogenic 
stimulus and antigenic targets are currently unknown. Having an in depth knowledge 
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of clonally expanded T cell populations in MS and investigating their antigenic targets 
would therefore be fundamental in understanding disease pathogenesis, identifying 
novel therapeutic targets and developing new drugs. 
 
5.1.3 Evidence for T cell clonal expansion in Multiple sclerosis 
Many early studies of T cell clonal expansions in MS did not differentiate between 
CD4+ and CD8+ T cells (see table 5.1 for a full summary of all studies). More recent 
studies have reported monoclonal or oligoclonal expansions in the CD8+ T cell 
repertoire of MS patients, which has not been observed in the CD4+ T-cell repertoire.51, 
53, 54, 127, 130 As such it has been suggested that the expanded CD8+ T-cell population 
might be central to MS pathogenesis. Several authors have stated that determining the 
antigen specificity of these expanded CD8+ T-cell clonotypes is a research priority for 
the future.353 However, many of these studies have been comprised of a small number 
of MS patients, a lack of control populations and if controls are included then limited 
access to sample material other than peripheral blood (i.e. no CSF and CNS samples).51, 
53, 54, 127, 130 Therefore, although a consensus seems to have arisen in the literature 
suggesting that CD8+ T cell clonal expansions in MS are pathogenic, the limitations of 
these studies should heed caution in over interpretation. Nevertheless, understanding 
T cell clonal expansions, and in particular T cell receptor (TCR) repertoires and their 
role in MS disease pathogenesis needs further attention and analysis.  
 
Following earlier studies, Babbe et al performed Vβ polymerase chain reaction (PCR) 
and subsequent sequencing of single cells isolated from inflammatory brain lesions 
from two MS patients, with blood analysed by CDR3 spectratyping and sequencing. 
Oligoclonal expansions were seen in the CD8+ T cell repertoire in brain lesions, which 
were not observed in the CD4+ T cell repertoire. Interestingly, the same clonal 
expansions were observed in the blood of one MS patient at two separate time 
points.51 The same clonal expansions seen in the CD8+ T cell repertoire of the brain 
were subsequently observed in the CSF and blood in a follow-up study, even in one 
sample taken 7 years after the original brain biopsy.54 Other studies have also reported 
an oligoclonal expansion in the CD8+ T cell repertoire. Jacobsen et al observed a 
skewing of the TCRVβ repertoire in the CSF-resident CD8+ T cell repertoire in MS 
patients although no control CSF in this study was available for comparison. In this 
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study, no difference was seen in the peripheral blood between patients and 
controls.130 Complementary determining region 3-length distribution (CDR3-LD) 
alteration has also been shown to be significantly higher in MS patients, and more 
prominent in the CD8+ T cell population.128 Junker et al identified identical T cell clones 
in separate brain regions in 4 MS patients although the TCR repertoire was private to 
each patient. Some TCR sequences in this study were identified to be expressed by 
CD8+ T cells.52 However, control brains also showed oligoclonal expansions. In a more 
recent study of TCRVβ clonality in blood, CSF and brain from 3 patients with MS, CD8+ 
T cell clones were shown to exhibit strong sharing between the 3 repertoires, 
especially between the CSF and brain lesions.53 Again, control samples of blood only 
were available for comparison. In another study of peripheral blood, a clonal 
dominance of myelin proteolipid protein (PLP)-specific CD8+ T cells was seen in 
patients with MS. However, in countenance to this, clonal dominance within myelin 
basic protein (MBP)-specific CD8+ T cells was observed in healthy controls but not in 
patients with MS.137 Other studies have demonstrated oligoclonal expansions in MS 
patients but without defining whether the expansions belong to the CD4+ or CD8+ T cell 
population.120-127, 129, 134 Another recent study using deep sequencing technology 
demonstrated a significantly higher frequency of clonal expansions in MS blood and 
CSF compared with controls, although cells were not sorted into CD4+ and CD8+ 
populations.138 
 
Although these studies make a convincing case for CD8+ T cell clonal expansions being 
pathogenic, other studies suggest caution in over interpreting these data. Early studies 
demonstrated no oligoclonal expansions in CSF-resident T cells in 2 MS patients,131 and 
a polyclonal repertoire seen in active MS plaques.132 In addition, although TCRVβ usage 
was shown to be skewed in blood, this was not observed in CSF or brain in another 
study.133 Gran et al also demonstrated TCRVβ skewing that was present in MS patients 
and controls, with MS TCRVβ expansion returning to normal when analysed at a 
second time point.134 In a separate study, the TCR Vβ5-JB and TCR Vβ17-JB repertoire 
showed a less diverse pattern in the CSF samples compared with blood not just in MS 
but also in patients with other neurological diseases.135 In an interesting twin study of 
blood, a Gaussian distribution was observed in CD4+ T cells with widely skewed TCR 
spectratypes in the CD8+ T cell population. However, no correlation was found 
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between oligoclonality and disease with sequencing revealing shared TCRs between 
intra- and inter-pair twin members.136  
 
These studies suggest that the case for CD8+ T cell clonal expansion being pathogenic is 
far from conclusive. In particular, the main limitations of all the studies performed on 
CD8+ T cell oligoclonality is either the lack of controls entirely or if present, the lack of 
access to CSF and CNS tissue to compare the CD8+ T cell repertoire. In addition, many 
studies have examined the T cell repertoire as a whole without focus on CD4+ and CD8+ 
T cells specifically. It is also of note that CD8+ T cell clonal expansions are thought to be 
a common feature of the human T cell repertoire139 even in normal subjects and may 
be important for CNS immune surveillance.52 CD8+ T cell clonal expansions also occur 
with increasing age.140 Clearly this area needs further exploration to understand the 
relevance of clonal T cell expansions in MS and whether it is indeed just a normal 
feature of the adaptive immune system. However, if these clonal T cell expansions are 
pathogenic then it will be important to identify the antigenic target of these cells in 
order to further understand MS pathogenesis and develop targeted therapies. 
 
5.1.4 Aims and objectives 
In this study, I aimed to fully characterise the TCR repertoire of CSF-resident CD4+ and 
CD8+ T cells in MS. In contrast to the majority of other studies, I also aimed to analyse 
TCR usage from a relatively large cohort of control patients in order to establish 
whether CD8+ T cell clonal expansions are unique to MS patients. In depth knowledge 
of the TCRs that are clonally expanded would also allow identification of their target 
antigens, which will be explored in more detail in chapter 6 of this thesis. 
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Table 5.1. Summary of studies investigating the clonal expansion of T cell subsets in Multiple sclerosis. SB=Southern blotting; MBP=Myelin basic protein; 
OND=Other neurological diseases; HV=Healthy volunteers; OIND=Other inflammatory neurological disease; PLP=Proteolipid protein; CDR3-LD=complementarity 
determining region 3-length distribution. 
.
Author No.)of)MS) No.)of)Controls Technique) Tissue)studied Findings
Rotteveel'et'al'(1987)131 2 0 T'cells'clones'grown'from'CSF. CSF No'evidence'of'a'clonal'expansion'
SB'of'TCR'βFchain'gene'rearrangement.
Oksenberg'et'al'(1990)120 3 3 PCR'amplification'of'TCRVα'sequences. Brain Only'2F4'rearranged'Vα'transcipts'detected'in'each'of'3'MS'brains.
No'Vα'transcipts'in'controls'brains.
Results'imply'restriction'of'TCRVα'gene'expression'in'MS'brain'lesions.
Kotzin'et'al'(1991)122 7 No.'not'available MBP'T'cell'clones'made.' Blood Bias'for'Vβ'5.2'and''6.1'in'patients'but'not'in'controls.
βFchain'(Vβ)'and'αFchain'(Vα)'variable'
regions'analysed'by'PCR.
Lee'et'al'(1991)121 9 8'OND T'cells'from'blood'and'CSF'cloned'before! Blood' Oligoclonal'T'cell'clones'identified'in'both'the'CSF'and'blood'in'5/9'MS'patients.
4'HV in'vitro'expansion. CSF No'clonal'expansion'in'controls.
Clonotypes'compared'by'SB'analysis' (Blood'only'for'HV) Common'Vβ12'usage'between'blood'and'CSF'in'3'MS'patients.
' of'TCR'β'and'α'chains.' Identical'clones'between'blood'and'CSF'in'3'MS'patients.
Birnbaum'et'al'(1992)133 4 4'OND T'cell'Vβ'PCR.' Blood Blood'Vβ'useage'skewed'in'genes'1F8.
CSF No'skewing'in'CSF'or'brain.
Brain'(2'MS'patients;'1'OND) Different'Vβ'expression'patterns'between'paired'blood'and'CSF.
No'disease'specific'pattern'in'CSF'or'blood.
Brain'Vβ'pattern'different'and'less'heterogeneous'than'paired'blood.
Vβ12'increased'in'MS'brains.'
Wucherpfennig'et'al'(1992)132 6 0 T'cell'Vα'and'Vβ'PCR'and'SB. Brain Broad'TCR'Vα'and'Vβ'repertoire'in'active'lesions.'
Fewer'TCR'V'genes'detected'in'chronic'plaques'and'control'samples.
Differences'in'the'TCR'repertoire'between'plaques'from'the'same'case.
Data'suggest'TCR'repertoire'in'MS'plaques'is'polyclonal.'
Monteiro'et'al'(1996)123 125 Unknown CD8+'T'cell'multiplex'PCR'assay' Unknown CD8+'T'cell'clonal'dominance'frequent'in'MS'patients.
(Abstract'only) for'CDR3'length. (Abstract'only) Increased'frequency'in'Vβ'9,'18'and'23.
High'sequence'diversity'in'clonally'dominant'TCRs.
Identical'TCR'Vβ'sequence'from'2'different'MS'patients.
Gran'et'al'(1998)134 40 20'HV TCR'Vβ'PCR'and'sequencing. Blood Nine'MS'patients'had'expansion'of'one'or'more'Vβ'segments.'
Six'MS'patients'had'expansion'of''Vβ9.'3'also'had'expansion'of'Vβ'1,'11'and'22.
TCR'Vβ9'further'analysed'and'found'to'be'polyclonal.
Skewed'repertoire'returned'to'normal'in'5'patients'assessed'at'2'time'points.'
Some'TCR'Vβ'expansions'were'present'in'controls'and'not'MS'patients.'
Lozeron'et'al'(1998)135 20 11'OND T'cell'Vβ'PCR'using'Vβ5'and'Vβ17' Blood' Less'diverse'Vβ5FJβ'and'Vβ17FJβ'repertoire'in'CSF'c/w'blood'in'all'samples.
with'a'combination'of'Jβ'primers. CSF Three'MS'patients'had'expansions'with'identical'CDR3'length'in'the'CSF.
CDR3'length'analysed'by''Immunoscope'.
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Table 5.1 (continued). Summary of studies investigating the clonal expansion of T cell subsets in Multiple sclerosis. 
 
 
 
 
Author No.)of)MS) No.)of)Controls Technique) Tissue)studied Findings
Babbe%et%al%(2000)51 2 0 Single%cell%T%cell%Vβ%PCR% Blood CD8+%T%cell%population%oligoclonal.
and%sequencing%from%MS%lesions. Brain 1%patient%had%matching%CD8+%clone%in%blood%and%brain.
Blood%analysed%by%CDR3% CD4+%T%cell%population%polyclonal.
spectratyping%and%sequencing.
Gestri%et%al%(2001)124 11 10%OIND T%cell%Vβ%seminested%PCR% Blood CSF%oligoclonal%T%cell%expansions%found%in%13%patients%
with%heteroduplex%analysis. CSF with%CNS%inflammatory%disease.
Monoclonal%expansions%found%in%5%patients.
Muraro%et%al%(2002)125 4 20%HV TCR%%Vβ%PCR. Blood Expansions%of%TCR%Vβ%genes%in%MS%patients%were
significantly%more%frequent%than%in%controls.%%%%%%%
Expansions%were%predominantly%oligoclonal.
Expansions%significantly%correlated%with%responses%
to%MBP%and%MRI%disease%activity.
Jacobsen%et%al%(2002)130 36 75%HV% Flow%cytometry% Blood No%difference%in%Vβ%expression%in%blood%between%patients%and%controls.%
with%Vβ%antibodies. CSF No%control%CSF%for%comparison.
TCR%sequencing%in%2%patients. (Blood%only%for%HV) TCR%Vβ%chain%expression%differs%between%CSF%and%blood%from%
MS%patients%and%mainly%in%CD8+%T%cells.
Skewing%of%CSF%is%due%to%expansion%of%CD8+%T%cells%with%
similar%or%identical%TCRs.
Matsumoto%et%al%(2003)126 42 30%HV% TCR%CDR3%spectratyping% Blood% Vβ5.2%and%24%%significantly%expanded%in%blood%%compared%with%controls.
and%sequencing. CSF%(5%patients) Vβ%5.2%most%dominant%in%CSF%but%unable%to%compare%as%no%control%CSF.%
(Blood%only%for%HV)
Skulina%et%al%(2004)54 2 0 CDR3%spectratyping% Blood FollowYon%from%Babbe%et%al%(2000).
(1%from%Babbe%et%al) and%sequencing.% CSF Several%identical%CD8+%T%cell%clones%found%in%blood,%CSF%and%brain.
Brain% One%clone%was%present%in%blood%7%years%after%original%brain%biopsy.%
Laplaud%et%al%(2004)128 35%(includes%CIS) 13%HV TCR%Vβ%CDR3YLD%spectratyping.% Blood Mean% %alteration%of%CDR3YLD%significantly%
higher%in%MS%compared%with%controls.
Alterations%more%prominent%in%CD8+%T%cells.
 125 
 
 
 
Table 5.1 (continued). Summary of studies investigating the clonal expansion of T cell subsets in Multiple sclerosis. 
 
Author No.)of)MS) No.)of)Controls Technique) Tissue)studied Findings
Muraro&et&al&(2006)129 1 0 Vβ&and&CDR3&spectratyping. CSF Relapse&vs.&remission&in&one&patient&with&MS.
(No&sequencing)& Changes&in&Vβ&gene&family&expression&between&
relapse&and&remission.
Laplaud&et&al&(2006)127 9 14&HV Vβ&CDR3&spectratyping. Blood Significant&blood&skewing&in&MS&compared&
with&controls&(Vβ&5.2,&12,&8&and&21).
TCR&alterations&also&seen&in&controls.
Positive&correlation&between&the&change&in&
blood&TCR&biases&and&lesion&activity.&
Somma&et&al&(2006)136 5&pairs&of&identical&twins& 0 TCR&CDR3&spectratyping. Blood Gaussian&distribution&of&CD4+&T&cells.
4&pairs&discordant&for&MS Skewed&TCR&spectratypes&for&CD8+&T&cells.
1&pair&concordant No&correlation&between&oligoclonality&and&disease.
Shared&TCRs&between&intraX&and&interXpair&twin&members.
Junker&et&al&(2007)52 4 0 Vβ&CDR3&spectratyping Brain Identical&T&cell&clones&detected&in&separate&brain&regions.
and&sequencing. TCR&repertoire&oligoclonally&diverse&in&each&brain.
Some&TCR&sequences&were&from&CD8+&T&cells.
The&TCR&repertoire&was&private&to&each&patient.&
Control&brains&also&showed&oligoclonal&expansions.
Biegler&et&al&(2011)137 3 3&HV ShortXterm&culture,&FACS& Blood Clonal&dominance&within&MBPXspecific&CD8+&T&cells&in&HV,&but&not&MS.
and&nonXbiased&PCR. Distinct&TCR&Vβ&usage&in&MBPXreactive&CD4+&T&cells&in&MS.
Clonal&dominance&of&PLPXspecific&CD8+&cells&in&MS.
Salou&et&al&(2015)53 3 4&MS& Vβ&CDR3&spectratyping&and Blood Post&mortem&tissue.
4&HV highXthroughput&sequencing. CSF Private&T&cell&clones&(CD8+).
Brain Brain&CD8+&TCR&repertoire&closer&to&CSF&than&blood.
(Blood&only&for&controls) Different&brain&lesions&had&the&same&CD8+&repertoire.
de&Paula&Alves&Sousa&(2016)138 5 5&IIH Deep&sequencing.& Blood TCR&repertoire&diversity&greater&in&blood&and&CSF&of&MS&
CSF compared&with&controls.
Frequency&of&clonal&expansions&in&MS&significanlty&higher&in&
blood&and&CSF&compared&with&controls.
Highly&expanded&T&cell&clones&enriched&in&MS&CSF&
compared&with&blood.
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5.2 Methods 
Patients included in this section of the study were recruited as described in Chapter 4 
of this thesis.  
 
5.2.1. Clonotyping of TCR repertoires 
CSF samples were sorted into CD4+ and CD8+ T cells by flow cytometry as described. 
TCR usage in these populations was analysed using a strand-switch anchored RT-PCR 
approach that enables quantitative characterisation of TCR gene usage without bias.291 
The clonotyping technique used for this analysis is described in detail in the materials 
and methods section (Chapter 2) of this thesis but will be briefly described below. 
 
Firstly, frozen CD4+ and CD8+ T cell samples stored in freezing media were thawed at 
room temperature then centrifuged at 15000g for 7 mins at 4oC. mRNA was then 
extracted using Miltenyi’s μMACS mRNA Isolation kit (Miltenyi Biotec, Bisley, UK) as 
described. cDNA was subsequently made using a SMARTerTM RACE cDNA Amplification 
kit (Takara Clontech, Saint-Germain-en-Laye, France) and either used immediately or 
stored at -80oC until required. The TCR β-chain product was then amplified by PCR. The 
cDNA PCR product was subsequently isolated by agarose gel electrophoresis and 
extracted under UV light, then extracted and cloned using the TOPO® TA Cloning® Kit 
for Sequencing with One Shot® MAX Efficiency® DH5α-T1R E. coli (Thermofisher, 
Waltham, MA, USA) as per the manufacturers instructions. Bacteria were subsequently 
grown and white colonies containing the CDR3 amplicon were picked into a 96 well 
plate and colony PCR performed. Plates were then sent for sequencing (Genewiz, 
South Plainfield, USA) and analysis performed using sequencher software (Gene codes 
corporation, Ann Arbor, USA), the IMGT (international ImMunoGeneTics information 
system) website, Microsoft Excel (Redmond, USA) and Graphpad prism (La Jolla, USA). 
Of note, sorted cell samples <100 cells were not clonotyped for all patient groups. 
 
5.2.2. Data processing and analysis 
Following sequencing, data was imported into sequencher and sequence ends 
trimmed. If quality scores for each individual sequence were <50%, data was excluded 
from the analysis. Included data was then converted to TCR sequences using the IMGT 
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website and exported into Microsoft Excel. TCRs were then filtered and only ‘in-frame’ 
sequences chosen for further analysis. TCR sequences were excluded if amino acid 
sequences were not consistent with known CDR3 regions to the particular TCRVb 
region. Once determined, TCR frequencies were sorted according to the following 
hierarchy: 1. TCR frequency 2. CDR3 amino acid length 3. Highest TRBV 4. Highest TRBJ. 
Data analysis was performed in Microsoft Excel (Redmond, USA) and Graphpad prism 
(La Jolla, USA). TCR diversity and the degree of clonal expansion was assessed as 
described below. Additional analysis was also performed by Dr Vanessa Venturi 
(Infection Analysis Program, The Kirby Institute, UNSW Australia, Sydney, NSW 2052, 
Australia) and Dr Adel Rahmani (School of Mathematical Sciences Physical Sciences, 
University of Technology Sydney, 15 Broadway, Ultimo, NSW 2007, Australia). Dr 
Venturi and Dr Rahmani have expertise in using computational biology approaches to 
understand immunological data. 
 
5.2.3 Samples with TCR frequencies <50 and overlapping TCRs 
Of note, where initial clonotyping yielded overall TCR frequencies of <50 these samples 
were repeated either from the original mRNA, cDNA or gel extraction stages of the 
clonotyping method. When the repeat sample was >50, this was included in the 
analysis and the original TCR analysis discarded. If the repeat sample had <50 TCR 
frequencies then this patient sample was excluded from the analysis. Similarly, 
clonotyping samples with overlapping TCRs were repeated. Original results were 
discarded if the repeat samples were unsuccessful. Following, this approach, the 
minimum remaining sample size across all the remaining CD4+ and CD8+ T cell 
repertoires was 54 TCR sequences. 
 
5.2.4 TCR repertoire sample diversity analysis 
To investigate the diversity of both the CD4+ and CD8+ T cell repertoires, two different 
approaches were used. The first was to evaluate the number of unique (V+CDR3+J) 
TCR clonotypes in each TCR repertoire and the second was to determine Simpson’s 
diversity index.354 Simpson’s diversity index provides a relative measure of the 
evenness of the abundances (i.e. number of copies) across the unique observations 
(i.e. unique TCR clonotypes) in each TCR repertoire, and ranges in value from 0 
(minimal diversity) to 1 (maximal diversity).355 To compare diversities between the MS, 
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IIH and OND groups, the Kruskall-Wallis test with Dunn’s post-test was used. The 
Mann-Whitney test was used to compare diversities between the MS group and the 
combined IIH and OND cohorts. The Wilcoxon test was used to compare diversities 
between the CD4+ and CD8+ T cell repertoires across patients for whom both CD4+ and 
CD8+ T cell samples were available. 
 
5.2.5 Clonal expansion analysis 
To determine the degree of clonal expansion, TCRs that constitute the top 10% of each 
TCR repertoire were identified and their contribution to the overall repertoire was 
assessed. Of note, if there were fewer than 10 TCR clonotypes within a patient sample, 
the top clonotype was taken to represent the top 10%. In some cases with for 
example, only 1 TCR, this TCR was taken to contribute 100% of the repertoire; similarly 
if there were only 2 TCR clonotypes, then the frequency of the top TCR was taken to 
represent the top 10% despite it actually being the top 50%. This continued for up to 
10 unique TCR clonotypes. When 3 groups were compared, the Kruskall-Wallis test 
with Dunn’s post test was used to calculate significance. When comparing 2 groups, 
the Mann-Whitney test was used. In addition to this initial analysis, a cumulative 
clonotype frequency distribution analysis was performed by Dr Venturi and Dr 
Rahmani. This analysis compared the cumulative proportion of unique clonotypes 
against the cumulative proportion of the total repertoire. 
 
5.2.6 TCR Vβ staining of peripheral blood 
TCRVβ staining was performed where matching peripheral blood was available. Patient 
PBMCs were thawed and centrifuged at 1500 rpm for 5 mins. Cells were resuspended 
in 8ml PBS and divided between 8 FACS tubes. Tubes were then centrifuged at 2000 
rpm for 2 mins and supernatant discarded. 8 μl aqua was then added to each sample 
and incubated for 10 mins at room temperature. After 10 mins, V beta antibodies (A-
H) (IOTest® Beta Mark, Beckman Coulter, Brea, USA) were added to each of the 8 
tubes along with the following antibodies (CD14, CD19, CD3, CD8, CD4, CD27, CD45, 
CD95, CCR7, CD127, CD49d) and incubated for 30 mins at 4oC. Following this, 1 ml PBS 
was added to each tube and centrifuged at 2000 rpm for 2 minutes. Supernatant was 
then discarded, 100 μl PBS added and samples analysed on a FACSAria II. The IOTest® 
Beta Mark Kit is a multi-parametric analysis tool designed for quantitative 
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determination of the TCRVβ repertoire of human T lymphocytes by flow cytometry. 
Eight vials (labeled A-H) each containing 3 different TCRVβ mAb are used. The first 
mAb within each labeled vial is FITC-conjugated, a second one is PE-conjugated and a 
third one is a mixture of a PE- and a FITC-conjugated form. The 8 vials containing 
mixtures of conjugated TCRVβ antibodies correspond to 24 different specificities 
(about 70% coverage of normal human TCR Vβ repertoire). The TCRVβ included in this 
assay were as follows; 4-1 4-2 4-3, 5-5, 28, 3-1, 19, 14, 5-1, 18, 30, 6-5 6-6 6-9, 6-6, 12-
3 12-4, 5-6, 10-3, 20-1, 9, 11-2, 13, 2, 25-1. Data analysis was performed in Microsoft 
Excel and Graphpad prism.  
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5.3 Results 
 
5.3.1. Inclusion and exclusion of samples 
Of the 21 patient samples available in the MS patient cohort, clonotyping was 
performed on 20 patients. One patient sample (DD22299) was not sorted due to 
technical issues with the flow cytometer. Of the 20 patient samples, CD4+ T cells only 
were clonotyped for 2 patient samples; one (CT25364) because of unsuccessful CD8+ T 
cell clonotyping and one (HD2165) where CD8+ T cell clonotyping was not performed 
due to a sorted cell count of <100. Of the 14 IIH patient samples, 3 samples were 
excluded from clonotyping analysis: 1 sample (DC37877) was lost after sorting; 1 
sample (FC24414) was excluded because of contamination of the CD4+ T cell sample, 
with the CD8+ T cell sample <100 cells; 1 sample (VE25562) was excluded because it 
was macroscopically bloodstained after lumbar puncture. In the OND group, 3 patient 
samples were excluded from clonotyping analysis: 1 sample had a low number of cells 
in both the CD4+ T cell and CD8+ T cell sort (DL37517); 1 sample had no live cells 
(JJ37566); 1 sample was macroscopically bloodstained and therefore excluded 
(JP24822).  
 
Overall, in the MS group, 18 complete (CD4+ and CD8+ T cell) samples were clonotyped. 
For 2 patient samples, CD4+ T cell clonotyping only was included for analysis. In the IIH 
group, there were 3 complete patient samples (CD4+ and CD8+ T cells), 7 patient 
samples with results for CD4+ T cells only and 1 patient sample with results for CD8+ T 
cells only. In the OND group, there were 5 complete patient samples (CD4+ and CD8+ T 
cells) and 3 patient samples with results for CD4+ T cells only. Figure 5.3 summarises 
the patient samples available for phenotyping and clonotyping analysis. Tables 5.2-5.4 
give more details as to which samples were included or excluded and the reasons why. 
Due to the exclusion of samples with <100 cells, fewer CD8+ T cell samples in the 
control groups were included for analysis.  
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Figure 5.3. Summary overview of samples included for phenotyping and clonotyping. 
 
Idiopathic*intracranial*
hypertension*(IIH)*
14*
Other*neurological*
disorders*(OND)**
11*
Phenotyped*
13*
1*not*sorted*
Clonotyped*
CD4+%&%CD8+%>*3*
CD4+%only%%>*7*
CD8+%only%>*1*
Clonotyped*
CD4+%&%CD8+%>*5*
CD4+%only%%>*3*
Phenotyped*
7*
4*not*included*(see*
text)*
46*CSF*samples*
MulGple*sclerosis*(MS)*
21*
*1*not*sorted*
1*not*saved*
Phenotyped*
19*
Clonotyped*
CD4+%&%CD8+%>*18*
CD4+%only%–*2*
1*not*sorted* 3*excluded*–*
see*text*
3*excluded*–*
see*text*
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Table 5.2. Patients included for phenotyping and clonotyping in the MS group. Reasons for exclusion in the clonotyping analysis are described in the text. 
N.B.*denotes patients where CSF was collected but not included in the phenotyping analysis as described in section 4.3.1. 
Patient'ID Diagnosis Phenotyped Reason'for'exclusion
CD4 CD8
LC20552 MS Yes Yes Yes N/A
LJ20639 MS Yes Yes Yes N/A
LS20460* MS No Yes Yes N/A
MJ19588 MS Yes Yes Yes N/A
EB21510 MS Yes Yes Yes N/A
KG19967 MS Yes Yes Yes N/A
LH18836 MS Yes Yes Yes N/A
NW21326 MS Yes Yes Yes N/A
MW21576 MS Yes Yes Yes N/A
CS21983 MS Yes Yes Yes N/A
AL28847 CIS Yes Yes Yes N/A
MK21405 MS Yes Yes Yes N/A
SA23376 MS Yes Yes Yes N/A
RM22664 MS Yes Yes Yes N/A
TL22789 MS Yes Yes Yes N/A
CT25364 MS Yes Yes No UnsuccessfulG(CD8)
HD21265 MS Yes Yes No <100GsortedGcellsG(CD8)
MH21407 MS Yes Yes Yes N/A
RW21309 MS Yes Yes Yes N/A
DD22299* MS No No No NotGsorted
CG41964 MS Yes Yes Yes N/A
Clonotyped'&'included'in'analysis
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Table 5.3. Patients included for phenotyping and clonotyping in the IIH group. Reasons for exclusion in the clonotyping analysis are described in the text. 
N.B.*denotes patients where CSF was collected but not included in the phenotyping analysis as described in section 4.3.1. 
 
Patient'ID Diagnosis Phenotyped Reason'for'exclusion
CD4 CD8
EC21870 IIH Yes Yes No Unsuccessful5(CD8)
HS25204 IIH Yes Yes No <1005sorted5cells5(CD8)
LH25311 IIH Yes Yes Yes N/A
ML25308 IIH Yes Yes No Clonotyping5contaminated5(CD8)
SW25353 IIH Yes Yes Yes N/A
RY21758 IIH Yes Yes No Unsuccessful5(CD8)
DC37877 IIH Yes No No Sample5lost
ES37889 IIH Yes Yes No <1005sorted5cells5(CD8)
FC24414 IIH Yes No No Clonotyping5contaminated5(CD4)
<1005sorted5cells5(CD8)
VE25562* IIH No No No Not5sorted
CC40712 IIH Yes Yes Yes N/A
RC41200 IIH Yes Yes No <1005sorted5cells5(CD8)
KA38079 IIH Yes No Yes 5<505clonotypes5(CD4)
CC41471 IIH Yes Yes No <1005sorted5cells5(CD8)
Clonotyped'&'included'in'analysis
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Table 5.4. Patients included for phenotyping and clonotyping in the OND group. Reasons for exclusion in the clonotyping analysis are described in the text. 
N.B.*denotes patients where CSF was collected but not included in the phenotyping analysis as described in section 4.3.1. 
 
Patient'ID Diagnosis Phenotyped Reason'for'exclusion
CD4 CD8
SE29703* Autoimmune1encephalitis No Yes Yes N/A
JG33488 Normal1pressure1hydrocephalus Yes Yes No Unsuccessful1(CD8)
ND37140 Fibromyalgia Yes Yes Yes N/A
DL37517* GuillainNBarré1syndrome No No No Minimal1sorted1cells1(CD4)
<1001sorted1cells1(CD8)
CS19395 Cerebrovascular1disease Yes Yes No Unsuccessful1(CD8)
AG20355 Visual1field1defect1of1unknown1aetiology Yes Yes No Clonotyping1contaminated1(CD8)
JM25229 Pseudopappiloedema1N1drusen/OSA Yes Yes Yes N/A
AB25236 Migraine1 Yes Yes Yes N/A
CJ26014 Migraine Yes Yes Yes N/A
JJ37566* Migraine No No No No1live1cells
JP24822* Small1vessel1disease No No No Bloody1sample
Clonotyped'&'included'in'analysis
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5.3.2 Initial TCR diversity analysis 
The raw data from the clonotyping analysis is displayed in Appendix, Section 8.2. Each 
patient sample is ordered as described in the methods: 1. TCR frequency, 2. CDR3 
amino acid length, 3. Highest TRBV; and 4. Highest TRBJ. Initially, the number of 
unique TCR clonotypes for each patient sample was calculated. In this regard, the 
number of unique TCR clonotypes was significantly higher in the CD4+ T cell repertoire 
of MS patients compared with both the IIH (p<0.05) and OND patient groups (p<0.05). 
No significant difference was seen between the number of unique clonotypes in the 
CD4+ T cell repertoire between IIH and OND controls. For CD8+ T cell repertoires, no 
significant differences were observed between the MS group and either the IIH or OND 
group alone, or between the IIH and OND groups. When TCR diversity in the MS 
patient group was compared to the IIH and OND groups pooled as one control group, 
significance was still observed in the CD4+ T cell repertoire (p<0.0001). In addition, 
significance was also observed in the CD8+ T cell repertoire (p=0.0324). These results 
are displayed in Figure 5.4. Although this analysis offered some insights into TCR 
repertoire diversity, additional analysis was performed in collaboration with 
computational biologists at the University of New South Wales and The University of 
Technology, Sydney, Australia. The results of these additional analyses are described in 
the following subsections. 
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Figure 5.4. Comparison of the number of unique clonotypes in the T cell repertoires. CD4+ (left panels) 
and CD8+ (right panels). When comparing across 3 patient groups (upper panels), the Kruskall-Wallis test 
with Dunn’s post test was used to calculate significance. When comparing 2 groups (lower panels) the 
Mann-Whitney test was used. 
 
5.3.3 Additional TCR repertoire sample diversity analysis 
In order to assess differences in TCR clonotype diversity between MS, IIH and OND 
groups, the number of unique TCR clonotypes and Simpson’s diversity index were 
estimated for a standard sample size of 54 TCR sequences (the lowest TCR frequency 
across all samples) obtained per sample. This analysis accounts for differences in the 
numbers of sequences obtained per sample. With regard to unique TCR clonotypes, 
significantly higher numbers of unique TCR clonotypes were observed in the CD4+ TCR 
repertoires in the MS group compared with both the IIH and OND groups. Similarly, 
the Simpson’s diversity index was significantly higher for the CD4+ TCR repertoires in 
the MS group compared with both the IIH and OND groups (Figure 5.5). Although the 
data suggests a trend towards a higher number of unique clonotypes and higher 
Simpson’s diversity index within the CD8+ TCR repertoire in the MS group compared to 
either the IIH or OND group alone, this did not reach significance. 
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Figure 5.5. Comparison of CD4+ and CD8+ TCR repertoire diversity between the MS, IIH and OND 
groups. The upper panels demonstrate the number of unique clonotypes (V+CDR3 sequence+J) 
estimated for a standard sample size of 54 TCR sequences per sample for the CD4+ (left panels) and 
CD8+ (right panels) T cell populations. The lower panels demonstrate the Simpson’s diversity indices 
estimated for a standard sample size of 54 TCR sequences per sample. Data points represent individual 
samples. The box plots show the inter-quartile range (IQR, shaded box) and median (horizontal line 
within box). Outliers are determined as data points more than 1.5x IQR below the 25th percentile or 
more than 1.5x IQR above the 75th percentile. The whiskers extend to the farthest non-outlier points. 
The TCR clonotype and TCR repertoire diversities of the MS, IIH and OND groups were compared using 
the Kruskall-Wallis and Dunn’s multiple comparison post-tests. Analysis performed by Dr Vanessa 
Venturi and Dr Adel Rahmani as described. 
 
As no significant differences were observed in TCR diversity between the IIH and OND 
groups, the two control groups were pooled together and compared with the MS 
group. This analysis demonstrated significantly higher numbers of unique TCR 
clonotypes in both the CD4+ and CD8+ TCR repertoires of MS patients compared with 
controls (IIH and OND combined) (Figure 5.6). In addition, Simpson’s diversity indices 
were significantly higher for both the CD4+ and CD8+ TCR repertoires of MS patients 
compared with patients in the combined control group (Figure 5.6). This additional 
analysis is in agreement with the initial analysis performed above (Figure 5.4). 
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Figure 5.6. Comparison of CD4+ and CD8+ TCR repertoire diversity between the MS and pooled control 
(IIH and OND) groups. The upper panels demonstrate the number of unique clonotypes estimated for a 
standard sample size of 54 TCR sequences per sample of CD4+ (left panels) and CD8+ (right panels) T cell 
populations. Simpson’s diversity indices are demonstrated in the lower panels, estimated for a standard 
sample size of 54 TCR sequences per sample. The TCR clonotype and TCR repertoire diversities of the 
MS and control group (IIH and OND) were compared using the Mann-Whitney test. Analysis performed 
by Dr Vanessa Venturi and Dr Adel Rahmani as described. 
 
5.3.4 Impact on number of sorted cells per sample on sample TCR 
diversity 
In order to assess whether the variation in the number of sorted cells per sample has 
an impact on TCR diversity analysis, further analyses were performed by Dr Venturi. A 
significant positive correlation was observed between TCR diversity (number of unique 
clonotypes and Simpson’s diversity index) and the number of sorted cells for both the 
CD4+ and CD8+ T cell populations in the MS group (Figure 5.7 & 5.8).  
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Figure 5.7. Correlation between TCR diversity and the number of sorted cells for the CD4+ population. 
Shown are the number of unique clonotypes (V+CDR3+J) and Simpson’s diversity index estimated for a 
standard sample size of 54 TCR sequences versus the number of sorted cells per sample. The data points 
are labelled by the sample ID. The correlation between TCR diversity and number of sorted cells for the 
MS group (upper panels) and the control group (lower panels) was assessed using a Spearman test. 
Analysis performed by Dr Vanessa Venturi and Dr Adel Rahmani as described. 
 
Conversely, no significant correlations were observed between TCR diversity (number 
of unique clonotypes and Simpson’s diversity index) and the number of sorted cells for 
either the CD4+ or CD8+ T cell populations in the control groups (Figures 5.7 & 5.8). 
However, there were fewer samples in total in the control groups, more CD4+ samples 
with <1000 cells and all of the CD8+ samples from control patients had <1000 cells. If 
the sorting of CD4+ and CD8+ T cells yielded a random sample of a much larger 
population with subsequent clonotyping revealing the TCR repertoire for a random 
sample of these sorted cells, then a correlation between TCR diversities (estimated for 
a standard-sized subsample) and the number of sorted cells would not be expected. 
Owing to the significant correlation in the MS group, further analysis was performed. 
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Figure 5.8. Correlation between TCR diversity and the number of sorted cells for the CD8+ population. 
Shown are the number of unique clonotypes (V+CDR3+J) and Simpson’s diversity index estimated for a 
standard sample size of 54 TCR sequences versus the number of sorted cells per sample. The data points 
are labelled by the sample ID. The correlation between TCR diversity and number of sorted cells for the 
MS group (upper panels) and the control group (lower panels) was assessed using a Spearman test. 
Analysis performed by Dr Vanessa Venturi and Dr Adel Rahmani as described. 
 
In order to understand more fully the correlation between TCR diversity and the 
number of sorted cells for both CD4+ and CD8+ T cell populations across MS but not for 
control patients, the depth of clonotype sequencing for the individual TCR repertoires 
was examined. Species accumulation curves were used to plot the accumulation of 
unique TCR clonotypes for increasing-sized subsamples of sequences from the original 
data (Appendix, Section 8.3). From this analysis, it was observed that many of the CD4+ 
and CD8+ T cell samples for MS patients were still accumulating new unique clonotypes 
at a high rate as the sample size approached the total number of sequences obtained 
per sample. This suggests that the MS TCR repertoires are more diverse and that the 
small samples obtained have not captured the full extent of the population diversity 
i.e. the observed sample diversity most likely underestimates the TCR repertoire 
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diversity more for MS than control samples. This suggests that the difference in TCR 
diversity between MS and control group may be larger than that observed.  
 
5.3.5 Comparison of TCR diversity between CD4+ and CD8+ TCR 
repertoires 
In order to assess the differences in the TCR clonotype diversities between the CD4+ 
and CD8+ T cell populations, the number of unique clonotypes and Simpson’s diversity 
index were estimated for a standard sample size of 54 TCR sequences per sample. Only 
patients with paired (CD4+ and CD8+) TCR repertoire data were considered for analysis. 
The MS and control (IIH and OND) groups were analysed separately. Following this 
analysis, significantly higher numbers of unique clonotypes and higher Simpson’s 
diversity indices in the CD4+ TCR repertoires compared with the CD8+ TCR repertoires 
were observed in MS patients (Figure 5.9).  No significant differences in diversity 
between the CD4+ and CD8+ TCR repertoire were observed in the combined control 
group (Figure 5.10).  
 
 
 
 
 
 
 
 
 
Figure 5.9. Comparison of TCR diversity between the CD4+ and CD8+ T cell repertoires of MS patients. 
The number of unique clonotypes (V+CDR3+J) estimated for a standard sample size of 54 TCR 
sequences per sample for the paired CD4+ and CD8+ T cell populations are shown in the left hand panel. 
Simpson’s diversity indices are demonstrated in the right hand panel. The TCR clonotype and TCR 
repertoire diversities of the CD4+ and CD8+ samples were compared using the Wilcoxon test. Analysis 
performed by Dr Vanessa Venturi and Dr Adel Rahmani as described. 
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Figure 5.10. Comparison of TCR diversity between the CD4+ and CD8+ T cell repertoires of control 
patients. The number of unique clonotypes (V+CDR3+J) estimated for a standard sample size of 54 TCR 
sequences per sample for the paired CD4+ and CD8+ T cell populations are shown in left hand panel. 
Simpson’s diversity indices are demonstrated in the right hand panel. The TCR clonotype and TCR 
repertoire diversities of the CD4+ and CD8+ samples were compared using the Wilcoxon test. Analysis 
performed by Dr Vanessa Venturi and Dr Adel Rahmani as described. 
 
5.3.6 TCR clonotype frequency and contribution to the overall repertoire 
Figures 5.11-5.16 demonstrate the frequency of each unique TCR clonotype across all 
three patient groups. This preliminary analysis demonstrates that clonotype frequency 
across the CD4+ and CD8+ T cell repertoires is not evenly distributed in the MS group 
and that oligoclonal expansions are frequently observed, which is consistent with what 
has been previously described in the literature. However, interestingly a similar 
hierarchical structure is also observed in the IIH and OND patient groups, which is even 
more marked than in the MS group. In fact, the CD4+ and CD8+ T cell repertoires in MS 
patient samples are composed of a greater number of lower frequency clonotypes 
compared to the control groups. In contrast, CD4+ and CD8+ T cell repertoires in the IIH 
and OND patient samples are composed of a small number of higher frequency 
clonotypes. Therefore skewing of both the CD4+ and CD8+ T cell populations occurs 
across all three patient groups but is less marked in the MS patient group.  
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Figure 5.11. Distribution of CD4+ TCR clonotype frequencies within the IIH group. Each unique TCR sequence was assigned a number sequentially i.e. 1, 2, 3 etc. The 
frequencies of these given TCR sequences were then plotted to demonstrate frequency distributions.  
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Figure 5.12. Distribution of CD4+ TCR clonotype frequencies within the OND group. Each unique TCR sequence was assigned a number sequentially i.e. 1, 2, 3 etc. 
The frequencies of these given TCR sequences were then plotted to demonstrate frequency distributions.  
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Figure 5.13. Distribution of CD4+ TCR clonotype frequencies within the MS group. Each unique TCR sequence was assigned a number sequentially i.e. 1, 2, 3 etc. The 
frequencies of these given TCR sequences were then plotted to demonstrate frequency distributions.  
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Figure 5.14. Distribution of CD8+ TCR clonotype frequencies within the IIH group. Each unique TCR sequence was assigned a number sequentially i.e. 1, 2, 3 etc. The 
frequencies of these given TCR sequences were then plotted to demonstrate frequency distributions.  
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Figure 5.15. Distribution of CD8+ TCR clonotype frequencies within the OND group. Each unique TCR sequence was assigned a number sequentially i.e. 1, 2, 3 etc. 
The frequencies of these given TCR sequences were then plotted to demonstrate frequency distributions.  
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Figure 5.16. Distribution of CD8+ TCR clonotype frequencies within the MS group. Each unique TCR sequence was assigned a number sequentially i.e. 1, 2, 3 etc. The 
frequencies of these given TCR sequences were then plotted to demonstrate frequency distributions.  
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5.3.7 Clonal expansion analysis 
It is important to understand how much each unique TCR clonotype contributes to the 
overall TCR repertoire in each patient. The contribution of the top 10% of TCRs in the 
MS group were significantly lower than the contribution of the top 10% of TCRs in the 
IIH (p<0.05) and OND groups (p<0.05) within the CD4+ T cell repertoire. No significant 
differences were seen between the MS group and either of the control groups or 
between each of the control groups themselves in the CD8+ T cell repertoire. With 
both control groups pooled together, significance was observed between the MS and 
control groups in the CD4+ T cell repertoire (p<0.0001) and also in the CD8+ T cell 
repertoire (p=0.0422). These results are displayed in Figure 5.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17. Comparison of the contribution of the top 10% TCR clonotypes to the overall TCR 
repertoire.  CD4+ (left panels) and CD8+(right panels). When comparing across 3 patient groups (upper 
panels), the Kruskall-Wallis test with Dunn’s post test was used to calculate significance. When 
comparing 2 groups (lower panels) the Mann-Whitney test was used. 
 
Further to my initial analysis, in order to determine if there were any clonal expansions 
within the CD4+ and CD8+ T cell repertoires, Dr Venturi and Dr Rahmani performed a 
cumulative clonotype frequency distribution analysis (Appendix, Section 8.4). Here, the 
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top 10% of the largest clonotypes were identified and their relative contribution to the 
total repertoire was examined. In the MS group, the top 10% of the largest clonotypes 
comprised more clonotypes and collectively made a smaller contribution to the 
repertoire that the combined (IIH and OND) control groups. This result was stronger 
for CD4+ than for the CD8+ TCR repertoire (Figures 5.18 & 5.19). This result was in 
agreement with the analysis performed in Figure 5.17. 
 
Figure 5.18. Cumulative clonotype frequency distribution analysis. The number of clonotypes 
comprising the top 10% of largest clonotypes within the repertoires (upper panels) and the collective 
relative contribution of these clonotypes to the total repertoires (lower panels) for the MS, IIH and OND 
patient groups. Analysis performed by Dr Vanessa Venturi and Dr Adel Rahmani as described. 
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Figure 5.19. Cumulative clonotype frequency distribution analysis. The number of clonotypes 
comprising the top 10% of largest clonotypes within the repertoires (upper panels) and the collective 
relative contribution of these clonotypes to the total repertoires (lower panels) for the MS and pooled 
IIH and OND patient groups. Analysis performed by Dr Vanessa Venturi and Dr Adel Rahmani as 
described. 
 
5.3.8 TCRVβ usage analysis of CSF-resident T cells and peripheral blood 
The results of the TCRVβ screen are displayed in Appendix, Sections 8.5 and 8.6. TCRVβ 
screening of CSF and blood was performed for a total of 14 MS patients, 5 IIH patients 
and 4 OND patients for the CD4+ T cell repertoire and 11 MS patients, 3 IIH patients 
and 3 OND patients for the CD8+ T cell repertoire. Of note, TRBV 5-1, 18 and 30 stained 
poorly on PBMCs both with the original supplied batch, and with a replacement vial 
from the manufacturers. The results for TRBV 5-1, 18 and 30 were therefore excluded 
from the analysis. As described in Appendix, Section 8.6, some CSF TCR clonotypes 
were not covered by the peripheral blood TCRVβ screen and therefore direct 
comparison could not to be made.  
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CSF-resident TCRVβs >10% were highlighted in the graphs to enable easier comparison 
with the PBMC TCRVβ screen. The data for the CD8+ T cell repertoire of patients 
NW21326 and RW21309 were excluded as there was a clear dominant TCRVβ 
expansion, which could not be detected by any of the antibodies in the TCRVβ panel. 
Some patients have results for CD4+ T cells only as CSF-resident CD8+ T cells were not 
clonotyped and therefore could not be compared with PBMC. Also, of note, some of 
the results for the PBMC TCRVβ screens total >100%. This is due to overlap in the 
analysis on Flowjo. Within the CD4+ T cell repertoire, TCRVβ 5-1 occurred at a higher 
frequency within CSF-resident T cells in the MS group occurring in 10/14 patients. This 
TCRVβ was seen at frequencies of 3/5 in the IIH group and 1/4 in the OND group within 
the CD4+ T cell repertoire. Within the CD8+ T cell repertoire, TCRVβ 27 was the most 
frequently seen TCR Vβ within CSF-resident T cells within the MS group, occurring in 
6/11 patients. This TCRVβ was not observed in the control populations although within 
the CD8+ T cell repertoire only 3 patients from each control group were analysed. 
Initial analysis did not identify any correlation between CSF TCRVβ usage when 
compared with peripheral blood. In order to investigate this further, Vβ usage of 
different T cell subpopulations was examined – naïve (CD45RA+CCR7+), central memory 
(CM, CD45RA-CCR7+), effector memory (EM, CD45RA-CCR7-)), effector memory-RA 
(TEMRA, CD45RA+CCR7-)) and all effector cells combined (All, CCR7-). Similar to the initial 
analysis, no definitive correlations were observed between the CSF and peripheral 
blood compartments. 
 
5.4 Discussion 
The current literature suggests that CD8+ T cells in the CNS of MS patients exhibit 
clonal expansion suggesting that they are antigen experienced and therefore likely to 
be pathogenic.51-54, 128, 130 However, several limitations to these studies exist, 
suggesting caution is required before a definitive conclusion is drawn. In previous 
studies, the number of MS patient samples has generally been small and control 
populations are either lacking entirely or there is no comparison with CNS repertoires 
i.e. CSF or CNS tissue. It is of obvious importance and consequence to further 
understand the T cell repertoire within the CNS of MS patients and how this differs, if 
at all, from the normal population or non-MS patients. In order to try and answer this 
question, I performed in depth clonotyping of CSF-resident T cells to examine the TCR 
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repertoires in both CD4+ and CD8+ T cell repertoires in MS patients and non-MS patient 
controls. Our existing ethics covered collecting CSF from patients attending for routine 
diagnostic (or therapeutic in the case of IIH) lumbar punctures but not from ‘normal’ 
volunteers. We therefore endeavoured to collect CSF from patients with IIH as this was 
bountiful and considered to be the closest match to ‘normal’ CSF as possible. Patients 
attending for diagnostic routine lumbar puncture for neuroinflammatory disease but 
later determined to have an alternative diagnoses were collected as a second control 
group. Other patients undergoing lumbar puncture for alternative diseases were also 
included in this group.  
 
The initial overview from my data (without standardisation for TCR frequency or 
sorted cell numbers) suggested that samples from MS patients contained more TCRs in 
the CD4+ and CD8+ T cell repertoire compared to control groups. In addition, it 
appeared that the CD4+ and CD8+ T cell repertoires were more skewed in the control 
groups compared with the MS group. In order to understand variations in TCR diversity 
further, the number of unique clonotypes and their contribution to the overall TCR 
repertoire was analysed. Analysis of the number of unique TCR clonotypes 
demonstrated that within the CD4+ T cell repertoire there were significantly more 
unique clonotypes in the MS group compared with both the IIH and OND groups. 
Significance was also observed when the IIH and OND group results were pooled 
together. With respect to the CD8+ T cell repertoire, no significance was initially 
observed between the MS group and either of the control groups, but significance was 
observed when the control groups were pooled together.  
 
To understand how these unique clonotypes contributed to the overall TCR repertoire, 
the total contribution of the top 10% TCRs to the overall repertoire was analysed. As 
expected from the above results, the top 10% of TCRs in the MS CD4+ T cell repertoire 
contributed significantly less to the overall TCR repertoire than those in both the IIH 
and OND groups. This significance also held when both control groups were pooled 
together. Within the CD8+ T cell repertoire, no significance was seen when comparing 
the MS group with the IIH and OND groups separately but significance was achieved 
when the groups were pooled together. This initial analysis suggested that the MS 
CD4+ T cell repertoire was more diverse with less skewing and thus less evidence of 
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clonal expansion. Similarly, although significance was not achieved when comparing 
the MS group with either control group in the MS repertoire within the CD8+ T cell 
repertoire, significance was achieved with the combined control group, again 
supporting the notion of a less clonally expanded repertoire in the MS group. If these 
results are considered the other way around, the control groups might be considered 
to be demonstrating clonal expansion, with fewer TCRs in the repertoire and the top 
10% contributing more to the overall repertoire. However, this initial analysis suffered 
from the lack of standardisation for overall TCR frequencies obtained from each 
sample and also for the number of sorted cells.  In order to attempt to confirm these 
findings and the effect of cell numbers on the results, further analysis was performed 
by Dr Venturi, as discussed in the methods and results section of this chapter.  
 
In order to account for the differences in overall TCR frequencies, Dr Venturi was able 
to standardise the data set to the minimum number of TCR frequencies observed in 
the patient samples. Therefore all data was standardised for a TCR frequency of 54 
clonotypes. After standardisation, the results for the number of unique clonotypes 
were similar to the initial analysis. Within the CD4+ T cell repertoire, there were 
significantly more unique TCR clonotypes in the MS group compared with both control 
groups individually as well as when combined. The initial results were also mirrored by 
the standardised CD8+ T cell analysis. A comparison of the number of unique TCR 
clonotypes did not demonstrate any difference between the MS groups and the 
control groups individually but was significant when the data from the control groups 
was pooled together. This result was further confirmed by calculating Simpson’s 
diversity index. The standardised data also yielded similar results with respect to 
overall contribution of individual TCR clonotypes to the TCR repertoire. The top 10% of 
TCRs in the CD4+ T cell repertoire in the MS group contributed less to the overall 
repertoire than those in the control groups individually and when data from each of 
the control groups was pooled. Again, as in the initial analysis, no significance was 
observed in the CD8+ T cell repertoire between the MS group and the individual 
control groups but was achieved when both of the control groups were combined.  
 
In order to examine whether there was any effect of the number of sorted cells per 
sample on the overall TCR diversity, correlation between the numbers of sorted cells, 
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the number of unique TCR clonotypes and Simpson’s diversity index was examined. 
This analysis demonstrated that significant positive correlations were present for both 
CD4+ and CD8+ T cell repertoires in the MS group. However, no correlation was found 
for the control groups. However, when the samples were analysed with species 
accumulation curves, it was found that CD4+ and CD8+ T cell repertoires in the MS 
group were still accumulating new unique clonotypes at a high rate as the sample size 
approached the total number of sequences obtained per sample. This suggests that 
the differences observed are likely to be an underestimate of TCR diversity in the MS 
group and that the difference in TCR diversity between MS and control groups may 
actually be larger and more pronounced than that observed. 
 
In addition to the differences observed between patient groups, it is also noteworthy 
that when comparing the CD4+ and CD8+ T cell repertoires, there were significantly 
higher numbers of unique TCR clonotypes and higher Simpson’s diversity indices in the 
CD4+ TCR repertoire compared with the CD8+ TCR repertoire of MS patients. However, 
no significant differences in TCR diversity between the CD4+ and CD8+ T cell repertoires 
were observed in the combined control group. Despite a difference in the CD8+ and 
CD4+ T cell repertoire in MS patients, suggesting clonal expansion in the CD8+ T cell 
repertoire (higher number of clonotypes and higher Simpson’s diversity index in the 
CD4+ T cell population), no differences were observed between CD4+ and CD8+ T cells 
in the control groups, with CD8+ T cells showing more evidence for clonal expansion in 
the control groups when compared with the MS group. 
 
Taken together, these results provide evidence for an intriguing interpretation of TCR 
repertoires in both the ‘normal population’ and in MS pathogenesis. Firstly, an 
important observation is that within all of the patient groups there seems to be 
evidence for clonal expansions in both the CD4+ and CD8+ T cell repertoires, which is to 
some extent lost in the MS patient group. The IIH and OND TCR repertoires are 
typically more skewed, with fewer large clonotypes making a substantial contribution 
to the repertoires with the remainder of the repertoire being comprised of low copy 
number clonotypes. The MS repertoires are more diverse and the frequencies more 
evenly distributed across TCR clonotypes. 
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Although clonal expansions have been reported previously in patients with MS, the 
lack of control data has hindered interpretation. Although these clonal expansions in 
previous studies may still be pathologically relevant, the observation that they are 
present in control populations here is of particular importance. It may suggest that 
clonal expansions are a universal finding within CSF with relevance to general CNS 
immune surveillance and anti-viral activity similar to that found in peripheral blood.139 
T cells are essential in maintaining CNS immune surveillance,16 identifying and 
destroying potential pathogens. Thus, it is logical that clonal expansions might be 
observed in ‘normal’ CSF if that is the case.  
 
Of course, caution should also be exercised in over interpreting these results, as IIH 
and OND can still not be totally comparative to the ‘normal’ general population. In 
addition, lower patient numbers in the control groups and less successfully clonotyped 
samples may have made a contribution to the overall results. Interestingly, a recent 
study has examined TCR repertoires through deep sequencing technology in a small 
sample of MS patients against a control population of IIH. This study did demonstrate a 
significantly higher frequency of clonal expansions in the MS group although there 
were only 5 patients in each group and samples were not sorted into CD4+ and CD8+ T 
cell repertoires.138 
 
If T cell clonal expansion is a feature of normal CSF immune surveillance, the question 
of why this would be lost in MS needs to be addressed. As discussed in chapter 4, a 
significantly higher number of both CD4+ and CD8+ T cells is observed in the CSF of MS 
patients compared with controls, possibly owing to the increased permeability in the 
blood-brain-barrier observed in MS.2 As such, the increased influx of CD4+ and CD8+ T 
cells may ‘even out’ the TCR repertoire. However, one could argue that this should still 
result in a skewed repertoire. An alternative explanation may be that T cells from MS 
patients have lower activation thresholds and make more diverse responses to pMHC 
antigen causing a flattening of the repertoire. Genome wide association studies have 
identified risk variants associated with T cell activation thresholds, which may support 
this.45, 356 T cells may also be reactive against multiple CNS epitopes, which may reflect 
the phenomenon of epitope spreading. It should be noted that this study as well as 
others only offers a snapshot of the CSF constituents at the time of sampling. The 
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results may be different if CSF sampling was undertaken at multiple time points. If this 
were possible, it may be postulated that different TCRs at different frequencies would 
be observed, reflecting normal turnover in the immune-surveillance of the CNS. 
Ideally, serial lumbar punctures would be performed to examine this in more detail but 
ethically this is difficult to justify.  
 
I also considered the overall contribution of individual TCRVβ genes to the observed 
clonotypes and investigated if any of the dominant expansions in the CSF could also be 
seen in the peripheral blood. Interestingly, there were no real correlates between CSF 
TCRVβ usage and that observed in peripheral blood. In addition, the most common CSF 
TCRVβ usage was not consistent with that seen in the literature previously (Table 5.1). 
 
In conclusion, CD4+ and CD8+ CSF T cell repertoires are skewed in all patient groups. 
Although, the IIH and OND repertoires are typically more skewed, with fewer large 
clonotypes making a substantial contribution to the repertoires and the remainder of 
the repertoire being comprised of low copy number clonotypes. The hierarchical 
structure of CSF resident T cell repertoires in all patient groups is likely to be a feature 
of ‘normal’ CNS immune-surveillance. The MS repertoires are more diverse and 
frequencies are more evenly distributed across clonotypes. Although this may be a 
result of non-specific T cell infiltration across a more permeable blood-brain-barrier 
present in MS patients, this would seem unlikely as a hierarchical structure is still 
maintained. In light of the results of recent GWAS studies it would seem much more 
likely to be the result of lower T-cell activation thresholds in MS patients resulting in 
more diverse TCR repertoires being mobilized in response to antigenic stimulus. This in 
turn would result in a T cell repertoire with a much higher probability of being able to 
react to self-antigen and drive autoimmune disease. These data have important 
implications for understanding normal CNS immune-surveillance and also MS disease 
pathogenesis. The evidence for CD4+ and CD8+ CSF-resident T cells being involved in 
MS disease pathogenesis is overwhelming, but relying on CD8+ T cell clonal expansions 
to identify the pathogenic TCRs may not be possible if this ‘evening out’ of the TCR 
repertoire is a consistent observation in future studies. However, under the premise 
that MS CSF-resident CD8+ T cell expansions are pathogenic, we aimed to identify the 
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pathogenic triggers and antigenic targets of these populations. This is discussed in 
more detail in chapter 6. 
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Chapter 6 
 
Identifying the pathogenic triggers and antigenic targets of CSF-
resident CD8+ T cells in Multiple sclerosis 
 
 
6.1 Introduction 
 
6.1.1 Identifying antigenic specificity of CD8+ T cells in MS 
Despite the weight of evidence convincingly demonstrating that MS is an autoimmune 
disease, one fundamental question remains unanswered: what is the target antigen of 
immune cells involved in MS pathogenesis? In addition, although CD8+ T cells have 
been shown to have an antigen-experienced phenotype and in some studies are 
characterized by an oligoclonal expansion, what triggers this expansion remains 
unknown. It is clear that MS is a clinically heterogeneous disease with patients 
experiencing a range of disease trajectories ranging from a relatively benign course to 
one of a more aggressive, rapidly disabling nature.3 Therefore knowledge of the 
pathogenic triggers and antigenic targets is especially important for both disease 
stratification and for the design of individualised therapy.353 
 
6.1.2 Candidate antigenic targets of CD8+ T cells in MS 
Studies to date have attempted to identify CD8+ T cells specific for certain CNS resident 
antigens in vitro or by studying their potentially pathogenic effects in murine models. 
These studies have focused on co-culturing peripheral blood CD8+ T cells with 
candidate antigens followed by functional assays investigating cytokine release and 
cytotoxicity. Antigens have included myelin basic protein (MBP), proteolipid protein 
(PLP), myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein 
(MOG), glial fibrillary acidic protein (GFAP) and transaldolase.63, 142, 143, 145, 146, 148 Whilst 
some of these studies demonstrate increased CD8+ T cell responses in MS patients142, 
145, 148 others have not demonstrated any differences from controls.143, 288 Two recent 
studies by the same group investigating CD4+ and CD8+ T cell responses from CSF-
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derived cell lines against a variety of candidate antigens did not demonstrate any 
substantial T-cell reactivity in MS patients.104, 149 In addition to in vitro studies, 
candidate antigen-specific CD8+ T cells have been shown to be pathogenic in animal 
models. These include CD8+ T cells specific to MOG,179, 180, 357 MBP,181, GFAP,144 in 
addition to haemagglutinin182 and ovalbumin expressed by oligodendrocytes.183 As 
well as pathogenic targets, CD8+ T cells may also target CD4+ T cells, acting in a 
regulatory capacity.147, 203, 210, 358, 359  
 
6.1.3 Epstein-Barr virus as a potential causative agent in MS 
pathogenesis 
In addition to antigenic targets, the initial causative agent in MS is also unknown. 
Based on epidemiological,153 serological154, 155, CSF156-159 and Epstein Barr Virus (EBV)-
reactive T cell frequencies163-167 there is some evidence that this virus may play a role 
in disease pathogenesis. Four different hypotheses exist as to its potential role in MS 
disease pathogenesis. Firstly, the EBV cross reactivity hypothesis proposes that T cells 
primed by exposure to EBV antigens cross-react with and attack CNS antigens.360 
Secondly, the EBV bystander hypothesis proposes that the CNS immune attack is 
primarily directed towards EBV but resulting in bystander CNS damage.361 The third 
hypothesis, the αβ-crystallin (mistaken self) hypothesis proposes that exposure to 
infectious agents induces the expression of αβ-crystallin, a heat-shock protein, in 
lymphoid cells. The immune system then mistakes self, oligodendrocyte-derived αβ-
crystallin for a microbial antigen resulting in demyelination.362 The final hypothesis 
(the EBV infected autoreactive B cell hypothesis) proposes that in genetically 
susceptible individuals, EBV-infected autoreactive B cells produce pathogenic 
autoantibodies and provide survival signals to autoreactive T cells in the target 
organ.363 
 
Despite these candidate antigen approaches and EBV-derived hypotheses, to date, no 
unbiased assessment of antigen specificity has been performed on CD8+ T cells isolated 
from the CSF of patients with MS. It is also of note that previous studies have 
predominantly investigated the antigen specificity of CD8+ T cells from the peripheral 
blood of MS patients. However, given that a poor correlation exists between blood and 
intrathecal T-cell phenotypes,111 there is some doubt about how data from peripheral 
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blood translates to CSF.149 In a recent article, the importance of performing an 
unbiased assessment of CD8+ T cell antigen specificity has been highlighted 
recommending an approach similar to the one undertaken in this study.353 This part of 
the thesis therefore aimed to determine the pathogenic triggers and antigenic targets 
of CSF-resident CD8+ T cells without prior hypothesis as to the potential target. 
 
6.1.4 Aims and objectives 
In this chapter, we aimed to utilise combinatorial peptide library (CPL) screen 
technology286 in an unbiased approach to determine the peptide specificity of an 
individual TCR identified from the CSF CD8+ T cell repertoire of a patient with MS. In 
addition we utilised a more targeted approach using B95.8 EBV to determine if CD8+ T 
cells reactive to this peptide were also present in the CSF. In response to antigenic 
stimuli (such as EBV), CD8+ T cells can induce apoptosis via Fas and TNFa. Therefore, by 
utilising a TNFa capture assay, EBV-specific TCRs can be identified. TCR EBV-
specificities were also analysed across the two control groups (IIH and OND). In 
summary, this part of the thesis aimed to utilise knowledge of TCRs from CSF-resident 
CD8+ T cells from MS and determine their pathogenic triggers and antigenic targets. 
 
6.2 Methods 
All methods are described in detail in the materials and methods section of this thesis 
(Chapter 2) but will be briefly summarised here. 
 
6.2.1 Lentiviral transfection of CD8+ T cells and combinatorial peptide 
library screening 
 
6.2.1.1 Cloning of donor TCR and lentivirus synthesis 
Following clonotyping of CSF-resident T cells, patients with an oligoclonal expansion in 
the CD8+ T cell population were identified. TCR α chain clonotyping was then 
performed and 2 patients with matching α and β chain frequencies were chosen for 
TCR design by Genewiz Inc (USA) and lentiviral construction. Briefly, donor TCR and 
pELN.003 plasmids were digested with Xbal and BamHI enzymes. Following digest 
isolation on a 1% agarose gel and DNA extraction, ligations were performed. 
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6.2.1.2 Bacterial transformation of ligation reactions 
Following ligation, products were added to XL10 gold bacteria and after incubation 
were spread on plates and incubated overnight. The following day, colonies were 
picked and further cultured in LB media overnight. Miniprep was performed the 
following day. 
 
6.2.1.3 Miniprep/maxiprep of amplified donor TCRs 
Incubated media was centrifuged and the pellet resuspended in PBS. Miniprep (Zymo 
Research, Irvine, USA) was performed as per the manufacturer’s instructions. 
Following miniprep, DNA was quantified and sequenced to confirm the presence of 
amplified TCR. Following confirmation, maxiprep was performed as per the 
manufacturer’s instructions. 
 
6.2.1.4 CaCl2 transfection for lentiviral production 
Lentiviral synthesis was performed by combining pELN lentivirus vector containing 
donor TCR, pRSV.Rev, pVSVg, pMDLg/pRRE, 150 μl of CaCl2 and pH 7.1 media. This 
lentiviral mix was then added to 293 T cells. Media was collected 48 hours after 
transfection and again at 72 hours. Collected media was centrifuged, the pellet 
resuspended then frozen until required. 
 
6.2.1.5 CD8+ T cell isolation and lentiviral transfection 
CD8+ T cells were isolated from PBMC by MACS separation as per the manufacturer’s 
instructions instructions (Miltenyi Biotec, Bisley, UK) and incubated overnight with 
CD3+ CD28+ beads. Lentivirus was subsequently added with polybreen. Lentivirus 
positive cells were subsequently sorted 1 week later into T cell media and further 
expanded in vitro.  
 
6.2.1.6 Sizing scan and combinatorial peptide library (CPL) screening of CD8+ T cells 
expressing dominant CSF-resident TCRs 
Individual CD8+ T cells recognise antigens presented at the cell surface by major 
histocompatibility complex class I (MHCI) molecules. These antigens are in the form of 
intracellular protein-derived peptide fragments, 8-14 amino acids in length.296 
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Individual MHCI-restricted TCRs exhibit a preference for a single MHCI-peptide 
length.293 What is more, each TCR is able to recognise up to 1 million different MHC-
bound peptides at each preferred length.286 It is therefore of importance to first 
determine the length restriction of each TCR before attempting to determine antigen 
specificity with CPL screens.  
 
On day 1, CD8+ T cells were washed in PSG and put in R2 overnight. On day 2, cell 
cultures were set up for sizing scans or CPL screens. 5 μl of either sizing scan or CPL 
peptide mix (at a concentration of 10mM or 1mM, respectively) per well was plated in 
96 well round bottom plates (in duplicate). For the sizing scan, the following mixtures 
were used to define the MHCI-peptide length preference of the donor TCR: X8, X9, X10, 
X11, X12, and X13 (where X is any of the 19 proteogenic L-amino acids excluding 
cysteine; Pepscan, Lelystad, The Netherlands). For combinatorial peptide library 
screens (CPL) the 8mer CPL was synthesized in a positional scanning format (Pepscan). 
60,000 target cells were added to each well and plates incubated at 37oC for 1-2 hours. 
30,000 CD8+ T cells were then added to each well and plates incubated overnight. The 
following day, supernatant was harvested and MIP1-β ELISA (Duoset kit, R&D Systems 
Inc. Minneapolis, MN, USA) performed as per the manufacturer’s instructions. Plates 
were read on a Biorad iMark microplate absorbance reader (Biorad, Hercules, USA). Of 
note, T2-A2 cells, autologous EBV-LCLs and B7 cells were initially used as targets for 
sizing scans. However due to the high background release of MIP-1β from autologous 
EBV-LCLs and B7 cells, T2-A2 cells were used as targets for the final sizing scans and 
CPL screens. 
 
6.2.1.7 Analysis of combinatorial peptide library screening 
Results from the CPL screen were inputted into the Warwick Systems Biology Centre 
webtool (http://wsbc.warwick.ac.uk/wsbcToolsWebpage/resetpass.php, University of 
Warwick, UK) for peptide identification.296  
 
An overview of the strategy employed to determine antigen specificity via CPL 
screening is shown below (Figure 6.1). 
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Figure 6.1. CPL-driven database screening. The peptide length preference of the isolated TCR is first 
determined followed by the number of peptides recognised at this preferred length. The sequence 
identity of these peptides is then determined. Figure taken from Szomolay et al.296 
 
6.2.1.8 Assessing TCR response against chosen peptides identified by combinatorial 
peptide library screen 
Peptides were chosen based on scores from the CPL screens (Appendix, Section 8.7) 
and for disease relevance (Pepscan, Lelystad, The Netherlands). Peptides were first 
diluted to an 8mM stock and then further diluted in PSG to a concentration of 1mM 
(10-3M). Peptides were then diluted to concentrations of 10-4, 10-5, 10-6, 10-7, 10-8, 10-9 
and 10-10. 5μl of each peptide concentration was then moved to an ELISA plate and 
made up to final concentrations of 10-5, 10-6, 10-7, 10-8, 10-9, 10-10 and 10-11 following 
the addition of 45μl of target cells. MIP-1β ELISA was then set up in duplicate as 
described in section 2.3.9.10. 
 
6.2.2 Tumour necrosis factor alpha (TNF-α) capture assay to determine 
antigen specificity of CSF-resident T cells 
 
6.2.2.1 Generation of EBV stimulated T cell lines 
Autologous donor PBMC were cultured with irradiated EBV-LCLs and regularly 
stimulated with further irradiated EBV-LCLs and IL-2. 
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6.2.2.2 TNFα capture assay 
Where enough PBMC samples were available, TNFα capture assay was performed as 
outlined in detail in Materials and Methods (Chapter 2). In some instances, although 
the assay was performed, clonotyping of the sorted samples was unsuccessful and 
therefore could not be included in the analysis. For some patients, CSF-derived CD4+ or 
CD8+ T cells were not clonotyped and therefore comparison with TNF+ PBMCs was not 
possible (Appendix, Section 8.8 & 8.9). 
 
On the day before the experiment, EBV stimulated T cell lines were restimulated with 
EBV-LCLs. TAPI-O and anti-TNFα PECy7 was added along with 3μl each of CD28 and 
CD49d. Samples were then incubated overnight at 37oC. Cells were then stained with 
aqua and the following antibodies: CD14, CD19, CD3, CD8 and CD4. Flow cytometry 
and cell sorting was performed of TNF+ CD4+ and CD8+ populations. Following cell 
sorting, clonotyping and TCR analysis of these cell populations was performed as 
previously described. 
  
6.2.2.3 HLA typing 
Donor PBMCs were HLA typed at A, B and C loci by Proimmune (Oxford, UK). 
 
6.3 Results 
 
6.3.1 Patient selection for lentiviral transfection of CD8+ T cells and 
combinatorial peptide library screening 
Two patients with MS were initially chosen for lentiviral construction and CD8+ T cell 
transfection; KG19967 and NW21326. Both patients had a large monoclonal CD8+ T cell 
expansion that was present in both β and α chain sequencing as shown in Tables 6.1-
6.4 below. 
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Table 6.1. TCR β chain sequencing of CSF-derived CD8+ T cells for KG19967. CSF-resident T cells were 
sorted into CD4+ and CD8+ T cell populations and then clonotyped and analysed as described in chapter 
2. The dominant TCR β chain was identified and paired with the dominant TCR α chain. 
 
 
 
 
 
 
 
 
 
Table 6.2. TCR α chain sequencing of CSF-derived CD8+ T cells for KG19967. CSF-resident T cells were 
sorted into CD4+ and CD8+ T cell populations and then clonotyped and analysed as described in chapter 
2. The dominant TCR β chain was identified and paired with the dominant TCR β chain. 
 
 
 
 
 
 
 
 
 
Table 6.3. TCR β chain sequencing of CSF-derived CD8+ T cells for NW21326. CSF-resident T cells were 
sorted into CD4+ and CD8+ T cell populations and then clonotyped and analysed as described in chapter 
2. The dominant TCR β chain was identified and paired with the dominant TCR α chain. 
 
TRBV CDR3 TRBJ Freq-(%) Count
12#3/12#4 CASSYGAYNEQF 2#1 59.30 51
29#1 CSVTGQGTTEQY 2#7 17.44 15
11#2 CASSLTAGGYEQY 2#7 12.79 11
29#1 CSVSMVGTSGRYEQF 2#1 6.98 6
20#1 CSAPQGVNTGELF 2#2 2.33 2
3#1 CASSPATGNTEAF 1#1 1.16 1
100 86
TRAV CDR3 TRAJ Freq-(%) Count
20 CAVQYNFNKFY 21 83.33 55
17 CATDKPTGNQFY 49 7.58 5
1272 CAVNNNDMR 43 6.06 4
20 CAVQYSFNKFY 21 1.52 1
20 CAVQYNFDKFY 21 1.52 1
100 66
TRBV CDR3 TRBJ Freq-(%) Count
7"9 CASSLGGTEAF 1"1 69.12 47
19 CASSYGRAVGELF 2"2 7.35 5
5"5 CASSFWEANEQF 2"1 7.35 5
4"1 CASSQDSTPTHSNQPQH 1"5 5.88 4
7"9 CASSLPGSSYEQY 2"7 5.88 4
7"9 CAGSLGGTEAF 1"1 2.94 2
20"1 CSVQDRTYEQY 2"7 1.47 1
100 68
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Table 6.4. TCR α chain sequencing of CSF-derived CD8+ T cells for NW21326. CSF-resident T cells were 
sorted into CD4+ and CD8+ T cell populations and then clonotyped and analysed as described in chapter 
2. The dominant TCR β chain was identified and paired with the dominant TCR β chain. 
 
Following attempts at cloning of donor TCR, only KG19967 was successful and 
therefore taken forward for lentiviral construction and CPL screening. 
 
6.3.2 HLA typing of KG19967 
Patient KG19967 underwent full HLA typing and was heterozygous at the A, B and C 
loci. The patient’s HLA type was as follows; HLA-A*02:01/A*30:02, HLA-
B*07:02/B*51:01, C*07:02/*16:01. Initially, T2-A2 cells were used as target cells to 
assess whether or not the KG19967 TCR was restricted by HLA A*0201 and if so, what 
peptides could be recognized.  
 
6.3.3 Sizing scan of KG19967 TCR 
Sizing scan of KG19967 demonstrated a strong preference for 8mer peptides (Figure 
6.2). 
 
 
 
 
 
 
 
TRAV CDR3 TRAJ Freq-(%) Count
14/DV4 CAMREREMNNAGNMLT 39 95.56 86
14/DV4 CATREREMNNAGNMLT 39 1.11 1
14/DV4 CAMREREMNSAGNMLT 39 1.11 1
14/DV4 CAMREREMNNAGYMLT 39 1.11 1
14/DV4 CAMREREMNNAGSMLT 39 1.11 1
100 90
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Figure 6.2. Sizing scan for KG19967 TCR demonstrating 8mer length preference. CD8+ T cells expressing 
the dominant TCR α and β chains from patient KG19967 were washed in PSG and put in R2 overnight. 
On day 2, cell cultures were set up for sizing scans. 5 μl of sizing scan mix at a concentration of 10mM 
per well was plated in 96 well round bottom plates (in duplicate). The following mixtures were used to 
define the MHCI-peptide length preference of the donor TCR: X8, X9, X10, X11, X12, and X13 (where X is any 
of the 19 proteogenic L-amino acids excluding cysteine). 60,000 target cells were added to each well and 
plates incubated at 37oC for 1-2 hours. 30,000 CD8+ T cells were then added to each well and plates 
incubated overnight. The following day, supernatant was harvested and MIP1-β ELISA performed. 
 
6.3.4 Combinatorial peptide library screening of KG19967 TCR 
Results of the 8mer CPL screen for the KG19967 TCR are shown in figure 6.3. These 
results give the preferences for the TCR for each amino acid position in the 8mer 
peptide. 
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Figure 6.3. 8mer combinatorial peptide library screen for KG19967. On day 1, CD8+ T cells were washed 
in PSG and put in R2 overnight. On day 2, cell cultures were set up for CPL screens. 5 μl of CPL peptide 
mix (at a concentration of 1mM) per well was plated in 96 well round bottom plates (in duplicate). For 
combinatorial peptide library screens (CPL) the 8mer CPL was synthesized in a positional scanning 
format (Pepscan). 60,000 target cells were added to each well and plates incubated at 37oC for 1-2 
hours. 30,000 CD8+ T cells were then added to each well and plates incubated overnight. The following 
day, supernatant was harvested and MIP1-β ELISA performed.  
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These results were then inputted into the Warwick Systems Biology Centre webtool for 
bioinformatics analysis, searching the human viral pathogen and human self-protein 
databases.296 Appendix, Section 8.7 details the comprehensive results from this search. 
Of these peptides, the highest scoring and those derived from human herpesviruses 
were chosen for peptide titration experiments. Tables 6.5, 6.6 and 6.7 demonstrate 
those peptides chosen. 
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Table 6.5. Results of CPL-driven searching of the human viral pathogen database. *peptide sequences were chosen for peptide screening experiments
Rank Score Peptide/sequence Viral/ID Rank Score Peptide/sequence Viral/ID
1 !12.339322 VMGISSLV* Human3polyomavirus39 39 !14.945093 VMAVSTCV Macacine3herpesvirus31
2 !12.525908 VMGLAMPV* Human3herpesvirus31 40 !14.945093 VMAVSTCV Papiine3herpesvirus32
3 !12.886705 VMAISRCV* Suid3Herpesvirus31 41 !14.945093 VMAVSTCV Herpes3simplex3virus3type32
4 !12.92213 ILGLSTSV* Human3herpesvirus36B 42 !14.945093 VMAVSTCV Human3herpesvirus31
5 !13.25906 VLGLASCV* Human3herpesvirus35 43 !14.945093 VMAVSTCV Human3herpesvirus31
6 !13.269185 ILGISCFV* Human3herpesvirus36B 44 !14.945093 VMAVSTCV Human3herpesvirus31
7 !13.384254 TLGISHLV* Human3cytomegalovirus 45 !14.945093 VMAVSTCV Human3herpesvirus31
8 !13.455771 ILGLANLV* GB3virus3C 46 !14.949824 TLSLSLNV Lake3Victoria3marburgvirus
9 !13.584583 TLALSQVV* Encephalomyocarditis3virus 47 !14.949824 TLSLSLNV Lake3Victoria3marburgvirus
10 !13.743453 ELGLAILV* Hepatitis3C3virus 48 !14.949824 TLSLSLNV Lake3Victoria3marburgvirus
11 !13.806443 VLALAPEV* Human3herpesvirus38 49 !14.949824 TLSLSLNV Marburg3marburgvirus
12 !13.891999 EMAIPGQV Coxsackievirus3B5 50 !14.949824 TLSLSLNV Lake3Victoria3marburgvirus
13 !13.904892 VMSLSGKV Wesselbron3virus 51 !15.021849 ALAIAYLV Yellow3fever3virus
14 !13.942427 FLGIPESV Rabies3virus 52 !15.021849 ALAIAYLV Yellow3fever3virus
15 !14.003154 ILALAPAV* Human3herpesvirus32 53 !15.021849 ALAIAYLV Yellow3fever3virus
16 !14.105484 TLALPSNV Banna3virus 54 !15.021849 ALAIAYLV Yellow3fever3virus
17 !14.153498 VLAIALVV* Human3herpesvirus35 55 !15.021849 ALAIAYLV Yellow3fever3virus
18 !14.288697 AMAIAKSV Human3parvovirus3B19 56 !15.038671 GMGVSCTV Measles3virus
19 !14.353902 FLGLMCSV* Human3herpesvirus34 57 !15.038671 GMGVSCTV Measles3virus
20 !14.474466 ALGIASLV Langat3virus 58 !15.038671 GMGVSCTV Measles3virus
21 !14.625151 ELAIPEAV Torgue3teno3virus33 59 !15.038671 GMGVSCTV Measles3virus
22 !14.666174 ELGLGGRV Macacine3herpesvirus31 60 !15.038671 GMGVSCTV Measles3virus
23 !14.674795 ALALAGGV* Human3herpesvirus34 61 !15.038671 GMGVSCTV Measles3virus
24 !14.729165 VLALGSFV Suid3Herpesvirus31 62 !15.038671 GMGVSCTV Measles3virus
25 !14.736338 EMSISTWV Human3papillomavirus 63 !15.038671 GMGVSCTV Measles3virus
26 !14.787583 FMSLAHCV Yaba!like3disease3virus 64 !15.038671 GMGVSCTV Measles3virus
27 !14.901285 FLALMPTV Human3herpesvirus33 65 !15.038671 GMGVSCTV Measles3virus
28 !14.910185 EMSLPPWV Thogoto3virus 66 !15.082923 RLGISSIV Human3herpesvirus33
29 !14.925875 ILALGLLV Suid3Herpesvirus31 67 !15.090857 VMGKSVLV Human3hepatitis3A3virus
30 !14.945093 VMAVSTCV* Human3herpesvirus31 68 !15.090857 VMGLVGGV Papiine3herpesvirus32
31 !14.945093 VMAVSTCV Human3herpesvirus31 69 !15.169798 GLGIGALV Human3immunodeficiency3virus3type31
32 !14.945093 VMAVSTCV Human3herpesvirus31 70 !15.182156 YLSLSDPV* Human3herpesvirus31
33 !14.945093 VMAVSTCV Human3herpesvirus31 71 !15.213557 ELALGFKV Simian3hemorrhagic3fever3virus
34 !14.945093 VMAVSTCV Human3herpesvirus31 72 !15.243933 VMGLSDDE Human3astrovirus
35 !14.945093 VMAVSTCV Human3herpesvirus32 73 !15.248486 TMGLLSIV Vaccinia3virus
36 !14.945093 VMAVSTCV Human3herpesvirus32 74 !15.248486 TMGLLSIV Vaccinia3virus
37 !14.945093 VMAVSTCV Human3herpesvirus31 75 !15.248486 TMGLLSIV Variola3virus
38 !14.945093 VMAVSTCV Human3herpesvirus31 76 !15.248486 TMGLLSIV Monkeypox3virus
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Table 6.6. Results of CPL-driven searching of the human self peptide database. *peptide sequences 
were chosen for peptide screening experiments. 
 
 
 
 
 
 
 
 
 
Table 6.7 Tube numbers and corresponding peptides chosen for titration experiments. 
Rank Score Peptide/sequence Self/ID
1 !12.513169 VMGLPWFV* Sodium7bicarbonate7cotransporter73
2 !12.525908 VMGLAAGV* APC7membrane7recruitment7protein717
3 !12.539651 VMALSAVV* Solute7carrier7family7437
4 !12.709879 IMGLPWFV* Electroneutral7sodium7bicarbonate7exchanger717
5 !12.72542 VLGLSAAV* Multidrug7resistance7protein71
6 !12.85143 TMALSVLV Sarcoplasmic/endoplasmic7reticulum7calcium7ATPase737isoform7d7
7 !12.860619 AMGLSLLV Glutamate7[NMDA]7receptor7subunit7epsilon!47precursor
8 !12.860619 AMGLSRAV Isoform727of7ATP!binding7cassette7sub!family7A7member777
9 !12.86222 FMGLPWYV Electrogenic7sodium7bicarbonate7cotransporter747isoform7c
10 !12.872962 VMGIALAV Claudin!47
11 !12.92213 ILGLSAAV Multidrug7resistance7protein737isoform7C7
12 !12.980283 GMGISNRV WNT1!inducible!signaling7pathway7protein737isoform717precursor
13 !13.0103 EMGLADVV Isoform727of7Uncharacterized7protein7C1orf1677
14 !13.0372 TLGLSCGV Protein7LAS17homolog7isoform727
15 !13.072474 VLGISAEV Prostamide/prostaglandin7F7synthase7
16 !13.072474 VLGISLTV Isoform727of7Ral7guanine7nucleotide7dissociation7stimulator
17 !13.072474 VLGISRDV Poly7[ADP!ribose]7polymerase7147
18 !13.072474 VLGISAEV Prostamide/prostaglandin7F7synthase7isoform7a7
19 !13.072474 VLGISRDV Isoform757of7Poly7[ADP!ribose]7polymerase714
20 !13.072474 VLGISAEV Isoform737of7Prostamide/prostaglandin7F7synthase7
21 !13.074471 FLGLSPHV Folliculin7isoform717
22 !13.180612 GMALSVLV Probable7low7affinity7copper7uptake7protein72
23 !13.246321 VLGLPQHV Uncharacterized7protein7KIAA15227isoform72
24 !13.25906 VLGLAVRV L!fucose7kinase7
25 !13.25906 VLGLASIV Lecithin7retinol7acyltransferase7precursor7
26 !13.269185 ILGISGCV Long!chain7fatty7acid7transport7protein767
27 !13.272803 VLALSTEV Claudin!5
28 !13.366381 GLGLSGVV Adiponectin7receptor7protein717
29 !13.371097 EMAISKTV Dual7specificity7protein7phosphatase767isoform7b
30 !13.38152 AMGLPEAV Inositol71,4,5!triphosphate7receptor!interacting7protein7precursor7
31 !13.408002 AMALSGHV Transcription7factor7SOX!77
32 !13.421525 FLGISIGV Isoform727of7Tetraspanin!127
33 !13.422342 FMALANGV RNA73'!terminal7phosphate7cyclase7isoform7a7
Tube%no. Peptide%sequence Tube%no. Peptide%sequence
D1 VMGISSLV D12 ILALAPAV
D2 VMGLAMPV E1 VLAIALVV
D3 VMAISRCV E2 FLGLMCSV
D4 ILGLSTSV E3 ALALAGGV
D5 VLGLASCV E4 VMAVSTCV
D6 ILGISCFV E5 YLSLSDPV
D7 TLGISHLV E6 VMGLPWFV
D8 ILGLANLV E7 VMGLAAGV
D9 TLALSQVV E8 VMALSAVV
D10 ELGLAILV E9 IMGLPWFV
D11 VLALAPEV E10 VLGLSAAV
 173 
Chosen peptides were synthesised by pepscan (Lelystad, The Netherlands) and further 
MIP-1β assays performed at effector:target (E:T) ratios of 2:1 and 1:1. Although 
positive responses were observed at high peptide concentrations for E10 (data not 
shown) and D5 in the 2:1 and 1:1 assays respectively, these are unlikely to be 
physiologically relevant. Other than for these peptides, both assays at different E:T 
ratios failed to demonstrate a positive response with any of the other peptides tested.  
Figure 6.4 demonstrates the results for an E:T ratio of 1:1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. Peptide titration experiment with E:T ratio of 1:1. Key for peptides is described in Table 6.7. 
Peptides were chosen based on scores from the CPL screens and for disease relevance. Peptides were 
first diluted to an 8mM stock and then further diluted in PSG to a concentration of 1mM (10-3M). 
Peptides were then diluted to concentrations of 10-4, 10-5, 10-6, 10-7, 10-8, 10-9 and 10-10. 5μl of each 
peptide concentration was then moved to an ELISA plate and made up to final concentrations of 10-5, 
10-6, 10-7, 10-8, 10-9, 10-10 and 10-11 following the addition of 45μl of target cells. MIP-1β ELISA was then 
performed. 
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6.3.5 Tumour necrosis factor alpha (TNF-α) capture assay to identify 
EBV-specific T cells in CSF and peripheral blood 
Patients were included for TNF capture if CSF samples had been clonotyped and if 
there was sufficient frozen PBMCs available. Table 6.8 below details which patient 
samples were utilised for this assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.8. Patients selected for EBV TNF-capture assay. 
 
After the setup of the assays as described, cells were sorted into either CD4+ TNF-α+  or 
CD8+ TNF-α+  cells. Figure 6.5 demonstrates a typical gating strategy that was utilised. 
 
 
 
 
 
 
Patient'ID TNF'capture Patient'ID TNF'capture Patient'ID TNF'capture
LC20552 No EC21870 No SE29703 Yes
LJ20639 No HS25204 Yes JG33488 Yes
LS20460 Yes LH25311 Yes ND37140 No
MJ19588 No ML25308 Yes DL37517 No
EB21510 Yes SW25353 Yes CS19395 No
KG19967 No RY21758 Yes AG20355 Yes
LH18836 Yes DC37877 No JM25229 Yes
NW21326 No ES37889 No AB25236 Yes
MW21576 Yes FC24414 No CJ26014 Yes
CS21983 No VE25562 No JJ37566 No
AL28847 No CC40712 No JP24822 No
MK21405 No RC41200 Yes
SA23376 Yes KA38079 Yes
RM22664 Yes CC41471 No
TL22789 No
CT25364 Yes
HD21265 Yes
MH21407 Yes
RW21309 No
DD22299 No
CG41964 No
MS IIH OND
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Figure 6.5. Example gating strategy for EBV-TNF capture assay. On the day before the experiment, EBV 
stimulated T cell lines were restimulated with EBV-LCLs. TAPI-O and anti-TNFα PECy7 was added along 
with 3μl each of CD28 and CD49d. Samples were then incubated overnight at 37oC. Cells were then 
stained with aqua and the following antibodies: CD14, CD19, CD3, CD8 and CD4. Flow cytometry and cell 
sorting was performed of TNF+ CD4+  and CD8+  T cell populations. Following cell sorting, clonotyping of 
these cell populations was performed as previously described. 
 
An example result demonstrating the matching of EBV-specific TCRs observed in the 
CD8+ T cell repertoire of CSF and blood is shown in Figure 6.6. Samples from 9 patients 
with MS were used in this assay with matching EBV-specific TCRs in the CSF and blood 
being identified in 3. Matching EBV-specific CD8+ T cells were seen in 3 MS patients (4 
different TCRs) and matching EBV-specific CD4+ T cells were seen in 1 MS patient. 
Within the IIH group, 2 matching EBV-specific CD8+ T cells were identified in 1 patient. 
In the OND group, 1 EBV-specific CD4+ T cell and 1 EBV-specific CD8+ T cell were 
identified in two separate patients. The example in the figure below demonstrates 2 
matching TCRs in the CD8+ T cell population. Table 6.9 summarises the findings across 
all patient groups. 
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Figure 6.6 Example of matching EBV-specific TCRs identified in the CD8+ T cell repertoire of the CSF 
and blood of an MS patient using an EBV-TNF capture assay. Sorted TNF-α positive CD4+ and CD8+ T 
cells were clonotyped and analysed as described. Matching TCRs were identified between CSF-resident T 
cells and those clonotyped in the TNF-α capture assay. 
MW21576(CSF(CD8+(T0cell(sort
TRBV CDR3 TRBJ Freq((%) Count
7"3 CASSPGQGQDEQY 2"7 27.06 23 *match(1
27 CASSGLGRREQY 2"7 21.18 18
6"2/6"3 CASSLGGTGWTEQF 2"1 10.59 9
20"1 CSAREAGELF 2"2 8.24 7
24"1 CATSDLPPTGDTGELF 2"2 4.71 4 *match(2
13 CASSRPFGRPYNEQF 2"1 4.71 4
2 CASRQLAGGDNEQF 2"1 4.71 4
7"8 CASSLGQAYEQY 2"7 4.71 4
6"5 CASGSGYYGYT 1"2 4.71 4
29"1 CSARLAGDSTDTQY 2"3 3.53 3
3"1 CASSLLAGGLTDTQY 2"3 2.35 2
11"2 CASSLDPGWSAGGIAKNIQY 2"4 1.18 1
7"3 CASSPGQGQGEQY 2"7 1.18 1
14 CASSQAGIHGYT 1"2 1.18 1
100 85
MW21576(PBMC(CD8+(TNF+(T2cell(sort
TRBV CDR3 TRBJ Freq((%) Count
7"3 CASSPGQGQDEQY 2"7 33.8 26 *match(1
7"3 CASSLGTGIYNEQF 2"1 29.9 23
3"1 CASSPSHRDIWDTQY 2"3 26.0 20
24"1 CATSDLPPTGDTGELF 2"2 7.8 6 *match(2
5"5 CASSHRTSGSTDKQY 2"3 1.3 1
5"5 CASSQRTSGSTDTQY 2"3 1.3 1
100 77
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Table 6.9. Number of cells sorted and clonotyped from donor PBMCs for EBV-TNF capture assay. Number of matching EBV-specific TCRs also shown. N.B. for 
sample AG20355, comparison between the clonotyped CD8+ samples was not possible because the CSF CD8+ clonotyping results were discarded due to 
contamination.
Patient'ID No.'of'sorted'CD4+"T'cells Clonotyped No.'of'sorted'CD8+"T'cells Clonotyped Matching'TCRs
MS
LS20460 10,000 Yes 1153 Yes No
EB21510 304 Yes 4802 Yes 1'x'CD8+"
LH18836 4673 Yes 78 No No"(CD4+"only)
MW21576 491 Yes 1159 Yes 2'x'CD8+"
SA23376 609 Yes 6954 Yes No
RM22664 466 Yes 5000 Yes 1'x'CD4+" '&'1'x'CD8+"
CT25364 908 Yes 591 No No"(CD4+"only)
HD21265 3395 Yes 83 Yes No
MH21407 119 Yes 4338 No No"(CD4"only)
IIH
HS25204 133 Yes 60 No No"(CD4+"only)
LH25311 1157 Yes 1201 Yes 2'x'CD8+"
ML25308 727 Yes 4097 No No"(CD4+"only)
SW25353 620 Yes 1336 Yes No
RY21758 962 Yes 2696 No" No"(CD4+"only)
RC41200 1530 Yes 101 No No"(CD4+"only)
KA38079 509 Yes 2808 Yes No
OND
SE29703 120 No 673 Yes No"(CD8+"only)
JG33488 355 Yes 4122 No No"(CD4+"only)
AG20355 2099 No 5000 Yes N/A
JM25229 380 Yes 782 Yes 1'x'CD4+"
AB25236 188 Yes 2176 Yes 1'x'CD8+"
CJ26014 148 Yes 90 No No
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6.4 Discussion 
Although more effective therapies have been introduced in the last few years for MS 
they tend to exert their immunomodulatory effects in a rather indiscriminate manner. 
For example, in the case of alemtuzumab (discussed in Chapter 3) this acts by 
depleting all B and T cells through anti-CD52 activity.364 Depletion and repopulation 
leads to long-term beneficial effects but secondary autoimmunity and risk of infections 
remain a concern.364 In addition, natalizumab, which prevents BBB migration through 
inhibition of α4-integrin262 is associated with an increased risk of progressive multifocal 
leucoencephalopathy (PML) due to lack of CNS surveillance against JC virus.261 
Therefore, it is clearly of interest to be able to identify what the pathogenic triggers 
and antigenic targets of T cells are so that they can be specifically targeted in more 
individualised therapy. Analysing the TCR repertoire in individual patients and 
determining which T cell population is pathogenic could lead to treatment that 
removes or induces tolerance in pathogenic cells only, leaving the remainder of the 
immune system intact. This would hopefully reduce the incidence of emergent 
infections and ameliorate the risk of secondary autoimmune disease. 
 
A recent review by Hohlfeld et al353 has outlined the methods that should be employed 
to attempt to identify the target antigens of CD8+  T cells in MS. This includes isolating 
cells from blood, CSF or brain and establishing T cell lines, which can then be used for 
antigen screening. In this study, we established the dominant TCR β and α chain 
populations of CSF-resident T cells from a patient with MS and used cloning and 
lentiviral technology to establish a CD8+ T cell line expressing this TCR. By utilising 
combinatorial peptide library screening technology we established an unbiased 
method for identifying target antigens. To our knowledge, this is the first example of 
this technique being utilised for CSF-resident CD8+ T cells in MS. Interestingly, our 
results initially suggested some preference for human herpesvirus 6 (HHV6) and other 
herpesviruses. However, no preference for myelin or oligodendrocyte proteins was 
seen. In addition to CPL screening, we also performed TNFα capture assay to attempt 
to identify EBV-reactive CSF-resident TCRs. This approached revealed EBV-specific TCRs 
in 3 patients with MS, 1 patient with IIH and 2 different OND patients.  
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Although the results of the peptide activation assay were negative against the HHV6 
peptide (and other peptides), it is interesting to review the possible role of HHV6 in the 
pathogenesis of MS. Early studies demonstrated elevated anti-HHV6 antibodies in MS 
patient sera365, 366 and HHV6 viral DNA in MS plaques.367 HHV6 was also shown to be 
present in the brains368 and CSF369 of MS patients and controls with higher levels of 
HHV-6 expression being demonstrated in MS brains compared to controls.370 In 
addition, the presence of HHV6 DNA is significantly increased in MS plaques compared 
with NAWM from normal controls.371 Previous studies therefore intimate that 
although HHV6 may be a commensal of normal brain, it’s replication and activity is 
enriched in MS.372 Interestingly, oligoclonal bands (OCBs) demonstrate HHV6 
specificity in approximately 20% of patients with MS.373 In relation to this, herpesvirus-
specific CSF OCBs in MS patients have been shown to be inversely correlated to the 
presence of viral DNA, whose presence in turn correlates with more contrast 
enhancing lesions on MRI.374 In addition to OCBs, HHV6 specific CD4+ T cells show 
strong intrathecal enrichment across MS patients and those with other inflammatory 
neurological disease with reactivities more pronounced in patients with MS.375 
Clinically, HHV6 IgG titres have been associated with relapses and disease 
progression.376, 377 In addition, an inverse correlation has been shown between the 
presence of HHV6 in serum and responsiveness to IFN-beta treatment.378 Molecular 
mimicry is one suggested mechanism for the involvement of viruses in MS pathology 
and it is interesting to note that there is an identical stretch of amino acids between 
HHV6 U24 and human MBP.372 A higher frequency of T cells reactive to both HHV6 U24 
and (MBP)93-105 has also been demonstrated in MS patients compared with controls.379 
It should be recognised that in addition to positive associations with MS, some studies 
have failed to find any significant correlation with diagnosis 380, 381 or relapses.382 
 
Specificity to another member of the human herpesvirus family, EBV (human 
herpesvirus 4) was also observed in the CPL screen data. Similarly, EBV-specific TCRs 
were observed across all patient groups in the EBV TNFa capture assays. These data 
suggest that EBV-specific TCRs are perhaps not pathogenic and may just represent 
ubiquitous cellular immunity against a common human pathogen. It is also noteworthy 
that human polyomavirus 9 was identified as the highest match in the CPL screens. JC 
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virus (polyomavirus 2) is causative of PML and demonstrates that CD8+ viral immunity 
exists against this virus family and hence is lost when treated with natalizumab. 
 
Although this study was novel and demonstrated some interesting results, several 
limitations exist when interpreting the data. Firstly, CPL screens were only performed 
for the dominant CD8+ T cell expansion in one patient. This makes extrapolating the 
results to a wider MS population difficult in particular without a control population for 
comparison. For example, although herpesviruses were seen as a ‘high-scoring’ target 
in the CPL screens, this may be the case across MS patients and controls but it is not 
possible to know this without further work. 
 
A second limitation of this study was the limited HLA-restriction of the target cell lines 
used in the MIP-1β assay of the CPL screens. Our patient’s HLA type was HLA-
A*02:01/A*30:02, HLA-B*07:02/B*51:01, C*07:02/*16:01 but only an HLA-A2 cell line 
was chosen as targets. It would be more complete if different target cell lines 
encompassing all the patient’s HLA alleles were used but due to time constraints this 
was not performed in this initial exploratory study. Ideally, future studies would 
involve examining TCRs from more MS patients and controls and screening all HLA 
alleles in the target cells. Indeed, with respect to this, a lack of response was seen in 
MIP-1β assays when individual chosen peptides were used. This may be explained by 
the limited use of only one HLA type for the target cells. Perhaps alternative HLA target 
cells would have yielded more promising results. In addition, the EBV TNFα capture 
assay was only performed on a limited number of patients determined by the 
successful outcome of CSF-resident T cell clonotyping and the availability of stored 
PBMCs. This again makes comparison of EBV-reactive TCRs in CSF across patient 
groups difficult. 
 
Despite these limitations, this initial study has demonstrated that human TCRs from 
CSF-derived T cells can be cloned into a lentivirus and used in unbiased screens of 
peptide libraries. Done on a larger scale, this technique may help to yield important 
information about potential pathogenic targets and antigenic triggers of MS, 
knowledge of which could lead to more individualised therapy. 
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Chapter 7 
 
General Discussion 
 
7.1. Multiple sclerosis, the immune system, CNS immune surveillance 
and the role of CD8+ T cells 
Multiple sclerosis (MS) is a common cause of neurological disability, widely accepted 
to be autoimmune in origin. Early in the disease, CNS-infiltrating immune cells cause 
demyelination, reflected clinically as subacute episodes of neurological dysfunction 
(relapses). As the disease progresses, relapses become less common and progressive 
neurological disability is the prevalent feature secondary to neurodegeneration. In 
other forms of the disease, disability progression occurs from onset without overt 
clinical episodes of subacute neurological dysfunction. The findings from genome wide 
association studies (GWAS)2, 45, the histopathological features of MS plaques 47; and, 
evidence from animal models of MS44 support MS being an inflammatory autoimmune 
disease. In particular, the available evidence suggests that T cells play a central role in 
the pathogenesis of MS. The current available treatments for MS are aimed at either 
achieving immunosuppression with subsequent remodelling of the immune system,9 
or immunomodulation.245, 254, 262, 265, 272, 279. The observed efficacy of these treatments, 
particularly against clinical relapses, further supports the accepted notion that the 
adaptive immune system in general and T cells in particular are key players in disease 
pathogenesis. Despite the evidence of a central role for T cells in MS disease 
pathogenesis, the initial antigen that triggers autoreactive T cells is unknown. Similarly, 
the target antigen within the CNS parenchyma is still to be determined. Within the T 
cell compartment, focus has largely been on the role of CD4+ T cells in MS, largely 
because disease in the most commonly used animal model for MS (Experimental 
Autoimmune Encephalitis (EAE)) is initiated by the CD4+ T cell subset. However, in 
recent years, there has been increasing evidence for the role of CD8+ T cells in MS 
pathogenesis and the aim of this thesis was to explore this in more detail. In particular, 
following a clinical study into the effect of a lymphocyte depleting agent 
(alemtuzumab) on MS clinical disease, I conducted an in-depth analysis of the 
phenotype and T cell receptor repertoire of CSF-resident T cells. Furthermore, I 
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attempted to characterise the antigen specificity of CSF-resident CD8+ T cells in MS 
patients. An increased understanding of the role of CD8+ T cells in MS is important for 
defining the disease pathogenesis of MS and ultimately in designing novel 
therapeutics. 
 
The adaptive immune system consists of antibody-secreting B cells, and T cells that 
recognise their cognate antigen expressed on the surface of antigen presenting cells. 
CD8+ and CD4+ T cells recognise peptides presented in association with major 
histocompatibility complexes class I (HLA-A, -B, -C in humans) and II (HLA-DR, -DQ and 
–DP in humans) respectively.35 CD8+ T cells are primary effector cells of the adaptive 
immune system with the ability to destroy cells infected with intracellular pathogens 
and cancerous cells.35 MHC class I is expressed by the majority of cells in the human 
body, enabling CD8+ T cells to mount a rapid and efficient response to intracellular 
pathogens.34 Following pMHCI antigen recognition and activation, CD8+ T cells expand 
and deliver a range of effector functions.34 After clearance of target cells, a 
subpopulation of these expanded cells survive and exist as a memory population in 
order to mount a further response to recurrent infection.36  
 
Before considering how MS pathogenesis may occur, it is important to understand the 
role of the immune system in normal CNS surveillance. The CNS has long been 
considered to be an immune privileged site for several reasons:16: (1) the expression of 
MHC molecules within the CNS parenchyma is limited;17 (2) the entry of adaptive 
immune cells into the CNS via the blood-cerebrospinal (CSF) fluid barrier, the CSF-brain 
barrier and the blood-brain-barrier is restricted;18 and, (3) the antigenic representation 
in peripheral lymph nodes of CNS antigens may not be an accurate representation of 
the CNS.19 However, recent discoveries have led to a revisiting of this immune-
privileged status, which are important to the understanding of normal CNS immune 
surveillance and MS disease pathogenesis. The discovery of CNS lymphatics21 and 
understanding the transfer of antigens from parenchymal interstitial fluid to CSF22 has 
led to a greater understanding of the lymphatic drainage of the CNS and how immune 
cells react within it. Indeed, as the CNS is a common target for viral infections and 
autoimmune disease then T cells must be able to access this supposed immune-
privileged compartment. This is further supported by the fact that immunosuppressive 
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disease (e.g. HIV) and drugs preventing lymphocyte egress into the CNS may lead to 
CNS infectious disease.383 It is thought that T cells can either be activated in local CNS-
draining lymph nodes or in a distant peripheral site before homing back to the CNS to 
eliminate the pathogens.16 It is still to be definitively determined whether autoreactive 
T cells in MS are activated in the periphery or more centrally. If stimulated in the 
periphery, it is postulated that autoreactive T cells may become activated through 
molecular mimicry,31 bystander activation or the co-expression of T cell receptors 
(TCRs) with different specificities.32  
 
The evidence for CD8+ T cells in MS pathogenesis begins with genome wide association 
studies. Although the strongest HLA association in GWAS are for HLA class II regions,42 
implicating CD4+ T cells, associations have also been observed for HLA class I.41 In 
particular, the HLA-A3 risk allele was identified, with further support for this coming 
from a landmark study using a mouse model transgenic for HLA-A3. which develops an 
MS-like disease.44 In addition to genetic studies, CD8+ T cells have been shown to be 
the most prominent immune cell present within MS plaques48, and within the MS 
plaque, CD8+ T cells have also been shown to interact with antigen presenting cells64 
and directly damage CNS target cells.67-72 In recent years, there has been a particular 
focus on CD8+ T cells due to the fact that clonal expansions have been observed in the 
CD8+ T cell repertoire in the blood, CSF and brain tissue of MS patients. Early studies 
demonstrated CD8+ T cell clonal expansions in MS patients within the blood and CSF121-
123 with subsequent studies confirming this in CSF and brain lesions.51-54 Given these 
observed expansions, it has been suggested that these expanded CD8+ T cell 
clonotypes are antigen-experienced T cells that may represent a pathogenic T cell 
population in MS and therefore identifying their target antigens is a research priority 
for the future. The effect of existing MS therapeutics on CD8+ T cell populations and 
activity also supports the notion of their central role in disease pathogenesis. 
 
There were four main aims of this thesis. The first aim was to investigate the clinical 
outcomes of MS patients treated with the anti-CD52, lymphocyte depleting 
monoclonal antibody, alemtuzumab. The second aim was to perform an in-depth 
phenotypic analysis of CSF-resident T cell populations in patients with MS. Thirdly I 
aimed to identify dominant TCRs that reside in the CSF of MS patients. Finally, with 
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knowledge of these dominant TCRs I aimed to define the pathogenic triggers and 
antigenic targets of CSF-resident T cells. 
 
7.2 Clinical outcomes of MS patients treated with the anti-CD52, 
lymphocyte depleting monoclonal antibody, alemtuzumab 
The first aim of this thesis was to investigate the clinical outcomes of MS patients 
treated with alemtuzumab. Alemtuzumab is a monoclonal antibody targeted against 
the CD52 molecule, present on the cell surface of B- and T- cells, therefore causing 
immunodepletion with subsequent beneficial reconstitution of the immune system. 
Clinical trials had demonstrated a significant benefit on clinical and MRI outcomes9, 240, 
241 but this observational, long-term follow up study was performed to examine its use 
in the ‘real-world’ setting. Knowledge of this would also be informative as to the role 
of T cells in disease pathogenesis and the effect of immunodepletion and repopulation 
on potential side effects and long-term outcomes. 
 
This section of the thesis examined the clinical outcomes of 100 patients treated with 
alemtuzumab across South Wales and Bristol. The effect of alemtuzumab on clinical 
relapse rates was profound, with a reduction in the annualised relapse rate of 90% 
after treatment. In addition, over the 6 years of follow-up data, disability outcomes 
were also encouraging. In a group of patients deemed to have highly aggressive 
disease, a very modest mean increase of expanded disability status scale (EDSS)326 of 
+0.14 was observed. In addition, only 27% met the definition for 6-month sustained 
accumulation of disability. Overall, the clinical outcomes were found to be similar to 
those reported in clinical trials as well as the incidence of the most commonly 
observed side effect of secondary autoimmune disease. Despite lymphodepletion, 
immune cells that escaped depletion and subsequent reconstitution meant that only 
minor infections (commonly urinary, respiratory and herpes zoster-related) were 
observed. 
 
These data suggest that T cells may play a role in disease pathogenesis and alteration 
of the immune repertoire following treatment with alemtuzumab is beneficial for 
clinical outcomes. To further understand the pathogenic role of T cells in MS, a 
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subsequent detailed investigation of the immunophenotype of CSF-resident T cells was 
performed. 
 
7.3 Phenotypic analysis of CSF-resident T-cell populations in MS 
Several studies have attempted to examine the phenotype of CSF-resident T cells in 
patients with MS. The findings of these studies have been inconsistent and in some 
cases limited by the number of cell surface markers studied, the number of patients or 
a lack of control populations. Both effector memory93 and central memory T cells98 
have been shown to be the dominant CSF population present in MS patients. To 
attempt to define these CSF-resident T cell populations further we performed an in-
depth phenotypic analysis using multicolour, state-of-the-art flow cytometry. Patients 
with idiopathic intracranial hypertension (IIH) and other neurological diseases (OND) 
were included as control populations.  
 
The most significant finding in the chapter of the thesis was the increased number of 
CD4+ and CD8+ T cells present in the CSF of MS patients compared with controls (IIH 
and OND). Interestingly, the majority of CSF-resident T cells were of an effector 
memory phenotype across all patient groups with similar expression of individual 
phenotypic markers (CCR7-CD45RA-CD27+CD49+CD57-CD95+) albeit with more variable 
expression of CD127 in CD8+ T cells. The only differences observed in the CD4+ T cell 
compartment were in CD27 and CD49d expression, with significantly higher expression 
in the MS population compared with IIH patients. Within the CD8+ T cell compartment, 
the expression of CD27, CD49d and CD57 were all significantly higher in the MS group 
as compared with IIH. TEMRA cells were significantly higher in the CD8+ T cell 
compartment compared with CD4+ T cell compartment across all patient groups. 
 
Aside from these minor differences, no other significant differences were observed 
across the patient groups. Therefore, rather than the phenotype of CSF-resident T cells 
being a determinant of disease, their presence may be indicative of ubiquitous CNS 
immune surveillance. Of note however, the increased expression of CD27 in the MS 
group may be associated with a regulatory phenotype.348 This would be interesting to 
explore in future work as Regulatory T cells (Tregs) are thought to play a key role in 
peripheral immune tolerance and as such, in MS disease pathogenesis.384 In addition, 
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CD49d (α-4 integrin) is the main adhesion molecule involved in lymphocyte trafficking 
to the CNS342 and the significantly higher expression of CD49d suggests greater homing 
activity of CSF-resident T cells in MS. In order to further investigate the pathological 
relevance of these CSF-resident T cells I performed TCR repertoire analysis. 
 
7.4 T cell receptor repertoire (TCR) analysis of CSF-resident T cells and 
identification of dominant TCRs 
The current literature suggests that the CD8+ T cell repertoire present in the central 
nervous system in patients with MS is characterised by clonal expansions suggesting 
that they are antigen experienced and therefore likely pathogenic.51-54, 128, 130 However, 
small numbers of study patients and either limited or no controls hamper 
interpretation. In addition, when controls have been present, there has been limited 
comparison between CSF and CNS compartments. Therefore, to attempt to 
understand the TCR repertoire further and answer whether these observed clonal 
expansions in the CD8+ T cell repertoire are a pathological finding, I performed in 
depth clonotyping of CSF-resident T cells from MS patients and controls.  
 
In MS patients, within the CD4+ T cell compartment, the TCR repertoire was 
significantly more diverse (higher Simpson’s diversity index) and had more unique 
clonotypes than both control groups individually and when combined. In addition, 
there was a significantly higher number of TCRs representing the top 10%, which 
contributed significantly less to the overall TCR repertoire. Within the CD8+ 
compartment, the TCR repertoire was significantly more diverse with more unique 
clonotypes in the MS group compared to controls, when both the IIH and OND groups 
were combined. As in the CD4+ T cell compartment, there was a significantly higher 
number of clonotypes within the top 10% of the repertoire, which contributed less to 
the overall repertoire compared to both control groups combined. Within the MS 
group a significantly higher number of unique clonotypes and more diversity was 
observed in the CD4+ compared to the CD8+ compartment. Conversely, no significant 
differences were observed in the control groups.  
 
My results demonstrate that clonal expansions can be observed in both the CD4+ and 
CD8+ T cell repertoires of CSF in MS patients, which is consistent with the current 
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literature. However, this is not a unique feature of MS and more skewing is actually 
observed in the CD4+ and CD8+ T cell repertoires of CSF from control patients. Set 
against the concept that CD8+ T cell clonal expansions in MS are proof of pathogenesis, 
these results offer a different interpretation. The control groups in this study were 
largely considered not to be inflammatory in aetiology. As such, the finding that TCR 
repertoires were more skewed in both the CD4+ and CD8+ T cell repertoires in the 
control groups suggests activation and expansion of CSF-resident T cells is an 
important part of CNS immune surveillance. The repertoires may be more ‘evened out’ 
to some extent in the MS groups because of non-specific T cell infiltration into the CSF 
and CNS parenchyma. However, it is more likely that the observed increase in TCR 
diversity in MS patients is due to the fact that the T cells in MS patients have a lower 
activation threshold and as a result, a more diverse response to antigenic stimulus is 
observed. Despite this perhaps somewhat surprising discovery, there is evidence for 
the role of CD8+ T cells in MS pathogenesis. Therefore although there is an ‘evening 
out’ of the TCR repertoire there must still be a population of cells that are pathogenic. 
It is of obvious importance to be able to recognise this population for the 
understanding of MS disease pathogenesis and for targeted therapeutics. As such, I 
aimed to investigate the antigenic specificity of these TCRs using a novel experimental 
approach utilising lentiviral and combinatorial peptide screening technology in 
addition to TNFα capture assays. 
 
7.5 Identifying the pathogenic triggers and antigenic targets of CSF-
resident CD8+ T cells in Multiple sclerosis 
Although a pathogenic role for CD8+ T cells in MS patients has been suggested, the 
antigen-specificity of these cells remains unknown. Studies to date have tried to define 
antigen specificity using a candidate antigen approach. These have included studying 
the reactivity of CD8+ T cells to myelin basic protein (MBP), proteolipid protein (PLP), 
myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein (MOG), 
glial fibrillary acidic protein and transaldolase.63, 142, 143, 145, 146, 148 The results of these 
studies have been inconclusive – increased CD8+ T cell responses have been observed 
in MS patients in some studies 142, 145, 148 but not in others104, 143, 149, 288. CD8+ T cells 
specific to MOG,179, 180, 357 MBP,181, GFAP,144 in addition to haemagglutinin182 and 
ovalbumin expressed by oligodendrocytes have been shown to be pathogenic in 
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animal models.183 In addition to antigenic targets, the initial triggering antigen in MS is 
also unknown. Considerable attention has been focused on Epstein-Barr virus (EBV). 
Based on epidemiological,153 serological154, 155, CSF156-159 and EBV-reactive T cell 
frequencies163-167 there is some evidence that this virus may play a role in disease 
pathogenesis.  
 
Within this section of the thesis, I aimed to identify the pathogenic triggers of 
dominant CSF-resident TCRs in MS patients. Two strategies were utilised; the first was 
to perform an EBV-antigen focused approached utilising a TNFα capture assay.292 The 
second approach was a novel, unbiased investigation using lentiviral and combinatorial 
peptide library screening technology. The results of the EBV TNFα capture assay 
demonstrated CSF-resident EBV-specific T cells across all patient groups. Results were 
obtained for 9 patients in the MS group with EBV-specific TCRs observed in 3 patients; 
1x CD8+ TCR in 1 patient; 2x CD8+ T CRS in 1 patient; 1x CD4+ and 1x CD8+ TCR in a final 
patient sample. In the IIH group, results were obtained for 7 patients. Two EBV-specific 
CD8+ TCRs were observed in 1 patient. In the OND group, results were obtained for 6 
patients with 1 CD4+ EBV-specific TCR observed in 1 patient and 1 CD8+ EBV-specific 
TCR observed in another. Utilising a novel, unbiased combinatorial peptide screening 
approach for 1 patient I identified the antigen specificities for the most dominant CSF-
resident MHCI restricted TCR. These results demonstrate a strong affiliation with 
several herpes viruses although not including EBV (human herpesvirus 4). 
Unfortunately, the patient’s TCR did not show a response against the selected peptides 
so more work is required. 
 
7.6 Overall results and limitations 
The clinical chapter of this thesis helped to confirm the impressive outcomes of 
patients treated with the lymphocyte-depleting agent alemtuzumab. This confirmed 
the findings of previous studies and adds to the weight of evidence implicating T cells 
in MS disease pathogenesis. Although there is evidence for both CD4+ and CD8+ T cells 
in MS aetiology, this thesis focused on the potential pathogenic role of CD8+ T cells. 
With recent evidence suggesting a clonal expansion of CD8+ T cells indicative of 
antigen-stimulation I focused on this population with the aim to ultimately identify the 
 189 
pathogenic triggers and antigenic targets of these cells. However, although CD4+ T cells 
were not the main focus of this thesis, data for this population was also collected. 
 
The detailed immunophenotyping of CSF-resident T cells did not establish many 
differences between MS and control patients. In addition, the clonotyping analysis of 
these T cell populations demonstrated more unique clonotypes, less diversity and 
more contribution to the overall TCR frequencies of the top TCRs in the control 
patients compared to MS. This finding was present for both CD4+ and CD8+ T cell 
compartments. These results in combination offer an intriguing insight into normal 
CNS immune surveillance. It is thought that T cells must regularly travel around the 
CNS through blood, CSF and newly discovered lymphatic channels.16, 21 This is essential 
in removing pathogenic antigens including infectious organisms. From these results it 
would seem reasonable to postulate that effector memory T cells are a common 
finding in CSF along with clonal expansions in the CD8+ T cell repertoire, which is 
‘evened out’ in MS. In further support of this, TNFα capture assay identified EBV-
specific TCRs across all patient groups. This suggests that T cells are constantly 
surveying the CNS and are activated against common antigens such as EBV. However, 
these results do not exclude a role for CD8+ T cells in the pathogenesis of MS. There is 
clearly enough evidence to support their role and although an ‘evening out’ of the 
repertoire is observed, the dominant populations present may still be pathogenic. 
Therefore it is still of importance to try and identify the pathogenic triggers and 
antigenic targets of these cells. As such, we performed a novel, unbiased approach to 
try and answer this question.  
 
There were several aspects of this thesis that contributes to the quality of the results 
but also several limitations, which should be considered when reflecting on the overall 
results obtained. In the alemtuzumab clinical chapter, the relatively large number of 
patients and detailed long-term follow-up data aided the results obtained. However, 
although the results suggest a central role for T cells in general, they are not specific to 
CD8+ T cells and therefore the results should not be over interpreted with respect to 
these cells. However, clinical trials of CD4+ T cell targeted monoclonal antibodies alone 
have not proven to be successful.236-238 With respect to the immunophenotyping 
chapter, the number of cell surface markers used was extensive and it was important 
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to be able to compare with control data. However, although we had control data and 
they were as close to normal as our ethics would allow, they were still not entirely 
representative of a ‘normal’ population. This may explain differences between the 
control immunophenotype in our study and those in others.50, 103 Of note, these earlier 
studies demonstrating central memory T cells as the most dominant population used 
different cell markers to determine differentiation status (CD45RA, CD27) rather than 
the more accepted CCR7 and CD45RA markers that are used now.96 Furthermore, it 
should be noted that I did not attempt to identify regulatory T cells in this study, which 
would be interesting to examine in future studies especially due to the significant 
differences observed with the expression of CD27. 
 
Similar positive attributes and limitations can be noted with regards to the TCR 
clonotyping studies performed. The presence of control populations was important for 
comparisons but again these may not entirely reflect the ‘normal’ population. In 
addition, the relatively low cell numbers in these groups made clonotyping technically 
difficult with samples of less than 100 cells not being clonotyped. These factors 
resulted in a lower success rate of clonotyping and hence less sequencing results for 
the samples. However, the difference in sorted cell numbers was investigated by Dr 
Venturi who concluded that the results of the MS patient samples were likely an 
underestimate i.e. they were likely to be more diverse than that observed. Currently 
we are aiming to perform further control experiments on different numbers of sorted 
cells in order to understand the effect of the number of sorted cells on TCR diversity 
analysis in order to confirm this finding. 
 
With respect to antigen specificity, the approach used to examine this was novel and 
to our knowledge has not been attempted in CSF-resident T cells from MS patients 
before. The lentiviral construction and peptide library screening utilised was time-
consuming and therefore this approach was only used in one MS patient. Because of 
this it is difficult to draw definitive conclusions from the results obtained. It was 
disappointing that the transduced patient TCR did not demonstrate a response to the 
selected peptides but this may have been because only one of the patient’s HLA types 
was expressed by the target cell line used. In the future, it would be interesting to 
perform combinatorial peptide library screens for more patients and more TCRs across 
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a wider range of HLA types. This would be an unbiased way of examining T-cell antigen 
specificity across a wide range of patients and controls. 
 
Aside from this, it is extremely encouraging that this approach was ultimately 
successful and could be harnessed again in future studies. Other overall limitations in 
this thesis included the lack of comparison with peripheral blood and the lack of access 
to CNS tissue. Obviously, comparison with brain or spinal cord tissue would be 
extremely intuitive but this is difficult to obtain from living patients. In addition, post-
mortem tissue has the obvious limitation that it may not be reflective of the situation 
in life. Access to CSF from normal people would also allow a greater understanding of 
normal immune surveillance and MS pathogenesis but our existing ethics did not allow 
this. This could be a consideration for future ethics applications but may be difficult to 
justify an invasive procedure with potential complications in normal individuals. 
 
7.7 Concluding remarks and future directions 
This thesis set out to better characterize the role of CD8+ T cells in MS disease 
pathogenesis but the results perhaps led in a slightly different direction. They have 
offered an insight into normal CNS immune surveillance and led to further questions 
about how CD8+ T cells contribute to the aetiology of MS and how best to identify 
pathogenic subsets. This will have particular importance for designing future 
therapeutics. With the existing evidence for the role of CD8+ T cells, it is clear that they 
are contributing to MS disease pathogenesis, but there must be additional 
mechanisms rather than just having a clonally expanded population. Our data 
demonstrate that there is an increased number of CD4+ and CD8+ T cells in the CSF of 
MS patients as may be expected and perhaps these T cells have other attributes that 
influences their pathogenicity. For example, they may be more cross-reactive, have 
different activation thresholds25 or may have different CNS migration markers.350 In 
addition, they may have more reactivity against multiple CNS epitopes. Recent 
approaches may also offer a novel approach to identifying antigen specificity.385, 386 
Understanding this and identifying pathogenic subsets will be important for future 
therapeutics. Current therapies are aimed at modulating the immune system in the 
periphery. Although they are effective at preventing relapses, they are often 
associated with other features of immunosuppression and immune reconstitution such 
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as secondary autoimmune disease, opportunistic infections and malignancies. 
Understanding pathogenesis so that more individualised, targeted therapeutics can be 
developed will therefore be an important area of future enquiry. 
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Appendix 
 
8.1 Immunophenotyping antibodies used per patient group 
 
8.1.1 Multiple sclerosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.1.2 Idiopathic intracranial hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient'ID CD45RA CCR7 CD27 CD49d CD57 CD95 CD127 Pan'γδ PD61
LC20552 ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✗ ✗
LJ20639 ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✗ ✗
LS20460*
MJ19588 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
EB21510 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
KG19967 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
LH18836 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
NW21326 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
MW21576 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
CS21983 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
AL28847 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
MK21405 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
SA23376 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
RM22664 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
TL22789 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
CT25364 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
HD21265 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
MH21407 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
RW21309 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
DD22299*
CG41964 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
Patient'ID CD45RA CCR7 CD27 CD49d CD57 CD95 CD127 Pan'γδ PD61
EC21870 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
HS25204 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
LH25311 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
ML25308 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
SW25353 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
RY21758 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
DC37877 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
ES37889 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
FC24414 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
VE25562*
CC40712 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
RC41200 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
KA38079 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
CC41471 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
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8.1.3 Other neurological diseases 
 
 
 
 
 
 
 
Patient'ID CD45RA CCR7 CD27 CD49d CD57 CD95 CD127 Pan'γδ PD61
SE29703*
JG33488 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
ND37140 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
DL37517*
CS19395 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
AG20355 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓
JM25229 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
AB25236 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
CJ26014 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
JJ37566*
JP24822*
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8.2 T cell receptor clonotyping of CSF-resident T Cells – Raw data 
 
8.2.1 Multiple sclerosis 
 
1. LC20552  
 
LC20552 CSF CD4+ T cell sort (5591 sorted cells)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSAGLAGHNEQF 2"1 11.27 8
29"1 CSVGRLAGGSYNEQF 2"1 8.45 6
4"1 CASSQDLGPYNEQF 2"1 8.45 6
12"3/12"4 CASSLTGGYQPQH 1"5 8.45 6
6"5 CASKKDRADTEAF 1"1 8.45 6
28 CASSGRGAPSTDTQY 2"3 4.23 3
25"1 CASSERTTGGAKLF 1"4 2.82 2
6"2/6"3 CASSYGQENYGYT 1"2 2.82 2
20"1 CSAPHPGANVLT 2"6 2.82 2
18 CASSPRVLRTESPLH 1"6 1.41 1
15 CATSKASGSWADTQY 2"3 1.41 1
7"2 CASSKPGLAEQETQY 2"5 1.41 1
5"6 CASSLNTGRISYEQY 2"7 1.41 1
11"1 CASSQKPGQVGEQY 2"7 1.41 1
7"9 CASSLRGLGGNEQF 2"1 1.41 1
7"2 CASSSHWGGRNEQY 2"7 1.41 1
7"2 CASSPSGGANYGYT 1"2 1.41 1
6"5 CASSYNGRSQETQY 2"5 1.41 1
6"5 CASSSRQGDTDTQY 2"3 1.41 1
5"1 CASSENSGANEKLF 2"2 1.41 1
5"1 CASSLADGGNSPLH 1"6 1.41 1
5"1 CASSLPDSGNSPLH 1"6 1.41 1
2 CASSELGQINYGYT 1"2 1.41 1
29"1 CSVGRGGSYNEQF 2"1 1.41 1
20"1 CSARSGSVTGEQY 2"7 1.41 1
20"1 CSARDSQRTYEQY 2"7 1.41 1
9 CASSPWTGPYEQY 2"7 1.41 1
7"2 CASSQRGPYNEQF 2"1 1.41 1
28 CASTGTLGNEQF 2"1 1.41 1
27 CASSRKPDRPQH 1"5 1.41 1
19 CASKDRVFTEAF 1"1 1.41 1
18 CASSPDWNYEQY 2"7 1.41 1
11"3 CASSFEENNEQF 2"1 1.41 1
10"3 CAIRREGGTEAF 1"1 1.41 1
10"1 CASSMGRTYEQY 2"7 1.41 1
4"2 CASSQGPFDEQY 2"7 1.41 1
20"1 CSAGVVGTSAF 1"1 1.41 1
13 CPSSHEQF 2"1 1.41 1
13 CASSHEQF 2"1 1.41 1
100 71
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LC20552 CSF CD8+ T cell sort (798 sorted cells)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. LJ20639  
 
LJ20639 CSF CD4+ T cell sort (5000 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSLGWGDTEAF 1.1 20.31 13
5.1 CASSFGAPAYNSPLH 1.6 15.63 10
13 CASSTGTSGSNEQF 2.1 9.38 6
27 CASRTSGVKNIQY 2.4 7.81 5
2 CASSDAGGHTEAF 1.1 7.81 5
4.1 CASSQETGLWDEQF 2.1 6.25 4
28 CASSLWAPSASSYEQY 2.7 4.69 3
7.9 CASSSHQGALNTEAF 1.1 4.69 3
2 CASRDSPGLTNTEAF 1.1 4.69 3
27 CASSNDRANQPQH 1.5 4.69 3
4.1 CASSPWTMDTQY 2.3 3.13 2
9 CASSPDRGVSGANVLT 2.6 1.56 1
5.1 CVSSFGAPAYNSPLH 1.6 1.56 1
13 CASSTGTSGGNEQF 1.1 1.56 1
10.3 CVISESGRGLAEAF 1.1 1.56 1
6.6 CASSEEDIRYTEAF 1.1 1.56 1
6.6 CATGTSGDSYEQY 2.7 1.56 1
5.4 CASSPLGGDEQF 2.1 1.56 1
100 64
TRBV CDR3 TRBJ Freq-(%) Count
12#3/12#4 CASRNSGSRDEQF 2#1 12.50 5
5#1 CASSLFQGPDTEAF 1#1 10.00 4
5#1 CASSVGDTDTQY 2#3 7.50 3
15 CATSSPFAGGQWEQF 2#1 5.00 2
5#1 CASSFPWTGGDTEAF 1#1 5.00 2
7#8 CASSLAGPMNTEAF 1#1 5.00 2
6#5 CASSYSIRQNQPQH 1#5 5.00 2
7#9 CASSLRSGGSPLH 1#6 5.00 2
5#1 CASSRQNEQF 2#1 5.00 2
3#1 CASSQRLAGDGTDTQY 2#3 2.50 1
6#1 CASSEPRTGKNTEAF 1#1 2.50 1
5#5 CASSLAWSSYNSPLH 1#6 2.50 1
5#1 CASSLARHPQDTEAF 1#1 2.50 1
20#1 CSARDMGKGNEKLF 2#2 2.50 1
4#1 CASSQAELRSYEQY 2#7 2.50 1
29#1 CSVGDLGLRGELF 2#2 2.50 1
6#6 CASSYSLFNEKLF 2#2 2.50 1
4#2 CASSQDGTGGEQY 2#7 2.50 1
29#1 CSVTGATTDTQY 2#3 2.50 1
29#1 CSVGTAFDNEQF 2#1 2.50 1
4#2 CASSQTRTDTQY 2#3 2.50 1
6#2/6#3 CASSYDRGEQY 2#7 2.50 1
6#1 CASIYRATEAF 1#1 2.50 1
7#8 CASSGGGEQY 2#7 2.50 1
3#1 CASSRDYEQY 2#7 2.50 1
100 40
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LJ20639 CSF CD4+ T cell sort (repeat) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
29#1 CSVGSVGTEAF 1#1 6.8 5
18 CASSRAGQAAGELF 2#2 5.5 4
6#5 CASSYSTPRGVNTEAF 1#1 4.1 3
6#1 CASSEPRTGKNTEAF 1#1 4.1 3
27 CASSLLGLAADTQY 2#3 4.1 3
6#5 CASSYGTSGSYEQY 2#7 4.1 3
5#1 CASSVGDTDTQY 2#3 4.1 3
12#4 CASSLGQRAAF 1#1 4.1 3
28 CASSPSRGLSGANVLT 2#6 2.7 2
5#1 CASSFPWTGGDTEAF 1#1 2.7 2
20#1 CSARDMGKGNEKLF 1#4 2.7 2
12#3 CASGRDNQGTGELF 2#2 2.7 2
9 CASSPRSDSGNTIY 1#3 2.7 2
11#2 CASSLYGGTNEKLF 1#4 2.7 2
29#1 CSVVGTGYNEQF 2#1 2.7 2
20#1 CSETSGSGNEQY 2#7 2.7 2
24#1 CASRGADTEAF 1#1 2.7 2
28 CASSYGNEQF 2#1 2.7 2
5#1 CASSRQNEQF 2#1 2.7 2
3#1 CASSHTSEAF 1#1 2.7 2
15 CATSSPFAGGQWEQF 2#1 1.4 1
5#1 CASSLARHPQDTEAF 1#1 1.4 1
2 CASRWSRGSYNEQF 2#1 1.4 1
6#5 CASSYSIRQNQPQH 1#5 1.4 1
2 CASSEGSHGANVLT 2#6 1.4 1
29#1 CSASRGQNTGELF 2#2 1.4 1
28 CASSFRRTGNTEAF 1#1 1.4 1
20#1 CSAVLAGGRNEQF 2#1 1.4 1
12#3 CASRNSGSRDEQF 2#1 1.4 1
7#6 CASSLEVRKDSPLH 1#6 1.4 1
5#1 CASSLFQGPDTEAF 1#1 1.4 1
3#1 CASSQVSARETQY 2#5 1.4 1
29#1 CSVGDLGLRGELF 2#2 1.4 1
7#9 CASSLRSGGSPLH 1#6 1.4 1
20#1 CSAVSANTGELF 2#2 1.4 1
6#6 CASSYSLFNEKLF 1#4 1.4 1
5#1 CASSSGQYYGYT 1#2 1.4 1
4#2 CASSQTRTDTQY 2#3 1.4 1
10#3 CAISPRGLDEQY 2#7 1.4 1
29#1 CSVDPGTIVQF 2#1 1.4 1
12#3 CASSFAGETQY 2#5 1.4 1
7#8 CASSGGGEQY 2#7 1.4 1
100 73
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LJ20639 CSF CD8+ T cell sort (673 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. LS20460  
 
LS20460 CSF CD4+ T cell sort (1176 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
6"6 CASSFGGNEQF 2"1 17.65 12
6"1 CASSELFSKGNQPQH 1"5 13.24 9
4"2 CASSLDGLARSPQY 2"5 8.82 6
4"1 CASSQDRLAGVEQF 2"1 7.35 5
27 CASSFGSGANVLT 2"6 7.35 5
27 CASSSPEWGYGYT 1"2 7.35 5
28 CASSIDRVETQY 2"5 7.35 5
9 CASSVAQGGEQY 2"7 7.35 5
5"1 CASSFGSYTGELF 2"2 5.88 4
28 CASSLASGNYNEQF 2"1 4.41 3
7"2 CASSLGSVYTEAF 1"1 4.41 3
5"1 CASSYALSYEQY 2"7 2.94 2
7"9 CASSRVSYEQY 2"7 2.94 2
5"4 CASSPGTSGNWNEQF 2"1 1.47 1
12"3/12"4 CASSLAFVGYEQY 2"7 1.47 1
100 68
TRBV CDR3 TRBJ Freq-(%) Count
12#3/12#4 CASIPLPAVGRDYGYT 1#2 21.43 15
20#1 CSAPEGARLNTEAF 1#1 12.86 9
7#2 CASSLGLADNEQF 2#1 11.43 8
28 CASTRPGGRSNQPQH 1#5 10.00 7
11#1 CASSNHMGQGRGYT 1#2 5.71 4
5#1 CASRTGPISGNTIY 1#3 5.71 4
15 CATSPTSGSKGNTGELF 2#2 4.29 3
7#8 CASRYRGENSPLH 1#6 2.86 2
7#2 CASSVRDSSYEQY 2#7 2.86 2
28 CASSRDRGETQY 2#5 2.86 2
5#1 CASSLGSNQPQH 1#6 2.86 2
3#1 CASRGLGNSPLH 1#6 2.86 2
12#3/12#4 CASPTTEPSSGANVLT 2#6 1.43 1
30 CAWGAGQGFYNEQF 2#1 1.43 1
6#2/6#3 CASWETYSSGNTIY 1#3 1.43 1
5#1 CASSFGSGGGETQY 2#5 1.43 1
5#1 CASSLRQGDTGELF 2#2 1.43 1
7#2 CASNLGLADNEQF 2#1 1.43 1
5#1 CASSLGGSRDEQY 2#7 1.43 1
5#1 CASSLAAANSPPH 1#6 1.43 1
20#1 CSAPGSNRNEQF 2#1 1.43 1
5#1 CASRMGSNQPQH 1#5 1.43 1
100 70
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LS20460 CSF CD8+ T cell sort (393 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"9 CATGKARSGTGELF 2"2 48.86 43
5"5 CASSPWTGLDNEQF 2"1 35.23 31
20"1 CSARDRQGLIGYNEQF 2"1 13.64 12
7"9 CATGKVRSGTGELF 2"2 1.14 1
5"5 CASSPGTGLDNEQF 2"1 1.14 1
100 88
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4. MJ19588 
 
MJ19588 CSF CD4+ T cell sort (5984 sorted cells) 
 
 
 
 
 
 
 																
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSPQGLAGDQETQY 2.5 5.41 4
5.1 CASSSSGSSGTGELF 2.2 5.41 4
27 CASSINGVQETQY 2.5 5.41 4
20.1 CSARSLLSYEQY 2.7 5.41 4
28 CASSGHRRTGFSYEQY 2.7 4.05 3
7.8 CASSLGAGAGPIGELF 2.2 2.70 2
5.1 CASSLETGKGETQY 2.5 2.70 2
5.4 CASSFISGGEETQY 2.5 2.70 2
29.1 CSARGTSGSINEQF 2.1 2.70 2
20.1 CSARDAGGPNEQF 2.1 2.70 2
5.1 CASSPGNGPYEQY 2.7 2.70 2
12.3/12.4 CASTRQMNTEAF 1.1 2.70 2
7.9 CASILGGNTEAF 1.1 2.70 2
5.1 CASRSDTGNEQF 2.1 2.70 2
12.3/12.4 CASSAGDTEAF 1.1 2.70 2
28 CAIKGNTEAF 1.1 2.70 2
7.8 CASSPPGELF 2.2 2.70 2
15 CATSTQPQH 1.5 2.70 2
28 CASRPTRGAGYTGELF 2.2 1.35 1
20.1 CSASGTGGGSTDTQY 2.3 1.35 1
20.1 CSARGQRDRPAGELF 2.2 1.35 1
6.5 CASRDLAGDSYNEQF 2.1 1.35 1
6.5 CASKGQGFEDNSPLH 1.6 1.35 1
6.5 CASSSLTGAGSTEAF 1.1 1.35 1
4.3 CASSQGTSGDTGELF 2.2 1.35 1
29.1 CSVEGTSGATDTQY 2.3 1.35 1
29.1 CSVPLANRVGTEAF 1.1 1.35 1
27 CASSPDRANSYEQY 2.7 1.35 1
12.3/12.4 CASSLVRSAYNEQF 2.1 1.35 1
11.3 CASSLNTGPYNEQF 2.1 1.35 1
7.2 CASSSLASGSSEQY 2.7 1.35 1
7.2 CASSLIIGLNTEAF 1.1 1.35 1
5.6 CASSSPGTGISGYT 1.2 1.35 1
5.1 CASSIITGETETQY 2.5 1.35 1
5.1 CASSIETGGSTEAF 1.1 1.35 1
5.1 CASSDERTANTEAF 1.1 1.35 1
2 CASSEALGGDQPQH 1.5 1.35 1
27 CASSLWGQAYGYT 1.2 1.35 1
20.1 CSAPSGSINNEQF 2.1 1.35 1
20.1 CSARDPTGPDGYT 1.2 1.35 1
12.3/12.4 CASSLGPGKETQY 2.5 1.35 1
6.5 CASSRPSGTDTQY 2.3 1.35 1
5.1 CASSLGRGVNEQY 2.7 1.35 1
5.1 CASSLGLAGIEQF 2.1 1.35 1
30 CAWRTGFNTEAF 1.1 1.35 1
7.8 CASSPWANTEAF 1.1 1.35 1
6.2/6.3 CATSQGNNQPQH 1.5 1.35 1
5.1 CASRSDTGKEQF 2.1 1.35 1
7.8 CASSEQTGELF 2.2 1.35 1
5.1 CASSLRTNEQF 2.1 1.35 1
12.3/12.4 CASSSQYEQY 2.7 1.35 1
100 78
 201 
MJ19588 CSF CD8+ T cell sort (887 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
29#1 CSVDLYGDDYGYT 1#2 23.86 21
20#1 CSAKGLAGRNEQF 2#1 23.86 21
7#9 CASSLGGTTAHTNTGELF 2#2 17.05 15
28 CASTPWANQETQY 2#5 12.50 11
12#5 CASGLLPRDRGDYGYT 1#2 4.55 4
7#3 RASSLRREGNQPQH 1#5 4.55 4
27 CASSLRTERAGELF 2#2 3.41 3
12#3/12#4 CASSRGQNIDEQF 2#1 3.41 3
5#1 CASSLGVANQPQH 1#5 2.27 2
7#9 CASSLGGTTAHRNTGELF 2#2 1.14 1
29#1 CSVAGLAGKTAETQY 2#5 1.14 1
7#3 RASSLRGEGNQPQH 1#5 1.14 1
29#1 CSAYDSSYEQY 2#1 1.14 1
100 88
 202 
5. EB21510 
 
EB21510 CSF CD4+ T cell sort (5000 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
20#1 CSARHSTGKIYYEQY 2#7 5.41 4
20#1 CSVPRGVPYNEQF 2#1 5.41 4
5#6 CASSQNWNEAF 1#1 5.41 4
20#1 CSASLGLAVMTSTDTQY 2#3 4.05 3
12#3/12#4 CASSFLPGRGLDGYT 1#2 4.05 3
29#1 CSVEWGRGDGYT 1#2 4.05 3
28 CASSWMTGLSSGNTIY 1#3 2.70 2
7#2 CASSLMPQGASYGYT 1#2 2.70 2
12#3/12#4 CASTLGLRGYGYT 1#2 2.70 2
28 CASSLKAGGTEQY 2#7 2.70 2
28 CAGTSGRGETQY 2#5 2.70 2
6#2/6#3 CASRRGGNTEAF 1#1 2.70 2
7#9 CASSFPGNTIY 1#3 2.70 2
5#1 CASSQNWNEAF 1#1 2.70 2
9 CASSPSSSSLSYNEQF 2#1 1.35 1
9 CASLRVGKGLSGNTIY 1#3 1.35 1
28 CASSLRAGRGTYEQY 2#7 1.35 1
28 CASRETDRAGANVLT 2#6 1.35 1
6#6 CASSYGDFSYNSPLH 1#6 1.35 1
5#1 CASSLGARSSYNEQF 2#1 1.35 1
3#1 CASSPTQLGAKNIQY 2#4 1.35 1
2 CASSKSRDFSYNEQF 2#1 1.35 1
29#1 CSVEDLGRGDTEAF 1#1 1.35 1
28 CASSTTGGLSYEQY 2#7 1.35 1
28 CASSLFPGMGYEQY 2#7 1.35 1
28 CASSSGGADSNEQF 2#1 1.35 1
27 CASSLRRLPGETQY 2#5 1.35 1
20#1 CSATEPKRGHEKLF 1#4 1.35 1
12#3/12#4 CASSSPAGSTDTQY 2#3 1.35 1
11#3 CASSLGTSGYNEQF 2#1 1.35 1
10#3 CAISGQLSGANVLT 2#6 1.35 1
9 CASSVASGTYNEQF 2#1 1.35 1
9 CASSGGQTVNSPLH 1#6 1.35 1
7#2 CASRTGTGLTGELF 2#2 1.35 1
7#2 CASSLGSSYNSPLH 1#6 1.35 1
5#1 CASSLNPSGRDEQY 2#7 1.35 1
29#1 CSVEEQGRGSPLH 1#6 1.35 1
28 CASSFYRGGYEQY 2#7 1.35 1
11#3 CASSLHGRPDTQY 2#3 1.35 1
7#2 CASSVGGVNYEQY 2#7 1.35 1
6#2/6#3 CASWGQTFTGELF 2#2 1.35 1
5#1 CASSFVTSTDTQY 2#3 1.35 1
5#1 CASSLFGQDTEAF 1#1 1.35 1
12#3/12#4 CASSLGRLGEQY 2#7 1.35 1
7#2 CASSLDYRGGYT 1#2 1.35 1
5#1 CASSLGYQETQY 2#5 1.35 1
2 CASRGQGGTEAF 1#1 1.35 1
25#1 CASAAPGTEAF 1#1 1.35 1
10#3 CAISEEVYEQY 2#7 1.35 1
10#3 CAISEAVYGYT 1#2 1.35 1
10#3 CAISEPPEAF 1#1 1.35 1
100 74
 203 
EB21510 CSF CD8+ T cell sort (911 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. KG19967 
 
KG19967 CSF CD4+ T cell sort (1582 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
27 CASTPSGANVLT 2,6 36.99 27
27 CASSFGGLEKLF 1,4 8.22 6
7,2 CASSLGGGQGLDWTEAF 1,1 6.85 5
11,2 CASSPYPSGRDVEQF 2,1 6.85 5
28 CASSLRLYEQY 2,7 6.85 5
5,5 CASSVVGALNQY 2,4 5.48 4
7,9 CASSLVERAEAF 1,1 4.11 3
7,3 CASSLTTNTEAF 1,1 4.11 3
5,5 CASSLTETGFNQPQH 1,5 2.74 2
28 CASTPRGGGYQPQH 1,5 2.74 2
6,2/6,3 CASSYVGLAEETQY 2,5 2.74 2
7,9 CASRGGRDAEKLF 1,4 2.74 2
6,6 CASLDGSTNEKLF 1,4 2.74 2
20,1 CSATDLASHQETQY 2,5 1.37 1
7,9 CASSDQDKGTDTQY 2,3 1.37 1
9 CASSFGTGNTEAF 1,1 1.37 1
20,1 CSARGRGVQPQH 1,5 1.37 1
29,1 CSVRGLAGVQY 2,7 1.37 1
100 73
TRBV CDR3 TRBJ Freq-(%) Count
12#3/12#4 CASSLAGTDTQY 2#3 18.29 15
27 CASSFYKTSYEQY 2#7 15.85 13
20#1 CSAPPRVPNTEAF 1#1 13.41 11
3#1 CASSRDLAGGQETQY 2#5 12.20 10
12#3/12#4 CASSRQGDSSPLH 1#6 9.76 8
27 CASSRTKQGNTEAF 1#1 6.10 5
7#2 CASSSGAAWGGEQF 2#1 4.88 4
29#1 CSVAEGNEQY 2#7 4.88 4
5#1 CASSLEFGETQY 2#5 3.66 3
29#1 CSVEDPGTVYT 1#2 3.66 3
11#3 CASSPVGRADNEQF 2#1 2.44 2
20#1 CSARDFGNTEAF 1#1 2.44 2
18 CASSPSGTGGTNEKLF 1#4 1.22 1
6#6 CASTRLGAGNTIY 1#3 1.22 1
100 82
 204 
KG19967 CSF CD8+ T cell sort (256 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
12#3/12#4 CASSYGAYNEQF 2#1 59.30 51
29#1 CSVTGQGTTEQY 2#7 17.44 15
11#2 CASSLTAGGYEQY 2#7 12.79 11
29#1 CSVSMVGTSGRYEQF 2#1 6.98 6
20#1 CSAPQGVNTGELF 2#2 2.33 2
3#1 CASSPATGNTEAF 1#1 1.16 1
100 86
 205 
7. LH18836 
 
LH18836 CSF CD4+ T cell sort (5000 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSLLSGSTDTQY 2,3 7.58 5
6,6 CASSYSDRLSGRYEQY 2,7 4.55 3
28 CASSPPDSSNQPQH 1,5 4.55 3
20,1 CSARTPRRADSEKLF 1,4 3.03 2
29,1 CSAETRADSGNTIY 1,3 3.03 2
20,1 CSARDPARSNEKLF 1,4 3.03 2
11,2 CASSPRLAGGYEQY 2,7 3.03 2
30 CAWSPGYKGQPQH 1,5 3.03 2
12,3/12,4 CASSPSGYTYEQY 2,7 3.03 2
5,1 CASSLLRTEEGYT 1,2 3.03 2
29,1 CSVTTGNTEAF 1,1 3.03 2
29,1 CSVEDKARGF 2,1 3.03 2
7,3 CANSPQPPGLAGSDTDTQY 2,3 1.52 1
5,1 CASSLPLAGEGPTDTQY 2,3 1.52 1
28 CASSLVRTGGLPYEQY 2,7 1.52 1
7,8 CASSLGVLAGVTGELF 2,2 1.52 1
5,6 CASSLGFMGQGQDTQY 2,3 1.52 1
5,1 CASSSGTSGHTRNTQY 2,3 1.52 1
4,1 CASSQATAGTSAGELF 2,2 1.52 1
25,1 CASSAALAGLTDTQY 2,3 1.52 1
6,5 CASSYQSPGVGTEAF 1,1 1.52 1
5,1 CASSPAASGNTGELF 2,2 1.52 1
5,1 CASSSSFGGRSGEQF 2,1 1.52 1
18 CASSRRQGNDSPLH 1,6 1.52 1
11,3 CASSLVQAGPDTQY 2,3 1.52 1
11,2 CASSPPGRNLETQY 2,5 1.52 1
9 CASSVDGRVLGGYT 1,2 1.52 1
7,8 CASSLRQGGPYEQY 2,7 1.52 1
29,1 CSVGTWSGTDTQY 2,3 1.52 1
19 CASSSDRWNYGYT 1,2 1.52 1
12,3/12,4 CASTRASGTYEQY 2,7 1.52 1
12,3/12,4 CASSRTGTGNTIY 1,3 1.52 1
7,9 CASSLTPVTDTQY 2,3 1.52 1
7,2 CASSLVSFTDTQY 2,3 1.52 1
6,5 CASSYRGQTYGYT 1,2 1.52 1
6,1 CASSPLGGRAEQF 2,1 1.52 1
5,1 CASSLLQTEEGYT 1,2 1.52 1
2 CASRKSGSLDEQY 2,7 1.52 1
20,1 CSARGPRLNEQF 2,1 1.52 1
12,3/12,4 CASSTRTLYEQY 2,7 1.52 1
9 CASSVSPRNEQF 2,1 1.52 1
5,1 CASSAEGTQPQH 1,5 1.52 1
5,1 CASSFGTDATAF 1,1 1.52 1
2 CASGRDSPYEQY 2,7 1.52 1
28 CASLGQNYGYT 1,2 1.52 1
12,3/12,4 CASMLSYNEQF 2,1 1.52 1
9 CASSVGFGELF 2,2 1.52 1
29,1 CSVDGAHGYT 1,2 1.52 1
29,1 CSGIGRNEAF 1,1 1.52 1
100 66
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LH18836 CSF CD8+ T cell sort (1795 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. NW21326 
 
NW21326 CSF CD4+ T cell sort (534 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSLVKAGGNEEQY 2"7 8.57 6
29"1 CSVEATGLAGAQEQF 2"1 7.14 5
12"3/12"4 CASSFPTGYYNEQF 2"1 7.14 5
7"8 CASSFGGRASNEQF 2"1 7.14 5
4"1 CASSGRTGTNYGYT 1"2 5.71 4
27 CASSLQGANYGYT 1"2 5.71 4
13 CASSRQGIPEAF 1"1 5.71 4
9 CASSEKGLAGADEQY 2"7 4.29 3
5"1 CASSLSNTGELF 2"2 4.29 3
20"1 CSAIIMLAGGPWHTDTQY 2"3 2.86 2
6"6 CASSPEKTGLNYGYT 1"2 2.86 2
20"1 CSAVSQQGGSYEQY 2"7 2.86 2
7"2 CASSLTSGPYNEQF 2"1 2.86 2
27 CASSLAAGGETQY 2"5 2.86 2
7"2 CASSSTLDNQPQH 1"5 2.86 2
29"1 CSVPGTVNNEQF 2"1 2.86 2
29"1 CSVPGTVNTEAF 1"1 2.86 2
7"9 CASSLDPAPEAF 1"1 2.86 2
27 CASHRKWLAGITNTGELF 2"2 1.43 1
20"1 CSAIIILAGGPWHTDTQY 2"3 1.43 1
11"3 CASTRGGHLKYSNQPQH 1"5 1.43 1
7"9 CASGGTLAGDYNEQF 2"1 1.43 1
7"2 CASSESQGPNTGELF 2"2 1.43 1
5"1 CASSLVKAGGSEEQY 2"7 1.43 1
27 CASSLRRQGEETQY 2"5 1.43 1
7"2 CASSLRGTTLDEQF 2"1 1.43 1
4"1 CASSEGLAGAYEQY 2"7 1.43 1
3"1 CASSHSVGARHEQF 2"1 1.43 1
7"3 CASSSTLDNQPQH 1"5 1.43 1
27 CASSSPTWDTQY 2"3 1.43 1
28 CASSLGYEQY 2"7 1.43 1
100 70
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSLGLGRNTEAF 1"1 44.44 40
5"1 CASSLGGQETQY 2"5 27.78 25
28 CASRASGRGPGELF 2"2 10.00 9
7"2 CASSLSFSSSGHEQY 2"7 7.78 7
28 CASSRQETQY 2"5 5.56 5
28 CASSLPGQGFPGELF 2"2 2.22 2
5"1 CASSLGLGRSTEAF 1"1 1.11 1
29"1 CSVEESTYTEAF 1"1 1.11 1
100 90
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NW21326 CSF CD8+ T cell sort (116 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
9. MW21576 
 
MW21576 CSF CD4+ T cell sort (1956 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"9 CASSLGGTEAF 1"1 69.12 47
19 CASSYGRAVGELF 2"2 7.35 5
5"5 CASSFWEANEQF 2"1 7.35 5
4"1 CASSQDSTPTHSNQPQH 1"5 5.88 4
7"9 CASSLPGSSYEQY 2"7 5.88 4
7"9 CAGSLGGTEAF 1"1 2.94 2
20"1 CSVQDRTYEQY 2"7 1.47 1
100 68
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSLIPGDGYT 1"2 10.26 8
9 CASSVDISGNTIY 1"3 6.41 5
5"1 CASSLGPDLNTEAF 1"1 6.41 5
5"1 CASSLGQGLF 2"1 6.41 5
7"8 CASSLGSRGQSTDTQY 2"3 5.13 4
6"2/6"3 CASSQGVLLSGYT 1"2 5.13 4
11"2 CASSLALLTSGKGQF 2"1 3.85 3
7"9 CASSQEYGGNTDTQY 2"3 3.85 3
7"6 CASSVQVGHSYEQY 2"7 3.85 3
18 CASSTGTDNTEAF 1"1 3.85 3
11"2 CASSFKQGDHSGNTIY 1"3 2.56 2
7"2 CASSFFTSGDRTDTQY 2"3 2.56 2
3"1 CASSQGAVAGFAETQY 2"5 2.56 2
27 CASSLLGSGGQPQH 1"5 2.56 2
3"1 CASSSGTGVGNEQF 2"1 2.56 2
30 CAWSPGTPLGYT 1"2 2.56 2
6"5 CASRSPRYNEQF 2"1 2.56 2
24"1 CATSVGIQPQH 1"5 2.56 2
28 CATSLSSGGRPDTQY 2"3 1.28 1
5"5 CASSLRTGRVNTEAF 1"1 1.28 1
29"1 CSVEYSGGGTGELF 2"2 1.28 1
24"1 CATSVLDTAGNTQY 2"3 1.28 1
12"3/12"4 CASSAAYRGGETQY 2"5 1.28 1
6"5 CASSYSAVFTDTQY 2"3 1.28 1
2 CASSQDGGSNQPQH 1"5 1.28 1
29"1 CSVEVMTSTDTQY 2"3 1.28 1
7"2 CASSLAGGLLEQY 2"7 1.28 1
6"6 CASYGQGRNSPLH 1"6 1.28 1
6"5 CASSLRQGNEKLF 1"4 1.28 1
6"5 CASSYGTGSLRAF 1"1 1.28 1
6"2/6"3 CASRRGGAGNEQF 2"1 1.28 1
6"1 CASSPGTGGQPQH 1"5 1.28 1
5"1 CASSLDKNNSPLH 1"6 1.28 1
20"1 CSANRQGGTEAF 1"1 1.28 1
2 CASKRQLNTEAF 1"1 1.28 1
29"1 CSVGQGHGELF 2"2 1.28 1
11"1 CASSSRQGEAF 1"1 1.28 1
100 78
 208 
MW21576 CSF CD8+ T cell sort (313 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"3 CASSPGQGQDEQY 2"7 27.06 23
27 CASSGLGRREQY 2"7 21.18 18
6"2/6"3 CASSLGGTGWTEQF 2"1 10.59 9
20"1 CSAREAGELF 2"2 8.24 7
24"1 CATSDLPPTGDTGELF 2"2 4.71 4
13 CASSRPFGRPYNEQF 2"1 4.71 4
2 CASRQLAGGDNEQF 2"1 4.71 4
7"8 CASSLGQAYEQY 2"7 4.71 4
6"5 CASGSGYYGYT 1"2 4.71 4
29"1 CSARLAGDSTDTQY 2"3 3.53 3
3"1 CASSLLAGGLTDTQY 2"3 2.35 2
11"2 CASSLDPGWSAGGIAKNIQY 2"4 1.18 1
7"3 CASSPGQGQGEQY 2"7 1.18 1
14 CASSQAGIHGYT 1"2 1.18 1
100 85
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10. CS21983 
 
CS21983 CSF CD4+ T cell sort (2125 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSTGLAGETQY 2"5 10.26 8
5"1 CASSLTSGSLSSYEQY 2"7 6.41 5
12"3/12"4 CASSLTNNQPQH 1"5 6.41 5
6"2/6"3 CASSRIGQEQF 2"1 6.41 5
7"8 CASSTVGGGTNTEAF 1"1 5.13 4
4"1 CASSQEFGGRNQPQH 1"5 5.13 4
29"1 CSVRTGGDGGYT 1"2 5.13 4
12"3/12"4 CASSPRRGQGPYGYT 1"2 3.85 3
11"2 CASSLVGTGSYNEQF 2"1 3.85 3
24"1 CATSPGGNMNTEAF 1"1 3.85 3
5"1 CASSTSRDRGYQETQY 2"5 2.56 2
12"3/12"4 CASSLITGWFQPQH 1"5 2.56 2
5"1 CASSFASGRTDTQY 2"3 2.56 2
2 CARRGARGNTGELF 2"2 2.56 2
5"1 CASSLRGDSYEQY 2"7 2.56 2
5"5 CASSKPETVWGT 1"1 2.56 2
5"1 CASRRTGSNEQF 2"1 2.56 2
5"1 CASRDLRGNEQF 2"1 2.56 2
7"8 CASSLQGEQY 2"7 2.56 2
6"1 CASRASGTSGRESTDTQY 2"3 1.28 1
5"1 CASSLTSGSLGSYEQY 2"7 1.28 1
28 CASSSPGTGLLYEQY 2"7 1.28 1
11"2 RASSLVGTGSYNEQF 2"1 1.28 1
7"8 CASSPSRLTASYEQY 2"7 1.28 1
5"1 CASSFGGVRTNEKLF 1"4 1.28 1
24"1 CAASPGGNMNTEAF 1"1 1.28 1
6"2/6"3 CASSYSDASLYEQY 2"7 1.28 1
29"1 CSVSSAYGANVLT 2"6 1.28 1
7"9 CASSDPGYSYEQY 2"7 1.28 1
7"3 CASSRTSGQETQY 2"5 1.28 1
7"2 CASSRALSGNTIY 1"3 1.28 1
7"2 CASSRAFSGNTIY 1"3 1.28 1
4"1 CASRPLAGGNEQF 2"1 1.28 1
12"3/12"4 CASSMSLSSPLH 1"6 1.28 1
29"1 CSGGQGVHEQF 2"1 1.28 1
100 78
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CS21983 CSF CD8+ T cell sort (590 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
9 CASSKGEGSMNTEAF 1-1 12.99 10
24-1 CATSEDTGFGSYNEQF 2-1 11.69 9
7-6 CASSLSGYSSYEQY 2-7 10.39 8
7-8 CASSWNTGGWEQY 2-7 10.39 8
10-3 CAIGDSPENTIY 1-3 10.39 8
20-1 CSAREGDRVNYGYT 1-2 7.79 6
12-3/12-4 CASRPENTGELF 2-2 7.79 6
6-5 CASGGTGPYNEQF 2-1 5.19 4
7-9 CASSRGLREQF 2-1 5.19 4
6-6 CASGHGDEQY 2-7 5.19 4
28 CASSFRQGYQETQY 2-5 2.60 2
6-2/6-3 CASSPPTGGNQPQH 1-5 2.60 2
9 CASSELTGTGRETQY 2-5 1.30 1
28 CVSSFRQGYQETQY 2-5 1.30 1
19 CASSIQETTNEKLF 2-2 1.30 1
6-2/6-3 CASRPPGRTYEQY 2-7 1.30 1
7-9 CASSLVRVNTEAF 1-1 1.30 1
6-6 CASSPRENIQY 2-4 1.30 1
100 77
 211 
11. AL28847 
 
AL28847 CSF CD4+ T cell sort (5000 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
6"5 CASSYVRLSERGYEQY 2"7 6.58 5
28 CASSLIHTGELF 2"2 6.58 5
5"1 CASSEDRAQF 2"1 6.58 5
20"1 CSAGNTGTGVNEQF 2"1 5.26 4
5"1 CASSLDSVQETQY 2"5 5.26 4
5"1 CASSLGSAFSYEQY 2"7 3.95 3
12"3/12"4 CASTRDRVEETQY 2"5 3.95 3
6"5 CASSPQGRDSRQY 2"7 3.95 3
5"1 CASSLDTGNTIY 1"3 3.95 3
2 CASSSSRNYEQY 2"7 2.63 2
5"1 CASSLWDEQF 2"1 2.63 2
18 CASSPLPGLAGPKNTGELF 2"2 1.32 1
25"1 CASSESPGQGADGDIQY 2"4 1.32 1
5"1 CASSSRTSGRAHGGEQF 2"1 1.32 1
28 CASSIGQGFSGANVLT 2"6 1.32 1
6"5 CAGSYVRLSERGYEQY 2"7 1.32 1
5"1 CASSLGPLRDIQETQY 2"5 1.32 1
30 CAWSVGGGAGANVLT 2"6 1.32 1
20"1 CSASRVQGAENYGYT 1"2 1.32 1
6"2/6"3 CASTWRQGARNTEAF 1"1 1.32 1
28 CASSPQGLAGGEQY 2"7 1.32 1
28 CASRLGQGGNQPQH 1"5 1.32 1
9 CASSVGAGAGNEQF 2"1 1.32 1
7"8 CASSLRTSRANEQY 2"7 1.32 1
7"8 CASNRGGVGGTEAF 1"1 1.32 1
6"2/6"3 CASSTGWTQTYEQY 2"7 1.32 1
5"1 CASRPRTGGLGEQY 2"7 1.32 1
5"1 CASSLGPAFSYEQY 2"7 1.32 1
5"1 CASSLVMGKNTEAF 1"1 1.32 1
12"3/12"4 CASSSTGTLNEQF 2"1 1.32 1
12"3/12"4 CASRQGMSNQPQH 1"5 1.32 1
7"6 CASSQSGSTDTQY 2"3 1.32 1
7"3 CASSLSGKSYEQY 2"7 1.32 1
7"3 CASRLGGRTGELF 2"2 1.32 1
6"2/6"3 CASSHVQGVETQY 2"5 1.32 1
5"1 CASSPRTKGNEQY 2"7 1.32 1
5"1 CASSPIAGVDTQY 2"3 1.32 1
5"1 CASSPNTIANEQF 2"1 1.32 1
30 CAWDRQGGTEAF 1"1 1.32 1
29"1 CSVSLGGSETQY 2"5 1.32 1
12"3/12"4 CASSSGIGTPKH 1"5 1.32 1
10"3 CAISEGVTYEQY 2"7 1.32 1
5"1 CASSFDRTYEQY 2"7 1.32 1
28 CASSLLYEKLF 1"4 1.32 1
20"1 CSARQGAYTLH 1"6 1.32 1
7"9 CASSLTEGRN 1"2 1.32 1
7"3 CASSSDTGELF 2"2 1.32 1
5"1 CASSLRYNEQF 2"1 1.32 1
100 76
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AL28847 CSF CD8+ T cell sort (2537 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
2 CASSEGGAYEQY 2)7 16.67 13
7)2 CASSPPGRAGYEQY 2)7 8.97 7
6)2/6)3 CASSYWGSYDEQY 2)7 8.97 7
28 CASSTQGAVLGYT 1)2 7.69 6
20)1 CSAGGTGGSYEQY 2)7 6.41 5
12)3/12)4 CASSLYRGEKLF 1)4 6.41 5
4)1 CASSQAGQETQY 2)5 5.13 4
7)9 CASSPGGISNTEAF 1)1 3.85 3
7)9 CASSLGQGFNEQY 2)7 3.85 3
7)2 CASSAAGGAHEQY 2)7 3.85 3
5)5 CASSLGSDQPQH 1)5 3.85 3
3)1 CASSQDFSGSAKNIQY 2)4 2.56 2
20)1 CSARDTGGYSGNTIY 1)3 2.56 2
7)9 CASSPEVRGAYEQY 2)7 2.56 2
15 CATSTRDGEETQY 2)5 2.56 2
20)1 CSARVRGLPSSGANVLT 2)6 1.28 1
10)1 CASSESRAAGPTGELF 2)2 1.28 1
6)2/6)3 CASSYKMTRGFRNEQF 2)1 1.28 1
28 CASSLPGQGVTGELF 2)2 1.28 1
9 CASRETSGSLGEQF 2)1 1.28 1
7)9 CASSPEARGAYEQY 2)7 1.28 1
6)2/6)3 CASSYSGARLDTQY 2)3 1.28 1
5)6 CASSRGFSSYNEQF 2)1 1.28 1
7)9 CASSLALGRDEQY 2)7 1.28 1
7)8 CASSSGTGNTEAF 1)1 1.28 1
6)1 CASVAGDYQETQY 2)5 1.28 1
100 78
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12. MK21405 
 
MK21405 CSF CD4+ T cell sort (3887 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSGPLSNEQF 2"2 8.97 7
5"5 CASSFNQGETEAF 1"1 7.69 6
7"3 CASSFSGGAPPDTQY 2"3 5.13 4
6"1 CASSEAPGLGRFHEQY 2"7 3.85 3
5"6 CASSSTSGGDYNEQF 2"1 3.85 3
7"2 CASSLATGVGEEQF 2"1 3.85 3
5"1 CASSLGLAKNNEQF 2"1 3.85 3
28 CASSITGSQETQY 2"5 3.85 3
5"1 CASSLAPGAGTQY 2"3 3.85 3
7"2 CASSSSPVPEQF 2"1 3.85 3
6"2/6"3 CASSYGEGYT 1"2 3.85 3
20"1 CSAETGTSGGTEQY 2"7 2.56 2
6"1 CASTLFPGMSYGYT 1"2 2.56 2
5"1 CASSSGLAEGNEQF 2"1 2.56 2
28 CASSSGPMGQRAF 1"1 2.56 2
5"1 CASSRAEGQETQY 2"5 2.56 2
5"1 CASRVYAQGTEAF 1"1 2.56 2
10"3 CAISVGHEQY 2"7 2.56 2
27 CASSLQAGAYHLRLAGAYEQY 2"7 1.28 1
6"1 CANSEAPGLGRFHEQY 2"7 1.28 1
25"1 CASSVTSGGTLGEQF 2"1 1.28 1
7"2 CASSLVATQSSYEQY 2"7 1.28 1
28 CASSSDRGLDNEQF 2"1 1.28 1
20"1 CSARNPTSGEGEQY 2"7 1.28 1
7"2 CASSLFGSSNQPQH 1"5 1.28 1
7"2 CASSLGQGVNYGYT 1"2 1.28 1
6"1 CASSFTDSTNYGYT 1"2 1.28 1
6"1 CASTFSPGMSYGYT 1"2 1.28 1
5"1 CVSSLDTGSLETQY 2"5 1.28 1
4"3 CASSQRDRDSGGYT 1"2 1.28 1
30 CAWSRPAGGNEQF 2"1 1.28 1
12"3/12"4 CASSPGQGLYGYT 1"2 1.28 1
7"3 CASSPPGGLIEQF 2"1 1.28 1
6"1 CASSNSGSYNEQF 2"1 1.28 1
28 CASSLAGANVLT 2"6 1.28 1
27 CASSMTGSDEQF 2"1 1.28 1
9 CASSVASNTEAF 1"1 1.28 1
29"1 CSYRRDSDTQY 2"3 1.28 1
28 CATRAADDGYT 1"2 1.28 1
19 CASSRGQYGYT 1"2 1.28 1
29"1 CSVRQQETQY 2"5 1.28 1
100 78
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MK21405 CSF CD8+ T cell sort (717 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
29#1 CSVEGDGRSYEQY 2#7 22.58 14
12#5 CASGSTGPGDSPLH 1#6 19.35 12
27 CASSLLQGDTGELF 2#2 17.74 11
19 CASSITGTLGQPQH 1#5 16.13 10
28 CASSPTTATNEKLF 1#4 6.45 4
2 CASSGREVSPGELF 2#2 6.45 4
20#1 CSARVPGGVNNEQF 2#1 3.23 2
9 CASSVALGDYGYT 1#2 3.23 2
7#8 CASSESAGILAGGRDEQF 2#1 1.61 1
27 CASSLLQGVSGELF 2#2 1.61 1
15 CATSRDSAGAEPQH 1#5 1.61 1
100 62
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13. SA23376 
 
SA23376 CSF CD4+ T cell sort (4463 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSLAGPNSPLH 1"6 10.13 8
12"3/12"4 CASSFGGQGLSQFNQPQH 1"5 7.59 6
29"1 CSVGQTNTGELF 2"2 6.33 5
5"1 CASSAGRSGNSDTQY 2"3 3.80 3
5"1 CASSSGGQASGGYT 1"2 3.80 3
19 CASSSPTSYQPQH 1"5 3.80 3
5"5 CASSGGFSDNEQF 2"1 3.80 3
12"3/12"4 CASSLNSGTEQF 2"1 3.80 3
7"2 CASRPGLAGTDTQY 2"3 2.53 2
6"1 CASRRGTTSTDTQY 2"3 2.53 2
5"1 CASSSNRGTNEKLF 1"4 2.53 2
2 CASRWLAGVTDTQY 2"3 2.53 2
10"2 CASLGGRSTDTQY 2"3 2.53 2
6"5 CASNRGGRNYGYT 1"2 2.53 2
2 CASSGTVANYGYT 1"2 2.53 2
18 CASSPTDGQPQH 1"5 2.53 2
12"3/12"4 CASSPQATGELF 2"2 2.53 2
7"9 CASSLGDSNEQY 2"7 2.53 2
5"1 CASSRSGAELF 2"2 2.53 2
24"1 CATSDLSQGSRENNQPQH 1"5 1.27 1
7"8 CASRLLASGAFYNEQF 2"1 1.27 1
12"3/12"4 CASSYGGSAGANVLT 2"6 1.27 1
5"1 CASSIRTGALTDTQY 2"3 1.27 1
20"1 CSAREPRGDTGELF 2"2 1.27 1
6"1 CASNPLQGGSYGYT 1"2 1.27 1
4"1 CASSQEVGFSYEQY 2"7 1.27 1
4"1 CASSRNRDYNQPQH 1"5 1.27 1
3"1 CASSQWTTNTGELF 2"2 1.27 1
28 CASTPGGVTDTQY 2"3 1.27 1
25"1 CASSRGGVHSPLH 2"6 1.27 1
11"2 CASGRLAGGNEQF 2"1 1.27 1
7"2 CASSSPGGFWGYT 1"2 1.27 1
5"1 CASGLAGRNSPLH 1"6 1.27 1
4"1 CASSYMVLGNTIY 1"3 1.27 1
29"1 CSVGQTSTGELF 2"2 1.27 1
28 CASSSSTSNEQF 2"1 1.27 1
7"9 CASTRGDTGELF 2"2 1.27 1
7"9 CASSRDSNQPQH 1"5 1.27 1
5"6 CASSLGLADEQF 2"1 1.27 1
5"1 CASSFIASETQY 2"5 1.27 1
5"1 CASSSIASETQY 2"5 1.27 1
20"1 CSASSPGTQY 2"3 1.27 1
100 79
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SA23376 CSF CD8+ T cell sort (961 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
11"2 CASSLDRDSPSSYNEQF 2"1 28.99 20
10"3 CAISSGTVSPYGYT 1"2 28.99 20
25"1 CASRKGTAYEQY 2"7 7.25 5
7"6 CASSLGQGTNLMNTEAF 1"1 5.80 4
27 CASSPSAGRREKLF 1"4 5.80 4
3"1 CASSQDRQGGQPQH 1"5 5.80 4
10"3 CAISESSRGQGGRTGELF 2"2 4.35 3
9 CASSWTSSYNEQF 2"1 4.35 3
5"1 CASSLRDSLSGNTIY 1"3 1.45 1
9 CASSVMTGDNYGYT 1"2 1.45 1
27 CASSSGGPYEQF 2"1 1.45 1
6"1 CASSEAASYEQY 2"7 1.45 1
24"1 CATSEGNSYT 1"2 1.45 1
6"4 CASSDGYGYT 1"2 1.45 1
100 69
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14. RM22664 
 
RM22664 CSF CD4+ T cell sort (5000 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"2 CASSPLAASYNEQF 2"1 5.80 4
20"1 CSATGQGGGYGYT 1"2 4.35 3
7"7 CASSWGLAEETQY 2"5 4.35 3
7"2 CASSWGQGANGYT 1"2 4.35 3
24"1 CAAPGTGWYEQY 2"7 4.35 3
6"1 CASGKAPGEQY 2"7 4.35 3
16 CASSQQAGPSSGTQY 2"3 2.90 2
27 CASSLSISGRAEQY 2"7 2.90 2
7"2 CASSLTVLSTDTQY 2"3 2.90 2
6"2/6"3 CASSSARGNNSPLH 1"6 2.90 2
27 CASSKLAGRDTQY 2"3 2.90 2
12"3/12"4 CASSFSSSGNTIY 1"3 2.90 2
10"3 CAITRQGARNEQF 2"1 2.90 2
12"3/12"4 CASSLGSVYEQY 2"7 2.90 2
28 CASSFTNTIY 1"3 2.90 2
27 CASSSGIGQLPANYGYT 1"2 1.45 1
4"3 CASSQAPIGGAGQETQY 2"5 1.45 1
7"6 CASSQGGLAGATDTQY 2"3 1.45 1
29"1 CSVPGTGEKFNYGYT 1"2 1.45 1
28 CASSPPGSPYQETQY 2"5 1.45 1
15 CATSRNPHRGQETQY 2"5 1.45 1
11"2 CASSSRAATGVYEQF 2"1 1.45 1
9 CASSLTSGGVQETQY 2"5 1.45 1
27 CASSLRGVVQDTQY 2"3 1.45 1
7"6 CASSPGAGSADTQY 2"3 1.45 1
7"2 CASNPLAASYNEQF 2"1 1.45 1
6"2/6"3 CASRLGTGRGNEQF 2"1 1.45 1
6"1 CASKPGASYFEKLF 1"4 1.45 1
5"1 CASSSSTGRQETQY 2"5 1.45 1
29"1 CSVVQRGIGTEAF 1"1 1.45 1
28 CASSFWAAQETQY 2"5 1.45 1
20"1 CSAREPGRSTEAF 1"1 1.45 1
12"3/12"4 CASSLSGTGNTIY 1"3 1.45 1
12"3/12"4 CASRKGRRNTEAF 1"1 1.45 1
10"3 CAVTRQGARNEQF 2"1 1.45 1
29"1 CSVDGTGGVEAF 1"1 1.45 1
20"1 CSVSGTNTDTQY 2"3 1.45 1
20"1 CSSPGDTAYGYT 1"2 1.45 1
12"3/12"4 CASSWDRTYEQY 2"7 1.45 1
12"3/12"4 CASGGNQVNTQY 2"3 1.45 1
5"6 CASSLAGRYEQY 2"7 1.45 1
5"1 CASSDRGAHEQY 2"7 1.45 1
12"3/12"4 CASSPDRYEQY 2"7 1.45 1
12"3/12"4 CASSFRNQPQH 1"5 1.45 1
2 CASRWNQGMQY 2"5 1.45 1
29"1 CSARGNTEAF 1"1 1.45 1
18 CASQTNTEAF 1"1 1.45 1
100 69
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RM22664 CSF CD8+ T cell sort (4881 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSPGQAYEQY 2+7 8.20 5
9 CASSAMTSGGADTQY 2+3 4.92 3
7+7 CASSNEQGLSTDTQY 2+3 4.92 3
4+1 CASTRGTSSYNSPLH 1+6 4.92 3
27 CASSSRDSSGNTIY 1+3 4.92 3
7+9 CASSLSALGNEQF 2+1 4.92 3
27 CASTPGQGYEQY 2+7 4.92 3
28 CASSFEGTSGGTDTQY 2+3 3.28 2
7+2 CASSLGGTGPFNSPLH 1+6 3.28 2
29+1 CSVGTGGTNEKLF 1+4 3.28 2
28 CASSFSTDVGGYT 1+2 3.28 2
7+2 CASSVGTEYNEQF 2+1 3.28 2
6+5 CASRASGSSYEQY 2+7 3.28 2
6+2/6+3 CASSPGIYTYEQY 2+7 3.28 2
4+1 CASSLPGDPYEQY 2+7 3.28 2
29+1 CSVETGVVEAF 1+1 3.28 2
6+2/6+3 CASSSILQGLDTGELF 2+2 1.64 1
4+3 CASSHPTPAGSTDTQY 2+3 1.64 1
4+3 CASSHDTPGGRTDTQY 2+3 1.64 1
28 CASSLTDGRLNQPQH 1+5 1.64 1
27 CASSLDGRALHQPQH 1+5 1.64 1
5+1 CASSLGQGRFTDTQY 2+3 1.64 1
20+1 CSARGLSVRNTEAF 1+1 1.64 1
2 CASSEALRTPYGHT 1+2 1.64 1
30 CAWSLGQPTGELF 2+2 1.64 1
27 CASRTHRASDEQY 2+7 1.64 1
12+3/12+4 CASSPGTGGHEQF 2+1 1.64 1
9 CASSPSGVQETQY 2+5 1.64 1
4+1 CASSQGSEGFEQY 2+7 1.64 1
11+2 CASTWGAHNEQF 2+1 1.64 1
11+2 CASTLGAHNEQF 2+1 1.64 1
7+2 CASSAGRGTTF 1+1 1.64 1
6+6 CASSYRRAEAF 1+1 1.64 1
5+6 CASSLRGNEQF 2+1 1.64 1
6+2/6+3 CASSLSYEQY 2+7 1.64 1
6+5 CASTADTQY 2+3 1.64 1
100 61
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15. TL22789 
 
TL22789 CSF CD4+ T cell sort (4994 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TL22789 CSF CD8+ T cell sort (837 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSSPSGGNEKLF 1.4 24.4 19
6.1 CASRTGTSGNEQF 2.1 7.7 6
7.2*028or87.2*03 CASSLQVLDTQY 2.3 7.7 6
29.1 CSAAGASNQPQH 1.5 6.4 5
12.3 CASTPPPTGNAEAF 1.1 5.1 4
29.1 CSVETGGGNTEAF 1.1 5.1 4
7.9 CASSLEVTQY 2.5 6.4 5
25.1 CASSPFGAGGSDEQY 2.7 3.8 3
9 CASRASGSSSYNEQF 2.1 3.8 3
9 CASSGGSLGNTEAF 1.1 3.8 3
5.1 CASSLARLAGAGNIQY 2.4 2.6 2
7.7 CASSPLVGRPDTQY 2.3 2.6 2
5.6 CASSLGTGVGGTEAF 1.1 2.6 2
20.1 CSARGLAGEVTQY 2.3 2.6 2
11.2 CASSAGK8 1.2 2.6 2
9 CASSVEFGTGTDTQY 2.3 1.3 1
5.1 CASSLAWDTSYNEQF 2.1 1.3 1
20.1 CSASMGGMGANVLT 2.6 1.3 1
5.1 CASSLAWGTSYNEQF 2.1 1.3 1
20.1 CSARGLAGEVAQY 2.3 1.3 1
5.1 CASSLAISNSYEQY 2.7 1.3 1
27 CASRPITGIASPLH 1.6 1.3 1
10.3 CAISGGTDNSPLH 1.6 1.3 1
20.1 CSAQPDSAYNEQF 2.1 1.3 1
29.1 CSVIRAAETQY 2.5 1.3 1
100 78
TRBV CDR3 TRBJ Freq-(%) Count
4"1 CASSQDGGVSMNTEAF 1"1 98.7 77
5"1 CASSNRGQGLNTEAF 1"1 1.3 1
100 78
 220 
16. CT25364 (CD4+ only) 
 
CT25364 CSF CD4+ T cell sort (1649 sorted cells) 
 
 
 
 
 
 
 
 
 
 
17. HD21265 (CD4+ only) 
 
HD21265 CSF CD4+ T cell sort (1485 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
18 CASSPGGDTQY 2-3 92.9 65
5-4 CASSSGSFQETQY 2-5 7.1 5
100 70
TRBV CDR3 TRBJ Freq-(%) Count
24#1 CATSDGNLQETQY 2#5 19.5 16
7#6 CASSSYSGGHNEQF 2#1 14.6 12
7#2 CASSFTGGSGNTIY 1#3 11.0 9
29#1 CSVPDTGRLGNTIY 1#3 8.5 7
7#3 CASSSGRHNEQF 2#1 7.3 6
12#3 CASSFSPAGQETQY 2#5 4.9 4
7#2 CASSLGAGGETQY 2#5 4.9 4
18 CASSTVQETQY 2#5 4.9 4
27 CASSLRGAGDNSPLH 1#6 3.7 3
7#7 CASSGPGGSQETQY 2#5 2.4 2
12#4 CASSGNRGMNTEAF 1#1 2.4 2
24#1 CATTSGLSTDTQY 2#3 2.4 2
20#1 CSGGQGDYNEQF 2#1 2.4 2
12#4 CASTLTGGYGYT 1#2 2.4 2
19 CASTNRGRVLDTEAF 1#1 1.2 1
18 CASSPPETGGRGYT 1#2 1.2 1
12#5 CASEPRTGTYNEQF 2#1 1.2 1
20#1 CSARGPLAAGELF 2#2 1.2 1
7#3 CASSLGGLNTEAF 1#1 1.2 1
20#1 CSATGQFYEQY 2#7 1.2 1
7#9 CASSSSYEQYF 2#7 1.2 1
100 82
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18. MH21470 
 
MH21470 CSF CD4+ T cell sort (5000 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MH21470 CSF CD8+ T cell sort (836 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSFLGQGASETQY 2"5 19.4 12
19 CASSIKGSGNTIY 1"3 9.7 6
12"4 CAIRGDTQY 2"3 9.7 6
7"2 CASSQISGTGSSYEQY 2"7 8.1 5
28 CASSSPAAGGGTDTQY 2"3 6.5 4
9 CASSVAPAGANTGELF 2"2 6.5 4
6"1 CASRNTGTGRTDTQY 2"3 4.8 3
27 CASRRTTGGIGEKLF 1"4 4.8 3
6"5 CASSYGGNYGYT 1"2 4.8 3
7"3 CASSPLAGGPASYNEQF 2"1 3.2 2
27 CASRLTGTVSHYGYT 1"2 3.2 2
7"2 CASTSRSGSSGELF 2"2 3.2 2
7"2 CASSLRPYEQY 2"7 3.2 2
2 CASRSTDYGYT 1"2 3.2 2
19 CASSIGTGWYPDTQY 2"3 1.6 1
7"3 CASSLMEGTENEQF 2"1 1.6 1
7"2 CASSFDDRLNEQF 2"1 1.6 1
6"5 CASSCGGNYGYT 1"2 1.6 1
12"3 CASNIRGGGGYT 1"2 1.6 1
4"3 CASSLTVYNEQF 2"1 1.6 1
100 62
TRBV CDR3 TRBJ Freq-(%) Count
29#1 CSVDLGDPEQF 2#1 56.1 46
2 CASSEASGGYYNEQF 2#1 26.8 22
13 CASSLEGKGGPQETQY 2#5 11.0 9
7#6 CASSLVLAGTSYNEQF 2#1 4.9 4
12#3 CASSLGVEKLFF 1#4 1.2 1
100 82
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19. RW21309 
 
RW21309 CSF CD4+ T cell sort (548 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RW21309 CSF CD8+ T cell sort (234 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
30 CAWQLQGSHQPQH 1-5 28.6 24
5-1 CASSQGGNNQPQH 1-5 25.0 21
13 CASSARAHNEQF 2-1 14.3 12
3-1 CASSLAGSSYNEQF 2-1 9.5 8
6-5 CASRLGQGGGYT 1-2 6.0 5
7-2 CASSPFTGELF 2-2 6.0 5
9 CASSLNPRPGNTIY 1-3 2.4 2
11-1 CASSQDRYGYT 1-2 2.4 2
24-1 CATSDTDRGYGFVQETQY 2-5 1.2 1
19 CASLRESNRGNGYT 1-2 1.2 1
30 CAWQLPGSHQPQH 1-5 1.2 1
28 CASGLGGGIYGYT 1-2 1.2 1
6-1 CASGTGGWTDTQY 2-3 1.2 1
100 84
TRBV CDR3 TRBJ Freq-(%) Count
7"9 CASTQTGDSYGYT 1"2 61.8 47
7"9 CASRGFTQY 2"3 28.9 22
27 CASSPKGPRWQPQH 1"5 7.9 6
19 CASSTLDYNEQF 2"1 1.3 1
100 76
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20. CG41964 
 
CG41964 CSF CD4+ T cell sort (5000 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CG41964 CSF CD4+ T cell sort (repeat) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
20#1 CSAKGALAGTISYNEQF 2#1 27.6 8
7#9 CASSYRGADTGELF 2#2 20.7 6
25#1 CASSEWSSYNSPLH 1#6 17.2 5
4#1 CASSQGGTSGVSGDTQY 2#3 10.3 3
5#5 CASSLVHVPNSNQPQH 1#5 6.9 2
18 CASSPLAGGHNEQF 2#1 6.9 2
5#1 CASSWKASGVFDEQF 2#1 3.4 1
27 CASRVGAGATGEGF 2#2 3.4 1
5#6 CASSFKALSYNEQF 2#1 3.4 1
100 29
TRBV CDR3 TRBJ Freq-(%) Count
20#1 CSAKGALAGTISYNEQF 2#1 31.8 21
25#1 CASSEWSSYNSPLH 1#6 19.7 13
4#1 CASSQGGTSGVSGDTQY 2#3 13.6 9
18 CASSPLAGGHNEQF 2#1 10.6 7
7#9 CASSYRGADTGELF 2#2 6.1 4
7#9 CASSYRGADAGELF 2#2 4.5 3
7#2 CASSSSNRGQWVETQY 2#5 3.0 2
5#5 CASSLVHVPNSNQPQH 1#5 3.0 2
5#1 CASSWKASGVFDEQF 2#1 3.0 2
7#9 CASSYRGTDTGELF 2#2 1.5 1
5#5 CASSWDINTGELF 2#2 1.5 1
5#1 CASSPGRE*GYT 1#2 1.5 1
100 66
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CG41964 CSF CD8+ T cell sort (514 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CG41964 CSF CD8+ T cell sort (repeat) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
4"1 CASSQEDRGYGYT 1"2 17.1 6
5"6 CASSLSYGSWGLNTGELF 2"2 14.3 5
7"9 CASSSQIMDLNYGYT 1"2 8.6 3
5"6 CASSLFYGSWGIDTGELF 2"2 5.7 2
20"1 CSASVRGFDGPYNEQF 2"1 5.7 2
27 CASSLAEGGSTEAF 1"1 5.7 2
6"4 CASSDSSTDTQY 2"3 5.7 2
27 CASSPLRGESSTEAF 1"1 2.9 1
7"9 CASSPTSGGGKNEQF 2"1 2.9 1
7"8 CASSPGVGGMNTEAF 1"1 2.9 1
5"1 CASSARGESYNSPLH 1"6 2.9 1
7"9 CASSRVGGPGDEQY 2"7 2.9 1
27 CASSPTGSQGKLF 1"4 2.9 1
18 CASSPRIREYEQY 2"7 2.9 1
28 CASSLGTAGEQF 2"1 2.9 1
28 CASSLGTPGEQF 2"1 2.9 1
20"1 CSALAGGPGEQF 2"1 2.9 1
7"3 CASSSELRSPLH 1"6 2.9 1
12"4 CASSLNIYEQY 2"7 2.9 1
11"2 CASSSLTREQF 2"1 2.9 1
100 35
TRBV CDR3 TRBJ Freq-(%) Count
5"6 CASSLSYGSWGLNTGELF 2"2 14.3 8
20"1 CSASVRGFDGPYNEQF 2"1 14.3 8
4"1 CASSQEDRGYGYT 1"2 10.7 6
7"9 CASSSQRRDLNYGYT 1"2 7.1 4
7"2 CASSLNRGGNEQF 2"1 7.1 4
28 CASSLGTAGEQF 2"1 7.1 4
28 CASSLSYMTSGSPDTQY 2"3 5.4 3
28 CASSFGGGTSGGDTQY 2"3 5.4 3
27 CASSPTGSQGKLF 1"4 3.6 2
20"1 CSALAGGPGEQF 2"1 3.6 2
6"4 CASSDSSTDTQY 2"3 3.6 2
23"1 CASSQSWDRDEGGNQPQH 1"5 1.8 1
28 CASRPPTTRREVGEQF 2"1 1.8 1
18 CASSPGQGPTSDYGYT 1"2 1.8 1
7"9 CVSSPTSGGGKNEQF 2"1 1.8 1
28 CASSTAGDYYNEQF 2"1 1.8 1
27 CASSLAEGGSTEAF 1"1 1.8 1
12"4 CASSFFGKADTQY 2"3 1.8 1
11"3 CASSLGTEDIYGYT 1"2 1.8 1
11"2 CASSSLTREQF 2"1 1.8 1
6"5 CASSYRLGEQF 2"1 1.8 1
100 56
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8.2.2 Idiopathic Intracranial Hypertension 
 
1. EC21870 (CD4+ only) 
 
EC21870 CSF CD4+ T cell sort (555 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
2. HS25204 (CD4+ only) 
 
HS25204 CSF CD4+ T cell sort (1073 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
HS25204 CSF CD4+ T cell sort (repeat) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
6"1 CASGASGRGLYEQY 2"7 53.4 47
12"3 CASSWDRGQSYNEQF 2"1 17.0 15
27 CASSLSAGTPNTEAF 1"1 10.2 9
7"3 CASSEAGTDTQY 2"3 10.2 9
29"1 CSVVSGGNQPQH 1"5 8.0 7
4"2 CASSQDLSGTRVTDTQY 2"3 1.1 1
100 88
TRBV CDR3 TRBJ Freq-(%) Count
7"9 CASSLPAPQGRYEQY 2"7 40.5 17
5"1 CASSLGGLYNEQF 2"1 23.8 10
5"1 CASSLSQPGANVLT 2"6 21.4 9
5"1 CASSARGESYNSPLH 1"6 7.1 3
7"9 CASSLPTPQGRYEQY 2"7 4.8 2
7"7 CASSLATAPWTSKETQY 2"5 2.4 1
100 42
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSLSQPGANVLT 2"6 41.4 29
7"9 CASSLPAPQGRYEQY 2"7 24.3 17
5"1 CASSLGGLYNEQF 2"1 22.9 16
5"1 CASSARGESYNSPLH 1"6 5.7 4
7"7 CASSLATAPWTSKETQY 2"5 2.9 2
18 CASSIGVAGGRDTQY 2"3 2.9 2
100 70
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3. LH25311 
 
LH25311 CSF CD4+ T cell sort (1096 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LH25311 CSF CD8+ T cell sort (312 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
4. ML25308 (CD4+ only) 
 
ML25308 CSF CD4+ T cell sort (1014 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSLGQGQYPLH 1"6 43.8 32
6"2/6"3 CASSYISAGNQPQH 1"5 20.5 15
29"1 CSVSGTSITDTQY 2"3 16.4 12
11"3 CASRRGGTGKLYTGELF 2"2 6.8 5
24"1 CATSDLPPGLAESTDTQY 2"3 4.1 3
11"2 CASSLEYSVNTGELF 2"2 2.7 2
23"1 CASSLDRLSSYEQY 2"7 2.7 2
4"2 CASSQDLSGTIPREQF 2"1 1.4 1
7"9 CASSLGSLLGQPQH 1"5 1.4 1
100 73
TRBV CDR3 TRBJ Freq-(%) Count
7"6 CASSHMTGDEREQY 2"7 74.7 62
20"1 CASSHMTGDEREQY 2"4 25.3 21
100 83
TRBV CDR3 TRBJ Freq (%) Count
4-2 CASSPSTSGGAAYNEQ 2-1 92.9 79
12-4 CASSISGGAQGDTQY 2-3 3.5 3
29-1 CSVHRDGNTIY 1-3 2.4 2
7-2 CASSSATGAGNTIY 1-3 1.2 1
100 85
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5. SW25353 
 
SW25353 CSF CD4+ T cell sort (4219 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SW25353 CSF CD8+ T cell sort (302 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
12#3 CASSPTGSTSGYT 1#2 65.2 45
5#1 CASSLSFSGSSHPY 2#3 11.6 8
7#9 CASSPPGQGNTIY 1#3 7.2 5
5#1 CASSRTGGARVTQY 2#3 5.8 4
12#4 CASSSGTQNQPQH 1#5 4.3 3
5#1 CASTLSFRGSSHPY 2#3 1.4 1
5#1 CASSHDPKDYGYT 1#2 1.4 1
5#1 CASSTGQNQPQH 1#5 1.4 1
12#4 CASSLVLGGKAF 1#1 1.4 1
100 69
TRBV CDR3 TRBJ Freq (%) Count
2 CASSENNEQF 2-1 29.6 24
6-5 CASSLSSGGLYNEQF 2-1 16.0 13
3-1 CASSQETEGPNQPQH 1-5 14.8 12
10-1 CASSEEDPNSPLH 1-6 12.3 10
30 CAWSPQGGMRQPQH 1-5 7.4 6
6-1 CASNTGGQPQH 1-5 7.4 6
7-9 CASRNRGDRGIEETQY 2-5 3.7 3
4-1 CASSQDPPPHSPLH 1-6 2.5 2
20-1 CSAPGQGTDTQY 2-3 2.5 2
4-1 CASSQPLAGGIGELF 2-2 1.2 1
27 CASSFQGEGNEQF 2-1 1.2 1
3-1 CASSSTGDIQY 2-4 1.2 1
100 81
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6. RY21758 (CD4+ only) 
 
RY21758 CSF CD4+ T cell sort (987 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. ES37889 (CD4+ only) 
 
ES37889 CSF CD4+ T cell sort (411 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"8 CASRVTGVNTEAF 1"1 39.2 29
2 CASRTGGGEKLF 1"4 24.3 18
7"8 CASSLRQPGQHSNQPQH 1"5 16.2 12
25"1 CASRFLCGSSSYNEQF 2"1 4.1 3
5"1 CASSATGMRGSNTEAF 1"1 2.7 2
29"1 CSVGTSGLGNEQF 2"1 1.4 1
28 CASSLFSRGQGSYNEQF 2"1 1.4 1
28 CASSLGQRAGFSEKLF 1"4 1.4 1
19 CASSSQREGEQF 2"1 1.4 1
11"2 CASSFDYEQY 2"7 1.4 1
7"9 CASSPVPETGNTEAF 1"1 1.4 1
5"4 CASSLRLAGLRPDTQC 2"3 1.4 1
4"2 CASSQERTSYEQY 2"7 1.4 1
4"1 CASSQDLNRGANIQY 2"4 1.4 1
2 CASSPGTSGAGELF 2"2 1.4 1
100 74
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSHRRGGDNTGELF 2"2 100 56
100 56
 229 
8. CC40712 
 
CC40712 CSF CD4+ T cell sort (2140 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CC40712 CSF CD8+ T cell sort (181 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
24#1 CATSDSGTGFQETQY 2#5 23.2 16
20#1 CSAPKGGGEQY 2#7 15.9 11
5#5 CASSLGGTSNTEAF 1#1 10.1 7
20#1 CSARTSGRASYNEQF 2#1 7.2 5
18 CASSPGQTEKLF 1#4 7.2 5
20#1 CSAREAGRVNTEAF 1#1 5.8 4
11#2 CASSPYNTETT 1#2 4.3 3
5#5 CASSFGLGTGGNYEQY 2#7 2.9 2
5#5 CASSLASGRGNQPQH 1#5 2.9 2
7#2 CASSLVGGGLAGSVGQF 2#1 1.4 1
7#2 CASSTRGGPNSYNEQF 2#1 1.4 1
7#9 CASSLRTGGAGTEAF 1#1 1.4 1
28 CASSPPRGQGDGYT 1#2 1.4 1
24#1 CAFSQSRLETGELF 2#2 1.4 1
7#6 CASSLLEGANEKLF 1#4 1.4 1
5#4 CASSLGGTSNTEDF 1#1 1.4 1
18 CASSPGLAEETQY 2#5 1.4 1
6#1 CATWLGGSSYEQY 2#7 1.4 1
29#1 CSVWDRGHTEAF 1#1 1.4 1
12#4 CASSSGEALGLF 1#4 1.4 1
20#1 CSSDRLPYEQY 2#7 1.4 1
18 CASSSYGDTQY 2#3 1.4 1
12#3 CASRRTVGEQF 2#1 1.4 1
100 69
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSSEYSYEQY 2"2 39.7 27
24"1 CATRGRGETYNEQF 2"1 16.2 11
5"1 CASRVGGGYEQY 2"7 14.7 10
28 CASSSEYSYEQY 2"7 11.8 8
6"4 CASSALGKTTTDTQY 2"3 7.4 5
5"6 CSSSLFSGQGREKLF 1"4 1.5 1
28 CASSFRALNSYEQY 2"7 1.5 1
27 CASSFSAGSPYEQY 2"7 1.5 1
24"1 CATSEGQAAGETQY 2"5 1.5 1
5"1 CASSLEGVGNQPQH 1"5 1.5 1
9 CASGGTTSSEQY 2"7 2.9 2
100 68
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9. KA38079 (CD4+ excluded from analysis as frequency of clonotypes 
<50) 
 
KA38079 CSF CD4+ T cell sort (3505 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KA38079 CSF CD4+ T cell sort (repeat) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSSRDSGANVLT 2"6 8.6 3
6"5 CASSYSQPWDRGFEQY 2"7 5.7 2
7"2 CASNTVGHPGNEQF 2"1 5.7 2
6"6 CASSQGGKNTEAF 1"1 5.7 2
5"6 CASSPGTARYGYT 1"2 5.7 2
5"1 CASSLAGSPNEQF 2"1 5.7 2
29"1 CSGVVDGGTEAF 1"1 5.7 2
10"3 CAISPGGSETQY 2"5 5.7 2
20"1 CSPQRNTEAF 1"1 5.7 2
6"2 CVSRPPPGQKREDTEAF 1"1 2.9 1
5"1 CASSKPTGTNQGYTEAF 1"1 2.9 1
10"2 VQSCNIVGTGSTDTQY 2"3 2.9 1
7"9 CASSSGTVGNSGNTIY 1"3 2.9 1
7"2 CASSRVTSAGSYNEQF 2"1 2.9 1
20"1 CSAPGLAGVQETQY 2"5 2.9 1
12"4 CASSLGKAWGQAQH 1"5 2.9 1
10"2 CATRDRQVINSPLH 1"6 2.9 1
5"1 CASSPDAWNPYEQY 2"7 2.9 1
5"1 CASSLEGAPNYGYT 1"2 2.9 1
12"5 CASGTDRLNEKLF 1"4 2.9 1
12"3 CASSLNSGTDTQY 2"3 2.9 1
5"6 CASSLGGGSETQY 2"5 2.9 1
5"6 CASSLERINTEAF 1"1 2.9 1
27 CASSFRRITEAF 1"1 2.9 1
5"1 CAIRDREREQY 2"7 2.9 1
100 35
TRBV CDR3 TRBJ Freq-(%) Count
12#3 CASSLRGQNTGELF 2#2 16.7 3
5#1 CASGLPPTGAPNTEAF 1#1 11.1 2
20#1 CSAVKLGGAFKGYT 1#2 11.1 2
5#1 CASSLGSADYNEQF 2#1 11.1 2
5#1 CAIRDREREQY 2#7 11.1 2
20#1 CSPQRNTEAF 1#1 11.1 2
7#9 CASSLSGTGASEQY 2#7 5.6 1
5#1 CASSGGRVQETQY 2#5 5.6 1
2 CASRSTGIDQPQH 1#5 5.6 1
12#3 CASSSPLGYGYT 1#2 5.6 1
10#3 CAISPGGSETQY 2#5 5.6 1
100 18
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KA38079 CSF CD8+ T cell sort (212 sorted cells) 
 
 
 
 
 
 
 
 
 
 
10. CC41471 (CD4+ only) 
 
CC41471 CSF CD4+ T cell sort (660 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11. RC41200 (CD4+ only) 
 
RC41200 CSF CD4+ T cell sort (747 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"9 CASSPTSGGGNEQF 1"4 85.2 46
7"9 CASRSGLSGEKLF 1"4 13.0 7
9 CASSEPLDSDSGNTIY 1"3 1.9 1
100 54
TRBV CDR3 TRBJ Freq-(%) Count
29#1 CSVAGLAGVDTQY 2#3 25.0 16
7#3 RASSLWVREVPESYNEQF 2#1 20.3 13
18 CASSPRIREYEQY 2#7 14.1 9
5#1 CASSPTTGTSSHEQY 2#7 10.9 7
7#2 CASSLGLGPTGELF 2#2 9.4 6
10#2 CASKRADSYNEQF 2#1 6.3 4
10#3 CAIRPGTGAYEQY 2#7 4.7 3
5#6 CASYRRTSGITYNEQF 2#1 3.1 2
19 CASKGLQGASEQF 2#1 3.1 2
29#1 CSVEPRGGDGYT 1#2 1.6 1
12#4 CASMRSYNEQF 2#1 1.6 1
100 64
TRBV CDR3 TRBJ Freq-(%) Count
2 CASSTLYEQY 2*7 100 89
100 89
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8.2.3 Other Neurological Diseases 
 
1. SE29703 
 
SE29703 CSF CD4+ T cell sort (2505 sorted cells) 
 
 
 
 
 
 
 
 
 
SE29703 CSF CD8+ T cell sort (305 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. JG22488 (CD4+ only) 
 
JG22488 SF CD4+ T cell sort (793 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
11"2 CASSLGTGALNTGELF 2"2 98.8 83
11"2 CASSLGTEALNTGELF 2"2 1.2 1
100 84
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSFESGTHNEQF 2"1 65.8 50
10"3 CATRPDREDQPQH 1"5 28.9 22
24"1 CATREGQTNAEAF 1"1 2.6 2
7"7 CASSPGLAGAFRDTQY 2"3 1.3 1
5"1 CASSWESGTHNEQF 2"1 1.3 1
100 76
TRBV CDR3 TRBJ Freq-(%) Count
7"2 CASSRRGQGGTEAF 1"1 95.2 80
25"1 CASPGTGGRNGYT 1"2 1.2 1
12"3 CASRPRGEGFGYT 1"2 1.2 1
12"4 CASSGGSYNEQF 2"1 1.2 1
28 CASSTRRAEAF 1"1 1.2 1
100 84
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3. ND37140 
 
ND37140 CSF CD4+ T cell sort (643 sorted cells) 
 
 
 
 
 
 
 
 
 
ND37140 CSF CD8+ T cell sort (129 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. CS19395 (CD4+ only) 
 
CS19395 CSF CD4+ T cell sort (356 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
29#1 CSAGRVAEAF 1#1 63.0 34
7#2 CASSSEIYNEQF 2#1 25.9 14
5#5 CASSLDPGSSNQPQH 1#5 9.3 5
5#1 CASSLGQSRATEAF 1#1 1.9 1
100 54
TRBV CDR3 TRBJ Freq-(%) Count
6"1 CASGRKGTIQPQH 1"5 52.3 34
4"1 CASSQGAGGGGTEAF 1"1 20.0 13
7"9 CASSYSEAGNNEQF 2"1 7.7 5
5"1 CASSLEGQASSYEQY 2"7 7.7 5
5"5 CASSLNMLAVTYNEQF 2"1 4.6 3
7"9 CASSSTGGAGDEQF 2"1 4.6 3
7"8 CASSLGQTQAQY 2"7 3.1 2
100 65
TRBV CDR3 TRBJ Freq-(%) Count
28 CASRTGGTRSYNEQF 2.1 18.52 15
20.1 CSARDFGSLYNEQF 2.1 18.52 15
20.1 CSAMGGAGSTDTQY 2.3 16.05 13
28 CASSLQGRSSYEQY 2.7 9.88 8
6.5 CASSKSLVWNEQF 2.1 8.64 7
5.1 CASRAGTGTDTQY 2.3 6.17 5
28 CASSSHTGELF 2.2 6.17 5
28 CASRANSGGELF 2.2 4.94 4
28 CASSPRPPPGELF 2.2 2.47 2
20.1 CSARGGAGSTDTQY 2.3 1.23 1
7.2 CASSFGTASGNTIY 1.3 1.23 1
29.1 CSVDLGQGSYEQY 2.7 1.23 1
2 CASKVRGQNNEQF 2.1 1.23 1
28 CAGRANSGGELF 2.2 1.23 1
6.6 CASSYARSDEQF 2.1 1.23 1
28 CASSSRTGELF 2.2 1.23 1
100 81
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5. AG20355 (CD4+ only) 
 
AG20355 CSF CD4+ T cell sort (432 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. JM25229 
 
JM25229 CSF CD4+ T cell sort (2810 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JM25229 CSF CD8+ T cell sort (650 sorted cells) 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSPGQGAGTEAF 1"1 31.6 25
7"8 CASSPSMREQF 2"1 25.3 20
28 CASRIQTGKRGTDTQY 2"3 20.3 16
7"9 CASSSPAEAF 1"1 8.9 7
28 CGGQGRGQPQH 1"5 5.1 4
27 CASLPLRGVYNEQF 2"1 3.8 3
2 CASSERRSF 1"1 2.5 2
4"3 CASSQVSGDNEAF 1"1 1.3 1
4"3 CASSQVSGDSEAF 1"1 1.3 1
100 79
TRBV CDR3 TRBJ Freq-(%) Count
20#1 CSAPASRGTGELF 2#2 41.3 33
12#3 CASSLGLYEQY 2#7 21.3 17
11#3 CASSGRAPRTQY 2#3 12.5 10
5#6 CASSLADQPQH 1#5 8.8 7
9 CASSVVGLSDTQY 2#3 5.0 4
7#8 CASSLDMQGINEKLF 1#4 3.8 3
3#1 CASSQDGASRDGTDTQY 2#3 2.5 2
12#3 CASSLGTGKADTQY 2#3 1.3 1
20#1 CSAPASRGAGELF 2#2 1.3 1
5#1 CASSLEGDYTEAF 1#1 1.3 1
5#6 CASSLMGVYEQY 2#7 1.3 1
100 80
TRBV CDR3 TRBJ Freq-(%) Count
7"2 CASSLVGGTGGTQY 2"5 80.7 46
7"9 CASSLVGQESPDEQF 2"1 14.0 8
7"9 CASSLVGRESPDEQF 2"1 3.5 2
7"2 CASSLVGGTGRTQY 2"5 1.8 1
100 57
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7. AB25236 
 
AB25236 CSF CD4+ T cell sort (4005 sorted cells) 
 
 
 
 
 
 
 
 
 
AB25236 CSF CD8+ T cell sort (545 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
12#3 CASSIPSGRAEEQF 2#1 98.8 79
12#3 CASSIPSGRAEDKF 2#1 1.3 1
100 80
TRBV CDR3 TRBJ Freq-(%) Count
15 CATSRSRGASYEQY 2-7 26.6 17
6-2 CASSSWTGLGNTEAF 1-1 17.2 11
12-3 CASSFDVRGETQY 2-5 15.6 10
2 CASSEEAAKNQETQY 2-5 12.5 8
4-2 CASSLETGTAPEQY 2-7 7.8 5
6-2 CASIQGPETYEQY 2-7 7.8 5
5-1 CASSLELAGYGYT 1-2 6.3 4
27 CASSLHSGQGFYEQY 2-7 3.1 2
10-3 CAISARDGREDTEAF 1-1 1.6 1
7-9 CASSEGVRGYT 1-2 1.6 1
100 64
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7. CJ26014 
 
CJ26014 CSF CD4+ T cell sort (844 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CJ26014 CSF CD8+ T cell sort (122 sorted cells) 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
20#1 CSARPLRDLGEAF 1#1 19.4 13
7#9 CASSLIGESETQY 2#5 17.9 12
12#4 CASSRGQGFFGNTEAF 1#1 13.4 9
12#4 CASSPRNSAEAF 1#1 11.9 8
12#3 CASSSGQGNRYSNQPQH 1#5 7.5 5
6#2/6#3 CASSYSSSGDTDTQY 2#3 7.5 5
12#4 CAGGRGGMNTEAF 1#1 7.5 5
7#2 CASEGRSGANVLT 2#6 3.0 2
5#1 CASSFRLGQDYYEQY 2#7 1.5 1
5#1 CASSRPPGRQPYEQY 2#7 1.5 1
20#1 CSARPLRDLSEAF 1#1 1.5 1
7#9 CASRVIGESETQY 2#5 1.5 1
9 CASSVGDNKKAF 1#1 1.5 1
9 CASSVGDNTEAF 1#1 1.5 1
4#2 CASSQDDNYGYT 1#2 1.5 1
30 CAWTDRKAF 1#1 1.5 1
100 67
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSLGRVRDEQY 2"7 87.7 57
7"9 CASSGRGSLYGYT 1"2 7.7 5
4"1 CASSQDVWYEQY 2"7 3.1 2
5"1 CASSLGRVRGEQY 2"7 1.5 1
100 65
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8.3 Accumulation of unique TCR clonotypes with increasing number of 
sequences for the CD4+ TCR repertoire of individual patients 
To better understand the correlation between sample TCR diversity and number of sorted cells for both 
CD4+ and CD8+ T cell populations across MS patients but not for control patients, the depth of 
clonotype sequencing for the individual TCR repertoires was examined. Species accumulation curves 
were used to plot the accumulation of unique TCR clonotypes for increasing-sized subsamples of 
sequences from the original data. A plateau in the number of unique clonotypes at higher numbers of 
sequences (i.e. no new clonotypes are identified as more sequences are considered) demonstrates that 
the diversity estimate is approaching the population diversity. 
 
CD4+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD8+ 
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8.4 Example showing interpretation of the cumulative frequency 
distributions 
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8.5 TCR Vb comparisons between CSF and peripheral blood 
 
8.5.1 Multiple sclerosis CD4+ T cells 
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8.5.2 Idiopathic intracranial hypertension CD4+ T cells 
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8.5.3 Other neurological diseases CD4+ T cells 
 
8.5.4 Multiple sclerosis CD8+ T cells 
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8.5.5 Idiopathic intracranial hypertension CD8+ T cells 
 
 
 
 
 
 
 
 
 
 
8.5.6 .Other neurological diseases CD8+ T cells 
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8.6 CSF T cell Vb usage  – Raw data from clonotyping (Grey boxes = TCRs >10% frequency; Orange = not covered by 
PBMC Vb screen; Green = PBMC stains excluded) 
 
8.6.1 Multiple sclerosis CSF CD4+ T cell Vb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EB21570 LC20552 LH18836 LJ20639 LS20460 MW21576 NW21326 AL22847 SA23376 RM22664 TL22789 HD21265 MH21407 RW21309
TRBV:4;1:4;2:4;3 9.9 1.5 3.6 3.8 1.4 1.6
TRBV:5;5 0.9 1.3 3.8
TRBV:28 16.2 5.6 7.6 4.4 12.9 1.3 17.8 11.8 2.5 5.8 6.5 1.2
TRBV:3;1 1.4 4.4 2.9 5.1 1.3 9.5
TRBV:19 1.4 1.5 3.8 1.2 11.3 1.2
TRBV:14
TRBV:5;1 9.5 15.5 13.6 19.5 15.7 24.4 73.3 35.5 27.8 2.9 6.4 19.4 25.0
TRBV:18 2.8 1.5 3.5 3.8 1.3 2.5 1.4 6.1
TRBV:30 3 1.4 2.6 2.6 29.8
TRBV:6;5:6;6:6;9 11.3 7.5 9.8 7.7 11.8 2.5 6.5 6.0
TRBV:6;6 1.4 4.5 1.8 1.3
TRBV:12;3:12;4 9.5 8.5 9.1 10.7 22.9 1.3 7.9 15.2 14.5 5.1 9.8 11.3
TRBV:5;6 5.4 1.4 1.5 1.3 1.4 2.6
TRBV:10;3 5.4 1.4 0.9 1.3 4.3 1.3
TRBV:20;1 16.2 7 7.6 6.2 14.3 1.3 7.9 2.5 8.7 6.4 4.9
TRBV:9 5.4 1.4 4.5 1.8 6.4 1.3 1.4 9 6.5 2.4
TRBV:11;2 4.5 1.8 6.4 1.3 1.4 2.6
TRBV:13 2.8 14.3
TRBV:2 2.7 1.4 3 1.8 2.6 2.6 5.1 1.4 3.2
TRBV:25;1 1.4 2.8 1.5 1.3 1.3 3.8
TRBV:27 1.4 1.4 7.6 2.7 2.6 8.7 25.6 3.7 8.1
TRBV:4;3
TRBV:6;2 4.1
TRBV:29;1 6.8 9.9 13.6 11.5 3.8 1.1 1.3 7.6 5.8 12.8 8.5
TRBV:24;1 1.8 3.8 1.3 4.3 22 1.2
TRBV:7;2 8.1 5.6 1.5 15.7 3.8 7.8 3.8 14.5 7.7 15.9 16.1 6.0
TRBV:7;3 1.5 3.9 8.5 4.8
TRBV:12;5 1.2
TRBV:7;6 0.9 3.8 1.3 2.9 14.6
TRBV:7;7 4.3 2.6 2.4
TRBV:7;9 2.7 1.4 1.5 2.7 3.8 1.3 5.1 6.4 1.2
TRBV:5;4
TRBV:11;3 2.7 1.4 1.5
TRBV:7;8 3 3.5 2.9 5.1 2.6 1.3
TRBV:6;1 1.5 4.4 1.3 3.8 5.8 7.7 4.8 1.2
TRBV:5;1
TRBV:7;3
TRBV:6;2/6;3 2.8 0.9 1.4 6.4 3.9 4.3
TRBV:15 1.4 2.7 4.3 1.4
TRBV:10;1 1.4
TRBV:6;4
TRBV:11;1 1.4 5.7 1.3 2.4
TRBV:10;2 2.5 2.5
TRBV:16 2.9
TRBV:23;1
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8.6.2 Multiple sclerosis CSF CD8+ T cell Vb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EB21570 LC20552 LH18836 LJ20639 LS20460 MW21576 AL22847 SA23376 RM22664 TL22789 MH21407
TRBV849184928493 9.38 7.1 16.17 5.1 13.1 98.7
TRBV8595 8.2 36.4 3.8
TRBV828 9.6 4.69 1.4 11.76 9 8.2
TRBV8391 1.4 2.4 2.6 5.8
TRBV819
TRBV814 1.2
TRBV8591 17.19 14.3 8.82 1.4 1.6 1.3
TRBV818
TRBV830 1.6
TRBV869586968699 4.7 6.5
TRBV8696 2.7 3.13 2.9 17.65 1.6
TRBV8129381294 7.1 1.47 6.4 1.6 1.2
TRBV8596 1.3 1.6
TRBV81093 1.56 33.3
TRBV82091 2.7 7.1 13.6 8.2 10.3 1.6
TRBV89 1.4 1.56 4.3 7.35 1.3 5.8 6.6
TRBV81192 6.8 1.2 29 3.3
TRBV813 10.94 5.7 4.7 11
TRBV82 12.5 4.7 16.7 1.6 26.8
TRBV82591 7.2
TRBV827 45.2 32.81 12.9 14.71 21.2 7.2 21.3
TRBV8493 3.3
TRBV8692
TRBV82991 1.4 12.9 3.5 6.6 56.1
TRBV82491 4.7 1.4
TRBV8792 6.8 8.6 4.41 12.8 8.2
TRBV8793 4.1 1.4
TRBV81295
TRBV8796 5.8 4.9
TRBV8797 4.9
TRBV8799 8.2 4.69 4.3 2.94 50 12.8 4.9
TRBV8594 1.56 1.47
TRBV81193 1.4
TRBV8798 7.1 4.7 1.3
TRBV8691 13.24 1.3 1.4
TRBV8793 28.2
TRBV8692/693 2.7 10.6 11.5 6.6
TRBV815 2.6
TRBV81091 1.3
TRBV8694 1.4
TRBV811.1
TRBV81092
TRBV816
TRBV82391
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8.6.3 Idiopathic intracranial hypertension CSF CD4+ T cell Vb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HS25204 LH25311 ML25308 SW25353 CC40712
TRBV344134423443 1.4 92.9
TRBV3545 15.9
TRBV328 1.4
TRBV3341
TRBV319
TRBV314
TRBV3541 63.4 43.8 21.7
TRBV318 1.8 10.1
TRBV330
TRBV364536463649
TRBV3646
TRBV3124331244 3.5 71 2.8
TRBV3546
TRBV31043
TRBV32041 30.4
TRBV39
TRBV31142 2.7 4.3
TRBV313
TRBV32
TRBV32541
TRBV327
TRBV3443
TRBV3642
TRBV32941 16.4 2.4 1.4
TRBV32441 4.1 24.6
TRBV3742 1.2 2.9
TRBV3743
TRBV31245
TRBV3746 1.4
TRBV3747 2.7
TRBV3749 32.1 1.4 7.2 1.4
TRBV3544 1.4
TRBV31143 6.8
TRBV3748
TRBV3641 1.4
TRBV3541
TRBV3743
TRBV3642/643 20.5
TRBV315
TRBV31041
TRBV3644
TRBV31141
TRBV31042
TRBV316
TRBV32341 2.7
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8.6.4 Idiopathic intracranial hypertension CSF CD8+ T cell Vb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LH25311 SW25353 CC40712
TRBV142114221423 3.7
TRBV1525
TRBV128 13.2
TRBV1321 16
TRBV119
TRBV114
TRBV1521 55.9
TRBV118
TRBV130 7.4
TRBV162516261629 16
TRBV1626
TRBV1122311224
TRBV1526 1.5
TRBV11023
TRBV12021 25.3 2.5
TRBV19 2.9
TRBV11122
TRBV113
TRBV12 29.6
TRBV12521
TRBV127 1.2 1.5
TRBV1423
TRBV1622
TRBV12921
TRBV12421 17.6
TRBV1722
TRBV1723
TRBV11225
TRBV1726 74.7
TRBV1727
TRBV1729 3.7
TRBV1524
TRBV11123
TRBV1728
TRBV1621 7.4
TRBV1723
TRBV1622/623
TRBV115
TRBV11021 12.3
TRBV1624 7.4
TRBV111.1
TRBV11022
TRBV116
TRBV12321
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8.6.5 Other neurological diseases CSF CD4+ T cell Vb  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SE29703 ND37140 AG20355 AB25236
TRBV445144524453 2.5
TRBV4555 9.3
TRBV428 25.3
TRBV4351
TRBV419
TRBV414
TRBV4551 1.9 31.6
TRBV418
TRBV430
TRBV465546564659
TRBV4656
TRBV4125341254 100
TRBV4556
TRBV41053
TRBV42051
TRBV49
TRBV41152 100
TRBV413
TRBV42 2.5
TRBV42551
TRBV427 3.8
TRBV4453
TRBV4652
TRBV42951 63
TRBV42451
TRBV4752 25.9
TRBV4753
TRBV41255
TRBV4756
TRBV4757
TRBV4759 8.9
TRBV4554
TRBV41153
TRBV4758 25.3
TRBV4651
TRBV4551
TRBV4753
TRBV4652/653
TRBV415
TRBV41051
TRBV4654
TRBV41151
TRBV41052
TRBV416
TRBV42351
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8.6.6 Other neurological diseases CSF CD8+ T cell Vb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SE29703 ND37140 AB25236
TRBV344134423443 20 7.8
TRBV3545 4.6
TRBV328
TRBV3341
TRBV319
TRBV314
TRBV3541 67.1 7.7 6.3
TRBV318
TRBV330
TRBV364536463649
TRBV3646
TRBV3124331244 15.6
TRBV3546
TRBV31043 28.9 1.6
TRBV32041
TRBV39
TRBV31142
TRBV313
TRBV32 12.5
TRBV32541
TRBV327 3.1
TRBV3443
TRBV3642 25
TRBV32941
TRBV32441 2.6
TRBV3742
TRBV3743
TRBV31245
TRBV3746
TRBV3747 1.3
TRBV3749 12.3 1.6
TRBV3544
TRBV31143
TRBV3748 3.1
TRBV3641 52.3
TRBV3743
TRBV3642/643
TRBV315 26.6
TRBV31041
TRBV3644
TRBV311.1
TRBV31042
TRBV316
TRBV32341
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8.7 Peptide library screen results for KG19967 CD8+ TCR 
 
8.7.1 Viral database results  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score Peptide Protein
!12.339322 VMGISSLV 4POQ1A[HUMAN1POLYOMAVIRUS19]
!12.339322 VMGISSLV >GI|326910937|REF|YP_004243705.1|1VP11[HUMAN1POLYOMAVIRUS19]
!12.525908 VMGLAMPV >GI|9628341|REF|NP_042932.1|1ENVELOPE1GLYCOPROTEIN1B1[HUMAN1HERPESVIRUS16A]
!12.525908 VMGLAMPV >GI|9633110|REF|NP_050220.1|1GLYCOPROTEIN1B1[HUMAN1HERPESVIRUS16B]
!12.525908 VMGLAMPV SP|P36319|GB_HHV6G1ENVELOPE1GLYCOPROTEIN1B1OS=HUMAN1HERPESVIRUS16A1(STRAIN1GS)1GN=GB1PE=31SV=1
!12.886705 VMAISRCV >GI|51557496|REF|YP_068330.1|1ENVELOPE1GLYCOPROTEIN1B1[SUID1HERPESVIRUS11]
!12.92213 ILGLSTSV >GI|9633101|REF|NP_050211.1|1CAPSID1ASSEMBLY1PROTEIN1[HUMAN1HERPESVIRUS16B]
!12.92213 ILGLSTSV SP|P52437|UL37_HHV6U1CAPSID1ASSEMBLY1PROTEIN1UL371HOMOLOG1OS=HUMAN1HERPESVIRUS16A1(STRAIN1UGANDA!1102)1GN=U301PE=31SV=1
!13.25906 VLGLASCV >GI|52139241|REF|YP_081514.1|1ENVELOPE1GLYCOPROTEIN1B1[HUMAN1HERPESVIRUS15]
!13.25906 VLGLASCV SP|P06473|GB_HCMVA1ENVELOPE1GLYCOPROTEIN1B1OS=HUMAN1CYTOMEGALOVIRUS1(STRAIN1AD169)1GN=GB1PE=11SV=1
!13.25906 VLGLASCV SP|P13201|GB_HCMVT1ENVELOPE1GLYCOPROTEIN1B1OS=HUMAN1CYTOMEGALOVIRUS1(STRAIN1TOWNE)1GN=GB1PE=11SV=1
!13.269185 ILGISCFV SP|Q9QJ45|U21_HHV6Z1U211GLYCOPROTEIN1OS=HUMAN1HERPESVIRUS16B1(STRAIN1Z29)1GN=U211PE=31SV=2
!13.269185 ILGISCFV >GI|9628323|REF|NP_042914.1|1MEMBRANE1PROTEIN1U211[HUMAN1HERPESVIRUS16A]
!13.269185 ILGISCFV >GI|9633090|REF|NP_050201.1|1PUTATIVE1MEMBRANE1GLYCOPROTEIN1[HUMAN1HERPESVIRUS16B]
!13.384254 TLGISHLV SP|P07387|TEGU_HCMV1TEGUMENT1PROTEIN1OS=HUMAN1CYTOMEGALOVIRUS1PE=41SV=1
!13.455771 ILGLANLV >GI|9628706|REF|NP_043570.1|1POLYPROTEIN1PRECURSOR1[GB1VIRUS1C]
!13.455771 ILGLANLV >GI|28971391|REF|NP_803203.1|1PUTATIVE1E21PROTEIN1[GB1VIRUS1C]
!13.584583 TLALSQVV SP|P17594|POLG_EMCVD1GENOME1POLYPROTEIN1OS=ENCEPHALOMYOCARDITIS1VIRUS1(STRAIN1EMC!D1DIABETOGENIC)1PE=11SV=2
!13.584583 TLALSQVV SP|P17593|POLG_EMCVB1GENOME1POLYPROTEIN1OS=ENCEPHALOMYOCARDITIS1VIRUS1(STRAIN1EMC!B1NONDIABETOGENIC)1PE=31SV=1
!13.584583 TLALSQVV SP|P03304|POLG_EMCV1GENOME1POLYPROTEIN1OS=ENCEPHALOMYOCARDITIS1VIRUS1PE=11SV=1
!13.584583 TLALSQVV >GI|9626693|REF|NP_056777.1|1HYPOTHETICAL1PROTEIN1EMCVGP11[ENCEPHALOMYOCARDITIS1VIRUS]
!13.584583 TLALSQVV >GI|25121612|REF|NP_740409.1|1PROTEIN13AB1[ENCEPHALOMYOCARDITIS1VIRUS]
!13.743453 ELGLAILV SP|P26661|POLG_HCVJ81GENOME1POLYPROTEIN1OS=HEPATITIS1C1VIRUS1GENOTYPE12B1(ISOLATE1HC!J8)1PE=11SV=3
!13.806443 VLALAPEV >GI|139472812|REF|YP_001129361.1|1ORF701[HUMAN1HERPESVIRUS18]
!13.891999 EMAIPGQV SP|Q03053|POLG_CXB5P1GENOME1POLYPROTEIN1OS=COXSACKIEVIRUS1B51(STRAIN1PETERBOROUGH1/11954/UK/85)1PE=31SV=3
!13.904892 VMSLSGKV >GI|238801615|REF|YP_002922020.1|1POLYPROTEIN1[WESSELSBRON1VIRUS]
!13.904892 VMSLSGKV >GI|119952253|REF|YP_950478.1|1POLYPROTEIN1[SEPIK1VIRUS]
!13.942427 FLGIPESV SP|Q0GBX5|L_RABVD1LARGE1STRUCTURAL1PROTEIN1OS=RABIES1VIRUS1(STRAIN1CHINA/DRV)1GN=L1PE=31SV=1
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8.7.1 Viral database results continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score Peptide Protein
!14.003154 ILALAPAV >GI|9629287|REF|NP_044487.1|:CAPSID:TRIPLEX:SUBUNIT:2:[HUMAN:HERPESVIRUS:2]
!14.105484 TLALPSNV 1W9Z:A[BANNA:VIRUS]
!14.105484 TLALPSNV >GI|23238122|REF|NP_694460.1|:VP9:[BANNA:VIRUS:STRAIN:JKT!6423]
!14.118223 TLALAPVV >GI|9629398|REF|NP_044619.1|:CAPSID:TRIPLEX:SUBUNIT:2:[HUMAN:HERPESVIRUS:1]
!14.153498 VLAIALVV >GI|52139283|REF|YP_081558.1|:MEMBRANE:GLYCOPROTEIN:UL119:[HUMAN:HERPESVIRUS:5]
!14.153498 VLAIALVV SP|P16739|UL119_HCMVA:VIRAL:FC!GAMMA:RECEPTOR!LIKE:PROTEIN:UL119:OS=HUMAN:CYTOMEGALOVIRUS:(STRAIN:AD169):GN=UL119/UL118:PE=2:SV=2
!14.288697 AMAIAKSV SP|P07298|VNCS_PAVHU:NON!CAPSID:PROTEIN:NS!1:OS=HUMAN:PARVOVIRUS:B19:(ISOLATE:AU):GN=NS1:PE=3:SV=1
!14.288697 AMAIAKSV >GI|356457873|REF|YP_004928144.1|:NON!STRUCTURAL:PROTEIN:NS1:[HUMAN:PARVOVIRUS:B19]
!14.288697 AMAIAKTV >GI|23343516|REF|NP_694863.1|:NS1:PROTEIN:[HUMAN:ERYTHROVIRUS:V9]
!14.288697 AMAIAKSV SP|Q9PZT1|NS1_PAVHV:NON!STRUCTURAL:PROTEIN:1:OS=HUMAN:PARVOVIRUS:B19:(STRAIN:HV):GN=NS:PE=1:SV=1
!14.353902 FLGLMCSV >GI|139424540|REF|YP_001129506.1|:BILF1:[HUMAN:HERPESVIRUS:4:TYPE:2]
!14.474466 ALGIASLV >GI|20260782|REF|NP_620108.1|:POLYPROTEIN:[LANGAT:VIRUS]
!14.474466 ALGIASLV >GI|25121533|REF|NP_740301.1|:NONSTRUCTURAL:PROTEIN:NS4B:[LANGAT:VIRUS]
!14.488209 ALAISGHV >GI|312164871|REF|YP_003896059.1|:VP2:[GREAT:ISLAND:VIRUS]
!14.625151 ELAIPEAV >GI|295413964|REF|YP_003587868.1|:ORF1:[TORQUE:TENO:VIRUS:3]
!14.666174 ELGLGGRV >GI|30984453|REF|NP_851885.1|:CAPSID:MATURATION:PROTEASE:[MACACINE:HERPESVIRUS:1]
!14.666174 ELGLGGRV >GI|83722594|REF|YP_443872.1|:CAPSID:MATURATION:PROTEASE:[PAPIINE:HERPESVIRUS:2]
!14.674795 ALALAGGV >GI|139424484|REF|YP_001129449.1|:BPLF1:[HUMAN:HERPESVIRUS:4:TYPE:2]
!14.729165 VLALGSFV >GI|51557555|REF|YP_068389.1|:ENVELOPE:GLYCOPROTEIN:E:[SUID:HERPESVIRUS:1]
!14.736338 EMSISTWV SP|Q02512|VE1_HPV17:REPLICATION:PROTEIN:E1:OS=HUMAN:PAPILLOMAVIRUS:TYPE:17:GN=E1:PE=3:SV=2
!14.787583 FMSLAHCV >GI|12085037|REF|NP_073439.1|:54R:PROTEIN:[YABA!LIKE:DISEASE:VIRUS]
!14.787583 FMSLAHCV >GI|157939677|REF|YP_001497049.1|:HYPOTHETICAL:PROTEIN:TANV_54R:[TANAPOX:VIRUS]
!14.901285 FLALMPTV >GI|9625894|REF|NP_040142.1|:RIBONUCLEOTIDE:REDUCTASE:SUBUNIT:1:[HUMAN:HERPESVIRUS:3]
!14.910185 EMSLPPWV >GI|56403980|REF|YP_145795.1|:PA:POLYMERASE:SUBUNIT:[THOGOTO:VIRUS]
!14.925875 ILALGLLV >GI|51557552|REF|YP_068386.1|:ENVELOPE:GLYCOPROTEIN:G:[SUID:HERPESVIRUS:1]
!14.945093 VMAVSTCV SP|P06437|GB_HHV1K:ENVELOPE:GLYCOPROTEIN:B:OS=HUMAN:HERPESVIRUS:1:(STRAIN:KOS):GN=GB:PE=1:SV=2
!14.945093 VMAVSTCV 3NWA:A[HUMAN:HERPESVIRUS:1]
!14.945093 VMAVSTCV 4BOM:A[HUMAN:HERPESVIRUS:1]
!14.945093 VMAVSTCV 3NW8:A[HUMAN:HERPESVIRUS:1]
!14.945093 VMAVSTCV 3NWF:A[HUMAN:HERPESVIRUS:1]
!14.945093 VMAVSTCV SP|P06763|GB_HHV23:ENVELOPE:GLYCOPROTEIN:B:OS=HUMAN:HERPESVIRUS:2:(STRAIN:333):GN=GB:PE=1:SV=1
!14.945093 VMAVSTCV >GI|9629297|REF|NP_044497.1|:ENVELOPE:GLYCOPROTEIN:B:[HUMAN:HERPESVIRUS:2]
!14.945093 VMAVSTCV 2GUM:A[HUMAN:HERPESVIRUS:1]
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8.7.1 Viral database results continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score Peptide Protein
!14.945093 VMAVSTCV 4L1R1A[HUMAN1HERPESVIRUS11]
!14.945093 VMAVSTCV >GI|30984455|REF|NP_851887.1|1ENVELOPE1GLYCOPROTEIN1B1[MACACINE1HERPESVIRUS11]
!14.945093 VMAVSTCV >GI|83722596|REF|YP_443874.1|1ENVELOPE1GLYCOPROTEIN1B1[PAPIINE1HERPESVIRUS12]
!14.945093 VMAVSTCV SP|P24994|GB_HSV2S1ENVELOPE1GLYCOPROTEIN1B1OS=HERPES1SIMPLEX1VIRUS1TYPE121(STRAIN1SA8)1GN=GB1PE=31SV=1
!14.945093 VMAVSTCV SP|P06436|GB_HHV1F1ENVELOPE1GLYCOPROTEIN1B1OS=HUMAN1HERPESVIRUS111(STRAIN1F)1GN=GB1PE=11SV=1
!14.945093 VMAVSTCV 4HSI1A[HUMAN1HERPESVIRUS11]
!14.945093 VMAVSTCV SP|P08665|GB_HHV1P1ENVELOPE1GLYCOPROTEIN1B1OS=HUMAN1HERPESVIRUS111(STRAIN1PATTON)1GN=GB1PE=31SV=1
!14.945093 VMAVSTCV >GI|9629408|REF|NP_044629.1|1ENVELOPE1GLYCOPROTEIN1B1[HUMAN1HERPESVIRUS11]
!14.949824 TLSLSLNV SP|P35262|L_MABVP1RNA!DIRECTED1RNA1POLYMERASE1L1OS=LAKE1VICTORIA1MARBURGVIRUS1(STRAIN1POPP!67)1GN=L1PE=31SV=1
!14.949824 TLSLSLNV SP|P31352|L_MABVM1RNA!DIRECTED1RNA1POLYMERASE1L1OS=LAKE1VICTORIA1MARBURGVIRUS1(STRAIN1MUSOKE!80)1GN=L1PE=31SV=2
!14.949824 TLSLSLNV SP|Q1PD54|L_MABVA1RNA!DIRECTED1RNA1POLYMERASE1L1OS=LAKE1VICTORIA1MARBURGVIRUS1(STRAIN1ANGOLA/2005)1GN=L1PE=31SV=1
!14.949824 TLSLSLNV >GI|678222048|REF|YP_009055228.1|1RNA!DEPENDENT1RNA1POLYMERASE1[MARBURG1MARBURGVIRUS]
!14.949824 TLSLSLNV SP|Q6UY63|L_MABVO1RNA!DIRECTED1RNA1POLYMERASE1L1OS=LAKE1VICTORIA1MARBURGVIRUS1(STRAIN1OZOLIN!75)1GN=L1PE=31SV=1
!15.021849 ALAIAYLV SP|Q98803|POLG_YEFVI1GENOME1POLYPROTEIN1OS=YELLOW1FEVER1VIRUS1(ISOLATE1IVORY1COAST/85!82H/1982)1PE=31SV=1
!15.021849 ALAIAYLV SP|Q1X880|POLG_YEFVU1GENOME1POLYPROTEIN1OS=YELLOW1FEVER1VIRUS1(ISOLATE1UGANDA/A7094A4/1948)1PE=31SV=1
!15.021849 ALAIAYLV SP|P29165|POLG_YEFV81GENOME1POLYPROTEIN1(FRAGMENT)1OS=YELLOW1FEVER1VIRUS1(ISOLATE1PERU/1899/1981)1PE=31SV=1
!15.021849 ALAIAYLV SP|Q074N0|POLG_YEFVE1GENOME1POLYPROTEIN1OS=YELLOW1FEVER1VIRUS1(ISOLATE1ETHIOPIA/COUMA/1961)1PE=31SV=1
!15.021849 ALAIAYLV SP|Q1X881|POLG_YEFVN1GENOME1POLYPROTEIN1OS=YELLOW1FEVER1VIRUS1(ISOLATE1ANGOLA/14FA/1971)1PE=31SV=1
!15.038671 GMGVSCTV SP|P26028|HEMA_MEASI1HEMAGGLUTININ1GLYCOPROTEIN1OS=MEASLES1VIRUS1(STRAIN1IP!3!CA)1GN=H1PE=31SV=1
!15.038671 GMGVSCTV >GI|9626951|REF|NP_056923.1|1HEMAGGLUTININ1PROTEIN1[MEASLES1VIRUS]
!15.038671 GMGVSCTV SP|P28081|HEMA_MEASY1HEMAGGLUTININ1GLYCOPROTEIN1OS=MEASLES1VIRUS1(STRAIN1YAMAGATA!1)1GN=H1PE=21SV=2
!15.038671 GMGVSCTV 4GJT1A[MEASLES1VIRUS]
!15.038671 GMGVSCTV 2ZB51A[MEASLES1VIRUS1STRAIN1EDMONSTON!B]
!15.038671 GMGVSCTV 3INB1A[MEASLES1VIRUS1STRAIN1EDMONSTON]
!15.038671 GMGVSCTV SP|P08362|HEMA_MEASE1HEMAGGLUTININ1GLYCOPROTEIN1OS=MEASLES1VIRUS1(STRAIN1EDMONSTON)1GN=H1PE=11SV=1
!15.038671 GMGVSCTV 2RKC1A[MEASLES1VIRUS]
!15.038671 GMGVSCTV SP|P35971|HEMA_MEASA1HEMAGGLUTININ1GLYCOPROTEIN1OS=MEASLES1VIRUS1(STRAIN1EDMONSTON!AIK!C1VACCINE)1GN=H1PE=11SV=1
!15.038671 GMGVSCTV SP|P06830|HEMA_MEASH1HEMAGGLUTININ1GLYCOPROTEIN1OS=MEASLES1VIRUS1(STRAIN1HALLE)1GN=H1PE=11SV=1
!15.082923 RLGISSIV >GI|9625921|REF|NP_040169.1|1TEGUMENT1SERINE/THREONINE1PROTEIN1KINASE1[HUMAN1HERPESVIRUS13]
!15.090857 VMGKSVLV SP|Q8V0N6|POLG_HAV881GENOME1POLYPROTEIN1OS=HUMAN1HEPATITIS1A1VIRUS1GENOTYPE1IIB1(ISOLATE1SLF88)1PE=31SV=1
!15.090857 VMGLVGGV >GI|83722596|REF|YP_443874.1|1ENVELOPE1GLYCOPROTEIN1B1[PAPIINE1HERPESVIRUS12]
!15.169798 GLGIGALV SP|O70901|VPU_HV1901PROTEIN1VPU1OS=HUMAN1IMMUNODEFICIENCY1VIRUS1TYPE111GROUP1M1SUBTYPE1H1(ISOLATE190CF056)1GN=VPU1PE=31SV=1
!15.182156 YLSLSDPV >GI|9629396|REF|NP_044618.1|1DNA1PACKAGING1TEGUMENT1PROTEIN1UL171[HUMAN1HERPESVIRUS11]
!15.213557 ELALGFKV >GI|25777551|REF|NP_742092.1|1ORF1AB1[SIMIAN1HEMORRHAGIC1FEVER1VIRUS]
!15.243933 VMGLSDDE SP|Q67815|CAPSD_HASV61CAPSID1POLYPROTEIN1VP901OS=HUMAN1ASTROVIRUS!61GN=ORF21PE=31SV=1
!15.248486 TMGLLSIV SP|P21040|C6_VACCC1PROTEIN1C61OS=VACCINIA1VIRUS1(STRAIN1COPENHAGEN)1GN=C6L1PE=31SV=1
!15.248486 TMGLLSIV >GI|66275819|REF|YP_232904.1|1HYPOTHETICAL1PROTEIN1VACWR0221[VACCINIA1VIRUS]
!15.248486 TMGLLSIV >GI|9627530|REF|NP_042053.1|1HYPOTHETICAL1PROTEIN1VARVGP0091[VARIOLA1VIRUS]
!15.248486 TMGLLSIV >GI|17974927|REF|NP_536441.1|1D11L1[MONKEYPOX1VIRUS1ZAIRE!96!I!16]
 254 
 
8.7.2 Self database results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score Peptide Protein
!12.513169 VMGLPWFV >gi|134288865|ref|NP_003606.3|<sodium<bicarbonate<cotransporter<3<[Homo<sapiens]
!12.513169 VMGLPWFV sp|Q9Y6M7!3|S4A7_HUMAN<Isoform<3<of<Sodium<bicarbonate<cotransporter<3<OS=Homo<sapiens<GN=SLC4A7
!12.513169 VMGLPWFV sp|Q9Y6M7!4|S4A7_HUMAN<Isoform<4<of<Sodium<bicarbonate<cotransporter<3<OS=Homo<sapiens<GN=SLC4A7
!12.513169 VMGLPWFV sp|Q9Y6M7!2|S4A7_HUMAN<Isoform<2<of<Sodium<bicarbonate<cotransporter<3<OS=Homo<sapiens<GN=SLC4A7
!12.513169 VMGLPWFV sp|Q9Y6M7!5|S4A7_HUMAN<Isoform<5<of<Sodium<bicarbonate<cotransporter<3<OS=Homo<sapiens<GN=SLC4A7
!12.525908 VMGLAAGV sp|Q5JTC6!2|AMER1_HUMAN<Isoform<2<of<APC<membrane<recruitment<protein<1<OS=Homo<sapiens<GN=FAM123B
!12.525908 VMGLAAGV >gi|124244056|ref|NP_689637.3|<protein<FAM123B<[Homo<sapiens]
!12.539651 VMALSAVV >gi|41056259|ref|NP_955361.1|<solute<carrier<family<43<member<3<[Homo<sapiens]
!12.709879 IMGLPWFV >gi|90403614|ref|NP_001035049.1|<electroneutral<sodium<bicarbonate<exchanger<1<isoform<a<[Homo<sapiens]
!12.709879 IMGLPWFV >gi|295821221|ref|NP_001171486.1|<sodium!driven<chloride<bicarbonate<exchanger<isoform<1<[Homo<sapiens]
!12.709879 IMGLPWFV >gi|90568034|ref|NP_004849.2|<electroneutral<sodium<bicarbonate<exchanger<1<isoform<b<[Homo<sapiens]
!12.709879 IMGLPWFV sp|Q2Y0W8!2|S4A8_HUMAN<Isoform<2<of<Electroneutral<sodium<bicarbonate<exchanger<1<OS=Homo<sapiens<GN=SLC4A8
!12.709879 IMGLPWFV >gi|295821223|ref|NP_001171487.1|<sodium!driven<chloride<bicarbonate<exchanger<isoform<3<[Homo<sapiens]
!12.709879 IMGLPWFV >gi|155722998|ref|NP_071341.2|<sodium!driven<chloride<bicarbonate<exchanger<isoform<2<[Homo<sapiens]
!12.709879 IMGLPWFV sp|Q2Y0W8!5|S4A8_HUMAN<Isoform<5<of<Electroneutral<sodium<bicarbonate<exchanger<1<OS=Homo<sapiens<GN=SLC4A8
!12.709879 IMGLPWFV sp|Q2Y0W8!4|S4A8_HUMAN<Isoform<4<of<Electroneutral<sodium<bicarbonate<exchanger<1<OS=Homo<sapiens<GN=SLC4A8
!12.72542 VLGLSAAV >gi|42741659|ref|NP_000918.2|<multidrug<resistance<protein<1<[Homo<sapiens]
!12.85143 TMALSVLV >gi|28373107|ref|NP_777614.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<3<isoform<d<[Homo<sapiens]
!12.85143 TMALSVLV >gi|28373113|ref|NP_777617.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<3<isoform<f<[Homo<sapiens]
!12.85143 TMALSVLV >gi|24638454|ref|NP_733765.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<2<isoform<b<[Homo<sapiens]
!12.85143 TMALSVLV >gi|28373105|ref|NP_777613.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<3<isoform<e<[Homo<sapiens]
!12.85143 TMALSVLV >gi|10835220|ref|NP_004311.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<1<isoform<a<[Homo<sapiens]
!12.85143 TMALSVLV sp|Q93084!7|AT2A3_HUMAN<Isoform<SERCA3F<of<Sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<3<OS=Homo<sapiens<GN=ATP2A3
!12.85143 TMALSVLV >gi|28373109|ref|NP_777615.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<3<isoform<b<[Homo<sapiens]
!12.85143 TMALSVLV sp|P16615!3|AT2A2_HUMAN<Isoform<3<of<Sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<2<OS=Homo<sapiens<GN=ATP2A2
!12.85143 TMALSVLV >gi|4502285|ref|NP_001672.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<2<isoform<a<[Homo<sapiens]
!12.85143 TMALSVLV >gi|27886529|ref|NP_775293.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<1<isoform<b<[Homo<sapiens]
!12.85143 TMALSVLV >gi|28373103|ref|NP_005164.2|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<3<isoform<a<[Homo<sapiens]
!12.85143 TMALSVLV sp|P16615!4|AT2A2_HUMAN<Isoform<4<of<Sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<2<OS=Homo<sapiens<GN=ATP2A2
!12.85143 TMALSVLV sp|P16615!5|AT2A2_HUMAN<Isoform<5<of<Sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<2<OS=Homo<sapiens<GN=ATP2A2
!12.85143 TMALSVLV >gi|28373115|ref|NP_777618.1|<sarcoplasmic/endoplasmic<reticulum<calcium<ATPase<3<isoform<c<[Homo<sapiens]
!12.860619 AMGLSLLV >gi|153946391|ref|NP_000827.2|<glutamate<[NMDA]<receptor<subunit<epsilon!4<precursor<[Homo<sapiens]
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8.7.2 Self database results continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score Peptide Protein
!12.860619 AMGLSRAV sp|Q8IZY2!2|ABCA7_HUMAN>Isoform>2>of>ATP!binding>cassette>sub!family>A>member>7>OS=Homo>sapiens>GN=ABCA7
!12.860619 AMGLSVAV >gi|25952134|ref|NP_116279.2|>protein>dispatched>homolog>1>[Homo>sapiens]
!12.860619 AMGLSRAV >gi|150417984|ref|NP_061985.2|>ATP!binding>cassette>sub!family>A>member>7>[Homo>sapiens]
!12.86222 FMGLPWYV >gi|19743827|ref|NP_597812.1|>electrogenic>sodium>bicarbonate>cotransporter>4>isoform>c>[Homo>sapiens]
!12.86222 FMGLPWYV sp|Q9BY07!8|S4A5_HUMAN>Isoform>8>of>Electrogenic>sodium>bicarbonate>cotransporter>4>OS=Homo>sapiens>GN=SLC4A5
!12.86222 FMGLPWYV >gi|125987596|ref|NP_067019.3|>electrogenic>sodium>bicarbonate>cotransporter>4>isoform>a>[Homo>sapiens]
!12.86222 FMGLPWYV sp|Q9BY07!4|S4A5_HUMAN>Isoform>4>of>Electrogenic>sodium>bicarbonate>cotransporter>4>OS=Homo>sapiens>GN=SLC4A5
!12.86222 FMGLPWYV sp|Q9BY07!7|S4A5_HUMAN>Isoform>7>of>Electrogenic>sodium>bicarbonate>cotransporter>4>OS=Homo>sapiens>GN=SLC4A5
!12.86222 FMGLPWYV sp|Q9BY07!2|S4A5_HUMAN>Isoform>2>of>Electrogenic>sodium>bicarbonate>cotransporter>4>OS=Homo>sapiens>GN=SLC4A5
!12.872962 VMGIALAV >gi|4502877|ref|NP_001296.1|>claudin!4>[Homo>sapiens]
!12.92213 ILGLSAAV >gi|9961252|ref|NP_061338.1|>multidrug>resistance>protein>3>isoform>C>[Homo>sapiens]
!12.92213 ILGLSAAV >gi|9961250|ref|NP_061337.1|>multidrug>resistance>protein>3>isoform>B>[Homo>sapiens]
!12.92213 ILGLSAAV >gi|4505771|ref|NP_000434.1|>multidrug>resistance>protein>3>isoform>A>[Homo>sapiens]
!12.980283 GMGISNRV >gi|4507925|ref|NP_003871.1|>WNT1!inducible!signaling>pathway>protein>3>isoform>1>precursor>[Homo>sapiens]
!12.980283 GMGISTRV sp|P29279|CTGF_HUMAN>Connective>tissue>growth>factor>OS=Homo>sapiens>GN=CTGF>PE=1>SV=2
!12.980283 GMGISTRV sp|P29279!2|CTGF_HUMAN>Isoform>2>of>Connective>tissue>growth>factor>OS=Homo>sapiens>GN=CTGF
!12.980283 GMGISTRV >gi|4503123|ref|NP_001892.1|>connective>tissue>growth>factor>precursor>[Homo>sapiens]
!12.980283 GMGISNRV >gi|38202241|ref|NP_937882.1|>WNT1!inducible!signaling>pathway>protein>3>isoform>3>[Homo>sapiens]
!13.0103 EMGLADVV sp|Q5SNV9!2|CA167_HUMAN>Isoform>2>of>Uncharacterized>protein>C1orf167>OS=Homo>sapiens>GN=C1orf167
!13.0103 EMGLADVV >gi|310113616|ref|XP_003119818.1|>PREDICTED:>uncharacterized>protein>C1orf167>[Homo>sapiens]
!13.0103 EMGLADVV >gi|310118524|ref|XP_003118897.1|>PREDICTED:>uncharacterized>protein>C1orf167>[Homo>sapiens]
!13.0103 EMGLADVV sp|Q5SNV9|CA167_HUMAN>Uncharacterized>protein>C1orf167>OS=Homo>sapiens>GN=C1orf167>PE=2>SV=2
!13.0103 EMGLACVV >gi|215599585|ref|NP_001135943.1|>integrator>complex>subunit>12>[Homo>sapiens]
!13.0372 TLGLSCGV >gi|282403491|ref|NP_001164120.1|>protein>LAS1>homolog>isoform>2>[Homo>sapiens]
!13.0372 TLGLSCGV >gi|282403493|ref|NP_001164121.1|>protein>LAS1>homolog>isoform>3>[Homo>sapiens]
!13.0372 TLGLSCGV >gi|13654270|ref|NP_112483.1|>protein>LAS1>homolog>isoform>1>[Homo>sapiens]
!13.072474 VLGISAEV sp|Q8TBF2|PGFS_HUMAN>Prostamide/prostaglandin>F>synthase>OS=Homo>sapiens>GN=FAM213B>PE=2>SV=1
!13.072474 VLGISRDV sp|Q460N5!1|PAR14_HUMAN>Isoform>1>of>Poly>[ADP!ribose]>polymerase>14>OS=Homo>sapiens>GN=PARP14
!13.072474 VLGISAEV sp|Q8TBF2!4|PGFS_HUMAN>Isoform>4>of>Prostamide/prostaglandin>F>synthase>OS=Homo>sapiens>GN=FAM213B
!13.072474 VLGISAEV >gi|307691194|ref|NP_001182670.1|>prostamide/prostaglandin>F>synthase>isoform>f>[Homo>sapiens]
!13.072474 VLGISRDV sp|Q460N5!4|PAR14_HUMAN>Isoform>4>of>Poly>[ADP!ribose]>polymerase>14>OS=Homo>sapiens>GN=PARP14
!13.072474 VLGISRDV sp|Q460N5!3|PAR14_HUMAN>Isoform>3>of>Poly>[ADP!ribose]>polymerase>14>OS=Homo>sapiens>GN=PARP14
!13.072474 VLGISAEV >gi|307691186|ref|NP_001182666.1|>prostamide/prostaglandin>F>synthase>isoform>c>[Homo>sapiens]
!13.072474 VLGISLTV sp|Q12967!2|GNDS_HUMAN>Isoform>2>of>Ral>guanine>nucleotide>dissociation>stimulator>OS=Homo>sapiens>GN=RALGDS
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Score Peptide Protein
!13.072474 VLGISRDV >gi|154813199|ref|NP_060024.2|>poly>[ADP!ribose]>polymerase>14>[Homo>sapiens]
!13.072474 VLGISAEV >gi|307691184|ref|NP_001182665.1|>prostamide/prostaglandin>F>synthase>isoform>a>[Homo>sapiens]
!13.072474 VLGISAEV >gi|307691182|ref|NP_689584.2|>prostamide/prostaglandin>F>synthase>isoform>b>[Homo>sapiens]
!13.072474 VLGISRDV sp|Q460N5!5|PAR14_HUMAN>Isoform>5>of>Poly>[ADP!ribose]>polymerase>14>OS=Homo>sapiens>GN=PARP14
!13.072474 VLGISAEV sp|Q8TBF2!3|PGFS_HUMAN>Isoform>3>of>Prostamide/prostaglandin>F>synthase>OS=Homo>sapiens>GN=FAM213B
!13.072474 VLGISAEV >gi|307691192|ref|NP_001182669.1|>prostamide/prostaglandin>F>synthase>isoform>e>[Homo>sapiens]
!13.074471 FLGLSPHV >gi|22907034|ref|NP_659434.2|>folliculin>isoform>1>[Homo>sapiens]
!13.074471 FLGLSPHV Folliculin>Homo>sapiens
!13.074471 FLGLSGLV >gi|148886707|ref|NP_001092142.1|>hephaestin!like>protein>1>precursor>[Homo>sapiens]
!13.180612 GMALSVLV >gi|4507017|ref|NP_001851.1|>probable>low>affinity>copper>uptake>protein>2>[Homo>sapiens]
!13.180612 GMALSKGV >gi|53933282|ref|NP_001005518.1|>olfactory>receptor>6C65>[Homo>sapiens]
!13.246321 VLGLPQHV >gi|312176416|ref|NP_001185901.1|>uncharacterized>protein>KIAA1522>isoform>2>[Homo>sapiens]
!13.246321 VLGLPQHV >gi|112734870|ref|NP_065939.2|>uncharacterized>protein>KIAA1522>isoform>1>[Homo>sapiens]
!13.246321 VLGLPQHV sp|Q9P206!3|K1522_HUMAN>Isoform>3>of>Uncharacterized>protein>KIAA1522>OS=Homo>sapiens>GN=KIAA1522
!13.25906 VLGLAVRV >gi|63175654|ref|NP_659496.2|>L!fucose>kinase>[Homo>sapiens]
!13.25906 VLGLAVRV sp|Q8N0W3!2|FUK_HUMAN>Isoform>2>of>L!fucose>kinase>OS=Homo>sapiens>GN=FUK
!13.25906 VLGLASIV >gi|46249410|ref|NP_004735.2|>lecithin>retinol>acyltransferase>precursor>[Homo>sapiens]
!13.25906 VLGLAAEV >gi|28212272|ref|NP_777573.1|>pumilio>domain!containing>protein>C14orf21>[Homo>sapiens]
!13.269185 ILGISGCV >gi|62865631|ref|NP_001017372.1|>long!chain>fatty>acid>transport>protein>6>[Homo>sapiens]
!13.272803 VLALSTEV >gi|195947374|ref|NP_001124333.1|>claudin!5>[Homo>sapiens]
!13.272803 VLALSTEV sp|O00501|CLD5_HUMAN>Claudin!5>OS=Homo>sapiens>GN=CLDN5>PE=1>SV=1
!13.366381 GLGLSGVV >gi|189095248|ref|NP_001121159.1|>adiponectin>receptor>protein>1>[Homo>sapiens]
!13.366381 GLGLSTPV sp|Q5SV97|CA170_HUMAN>Uncharacterized>protein>C1orf170>OS=Homo>sapiens>GN=C1orf170>PE=2>SV=3
!13.371097 EMAISKTV >gi|42764687|ref|NP_073143.2|>dual>specificity>protein>phosphatase>6>isoform>b>[Homo>sapiens]
!13.371097 EMAISKTV >gi|42764683|ref|NP_001937.2|>dual>specificity>protein>phosphatase>6>isoform>a>[Homo>sapiens]
!13.371097 EMAISKTV DUAL>SPECIFICITY>PROTEIN>PHOSPHATASE>6>Homo>sapiens
!13.38152 AMGLPEAV >gi|29789287|ref|NP_203755.1|>inositol>1,4,5!triphosphate>receptor!interacting>protein>precursor>[Homo>sapiens]
!13.394259 AMGLALYV >gi|4504079|ref|NP_003792.1|>glycosylphosphatidylinositol>anchor>attachment>1>protein>[Homo>sapiens]
!13.394259 AMGLALYV sp|O43292!2|GPAA1_HUMAN>Isoform>2>of>Glycosylphosphatidylinositol>anchor>attachment>1>protein>OS=Homo>sapiens>GN=GPAA1
!13.394259 AMGLALLV >gi|55770854|ref|NP_000826.2|>glutamate>[NMDA]>receptor>subunit>epsilon!3>precursor>[Homo>sapiens]
!13.408002 AMALSGHV >gi|13899269|ref|NP_113627.1|>transcription>factor>SOX!7>[Homo>sapiens]
!13.421525 FLGISIGV sp|O95859!2|TSN12_HUMAN>Isoform>2>of>Tetraspanin!12>OS=Homo>sapiens>GN=TSPAN12
!13.421525 FLGISIGV >gi|6912528|ref|NP_036470.1|>tetraspanin!12>[Homo>sapiens]
!13.422342 FMALANGV >gi|195927044|ref|NP_001124313.1|>RNA>3'!terminal>phosphate>cyclase>isoform>a>[Homo>sapiens]
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8.8. TNF capture assay results – Raw data 
 
8.8.1 Multiple sclerosis 
 
1. LS20460 
 
LS20460 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LS20460 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
13 CASSPGQVGGAF 1+1 29.23 19
7+3 CASSIRGSRGELF 2+2 21.54 14
6+1 CASSEGPSRVSYEQY 2+7 20.00 13
11+3 CASSLRGLAGSYEQY 2+7 10.77 7
20+1 CSAGVGGYEQY 2+7 9.23 6
7+3 CASSNTGDTEAF 1+1 3.08 2
11+3 CASSLGGGNYNEQF 2+1 1.54 1
15 CATSEDRAYNEQF 2+1 1.54 1
7+2 CASRTAVSTGELF 2+2 1.54 1
29+1 CSVEGGAETQY 2+5 1.54 1
100 65
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSLQGANYEQY 2,7 41.56 32
19 CASRTTSGSYNEQF 2,1 18.18 14
7,3 CASRLTSGGTDTQY 2,3 18.18 14
7,9 CASSSRQARRHEQY 2,7 9.09 7
13 CASSPGQVGGAF 1,1 3.90 3
24,1 CATSDSRESGARETQY 2,5 2.60 2
19 CASTMTSGSLWEQY 2,7 1.30 1
19 CASSPTSGAFNEQF 2,1 1.30 1
27 CASSLQGAKYEQY 2,7 1.30 1
27 CASSLQGAKNEQY 2,7 1.30 1
27 CASSLQGAKDEQY 2,7 1.30 1
100 77
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2. EB21570 
 
EB21570 CD4+TNF+ 
 
 
 
 
 
\ 
EB21570 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EB21570 matching CD8+ CSF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"4 CASSTPGQPNTGELF 2"2 70.42 50
7"2 CASSSWTSGRTDTQY 2"3 29.58 21
100 71
TRBV CDR3 TRBJ Freq-(%) Count
5"6 CASSAYRGPNTGELF 2"2 21.13 15
2 CASSDPGGPGNEQF 2"1 14.08 10
5"6 CASSLRQGADTQY 2"3 14.08 10
7"3 CASSSETYSTDTQY 2"3 11.27 8
28 CASSSGQDPFYEQY 2"7 8.45 6
7"2 CASSLGGGQGLDWTEAF 1"1 5.63 4
5"6 CASSLGGRAGSRTDTQY 2"3 4.23 3
12"3/12"4 CASSLGDGGLIYNEQF 2"1 4.23 3
19 CASRDGPSYEQY 2"7 4.23 3
12"3/12"4 CASSFGDGGVIYNEQF 2"1 1.41 1
30 CAWSQIRRPYNEQF 2"1 1.41 1
27 CASSLFTGDRSGQY 2"7 1.41 1
7"9 CASSSTTAGDQPQH 1"5 1.41 1
5"5 CASSLYTSGSNEQF 2"1 1.41 1
20"1 CSARGEGLSYEQY 2"7 1.41 1
19 CASTFGQAGEAF 1"1 1.41 1
12"3/12"4 CASSLAYNEQF 2"1 1.41 1
7"9 CASSSGPDEQF 2"1 1.41 1
100 71
TRBV CDR3 TRBJ Freq-(%) Count
27 CASTPSGANVLT 2,6 36.99 27
27 CASSFGGLEKLF 1,4 8.22 6
7,2 CASSLGGGQGLDWTEAF 1,1 6.85 5
11,2 CASSPYPSGRDVEQF 2,1 6.85 5
28 CASSLRLYEQY 2,7 6.85 5
5,5 CASSVVGALNQY 2,4 5.48 4
7,9 CASSLVERAEAF 1,1 4.11 3
7,3 CASSLTTNTEAF 1,1 4.11 3
5,5 CASSLTETGFNQPQH 1,5 2.74 2
28 CASTPRGGGYQPQH 1,5 2.74 2
6,2/6,3 CASSYVGLAEETQY 2,5 2.74 2
7,9 CASRGGRDAEKLF 1,4 2.74 2
6,6 CASLDGSTNEKLF 1,4 2.74 2
20,1 CSATDLASHQETQY 2,5 1.37 1
7,9 CASSDQDKGTDTQY 2,3 1.37 1
9 CASSFGTGNTEAF 1,1 1.37 1
20,1 CSARGRGVQPQH 1,5 1.37 1
29,1 CSVRGLAGVQY 2,7 1.37 1
100 73
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3. LH18836 (CD4+ only) 
 
LH18836 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. MW21576 
 
MW21576 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
12#3/12#4 CASSLRGGELF 2#2 53.75 43
12#3/12#4 CASRTGVNTEAF 1#1 21.25 17
6#1 CASTLGIGHEQY 2#7 12.50 10
9 CASSGEGKRLH 1#6 5.00 4
12#3/12#4 CASRRTLDSTYEQY 2#7 2.50 2
12#3/12#4 CASSLEGHRSYEQY 2#7 2.50 2
20#1 CSARAEGRETQY 2#5 1.25 1
12#3/12#4 CASSVRGGELF 2#2 1.25 1
100 80
TRBV CDR3 TRBJ Freq-(%) Count
18 CASSPRPQGSSYNSPLH 1.6 98.4 63
7.3 CASSLSSNQPQH 1.5 1.6 1
100 64
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MW21576 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
MW21576 matching CD8+ CSF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"3 CASSPGQGQDEQY 2"7 33.8 26
7"3 CASSLGTGIYNEQF 2"1 29.9 23
3"1 CASSPSHRDIWDTQY 2"3 26.0 20
24"1 CATSDLPPTGDTGELF 2"2 7.8 6
5"5 CASSHRTSGSTDKQY 2"3 1.3 1
5"5 CASSQRTSGSTDTQY 2"3 1.3 1
100 77
TRBV CDR3 TRBJ Freq-(%) Count
7"3 CASSPGQGQDEQY 2"7 27.06 23
27 CASSGLGRREQY 2"7 21.18 18
6"2/6"3 CASSLGGTGWTEQF 2"1 10.59 9
20"1 CSAREAGELF 2"2 8.24 7
24"1 CATSDLPPTGDTGELF 2"2 4.71 4
13 CASSRPFGRPYNEQF 2"1 4.71 4
2 CASRQLAGGDNEQF 2"1 4.71 4
7"8 CASSLGQAYEQY 2"7 4.71 4
6"5 CASGSGYYGYT 1"2 4.71 4
29"1 CSARLAGDSTDTQY 2"3 3.53 3
3"1 CASSLLAGGLTDTQY 2"3 2.35 2
11"2 CASSLDPGWSAGGIAKNIQY 2"4 1.18 1
7"3 CASSPGQGQGEQY 2"7 1.18 1
14 CASSQAGIHGYT 1"2 1.18 1
100 85
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5. SA23376 
 
SA23376 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
SA23376 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
21#1 CASTPSRQGLIDIQY 2#4 55.6 35
20#1 CSARGNTIY 1#3 41.3 26
21#1 CASTPFRQGVIDIQY9 2#4 1.6 1
21#1 CASTPSRQGMIDIQY 2#4 1.6 1
100 63
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSEMGTGTFDGYT 1"2 68.7 46
7"9 CASSLNERLEQF 2"1 9.0 6
2 CASSVVVGELF 2"2 6.0 4
27 CASSWLSGGVRDTQY 2"3 4.5 3
4"2 CASSQDVAEQY 2"7 4.5 3
27 CASSWLSGGVRDAQY 2"3 3.0 2
4"1 CASSPGARLVDTQY 2"3 3.0 2
7"9 CASSYQPATGTDSYNEQF 2"1 1.5 1
100 67
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6. RM22664 
 
RM22664 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
3"1 CASSSLADYEQY 2"7 5.5 3
5"1 CASRSGTGTYEQY 2"7 5.5 3
7"9 CASSLAPGFSSGNTIY 1"3 3.6 2
6"6 CASSYNPSGGAYNEQF 2"1 3.6 2
28 CASSLGRRGSPLH 1"6 3.6 2
6"6 CASITWAANTEAF 1"1 3.6 2
6"5 CASNTRASNYGYT 1"2 3.6 2
4"2 CASSQLTGHYGYT 1"2 3.6 2
10"3 CAIRDSLGHEQF 2"1 3.6 2
6"2 CASSPSEVTTLH 1"6 3.6 2
6"6 CASSSLYNEQF 2"1 3.6 2
12"3 CASTTRWIRMGGTKNIQY 2"4 1.8 1
5"1 CASSIRTRGGHSNPIEQF 2"1 1.8 1
7"8 CASSFGEGGQSSGNTIY 1"3 1.8 1
5"5 CASSSPATTGGRTEAF 1"1 1.8 1
5"5 CASSSSATTGGRTEAF 1"1 1.8 1
3"1 CASSQVGGAAANYGYT 1"2 1.8 1
28 CASSFSLGSQNEKLF 1"4 1.8 1
20"1 CSASRRTSTYNSPLH 1"6 1.8 1
12"4 CASSPTDAGGGETQY 2"5 1.8 1
12"3 CASRQMSGAVTGELF 2"2 1.8 1
7"8 CASSLVTGTLTDTQY 2"3 1.8 1
5"1 CASSPGQGMLNNEAF 1"1 1.8 1
4"3 CASSLNPVGPYNEQF 2"1 1.8 1
11"2 CASSRDRTTSDGYT 1"2 1.8 1
7"2 CASSSPQGTGSPLH 1"6 1.8 1
7"2 CASSLEGRSNSPLH 1"6 1.8 1
7"2 CASSLGGARSGEAF 1"1 1.8 1
5"1 CASSLVDGEVDGYT 1"2 1.8 1
29"1 CSVVQRGIGTEAF 1"1 1.8 1
12"3 CASSFTGMNTEAF 1"1 1.8 1
7"2 CASSPGQSQETQY 2"5 1.8 1
6"5 CASRLARAYNEQF 2"1 1.8 1
6"2 CASSFGTPAYEQY 2"7 1.8 1
3"1 CASSQVPSSNEQF 2"1 1.8 1
30 CAWSPRQQETQY 2"5 1.8 1
20"1 CSARDRVFDTQY 2"3 1.8 1
7"8 CASSQGQGQPQH 1"5 1.8 1
28 CASSLGLYEQY 2"7 1.8 1
7"2 CASSLGNNEAF 1"1 3.6 2
18 CASSADSGQY 2"7 1.8 1
100 55
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RM22664 matching CD4+ CSF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"2 CASSPLAASYNEQF 2"1 5.80 4
20"1 CSATGQGGGYGYT 1"2 4.35 3
7"7 CASSWGLAEETQY 2"5 4.35 3
7"2 CASSWGQGANGYT 1"2 4.35 3
24"1 CAAPGTGWYEQY 2"7 4.35 3
6"1 CASGKAPGEQY 2"7 4.35 3
16 CASSQQAGPSSGTQY 2"3 2.90 2
27 CASSLSISGRAEQY 2"7 2.90 2
7"2 CASSLTVLSTDTQY 2"3 2.90 2
6"2/6"3 CASSSARGNNSPLH 1"6 2.90 2
27 CASSKLAGRDTQY 2"3 2.90 2
12"3/12"4 CASSFSSSGNTIY 1"3 2.90 2
10"3 CAITRQGARNEQF 2"1 2.90 2
12"3/12"4 CASSLGSVYEQY 2"7 2.90 2
28 CASSFTNTIY 1"3 2.90 2
27 CASSSGIGQLPANYGYT 1"2 1.45 1
4"3 CASSQAPIGGAGQETQY 2"5 1.45 1
7"6 CASSQGGLAGATDTQY 2"3 1.45 1
29"1 CSVPGTGEKFNYGYT 1"2 1.45 1
28 CASSPPGSPYQETQY 2"5 1.45 1
15 CATSRNPHRGQETQY 2"5 1.45 1
11"2 CASSSRAATGVYEQF 2"1 1.45 1
9 CASSLTSGGVQETQY 2"5 1.45 1
27 CASSLRGVVQDTQY 2"3 1.45 1
7"6 CASSPGAGSADTQY 2"3 1.45 1
7"2 CASNPLAASYNEQF 2"1 1.45 1
6"2/6"3 CASRLGTGRGNEQF 2"1 1.45 1
6"1 CASKPGASYFEKLF 1"4 1.45 1
5"1 CASSSSTGRQETQY 2"5 1.45 1
29"1 CSVVQRGIGTEAF 1"1 1.45 1
28 CASSFWAAQETQY 2"5 1.45 1
20"1 CSAREPGRSTEAF 1"1 1.45 1
12"3/12"4 CASSLSGTGNTIY 1"3 1.45 1
12"3/12"4 CASRKGRRNTEAF 1"1 1.45 1
10"3 CAVTRQGARNEQF 2"1 1.45 1
29"1 CSVDGTGGVEAF 1"1 1.45 1
20"1 CSVSGTNTDTQY 2"3 1.45 1
20"1 CSSPGDTAYGYT 1"2 1.45 1
12"3/12"4 CASSWDRTYEQY 2"7 1.45 1
12"3/12"4 CASGGNQVNTQY 2"3 1.45 1
5"6 CASSLAGRYEQY 2"7 1.45 1
5"1 CASSDRGAHEQY 2"7 1.45 1
12"3/12"4 CASSPDRYEQY 2"7 1.45 1
12"3/12"4 CASSFRNQPQH 1"5 1.45 1
2 CASRWNQGMQY 2"5 1.45 1
29"1 CSARGNTEAF 1"1 1.45 1
18 CASQTNTEAF 1"1 1.45 1
100 69
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RM22664 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RM22664 matching CD8+ CSF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSSGTTKDSPLH 1.6 24.5 13
7.9 CASRRDGGLTEAF 2.5 13.2 7
9 CASSVGTDGTNEKLF 1.4 9.4 5
28 CASRIQEEETQY 1.1 9.4 5
11.2 CASTLGAHNEQF 2.1 7.5 4
20.1 CSARGLAGGHPYEQY 2.7 5.7 3
27 CASSGQGSRYEQY 2.7 5.7 3
7.9 CASSLADGPTEAF 1.1 5.7 3
7.3 CASSTLRARFSNQPQH 1.5 3.8 2
4.3 CASSLNPVGPYNEQF 2.1 3.8 2
11.2 CASSLAAAVEAF 1.1 3.8 2
25.1 CASSELGGDLYEQY 2.7 1.9 1
7.9 CASSTDRGLGGEQF 2.1 1.9 1
27 CASSGQASSYEQY 2.7 1.9 1
7.9 CASSLVQGGPGYT 1.2 1.9 1
100 53
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSPGQAYEQY 2+7 8.20 5
9 CASSAMTSGGADTQY 2+3 4.92 3
7+7 CASSNEQGLSTDTQY 2+3 4.92 3
4+1 CASTRGTSSYNSPLH 1+6 4.92 3
27 CASSSRDSSGNTIY 1+3 4.92 3
7+9 CASSLSALGNEQF 2+1 4.92 3
27 CASTPGQGYEQY 2+7 4.92 3
28 CASSFEGTSGGTDTQY 2+3 3.28 2
7+2 CASSLGGTGPFNSPLH 1+6 3.28 2
29+1 CSVGTGGTNEKLF 1+4 3.28 2
28 CASSFSTDVGGYT 1+2 3.28 2
7+2 CASSVGTEYNEQF 2+1 3.28 2
6+5 CASRASGSSYEQY 2+7 3.28 2
6+2/6+3 CASSPGIYTYEQY 2+7 3.28 2
4+1 CASSLPGDPYEQY 2+7 3.28 2
29+1 CSVETGVVEAF 1+1 3.28 2
6+2/6+3 CASSSILQGLDTGELF 2+2 1.64 1
4+3 CASSHPTPAGSTDTQY 2+3 1.64 1
4+3 CASSHDTPGGRTDTQY 2+3 1.64 1
28 CASSLTDGRLNQPQH 1+5 1.64 1
27 CASSLDGRALHQPQH 1+5 1.64 1
5+1 CASSLGQGRFTDTQY 2+3 1.64 1
20+1 CSARGLSVRNTEAF 1+1 1.64 1
2 CASSEALRTPYGHT 1+2 1.64 1
30 CAWSLGQPTGELF 2+2 1.64 1
27 CASRTHRASDEQY 2+7 1.64 1
12+3/12+4 CASSPGTGGHEQF 2+1 1.64 1
9 CASSPSGVQETQY 2+5 1.64 1
4+1 CASSQGSEGFEQY 2+7 1.64 1
11+2 CASTWGAHNEQF 2+1 1.64 1
11+2 CASTLGAHNEQF 2+1 1.64 1
7+2 CASSAGRGTTF 1+1 1.64 1
6+6 CASSYRRAEAF 1+1 1.64 1
5+6 CASSLRGNEQF 2+1 1.64 1
6+2/6+3 CASSLSYEQY 2+7 1.64 1
6+5 CASTADTQY 2+3 1.64 1
100 61
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7. HD21265 
 
HD21265 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HD21265 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
28 CASSLLSGGDVRHEQY 2/7 28.1 16
4/1 CASSRRDTTNYGYT 1/2 19.3 11
7/2 CASSLRTQPPGELF 2/2 10.5 6
10/3 CAISESVRDGGYT 1/2 7.0 4
5/1 CASSFEWGAGADTQY 2/3 5.3 3
6/6 CASSTGIESRGYT 1/2 5.3 3
20/1 CSARQGVNQPQH 1/5 3.5 2
18 CASSSTGGEYAF 1/1 3.5 2
30/1 CAWSTGGYGYT 1/2 3.5 2
12/3 CASSPPWASGHNEQF 2/1 1.8 1
9 CASSVGGTGVYEQY 2/7 1.8 1
7/2 CASTFSGDVVGIQY 2/4 1.8 1
7/2 CASTLSGDVVGIQY 2/4 1.8 1
4/1 CASSPSVGFAYGYT 1/2 1.8 1
6/5 CSVGGQGAYNEQF 2/1 1.8 1
6/2 CASSYGVPGELF 2/2 1.8 1
5/1 CASSLGPYEQY 2/7 1.8 1
100 57
TRBV CDR3 TRBJ Freq-(%) Count
6"2 CASSESFSRGQETQY 2"5 24.3 18
27 CASSNRPRDYRSYNEQF 2"1 20.3 15
7"8 CASSITGRYYGYT 1"2 18.9 14
4"1 CASSQDRVGTTLSNQPQH 1"5 12.2 9
4"2 CASSQDSSGGPSSYEQY 2"7 6.8 5
4"2 CASMAGGSSSGANVLT 2"6 4.1 3
5"1 CASSGMGRGTEAF 1"1 4.1 3
6"6 CASSYREEQF 2"1 4.1 3
7"9 CASSAFNSPLH 1"6 2.7 2
2 CASSDVGTEAF 1"1 2.7 2
100 74
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8. MH21407 (CD4+ only) 
 
MH21407 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.CT25364 (CD4+ only) 
 
CT25364 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSASGLSYNEQF 2"1 35.3 24
10"2 CASNSKGYNSPLH 1"6 23.5 16
12"3 CASSPLEGLELF 1"4 16.2 11
7"9 CASSPDRGFGPAYGYT 1"2 8.8 6
6"2 CASRKLAGGTDSYNEQF 2"1 2.9 2
2 CASSDIGGGSSYEQY 2"7 2.9 2
5"1 CASSSLQGQSGGYT 1"2 2.9 2
7"3 CASSLTGDRLGTEAF 1"1 1.5 1
2 CASSGIGGGSSYEQY 2"7 1.5 1
7"9 CASSPPGLADNEQF 2"1 1.5 1
7"2 CASSLQGTGRFEQY 2"7 1.5 1
7"9 CASSSPHTDTQY 2"3 1.5 1
100 68
TRBV CDR3 TRBJ Freq-(%) Count
9 CASSVASGGAYEQY 2+7 69.1 56
7+2 CASSETGGGGQPQH 1+5 19.8 16
2 CASSPGGGYSGNTIY 1+3 11.1 9
100 81
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8.8.2 Idiopathic Intracranial Hypertension 
 
1. HS25204 (CD4+ only) 
 
HS25204 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
2. LH25311 
 
LH25311 CD4+TNF+ 
 
 
 
 
 
 
 
 
LH25311 CD8+TNF+ 
 
 
 
 
 
 
 
LH25311 matching CD8+ CSF 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"2 CASTKGRGGSPLH 1"6 45.8 27
7"9 CASSSREVLDEQY 2"7 15.3 9
27 CASSLKEITEAF 1"1 11.9 7
27 CASSLSGNEQF 2"1 11.9 7
5"1 CASSLERPSDTQY 2"3 6.8 4
18 CASSPRDTGELF 2"2 5.1 3
5"4 CASSPWDRGKDTQY 2"3 1.7 1
7"8 CASSLASNTGELF 2"2 1.7 1
100 59
TRBV CDR3 TRBJ Freq-(%) Count
30 CAWSFTSSGANVLT 2.6 48.1 37
20.1 CSARATGWGETQY 2.5 44.2 34
21.1 CASSKEIKGCYGYT 1.2 3.9 3
6.4 CASSPQGGGDTQY 2.3 2.6 2
30 CAWSFTSSGVNVLT 2.6 1.3 1
100 77
TRBV CDR3 TRBJ Freq-(%) Count
20#1 CSARAGAYPKNIQY 2#4 77 62
7#6 CASSHMTGDEREQY 2#7 15 12
9 CASSVEGSYEQY 2#7 9 7
100 81
TRBV CDR3 TRBJ Freq-(%) Count
7"6 CASSHMTGDEREQY 2"7 74.7 62
20"1 CSARAGAYPKNIQY 2"4 25.3 21
100 83
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3. SW25353 
 
SW25353 CD4+TNF+ 
 
 
 
 
 
 
 
SW25353 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
4. KA38079 
 
KA38079 CD4+TNF+ 
 
 
 
 
 
 
KA38079 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
7"2 CASSARTANTGELF 2"2 98.9 87
7"2 CTSSARTANTGELF 2"2 1.1 1
100 88
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSLQGGNYGYT 1-2 70.9 56
13 CASSSRTGNTYEQY 2-7 12.7 10
27 CASSIQGSEAF 1-1 10.1 8
4-1 CASSQDRLAGRSEQF 2-1 3.8 3
6-7 CASSYWTGGHQPQH 1-5 2.5 2
100 79
TRBV CDR3 TRBJ Freq-(%) Count
7"2 CASSLNRGTSDLSTDTQY 2"3 97.8 44
7"2 CSSRINRGSNDLSTDTQY 2"3 2.2 1
100 45
TRBV CDR3 TRBJ Freq-(%) Count
15 CATSRELGGHEQF 2/1 43.8 21
5/6 CASSLGRDNRRSYEQY 2/7 18.8 9
5/1 CASSLEGQASSYEQY 2/7 18.8 9
13 CASSLTERETQY 2/5 12.5 6
6/1 CASSSRTGLTTEAF 1/1 4.2 2
7/6 CASSLSTDTQY 2/3 2.1 1
100 48
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5. ML25308 (CD4+ only) 
 
ML25308 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. RY21758 (CD4+ only) 
 
RY21758 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
6"2 CASTQIFRAATYLPYEQY 2"7 22.0 13
5"4 CASSSRLAGGPTDTQY 2"3 20.3 12
27 CASSPILPDRDQRGV 1"1 13.6 8
7"8 CASSHRVAGGPTDTQY 2"3 8.5 5
6"1 CASSLTPAGSSTDTQY 2"3 8.5 5
18 CASSPTSGGGEGEQY 2"7 6.8 4
6"2 CASSYSTSGGNEQF 2"1 5.1 3
6"2 CASSYRLGQGGSLDEQF 2"1 3.4 2
7"3 CASSLWGASGGDTQY 2"3 3.4 2
5"1 CASSLGQITDTQY 2"3 3.4 2
12"4 CASSFVAGRGPGSTDTQY 2"3 1.7 1
6"5 CASRARQGENYGYT 1"2 1.7 1
20"1 CSAKGQGYEQY 2"7 1.7 1
100 59
TRBV CDR3 TRBJ Freq-(%) Count
10#2 CASSEDGMNTEAF 1#1 62.5 30
2 CASSSGFSYEQY 2#7 22.9 11
5#4 CASSSGQSNEKLF 1#4 10.4 5
7#9 CASSVTTHLAKNIQY 2#4 4.2 2
100 48
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7. RC41200 (CD4+ only) 
 
RC41200 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
30 CAWSPGYQETQYF 2/5 44.0 22
7/3 CASSALTGRMNTEAFF 1/1 16.0 8
6/2 CASSSPGGSTNEQFF 2/1 10.0 5
5/1 CASSSGTGQTTGELFF 2/2 8.0 4
12/4 CASSLYPPGQGRDGELFF 2/2 4.0 2
25/1 CASSIYRGTSTDTQYF 2/3 2.0 1
5/4 CASSSIGTPSYEQYF 2/7 2.0 1
6/5 THYRASSGINAEYF 2/7 2.0 1
5/1 CASKERAGTDTQYF 2/3 2.0 1
5/1 CASRGQGFDEQYF 2/7 2.0 1
7/2 CASSPLVDSPPHF 1/6 2.0 1
25/1 CASSRSSDRGYTF 1/2 2.0 1
15 CATSRNRQETQYF 2/5 2.0 1
20/1 CSAQRGQETQYF 2/5 2.0 1
100 50
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8.8.3 Other Neurological Diseases 
 
1. SE29703 (CD8+ only) 
 
SE29703 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. JG33488 (CD4+ only) 
 
JG33488 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSWTDTGELF 2"2 48.7 37
7"2 CASSPGPYEQF 2"1 22.4 17
24"1 CATSDSGYGYT 1"2 21.1 16
10"3 CAISEGAYSNQPQH 1"5 3.9 3
7"2 CASSLNRGTSDLSTDTQY 2"3 1.3 1
24"1 CASSDCEYGHT 1"2 1.3 1
24"1 CAASGSGQGYT 1"2 1.3 1
100 76
TRBV CDR3 TRBJ Freq-(%) Count
5"1 CASSFEGQASSYEQY 2"7 14.7 10
6"5 CASSLQGGNEQF 2"1 14.7 10
6"5 CASSYTETSGNEQF 2"1 11.8 8
4"1 CASSPRAGWDEQF 2"1 10.3 7
2 CASSDLGSGVSRIAKNIQY 2"4 10.3 7
7"9 CASSLTGPGDNEQF 2"1 7.4 5
7"3 CASSLIVSGGEQF 2"1 5.9 4
7"6 CASSLVIGEGVGEQF 2"1 4.4 3
10"3 CAISPGEGTQY 2"5 4.4 3
9 CASSVGIGAALNTEAF 1"1 2.9 2
7"9 CASSQRGTSGTTDTQY 2"3 2.9 2
29"1 CGVERGVGAGELF 2"2 4.4 3
7"3 CASSLVASGGWETQY 2"5 1.5 1
7"3 CASSYGQGQDTQY 2"3 1.5 1
6"5 CASRYRGGADGYT 1"2 1.5 1
12"3 CASSWGPAPEAF 1"1 1.5 1
100 68
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3. AG20355 (CD8+ only) 
 
AG20355 CD8+TNF+ (N.B. CSF CD8+ sort discarded because of 
contamination) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. JM25229 
 
JM25229 CD4+TNF+ 
 
 
 
 
 
 
JM25229 matching CD4+ CSF 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
6"2 CASSPGTARYEQY 2"7 27.5 19
9 CASSFPEGGSSGNTIY 1"3 23.2 16
7"2 CASRETSGLRSEQY 2"7 20.3 14
28 CASTLGGGGAGETQY 2"5 8.7 6
28 CASSINRGADEQY 2"7 7.2 5
27 CAGKTQAAGDAFFTDTQY 2"3 2.9 2
7"2 CASSAPGRSVNNEQF 2"1 2.9 2
9 CASREGDPTDTQY 2"3 2.9 2
27 CASKTQAAGDAFFTDTQY 2"3 1.4 1
27 CASRISGAHNEQF 2"1 1.4 1
28 CASSWGIAYEQY 2"7 1.4 1
100 69
TRBV CDR3 TRBJ Freq-(%) Count
12#3 CASSLGLYEQY 2#7 98.6 73
12#3 CAGSLGLYEQY 2#7 1.4 1
100 74
TRBV CDR3 TRBJ Freq-(%) Count
20#1 CSAPASRGTGELF 2#2 41.3 33
12#3 CASSLGLYEQY 2#7 21.3 17
11#3 CASSGRAPRTQY 2#3 12.5 10
5#6 CASSLADQPQH 1#5 8.8 7
9 CASSVVGLSDTQY 2#3 5.0 4
7#8 CASSLDMQGINEKLF 1#4 3.8 3
3#1 CASSQDGASRDGTDTQY 2#3 2.5 2
12#3 CASSLGTGKADTQY 2#3 1.3 1
20#1 CSAPASRGAGELF 2#2 1.3 1
5#1 CASSLEGDYTEAF 1#1 1.3 1
5#6 CASSLMGVYEQY 2#7 1.3 1
100 80
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JM25229 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
5. AB25236 
 
AB25236 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AB25236 CD8+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
27 CASSLWARATGELF 2-2 44 27
7-9 CASTQTGDSYGYT 1-2 26 16
5-5 CASSQRTSGSTDTQY 2-3 13 8
27 CASSPKGPRWQPQH 1-5 10 6
7-2 CASSLAYGRLHYGYT 1-2 5 3
28 CASESGTSGSRTDTQY 2-3 2 1
100 61
TRBV CDR3 TRBJ Freq-(%) Count
3"1 CASSQLLAANEQF 2"1 20.9 9
20"1 CSARDPGQTYEQY 2"7 18.6 8
28 CASRRTGTDYGYT 1"2 18.6 8
18 CASSPLSLTYEQY 2"7 18.6 8
6"2 CASRDLEGILNEQF 2"1 9.3 4
20"1 CSANRGDTQY 2"3 4.7 2
7"2 CASSSPTALRGREQY 2"7 2.3 1
6"5 CASSYMLAGDTQY 2"3 2.3 1
30 CAWGGRGPEAF 1"1 2.3 1
20"1 CSARGDQPQH 1"5 2.3 1
100 43
TRBV CDR3 TRBJ Freq-(%) Count
4"2 CASSPVTGSSGAEAF 1"1 56.7 17
7"3 CASSLTLLAGGPGTEAF 1"1 13.3 4
29"1 CSVVRQGAPGGYT 1"2 10.0 3
3"1 CASSQDNVVAGRAGHTDTQY 2"3 6.7 2
7"3 CASSLGVGNSPLH 1"6 6.7 2
7"3 CASSTKQGEYTEAF 1"1 3.3 1
5"1 CASSLELAGYGYT 1"2 3.3 1
100 30
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AB25236 JM25229 matching CD8+ CSF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CJ26014 (CD4+ only) 
 
CJ26014 CD4+TNF+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRBV CDR3 TRBJ Freq-(%) Count
15 CATSRSRGASYEQY 2-7 26.6 17
6-2 CASSSWTGLGNTEAF 1-1 17.2 11
12-3 CASSFDVRGETQY 2-5 15.6 10
2 CASSEEAAKNQETQY 2-5 12.5 8
4-2 CASSLETGTAPEQY 2-7 7.8 5
6-2 CASIQGPETYEQY 2-7 7.8 5
5-1 CASSLELAGYGYT 1-2 6.3 4
27 CASSLHSGQGFYEQY 2-7 3.1 2
10-3 CAISARDGREDTEAF 1-1 1.6 1
7-9 CASSEGVRGYT 1-2 1.6 1
100 64
TRBV CDR3 TRBJ Freq-(%) Count
7"2 CASSVMESSYEQY 2"7 96.9 63
7"2 CASSVMESSYERY 2"7 1.5 1
12"4 CASSLGRGSGYT 1"2 1.5 1
100 65
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8.9 Overview of samples included for phenotyping, clonotyping and 
TNFα capture assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phenotyping
CD4 CD8 CD4 CD8 CD4 CD8
MS1
LC20552 Yes Yes Yes Yes Yes No No
LJ20639 Yes Yes Yes Yes Yes No No
LS20460 No Yes Yes Yes Yes Yes Yes
MJ19588 Yes Yes Yes No No No No
EB21510 Yes Yes Yes Yes Yes Yes Yes
KG19967 Yes Yes Yes No No No No
LH18836 Yes Yes Yes Yes Yes Yes No
NW21326 Yes Yes Yes Yes No No No
MW21576 Yes Yes Yes Yes Yes Yes Yes
CS21983 Yes Yes Yes No No No No
AL22847 Yes Yes Yes Yes Yes No No
MK21405 Yes Yes Yes No No No No
SA23376 Yes Yes Yes Yes Yes Yes Yes
RM22664 Yes Yes Yes Yes Yes Yes Yes
TL22789 Yes Yes Yes Yes Yes No No
CT25364 Yes Yes No No No Yes No
HD21265 Yes Yes No Yes No Yes Yes
MH21407 Yes Yes Yes Yes Yes Yes No
RW21309 Yes Yes Yes Yes No No No
DD22299 No No No No No No No
CG41964 Yes Yes Yes No No No No
IIH
EC21870 Yes Yes No No No No No
HS25204 Yes Yes No Yes No Yes No
LH25311 Yes Yes Yes Yes Yes Yes Yes
ML25308 Yes Yes No Yes No Yes No
SW25353 Yes Yes Yes Yes Yes Yes Yes
RY21758 Yes Yes No No No Yes No
DC37877 Yes No No No No No No
ES37889 Yes Yes No No No No No
FC24414 Yes No No No No No No
VE25562 No No No No No No No
CC40712 Yes Yes Yes Yes Yes No No
RC41200 Yes Yes No No No Yes No
KA38079 Yes No Yes No No Yes Yes
CC41471 Yes Yes No No No No No
OND
SE29703 NoA Yes Yes Yes Yes No Yes
JG33488 Yes Yes NoA No No Yes No
ND37140 Yes Yes Yes Yes Yes No No
DL37140 No No No No No No No
CS19395 Yes Yes No No No No No
AG20355 Yes Yes No Yes No No No
JM25229 Yes Yes Yes No No Yes Yes
AB25236 Yes Yes Yes Yes Yes Yes Yes
CJ26014 Yes Yes Yes No No Yes No
JJ37566 No No No No No No No
JP24822 NoA No No No No No No
VbetaClonotyping TNF1capture
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8.10 Publications and presentations arising from this thesis 
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Willis MD, Pickersgill TP, Robertson NP, Lee RW, Dick AD, Carreño E. Alemtuzumab-
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